SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

No. 11-147742- -00000-0000

Fecha: 2011-11-01 11:31:46 Dep: 2020 DIR.NUEVASCR
Tra: 11 PATENTEIYII Eve: 378 FASENACIONALI
Act: 411 PRESENTACION Folios: 517

Industria y Comercio

SUPERINTENDENCIA

DELEGATURA DE PROPIEDAD INDUSTRIAL

División de Nuevas Creaciones

SOLICITUD
PATENTE DE INVENCIÓN

21. **EXPEDIENTE No.** _____

54. **TÍTULO** COMPUESTOS Y METODOS PARA TRATAMIENTO ANTIVIRAL

51. **CLASIFICACIÓN INTERNACIONAL** _____

71. **SOLICITANTE** PTC THERAPEUTICS, INC.

DOMICILIO SOUTH PLAINFIELD, NEW JERSEY, ESTADOS UNIDOS DE AMERICA

74. **APODERADO** LUZ CLEMENCIA DE PAEZ
C.C. 35.456.344 de Usaquén

22. **BOGOTÁ, D.C.,** _____

(FORMA P-10)

Industria y Comercio
SUPERINTENDENCIA

PETITORIO

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 11-147742- -00000-0000
Fecha: 2011-11-01 11:31:46 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 517

FORMULARIO UNICO DE SOLICITUD DE PATENTE PCT ENTRADA EN FASE NACIONAL

1 SOLICITUD DE:

☒ Patente de Invención. ☐ Patente de Modelo de Utilidad.
☒ Capítulo I. ☐ Capítulo II.

2 SOLICITANTE (71)

Nombre: **PTC THERAPEUTICS, INC.**
Sociedad constituida y existente bajo las leyes del Estado de Delaware, Estados Unidos de América.

Dirección: 100 Corporate Court,
Middlesex Business Center,
South Plainfield,
New Jersey 07080,
Estados Unidos de América

Domicilio: South Plainfield,
New Jersey,
Estados Unidos de América

IDENTIFICACIÓN
C.C. ☐ NIT ☐
C.E. ☐ Otro ☐
Cual ____
Número ____

3 REPRESENTANTE O APODERADO

Nombre: LUZ CLEMENCIA DE PAEZ
Dirección: Carrera 4ª. No. 72-35
Teléfono: 347 36 11
Fax: 211 86 50
E-mail: clientes@cavelier.com
Domicilio: Bogotá, Colombia.

IDENTIFICACIÓN
C.C. ☒ NIT ☐
C.E. ☐ Otro ☐
Cual ____
Número 35.456.344 T.P 23.555

4 INVENTOR (ES) (72)

1. **Malcom MACCOSS**
2556 Seabrook Island Road,
Seabrook Island,
South Carolina 29455,
Estados Unidos de América

2. **George F. NJOROGE**
11 Softwood Way,
Warren,
New Jersey 07059,
Estados Unidos de América

3. **Amin NOMEIR**
8 Benjamin Court,
Milford,
New Jersey 08848,
Estados Unidos de América

4. **Guangming CHEN**
1402 Stech Drive,
Bridgewater,
New Jersey 08807,
Estados Unidos de América

5. **Song Xiao HUANG**
159 Southgate Road,
New Providence,
New Jersey 07974,
Estados Unidos de América

6. **Ramesh KAKARLA**
439 Foote Road,
South Glastonbury,
Connecticut 06073,
Estados Unidos de América

7. **Gary Mitchell KARP**
37 Cartwright Drive,
Princeton Junction,
New Jersey 08550,
Estados Unidos de América

8. **William Joseph LENNOX**
184 Hillside Avenue,
Bedminster,
New Jersey 07921,
Estados Unidos de América

9. **Chunshi LI**
10 Albermarle Road,
East Brunswick,
New Jersey 08816,
Estados Unidos de América

10. **Ronggang LIU**
187 Daylesford Boulevard,
Berwyn,
Pennsylvania 19312,
Estados Unidos de América

11. Yalei LIU
106 Perince Pike,
Hillsborough,
New Jersey 08844,
Estados Unidos de América

12. Christie RILL
1 Greenway Lane,
Green Brook,
New Jersey 08812,
Estados Unidos de América

13. Steven D. PAGET
2 Camden Road,
Hillsborough,
New Jersey 08844
Estados Unidos de América

14. Sean W. SMITH
1 Richmond Street, Apt. 4099,
New Brunswick,
New Jersey 08901,
Estados Unidos de América

15. James TAKASUGI
11 Pembroke Court,
Lawrenceville,
New Jersey 08648,
Estados Unidos de América

16. Anthony A. TURPOFF
94 Meadowbrook Drive,
Hillsborough,
New Jersey 08844,
Estados Unidos de América

17. Hongyu REN
407 Blossom Circle,
Dayton,
New Jersey 08810,
Estados Unidos de América

18. Nanjing ZHANG
4 Pickering Circle,
Princeton,
New Jersey 08540,
Estados Unidos de América

19. Xiaoyan ZHANG
7 Livingston Drive,
Belle Mead,
New Jersey 08502,
Estados Unidos de América

20. Jin ZHU
5 Roderer Drive,
Raritan,
New Jersey 08869
Estados Unidos de América

(5) **PCT (86)**
Solicitud Internacional No. PCT/US2010/029923 Fecha: 05 de abril de 2010
Publicación Internacional No. WO 2010/117932 A1 Fecha: 14 de octubre de 2010

(6) **Título (54)**
COMPUESTOS Y MÉTODOS PARA TRATAMIENTO ANTIVIRAL

(7) **Clasificación Internacional (51)** C07D/401/004

(8) **Prioridad** SI ☒ NO ☐

(33) País de Origen	(32) Fecha	(31) Número de Solicitud
US	06 de abril de 2009	61/166,893

(9) **Comprobante de pago No.:** 11-103545 **Fecha:** 21 de octubre de 2011
Comprobante de pago No.: 11-103523 **Fecha:** 21 de octubre de 2011


10

Anexos:

- [x] Comprobante de pago de la tasa de presentación de la solicitud por $ 571.000.oo.
- [x] Comprobante de pago por 12 reivindicaciones adicionales después de la décima reivindicación por $324.000.oo.
- [x] Documento que acredita la existencia y representación legal cuando el solicitante sea persona jurídica.
- [ ] Poder, si fuere el caso de **PTC THERAPEUTICS, INC.**
- [ ] Documento de cesión del inventor al solicitante o a su causante.
- [ ] Declaraciones.
- [ ] Copia de la solicitud internacional. (Resumen, descripción, reivindicaciones, dibujos)
- [x] Copia de la carátula de la Publicación Internacional WO 2010/117932 A1.
- [x] Traducción de la solicitud internacional al castellano. (Resumen, descripción, reivindicaciones, dibujos)
- [ ] Copia del examen preliminar efectuado por la IPEA.
- [ ] Traducción del examen preliminar efectuado por la IPEA.
- [ ] De ser el caso, copia del contrato de acceso.
- [ ] De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas.
- [ ] De ser el caso, certificado de depósito del material biológico.
- [ ] Arte final 12x12
- [ ] De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- [x] Otros: VER HOJA DE DOCUMENTOS ANEXOS

4

11 **FIGURA CARACTERÍSTICA**



12 Solicito la concesión de la patente,

NOMBRE: LUZ CLEMENCIA DE PAEZ

FIRMA : Luz Clemencia Páez

C.C. 35.456.344 de Usaquén T.P. 23.555

JGG

DOCUMENTOS ANEXOS

1. ☒ Publicación Internacional WO 2010/117932 A1

   Descripción:

   Páginas 391 en español

   Reivindicaciones: Número (s) 22

   Figuras: Número (s)

2. ☒ **Forma PCT/ISA/210.** Informe de Búsqueda Internacional.

3. ☒ **Forma PCT/IB/306.** Notificación de la inscripción de la exclusión como solicitante de la sociedad **SCHERING CORPORATION**.

4. ☒ Extracto de publicación.

NO SE REALIZARON MODIFICACIONES EN LA FASE INTERNACIONAL

4788

6

75565
8938

APOSTILLE

(CONVENTION DE LA HAYE DU 5 OCTOBRE 1961)

1. COUNTRY: UNITED STATES OF AMERICA

2. THIS PUBLIC DOCUMENT HAS BEEN SIGNED BY:
SONJA K BENSON

3. ACTING IN THE CAPACITY OF:
NOTARY PUBLIC OF NEW JERSEY

4. BEARS THE SEAL/STAMP OF:
SONJA K BENSON, NOTARY

CERTIFIED

5. AT TRENTON, NEW JERSEY

6. THE 17TH DAY OF NOVEMBER 2006

7. BY: Bradley Abelow, NEW JERSEY TREASURER

8. NO. A276173

9. SEAL/STAMP:

10. SIGNATURE

Bradley Abelow

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTA, D.C. HAGO CONSTAR QUE LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA
18 OCT 2011
AMPARO QUINTERO ARTURO
NOTARIA

CAVELIER
ABOGADOS
EDIFICIO SISKI
CARRERA 4a N° 72-35
BOGOTA, 8 - COLOMBIA

181

Representación y Poder con autenticación notarial y Apostille para patentes, modelos de utilidad, diseños industriales, marcas de fábrica, nombres comerciales, enseñas, nombres de dominio, lemas comerciales, licencias.

Representation and Power-of-Attorney with notarial authentication and Apostille for patents, utility models, industrial designs, trademarks, commercial names, trade emblems, domain names, slogans, licenses.

REPRESENTACION Y PODER

REPRESENTATION AND POWER-OF-ATTORNEY

Yo (nosotros), abajo firmado (s)/I (we), the undersigned

PTC THERAPEUTICS, INC.

domiciliado (s) en/of

100 Corporate Court, Middlesex Business Center,
South Plainfield,
New Jersey 07080,
US

Por el presente nombramos a EMILIO FERRERO, tpa. 31929; GONZALO PERDOMO, tpa. 831; LUZ CLEMENCIA DE PAEZ, tpa. 23555 y DANIEL PEÑA, tpa. 65.620, domiciliados en la Carrera 4a N° 72-35, Bogotá, Colombia, en obedecimiento a lo dispuesto en el parágrafo 1o del Artículo 543 del Código de Comercio, el primero como principal y los demás como suplentes, en su orden, como mis (nuestros) representantes en todos los asuntos de propiedad industrial con facultad para recibir notificaciones y nombrar apoderados judiciales o extrajudiciales. El primer representante suplente reemplazará al principal en caso de ausencia o impedimento temporal o definitivo de aquél. La misma regla se aplicará cuando el segundo representante suplente haya de reemplazar al primero, o el tercero al segundo. En tales casos, el representante principal, o el primero, o segundo suplente, en su caso, o ambos, declararán su intención de no ejercer la representación mediante declaración autenticada por Notario Público en Colombia, o por Notario u otro Funcionario Público, o Cónsul de Colombia, en el extranjero; y si se tratare de impedimento, con el certificado respectivo. Si alguno de los nombrados faltare definitivamente, el siguiente tomará su lugar. Cuando cesare la ausencia o impedimento del representante principal, o de su primero o segundo suplentes, en su caso, podrán ejercer la representación, en su orden, uno u otros según el caso, asumiéndola por el solo hecho de ejercerla, cesando en ese momento el ejercicio de la representación por el primero, segundo o tercer suplente en su caso.

Además, confiero (conferimos) poder a los abogados arriba nombrados, para obtener la protección de mi (nuestra) propiedad industrial y contra la competencia desleal, a cuyo efecto autorizo (amos) a los dichos apoderados para que me (nos) representen ante cualesquiera entidades o personas, ejerzan o no jurisdicción, especialmente ante las del orden administrativo, contencioso- administrativo y judicial, así como los tribunales de arbitramento, en todo lo concerniente a los siguientes asuntos: a) Obtención de patentes de invención, modelos de utilidad y diseños industriales; el registro de marcas de fábrica, colectivas, defensivas, de servicio, lemas comerciales, nombres comerciales, enseñas, nombres de dominio, variedades vegetales y denominaciones de origen; su renovación, traspaso, cambio de nombre

in due compliance with the terms of paragraph 1st. of article 543 of the Commercial Code, do hereby appoint EMILIO FERRERO, tpa. 31929; GONZALO PERDOMO, tpa. 831; LUZ CLEMENCIA DE PAEZ, tpa. 23555 and DANIEL PEÑA, tpa. 65620, domiciled at Carrera 4a N° 72 35, Bogotá, Colombia, the first as principal and the others as alternates, in the order of their appointment, as our representatives for all industrial property matters with faculty to receive notifications and to appoint attorneys in and out of Court. The first alternate shall replace the principal in case of his absence or of temporal or definitive impediment. The same rule will apply when the second alternate representative is to replace the first one, or when the third is to replace the first or second alternates in their turn, or both of them, second. In such cases, the principal representative, or the first or second alternates in their turn, or both of them, shall state their intention not to act as representatives through a declaration given before a Notary Public in Colombia, or before a Notary or another Official or a Colombian Consul abroad; and in case of impediment, the appropriate certificate shall suffice. If any of the appointees were to be definitely absent, the following alternate shall take his place. When the absence or impediment of the principal representative, or of the first or second alternate in their turn ceases, the representation can be taken again in their sequence, by the principal, the first or second alternate depending on case, and the mere fact or its exercise will suffice. The exercise of the representation by the first, second or third alternates in their turn shall end at such time. In addition, we grant a Power of Attorney in favor of the above named attorneys at law so that they may obtain the protection of my (our) industrial property and against the unfair competition, for which purpose I (we) authorize the said attorneys to represent me (us) before any authorities or persons, with or without jurisdiction, specially those administrative, administrative contentious and judicial, as well as before Arbitration Court, in all matters concerning the following: a) Obtainment of patents, utility models and industrial designs; the registration of trademarks, collective, defensive and service marks, slogans, commercial names, trade emblems, domain names, vegetal varieties and denominations of origin; its renewal, assignment, change of name or domicile, voluntary

DUANE NOTARIA SEXTA DEL CIRCULO DE BOGOTA
FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA
18 OCT 2011
AMPARO QUINTERO
NOTARIA

© CAVELIER ABOGADOS

o domicilio, cancelación voluntaria; y el registro de licencias de uso de esos derechos; b) Las acciones de competencia desleal, protección del consumidor, oposiciones u observaciones, cancelación administrativa y judicial, nulidad, medidas cautelares, concesión de licencias, la tutela, la protección de secretos industriales, y en general los juicios civiles, penales, administrativos o contencioso-administrativos relacionados con estos derechos; acciones y procesos que promovamos o se nos promuevan. Y para que en todos los asuntos arriba determinados, puedan sustituir este mandato, transigir, conciliar, admitir los hechos del proceso, desistir, cancelar, recibir, renunciar, y ratificar los actos de agentes oficiosos.

cancellation; and the registration of licenses of use of the above rights; b) Actions of unfair competition, protection to the consumer, oppositions or observations, administrative or Court cancellation, nullity, infringement, granting of licenses, the action for writ mandamus, the protection of trade secrets, and in general the civil, penal, and administrative suits relating to those rights; actions and suits instituted by me (us) or against me (us). And that in all the above matters they may substitute this Power of Attorney, compromise, conciliate, admit the facts of the case, desist, cancel, receive, resign, and ratify acts done by representatives without a power of attorney.

Dado y firmado hoy/Given and signed this 10th October 2006

en/in South Plainfield, NJ, USA

por/by **PTC THERAPEUTICS, INC.**

Firma/Signature

MARK E. BOULDING
Senior Vice President General Counsel

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTA. D.C. HAGO CONSTAR QUE LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA
18 OCT 2011
AMPARO QUINTERO ARTURO
NOTARIA

© CAVELIER ABOGADOS

CERTIFICACIÓN NOTARIAL (INDIVIDUO)

A los _____ días del mes de _____

de 200 ___ ante mí, Notario Público o Funcionario Autorizado de

_____

compareció(eron) personalmente _____

_____

_____

a quien(es) doy fe de conocer y me consta que es(son) la(s) persona(s) firmante(s) del documento que precede, y quien(es) tiene(n) capacidad legal para otorgarlo

NOTARIAL CERTIFICATION (INDIVIDUAL)

On this 16th day of October

200 6 before me, a Notary Public or Attesting Official of

_____

personally appeared Mark E. Boulding

_____

_____

to me known, and known to me to be the person(s) who executed that foregoing document, and who has(have) legal capacity to execute it.

--- NOTARIO PÚBLICO O FUNCIONARIO AUTORIZADO --- NOTARY PUBLIC OR ATTESTING OFICIAL ---

CERTIFICACIÓN NOTARIAL (SOCIEDAD)

A los _____ días del mes de _____

de 200 _____ compareció(eron) ante mí,

_____

_____

Quien(es) conozco personalmente y que firma(n) este documento en representación de la Sociedad/compañía denominada

PCT THERAPEUTICS, INC

Certifico:

1. Que he visto los siguientes documentos:*

2.Que dichos documentos prueban lo siguiente:

2.1.Que es una Sociedad/Compañía legalmente constituida y existente de acuerdo con las leyes del Estado de

2.2.Que el domicilio de dicha Sociedad/Compañía es
100 Corporate Court, Middlesex Business Center,
South Plainfield,
New Jersey 07080,
US.

2.3. Que el objeto u objetos para los cuales se otorga el presente poder están comprendidos dentro del objeto social de la mencionada Sociedad/Compañía.

2.4.Que el(los) Sr.(Sres.) _____

_____

está(n) autorizado(s) para otorgar el presente Poder.

Ciudad _____

Estado _____

Hoy _____ de 200 __

NOTARIAL CERTIFICATION (CORPORATION)

On this 16th day of October

200 6 appeared before me

Mark E. Boulding

_____

who(m) I know personally and who(m) signed this document as representative(s) of the Corporation/Company named

PTC THERAPEUTICS, INC.

I certify:

1.That I have seen the following documents:*

Certificate of Incorporation and Good Standing Certificate; Minutes of Board meeting of March 8, 2002

2. That the above documents duly prove the following:

2.1.That PTC Therapeutics, Inc. is a Corporation/Company legally constituted and in existence in accordance with the laws of the State of Delaware

2.2.That the domicile of said Corporation/Company is
100 Corporate Court, Middlesex Business Center,
South Plainfield,
New Jersey 07080,
US.

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTA, D.C. HAGO CONSTAR QUE LA COPIA QUE HE TENIDO A LA VISTA

18 OCT 2011

AMPARO QUINTERO ARTURO
NOTARIA

2.3. That the purpose or purposes for which the present Power of Attorney is granted are comprised within the corporation purposes set forth in the charter of the mentioned Corporation/Company.

2.4. That Mr.(Messrs.) Mark E. Boulding

_____

is(are) authorized to grant the present Power of Attorney

City South Plainfield

State New Jersey

This 16th day of October 200 6

--- NOTARIO PÚBLICO O FUNCIONARIO AUTORIZADO --- NOTARY PUBLIC OR ATTESTING OFICIAL ---

* Los documentos deben identificarse con fecha y origen

* Documents must be identified with date and origin

© CAVELIER ABOGADOS
WPPODE01-181

Sonja Benson

SONJA K. BENSON
NOTARY PUBLIC OF NEW JERSEY
Commission Expires 12/17/2007

10

TRADUCCIÓN OFICIAL No.6.398 de un documento escrito en inglés el cual para su identificación se sella con el sello del traductor al tiempo con la presente. Esta traducción ha sido preparada por Hilda Aguilera de Piedrahita, *traductora e intérprete oficial debidamente reconocida por el Ministerio de* Relaciones Exteriores y autorizada por el Ministerio del Interior y Justicia, por Resolución No. 323 de 1980)
(Se traduce un Documento de Representación y Poder con autenticación Notarial para patentes, diseños industriales, marcas, nombres comerciales, emblemas, nombres de dominio, licencias y **Apostilla No. A276173**

181 REPRESENTACION Y PODER

Nosotros, los abajo firmados **PTC THERAPEUTICS INC.** domiciliados en 100 Corporate Court, Middlesex Business Center, South Plainfield, New Jersey 07080, United States of America por el presente nombramos a EMILIO FERRERO, T.P.A. No. 31.929, GONZALO PERDOMO, T.P.A. No. 831; LUZ CLEMENCIA DE PAEZ, T.P.A. No. 23.555 y DANIEL PENA T P.A. No.65620 , domiciliados en Carrera 4 No. 72-35. Bogotá, Colombia, en obedecimiento a los términos del Parágrafo 1º. del Artículo 543 del Código de Comercio, el primero como principal y los demás como suplentes en el orden de su nombramiento como representantes para todos los asuntos de propiedad industrial, con poder para aceptar notificaciones y nombrar apoderados judiciales y extrajudiciales. El primer representante suplente deberá reemplazar al principal en caso de ausencia temporal o impedimento definitivo de aquel. La misma regla deberá aplicarse cuando el segundo representante deba reemplazar al primero, o cuando el tercero deba reemplazar al segundo. En tales casos, el representante principal, o el primero o segundo representante o ambos de ellos deberán manifestar su intención de no actuar como representantes a través de una

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTA D.C. LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA
18 OCT 2011
AMPARO QUINTERO ARTURO
NOTARIA

TRADUCCION OFICIAL No. 6.398
HILDA AGUILERA DE PIEDRAHITA
INTERPRETE OFICIAL
RES No. 323 DEL MIN. DE JUSTICIA

1

declaración juramentada otorgada ante un Notario Público u otro funcionario público o un Cónsul de Colombia en el Exterior y en caso de impedimento el correspondiente certificado será suficiente. Si alguno de los nombrados se ausentare definitivamente, el siguiente suplente deberá tomar su lugar. Cuando el siguiente suplente en turno asumirá su lugar.

Adicionalmente otorgamos Poder a favor de los mencionados apoderados de tal forma que ellos puedan obtener protección de nouestra propiedad industrial y contra la competencia desleal, para cuyo propósito autorizamos a los mencionados apoderados para que nos represententen ante cualesquiera autoridades o personas, con o sin jurisdicción, especialmente las administrativas, contencioso-administrativas y judiciales, así como ante el Tribunal de Arbitramento en todos los asuntos referentes a a) marcas; marcas colectivas, marcas defensivas y marcas de servicio, emblemas comerciales; nombres comerciales , lemas comerciales, nombres de dominio, variedades vegetales y denominaciones de oriigen; sus renovacioneos, licencias cambio de nombre o domicilio, cancelación voluntaria y registro de licencias de uso de los derechosindicados arriba; b) Acciones de competencia desleal, protección al consumidor, oposiciones u observaciones. Cancelaciones, administrativas o judiciales, acciones de nulidad, infracción, otorgamiento de licencias acciones de tutela, protección de secretos industriales, y eon general pleitos civiles, penales y administrativos relacionaos con tales derechos; acciones y procesos instaurados poro nosotros o que nos promuevan y que en todos los asuntos mencionados arriba puedan sustituir este Poder, transar, conciliar, admitir los

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTA, CERTIFICO QUE LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA
18 OCT 2011
AMPARO QUINTERO ARTURO
NOTARIA

TRADUCCION OFICIAL No. 6398
HILDA AGUILERA DE PIEDRAHITA
INTERPRETE OFICIAL
RES. No. 323 DEL MIN. DE JUSTICIA

hechos de la demanda, desistir, cancelar, recibir renunciar y ratificar los actos de agentes oficiosos.

Dado y firmado, hoy 10 de Octubre, 2006

PTC THERAPEUTICS INC.

(Firmado) MARK E. BOULDING

Signatario Vicepresidente Principal & Asesor Legal

Suscrito en South Plainfield, New Jersey, EE.UU de América

-.-.-.-

CERTIFICADO NOTARIAL (COMPAÑÍA)

El suscrito Notario Certifica que la firma que antecede de Mark E. Boulding hoy día 15 de Octubre, 2006 a quien conozco personalmente es auténtica , que el signatario en la actualidad obra en el cargo de Vicepresidente Principal y Asesor Legal de **PTC THERAPEUTICS, INC**. Certifico que he tenido a la vista el Certificado de Constitución y Cumplimiento de su objeto social y el acta de la Reunión de Junta Directiva de la Compañía que existe y cumple con las leyes del Estado de Delaware.

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTÁ, D.C. HAGO CONSTAR QUE LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA
NOTARIA

Que el domicilio de la compañía es No. 100 Corporate Court Middlesex Business Center , South Plainfield New Jersey 07080 y que el signatario tiene facultad legal para otorgar este documento. .

Todos los hechos anteriores le constan por haber examinado los documentos respectivos y de todo ello da fe, en South Plainfield, New Jersey.

(Firmado) SONJA K BENSON NOTARIO PUBLICO

TRADUCCION OFICIAL No. 6398
HILDA AGUILERA DE PIEDRAHITA
INTERPRETE OFICIAL
RES. No. 323 DEL MIN. DE JUSTICIA

de New Jersey Comisión Expira en 12/17/2007

-.-.-.-

APOSTILLA

(Convención de La Haya del 5 de Octubre, 1961)

1 País: Estados Unidos de América

Este dpcumento público

2. está suscrito por SONJA K. BENSON

3 obrando en calidad de Notario Público

de New Jersey

4. Lleva el sello/estampilla de Sonja Benson, Notario Público

Certificada

5. En TRENTON, NEW JERSEY<

6. El 17 de NOVIEMBRE, 2006

7. Por BRADLEY ABELOW, TESORERO DE NEW JERSEY

8. No. A276173

9. SELLO/ESTAMPILLA

10 (Firmado) BRADLEY ABELOW

NOTARÍA SEXTA DEL CIRCULO DE BOGOTA, D.C. HAGO CONSTAR QUE LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA
18 OCT 2011
AMPARO QUINTERO ARTURO
NOTARIA

-.-.-.-

(Sello DE OBLEA DE LA TESORERIA DEL ESTADO)

Es TRADUCCION FIEL Y COMPLETA DE la cual se deja copia en los archivos de esta oficina para su confrontación y a la cual me remito, habiendo tenido a la vista el documento original. Colo-15565-841-001-6

Solic.J Gonzalez

©CAVELIER ABOGADOS

eppoder1-180 (12.1.6)

TRADUCCION OFICIAL No. 6398
HILDA AGUILERA DE PIEDRAHITA
INTERPRETE OFICIAL
RES. No. 323 DEL MIN. DE JUSTICIA

COMO NOTARIO SEXTO DEL CIRCULO DE SANTAFE DE BOGOTA, HAGO CONSTAR QUE LA(S) FIRMA(S) DE

Ofelia Orjuela R.
El firmante

COINCIDE(N) CON LA FIRMA REGISTRADA POR EL (ELLOS) EN ESTA NOTARIA

SANTAFE DE BOGOTA, 22 DIC 2005

COLOMBIA
Juan Manuel Santos
Notario Sexto
SANTAFE DE BOGOTA, D.C.

NO SE ASUME RESPONSABILIDAD SOBRE EL TEXTO

2007 DIC 22 A 11:10

MINISTERIO DE COMUNICACIONES
DIRECCION DE TELECOMUNICACIONES
OFICINA DE CORRESPONDENCIA
BOGOTA D.C.

5th 7738
Ida Aguilera

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTA, D.C. HAGO CONSTAR QUE LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA

18 OCT 2011

AMPARO QUINTERO ARTURO
NOTARIA

14

CAVELIER
ABOGADOS

EDIFICIO SISKI
CARRERA 4 No. 72 - 35
BOGOTA 8, COLOMBIA

WEB SITE: www.cavelier.com
E-MAIL: cavelier@cavelier.com

TELEFONO: (57) (1) 347-3611
TELEFAX: (57) (1) 217-9211 (57) (1) 310-4995

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

E. S. D.

Poderdante : PTC THERAPEUTICS, INC.

Poder conferido el : 10/10/2006

Yo, EMILIO FERRERO, obrando como apoderado principal del poderdante arriba mencionado, mediante el presente escrito sustituyo el poder a mi otorgado a la doctora LUZ CLEMENCIA DE PAEZ, identificada con cédula de ciudadanía No. 35.456.344 y Tarjeta Profesional N°23.555, con todas las facultades que me fueron conferidas.

Hago la anterior sustitución conforme al artículo 66 del Código de Procedimiento Civil.

EMILIO FERRERO
T.P.A. N° 31.929
C.C. N° 438.019 de Usaquén

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTA, D.C. HAGO CONSTAR QUE LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA
18 OCT 2011
AMPARO QUINTERO ARTURO
NOTARIA

Acepto:

LUZ CLEMENCIA DE PAEZ
T.P.A. N° 23.555
C.C. No. 35.456.344 de Usaquén

15362

NOTARIA SEXTA DE BOGOTA

RECONOCIMIENTO Y PRESENTACION PERSONAL

Bogotá, D.C. 21 OCT 2009

Ante Mi MARÍA FERNANDA CASAS COLL,

NOTARIA SEXTA (E) DEL CIRCULO DE

BOGOTÁ D.C

Compareció (eron)

Quien(es) exhibió(eron) la(s) C.C.

Y declaró(aron) que la(s) firma(s) que aparece(n) en el presente documento es(son) la(s) suya(s) y que el contenido del mismo es cierto.

En constancia se firma esta diligencia

REPUBLICA DE COLOMBIA
María Fernanda Casas Coll
NOTARIA (E)
NOTARIA SEXTA DE BOGOTA

COMO NOTARIA SEXTA DEL CIRCULO DE BOGOTA, D.C. HAGO CONSTAR QUE LA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE HE TENIDO A LA VISTA

18 OCT 2011

AMPARO QUINTERO ARTURO
NOTARIA

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2010 (14.10.2010)

PCT

(10) International Publication Number
WO 2010/117932 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *A61P 31/12* (2006.01)
C07D 401/14 (2006.01) *A61K 31/4439* (2006.01)
C07D 403/04 (2006.01) *A61K 31/444* (2006.01)
C07D 405/14 (2006.01) *A61K 31/4436* (2006.01)
C07D 409/14 (2006.01) *A61K 31/443* (2006.01)
C07D 413/14 (2006.01) *A61K 31/4433* (2006.01)
C07D 417/14 (2006.01) *A61K 31/506* (2006.01)

(21) International Application Number:
PCT/US2010/029923

(22) International Filing Date:
5 April 2010 (05.04.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/166,893 6 April 2009 (06.04.2009) US

(71) Applicants *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US). **PTC THERAPEUTICS, INC** [US/US]; 100 Corporate Circle, South Plainfield, New Jersey 07080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MACCOSS, Malcolm** [GB/US]; 2556 Seabrook Island Road, Seabrook Island, South Carolina 29455 (US). **NJOROGE, F., George** [US/US]; 11 Softwood Way, Warren, New Jersey 07059 (US). **NOMEIR, Amin** [US/US]; 8 Benjamin Court, Milford, New Jersey 08848 (US). **CHEN, Guangming** [US/US]; 1402 Stech Drive, Bridgewater, New Jersey 08807 (US). **HUANG, Song, Xiao** [US/US]; 159 Southgate Road, New Providence, New Jersey 07974 (US). **KAKARLA, Ramesh** [US/US]; 439 Foote Road, South Glastonbury, Connecticut 06073 (US). **KARP, Gary, Mitchell** [US/US]; 37 Cartwright Drive, Princeton Junction, New Jersey 08550 (US). **LENNOX, William, Joseph** [US/US]; 184 Hillside Avenue, Bedminster, New Jersey 07921 (US). **LI, Chunshi** [US/US]; 10 Albermarle Road, East Brunswick, New Jersey 08816 (US). **LIU, Ronggang** [US/US]; 187 Daylesford Boulevard, Berwyn, Pennsylvania 19312 (US). **LIU, Yalei** [CN/US]; 106 Perrine Pike, Hillsborough, New Jersey 08844 (US). **MORRILL, Christie** [US/US]; 1 Greenway Lane, Green Brook, New Jersey 08812 (US). **PAGET, Steven, D.** [US/US]; 2 Camden Road, Hillsborough, New Jersey 08844 (US). **SMITH, Sean, W.** [US/US]; 1 Richmond Street, Apt. 4099, New Brunswick, New Jersey 08901 (US). **TAKASUGI, James** [US/US]; 11 Pembroke Court, Lawrenceville, New Jersey 08648 (US). **TURPOFF, Anthony, A.** [US/US]; 94 Meadowbrook Drive, Hillsborough, New Jersey 08844 (US). **REN, Hongyu** [CN/US]; 407 Blossom Circle, Dayton, New Jersey 08810 (US). **ZHANG, Nanjing** [CN/US]; 4 Pickering Circle, Princeton, New Jersey 08540 (US). **ZHANG, Xiaoyan** [US/US]; 7 Livingston Drive, Belle Mead, New Jersey 08502 (US). **ZHU, Jin** [US/US]; 5 Roderer Drive, Raritan, New Jersey 08869 (US).

(74) Agent: **RUSSELL, Mark, W.**; Schering-Plough Corporation, Patent Department, K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2010/117932 A1

(54) Title: INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT

(57) Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.

16

COMPUESTOS Y MÉTODOS PARA TRATAMIENTO ANTIVIRAL

SOPORTE GUBERNAMENTAL

La presente invención no se hizo con soporte del gobierno de los Estados Unidos.

REFERENCIA CRUZADA A SOLICITUDES RELACIONADAS

Esta solicitud reivindica beneficio de la USSN 61/166.893 provisional, presentada el 6 de abril de 2009, incorporada en la presente por referencia.

Esta solicitud se refiere a la solicitud de patente de los Estados Unidos con número de serie _____ (expediente N.º: 2009.6978), intitulada "Inhibidor de HCV y combinaciones de agentes terapéuticos".

DECLARACIÓN DE ACUERDO CONJUNTO DE BÚSQUEDA

La presente invención fue realizada por o a nombre de partes de un acuerdo conjunto de búsqueda que entró en efecto el día de la fecha o antes del día de la fecha en que se hizo la invención, la presente invención se realizó como un resultado de actividades efectuadas dentro del alcance del acuerdo conjunto de búsqueda y la solicitud de patente de la presente invención revela los nombres de las partes del acuerdo conjunto de búsqueda.

CAMPO DE LA INVENCIÓN

La presente invención se refiere a compuestos, composiciones farmacéuticas y métodos de uso de tales compuestos o composiciones para el tratamiento de una infección viral o para afectar la actividad viral al modular la replicación viral. Más en particular, la presente invención se refiere a compuestos o composiciones de indol y a métodos para su uso para el tratamiento o la mejora de infección por el virus de hepatitis C (HCV) o trastornos o síntomas asociados con ello al inhibir la replicación viral C.

17

ANTECEDENTES DE LA INVENCIÓN

Se informó que aproximadamente 170 millones de personas en el mundo están infectadas con el virus de la hepatitis C, agente causante de la hepatitis C. Del setenta al ochenta por ciento de las infecciones de HCV conducen a infección hepática crónica que, a su vez, puede dar como resultado una enfermedad hepática severa, incluyendo fibrosis hepática, cirrosis y carcinoma hepatocelular (ver Saito I, et al., Hepatitis C virus infection is associated with the development of hepatocellular carcinoma, *Proc Natl Acad Sci USA*, **2003,** 87:6547–6549).

A pesar de que el éxito del tratamiento es variable entre los seis principales genotipos de HCV, sólo aproximadamente una mitad de todos los pacientes tratados responden a la terapia, lo que sugiere que el virus codifica los productos proteicos que pueden atenuar directa o indirectamente la acción antiviral del interferón (IFN). Los IFN se producen naturalmente en respuesta a la infección viral y la exposición celular a IFN conduce a la expresión inducida de una variedad de genes estimulados por IFN (ISG), muchos de los cuales tienen una función antiviral. La acción de ISG puede limitar la replicación viral en múltiples puntos dentro del ciclo replicativo.

Los compuestos y los métodos para el tratamiento de la hepatitis C se describieron en la solicitud de patente de los Estados Unidos N.º 11/653.450, presentada el 16 de enero de 2007 (con su correspondiente solicitud internacional N.º PCT/US2007/00996, presentada el 16 de enero de 2007), la solicitud de patente de los Estados Unidos N.º 11/653.448, presentada el 16 de enero de 2007 (con su correspondiente solicitud internacional N.º PCT/US2007/00923, presentada el 16 de enero de 2007), cada una de las cuales son una continuación en parte de la solicitud de patente de los Estados Unidos N.º 11/331.180, presentada el 13 de enero de 2006, que es una continuación en parte de la solicitud de patente de los Estados Unidos N.º 11/180.961, presentada el 14 de

18


julio de 2005 (con su correspondiente solicitud internacional N.º PCT/US2005/024881, presentada el 14 de julio de 2005), cada una de las cuales está incorporada en la presente por referencia en su totalidad y para todos los fines.

La publicación de patente de los Estados Unidos 2006/0235028 revela ciertos compuestos de arilo y heteroarilo como inhibidores de la 11–beta–hidroxiesteroide deshidrogenasa de tipo I.

Todos los otros documentos mencionados en la presente se incorporan por referencia en la presente solicitud como establecida por completo en la presente.

SÍNTESIS DE LA INVENCIÓN

La presente invención se refiere a un compuesto de la fórmula (I):




(I)

en donde R_1, R_2, X, Z y Ar son como se definen en la presente y sus formas y composiciones y métodos de uso de tales compuestos, formas o composiciones para tratar una infección viral o para afectar la actividad viral al modular la replicación viral.

DESCRIPCIÓN DETALLADA DE LA INVENCIÓN

La presente invención se refiere a un compuesto de la fórmula (I):



(I)

o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o sus formas polimórficas, en donde

X es hidrógeno, halógeno, ciano, nitro, carboxilo, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, formilo, amino, alquil C_{1-8}–amino, amino–carbonilo, alquil C_{1-8}–amino–carbonilo o alquil C_{1-8}–sulfonilo–;

Ar es heteroarilo o heterociclilo, cada uno opcionalmente sustituido con uno o dos sustituyentes seleccionados, de modo independiente, de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino;

Z es alquilo C_{1-8}, alquenil C_{2-8}–alquilo C_{1-8}, alquinil C_{2-8}–alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, alcoxi C_{1-8}–carbonilo, carboxilo, cicloalquilo C_{3-14}, cicloalquenilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo y heteroarilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de hidroxi, ciano, nitro, halógeno, alquilo C_{1-8}, alquenilo C_{2-8}, alquinilo C_{2-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino, alquil C_{1-8}–amino, alcoxi C_{1-8}–alquilo C_{1-8}, alquil C_{1-8}–tio, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi o amino–sulfonilo;

R_1 es $–N(R_3)–SO_2–R_4$, $–N(R_3)–SO_2–N(R_5)–R_6$, $–SO_2–N(R_5)–R_6$ o $–SO_2–R_7$;

R_2 es uno, dos, tres o cuatro sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, ciano, nitro, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, alquenilo C_{2-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi, alquil C_{1-8}–carboniloxi–alquilo C_{1-8}, alquil C_{1-8}–carboniloxi–alcoxi C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil

C_{1-8}–amino–alquilo C_{1-8}, amino–alcoxi C_{1-8}, alquil C_{1-8}–amino–alcoxi C_{1-8}, alcoxi C_{1-8}–alquil C_{1-8}–amino–alcoxi C_{1-8}, amino–alquil C_{1-8}–amino–alcoxi C_{1-8}, alquil C_{1-8}–amino–alquil C_{1-8}–amino–alcoxi C_{1-8}, alcoxi C_{1-8}–carbonil–amino, carboxil–amino, amino–carbonilo, amino–carbonil–amino, alquil C_{1-8}–amino–carbonil–amino, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, alquil C_{1-8}–sulfonil–amino, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, cicloalquil C_{3-14}–alcoxi C_{1-8}, cicloalquil C_{3-14}–oxi, arilo, aril–alquilo C_{1-8}, aril–alcoxi C_{1-8}, ariloxi, aril–carbonil–amino, heteroarilo, heteroaril–alquilo C_{1-8}, heteroaril–alcoxi C_{1-8}, heteroariloxi, heterociclilo, heterociclil–alquilo C_{1-8}, heterociclil–alcoxi C_{1-8}, heterocicliloxi o heterociclil–carboniloxi, en donde cada instancia de cicloalquilo C_{3-14}, arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de halógeno, ciano, alquilo C_{1-8}, alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8} o alquil C_{1-8}–amino–alquilo C_{1-8};

R_3 es hidrógeno o alquilo C_{1-8}, opcionalmente sustituido en el alquilo C_{1-8} con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi, ciano, alcoxi C_{1-8}, amino o alquil C_{1-8}–amino;

R_4 es alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C_{3-14} está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino;

R_5 es hidrógeno, alquilo C_{1-8}, alquil C_{1-8}–carbonil– o cicloalquilo C_{3-14}, opcionalmente sustituido en el alquilo C_{1-8} con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi, ciano o alcoxi C_{1-8};

R_6 es hidrógeno, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, ciano–alquilo C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C_{3-14} está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino; y

R_7 es alquilo C_{1-8}, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo, heteroarilo, cicloalquilo C_{3-14} y heterociclilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde

X está seleccionado de hidrógeno, ciano, carboxilo, amino–carbonilo o alquil C_{1-8}–amino–carbonilo;

Ar es heteroarilo;

Z es alquilo C_{1-8}, cicloalquilo C_{3-14}, cicloalquenilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo y heteroarilo

22

está opcionalmente sustituido con un sustituyente seleccionado de ciano, halógeno, alquilo C_{1-8}, alcoxi C_{1-8}, amino o alquil C_{1-8}–amino;

R_2 es uno, dos o tres sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, cicloalquil C_{3-14}–alcoxi C_{1-8}, cicloalquil C_{3-14}–oxi, heteroarilo, heteroaril–alquilo C_{1-8}, heteroaril–alcoxi C_{1-8}, heteroariloxi, heterociclilo, heterociclil–alquilo C_{1-8}, heterociclil–alcoxi C_{1-8} o heterocicliloxi, en donde el heteroariloxi está opcionalmente sustituido con un sustituyente de ciano;

R_3 es hidrógeno o alquilo C_{1-8}, opcionalmente sustituido en el alquilo C_{1-8} con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi o ciano;

R_4 es alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8};

R_5 es hidrógeno;

R_6 es hidrógeno, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, ciano–alquilo C_{1-8}, cicloalquilo C_{3-14} o cicloalquil C_{3-14}–alquilo C_{1-8}, en donde cada instancia de cicloalquilo C_{3-14} está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8} o halo–alquilo C_{1-8}; y

R_7 es alquilo C_{1-8} o heterociclilo;

y todas las otras variables previamente definidas.

77

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde

X es ciano;

Ar es piridinilo, pirimidinilo o piridazinilo;

Z es alquilo C_{1-8}, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclohexenilo, ciclopropil–metilo, fenilo, tiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo, triazinilo o tetrahidrofurano, en donde fenilo está opcionalmente sustituido con un sustituyente seleccionado de ciano, halógeno, alquilo C_{1-8} o alcoxi C_{1-8};

R_2 es uno, dos o tres sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, ciclopropilo, ciclobutilo, ciclobutoxi, piridiniloxi, pirimidiniloxi, piraziniloxi o morfolinilo, en donde piridinilo y pirazinilo están cada uno opcionalmente sustituidos con un sustituyente de ciano;

R_3 es hidrógeno, metilo, etilo, propilo, isopropilo o ter–butilo, en donde metilo, etilo, propilo e isopropilo están cada uno opcionalmente sustituidos con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi o ciano;

R_4 es alquilo C_{1-8} o ciclopropilo;

R_6 es hidrógeno, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, ciano–alquilo C_{1-8}, ciclopropilo, ciclobutilo o 1–ciclopropil–etilo, en donde cada instancia de ciclopropilo y ciclobutilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8} o halo–alquilo C_{1-8}; y

R_7 es alquilo C_{1-8} o piperidinilo;

y todas las otras variables previamente definidas.

24

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde el isotopólogo es deuterio.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde

R_2 es alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio;

R_4 es alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio o halo–alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio;

R_6 es alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio o halo–alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio; y

R_7 es alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio o halo–alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde

Z es metilo, etilo, 2–hidroxi–etilo–, propilo, isopropilo, ter–butilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclohexenilo, ciclopropil–metilo, (ciclopropilo, metil)metilo–, fenilo, tiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo, pirazolilo, tetrahidro–*2H*–piranilo, 1,6–dihidropirimidinilo, tienilo, furanilo, oxazolilo, triazinilo o tetrahidrofurano, en donde fenilo, oxazolilo, piridinilo, pirimidinilo, pirazinilo, pirazolilo, tienilo, furanilo, tiazolilo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados cada uno de cloro, ciano, nitro, trifluorometilo, metil–carbonilo–, metoxi–carbonilo, amino–sulfonilo–, hidroximetilo–, flúor, metilo o metoxi;

R_2 es uno, dos o tres sustituyentes seleccionados cada uno de hidrógeno, cloro, flúor, bromo, hidroxi, ciano, metilo, etilo, isopropilo, fluorometilo, difluorometilo, trifluorometilo, difluoroetilo, difluoroetenilo, etoxi, metoxi, isopropoxi, difluorometoxi, trifluorometoxi, difluoroetoxi, trifluoroetoxi, metiltio, isopropiltio, 1–hidroxi–etilo–, 2–metil–1,3–dioxolanilo, propenilo, ciclopropilo, ciclobutilo, ciclobutoxi, piridiniloxi, pirimidiniloxi, piraziniloxi, vinilo, metil–carbonil– o morfolinilo, en donde piridinilo y pirazinilo están cada uno opcionalmente sustituidos con un sustituyente de ciano;

R_4 es metilo, etilo, propilo, isopropilo, ter–butilo o ciclopropilo;

R_6 es hidrógeno, metilo, etilo, propilo, isopropilo, ter–butilo, dihidroxiisopropilo, difluoroisopropilo, trifluoroisopropilo, fluoro–ter–butilo, trifluoro–ter–butilo, ciano–metilo, 1–ciano–etilo, ciclopropilo, ciclobutilo o 1–ciclopropil–etilo, en donde cada instancia de ciclopropilo y ciclobutilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de flúor, metilo o trifluorometilo;

R_7 es metilo, etilo, propilo, isopropilo, ter–butilo o piperidinilo;

y todas las otras variables previamente definidas.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde X está seleccionado de hidrógeno, cloro, ciano, amino–carbonilo, metoxi–carbonilo–, carboxilo–, metil–amino–carbonilo, etil–amino–carbonilo, isopropil–amino–carbonilo, dimetil–amino–carbonilo, metil–sulfonilo o metil–carbonilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde X es ciano.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde Ar es heteroarilo o heterociclilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde Ar es heteroarilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde Ar es piridinilo, pirimidinilo o piridazinilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde Z es alquilo C_{1-8}, cicloalquilo C_{3-14}, cicloalquenilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo y heteroarilo está opcionalmente sustituido con un sustituyente seleccionado de ciano, halógeno, alquilo C_{1-8}, alcoxi C_{1-8}, amino o alquil C_{1-8}–amino.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde Z es alquilo C_{1-8}, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclohexenilo, ciclopropil–metilo, (ciclopropilo, metil)metilo–, fenilo, tiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo, pirazolilo, tetrahidro–2*H*–piranilo, 1,6–dihidropirimidinilo, tienilo, furanilo, oxazolilo, triazinilo o tetrahidrofurano, en donde fenilo, oxazolilo, piridinilo, pirimidinilo, pirazinilo, pirazolilo, tienilo, furanilo, tiazolilo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados cada uno de cloro, ciano, nitro, halo–alquilo C_{1-8}, alquil C_{1-8}–carbonilo–, alcoxi C_{1-8}–carbonilo, amino–sulfonilo, hidroxil–alquil C_{1-8}–, ciano, halógeno, alquilo C_{1-8} o alcoxi C_{1-8}.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde Z es metilo, etilo, 2–hidroxi–etilo–, propilo, isopropilo, ter–butilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclohexenilo, ciclopropil–metilo, (ciclopropilo, metil)metilo–, fenilo, tiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo, pirazolilo, tetrahidro–2*H*–piranilo, 1,6–dihidropirimidinilo, tienilo, furanilo, oxazolilo, triazinilo o tetrahidrofurano, en donde

fenilo, oxazolilo, piridinilo, pirimidinilo, pirazinilo, pirazolilo, tienilo, furanilo, tiazoilo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados cada uno de cloro, nitro, trifluorometilo, metil–carbonilo–, metoxi–carbonilo, amino–sulfonilo, hidroximetilo–, ciano, flúor, metilo o metoxi.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_2 es uno, dos o tres sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, cicloalquil C_{3-14}–alcoxi C_{1-8}, cicloalquil C_{3-14}–oxi, heteroarilo, heteroaril–alquilo C_{1-8}, heteroaril–alcoxi C_{1-8}, heteroariloxi, heterociclilo, heterociclil–alquilo C_{1-8}, heterociclil–alcoxi C_{1-8} o heterocicliloxi, en donde heteroariloxi está opcionalmente sustituido con un sustituyente de ciano.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_2 es uno, dos o tres sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–oxi, heteroariloxi o heterociclilo, en donde heteroariloxi está opcionalmente sustituido con un sustituyente de ciano.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_2 es uno, dos o tres sustituyentes seleccionados cada uno de hidrógeno, cloro, flúor, bromo, hidroxi, ciano, metilo, etilo, isopropilo, fluorometilo, difluorometilo, trifluorometilo, difluoroetilo, difluoroetenilo, etoxi, metoxi, isopropoxi, difluorometoxi, trifluorometoxi,

difluoroetoxi, trifluoroetoxi, metiltio, isopropiltio, 1–hidroxi–etilo–, 2–metil–1,3–dioxolanilo, propenilo, ciclopropilo, ciclobutilo, ciclobutoxi, piridiniloxi, pirimidiniloxi, piraziniloxi vinilo, metil–carbonil– o morfolinilo, en donde piridinilo y pirazinilo están cada uno opcionalmente sustituidos con un sustituyente de ciano.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_3 es hidrógeno o alquilo C_{1-8}, opcionalmente sustituido en el alquilo C_{1-8} con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi o ciano.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_3 es hidrógeno, metilo, etilo, propilo, isopropilo o ter–butilo, en donde metilo y etilo están cada uno opcionalmente sustituidos con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi o ciano.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_4 es alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_4 es alquilo C_{1-8} o cicloalquilo C_{3-14}.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_4 es alquilo C_{1-8} o ciclopropilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_4 es metilo, etilo, propilo, isopropilo, ter–butilo o ciclopropilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_5 es hidrógeno.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_6 es hidrógeno, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, ciano–alquilo C_{1-8}, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C_{3-14} está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_6 es hidrógeno, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, ciano–alquilo C_{1-8}, cicloalquilo C_{3-14} o cicloalquil C_{3-14}–alquilo C_{1-8}, en donde cada instancia de cicloalquilo C_{3-14} está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8} o halo–alquilo C_{1-8}.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_6 es hidrógeno, metilo, etilo, propilo, isopropilo, ter–butilo, dihidroxiisopropilo, difluoroisopropilo, trifluoroisopropilo, fluoro–ter–butilo, trifluoro–ter–butilo, ciano–metilo, 1–ciano–etilo, ciclopropilo, ciclobutilo, ciclobutil–metilo–, 1–(trifluorometil)etilo–, 1–(trifluorometil)isopropilo, 1–(trifluorometil)propilo, pirimidinilo, fenilo o 1–ciclopropil–etilo, en donde cada instancia de ciclopropilo y ciclobutilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de flúor, metilo o trifluorometilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_7 es alquilo C_{1-8} o heterociclilo.


Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_7 es alquilo C_{1-8} o piperidinilo.

30

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_7 es metilo, etilo, propilo, isopropilo, ter–butilo o piperidinilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I) y sus formas, en donde R_7 es piperidinilo.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (I), seleccionado de un compuesto de la fórmula (Ia):



(Ia)

o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o sus formas polimórficas, en donde

R_8 es hidrógeno, halógeno o alcoxi C_{1-8};

R_9 es hidrógeno, halógeno, hidroxi, ciano, nitro, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, alquil C_{1-8}–tio, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alcoxi C_{1-8}, arilo, aril–alcoxi C_{1-8}, heteroarilo, heteroaril–alcoxi C_{1-8}, heterociclilo o heterociclil–alcoxi C_{1-8}, en donde cada instancia de cicloalquilo C_{3-14}, arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de halógeno, ciano, alquilo C_{1-8}, alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8} o alquil C_{1-8}–amino–alquilo C_{1-8};

R_{10} es hidrógeno, halógeno, hidroxi, ciano, nitro, alquilo C_{1-8}, halo–alquilo C_{1-8}, alquenilo C_{2-8}, halo–alquenilo C_{2-8}, hidroxi–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi, alquil C_{1-8}–carboniloxi–alcoxi C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, amino–alcoxi C_{1-8}, alquil C_{1-8}–amino–alcoxi C_{1-8}, alcoxi C_{1-8}–alquil C_{1-8}–amino–alcoxi C_{1-8}, amino–alquil C_{1-8}–amino–alcoxi C_{1-8}, alquil C_{1-8}–amino–alquil C_{1-8}–amino–alcoxi C_{1-8}, alcoxi C_{1-8}–carbonil–amino, carboxil–amino, amino–carbonilo, amino–carbonil–amino, alquil C_{1-8}–amino–carbonil–amino, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, alquil C_{1-8}–sulfonil–amino, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, cicloalquil C_{3-14}–alcoxi C_{1-8}, cicloalquil C_{3-14}–oxi, arilo, aril–alquilo C_{1-8}, aril–alcoxi C_{1-8}, ariloxi, aril–carbonil–amino, heteroarilo, heteroaril–alquilo C_{1-8}, heteroaril–alcoxi C_{1-8}, heteroariloxi, heterociclilo, heterociclil–alquilo C_{1-8}, heterociclil–alcoxi C_{1-8}, heterocicliloxi o heterociclil–carboniloxi, en donde cada instancia de cicloalquilo C_{3-14}, arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de halógeno, ciano, alquilo C_{1-8}, alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8} o alquil C_{1-8}–amino–alquilo C_{1-8}; y

R_{11} es hidrógeno, halógeno, hidroxi, ciano, nitro, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi o alquil C_{1-8}–carboniloxi–alquilo C_{1-8};

y todas las otras variables previamente definidas.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (Ia) y sus formas, en donde

R_8 es hidrógeno o halógeno;

R_9 es hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio o cicloalquilo C_{3-14};

R_{10} es hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–oxi, heteroariloxi o heterociclilo, en donde heteroariloxi está opcionalmente sustituido con un sustituyente de ciano; y

R_{11} es hidrógeno o halógeno;

y todas las otras variables previamente definidas.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (Ia) y sus formas, en donde

R_9 es hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio o ciclopropilo; y

R_{10} es hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio, ciclopropilo, ciclobutilo, ciclobutoxi, piridiniloxi, pirimidiniloxi, piraziniloxi o morfolinilo, en donde piridinilo y pirazinilo están opcionalmente sustituidos con un sustituyente de ciano;

y todas las otras variables previamente definidas.

Las formas de realización de la presente invención incluyen un compuesto de la fórmula (Ia) y sus formas, en donde

R_8 es hidrógeno, fluoro o metoxi;

R_9 es hidrógeno, cloro, flúor, bromo, hidroxi, ciano, metilo, etilo, fluorometilo, difluorometilo, difluoroetilo, metoxi, difluorometoxi, trifluorometoxi, metiltio o ciclopropilo;


R_{10} es hidrógeno, bromo, cloro, flúor, hidroxi, ciano, metilo, etilo, isopropilo, fluorometilo, difluorometilo, difluoroetilo, difluoroetenilo, metoxi, etoxi, isopropoxi, difluorometoxi, trifluorometoxi, fluoroetoxi, difluoroetoxi,

trifluoroetoxi, metiltio, isopropiltio, metil–carbonilo, vinilo, propenilo, 1–hidroxi–etilo, 2–metil–1,3–dioxolanilo, propenilo, ciclopropilo, ciclobutilo, ciclobutoxi, piridiniloxi, pirimidiniloxi, piraziniloxi o morfolinilo, en donde piridinilo y pirazinilo están opcionalmente sustituidos con un sustituyente de ciano; y


R_{11} es hidrógeno, cloro, fluoro o metilo;

y todas las otras variables previamente definidas.


En una forma de realización de la presente invención, un compuesto de la fórmula (I) o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o formas polimórficas está seleccionado de:




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27



28




29




30


35




31




32




33




34




35




36




37




38




39




40




41




42




43




44




45




46




47




48




49




50




51




52




53




54




55




56




57




58




59




60




61




62




63




64




65




66




67




68




69



70




71




72


37




73




74




75




77




78




79




80




81




82




83




84




85




86




87




88




89




90




92



93




94




95


38




96




97




98




99




100




101




102




103




104




105




106




107




108




109




110




111




112




113




114




115




116




117




118




119




120




121




122




123




124




125




126




127




128




129




130




131




132




133




134



135




136




137


40




138




139




140




141




142




143




144




145




146




147




148




149




150




151




152




153




154




155



156




157




158


41




159




160




161




162




163




164




165




166




167




168




169




170




171




172




173




174




175




176



177




178




179


42




180




181




182




183




184




185




186




187




188




189




190




191




192




193




194




195




196




197




198




199




200




201




202




203




204




205




206




207




208




209




210




211




212




213




214




215




216




217




218




219




220




221




222




223




224




225




226




227




228




229




230




231




232




233




234




235




236




237




238




239




240




241




242




243




244




245




246




247




248




249




250




251




252




253




254




255




256




257




258




259




260




261




262




263




264




265




266




267




268




269




270




271




272




273




274




275




276




277




278




279




280




281




282




283




284




285




286




287




288




289




290




291




292




293




294




295




296




297




298




299




300




301




302




303




304




305




306




307




308




309




310




311




312




313




314




315




316




317




318




319




320




321




322




323




324




325




326




327




328




329




330




331




332




333




334




335



336




337




338


50




339




340




341




342




343




344




345




346




347




348




349




350




351




352




353




354




355




356




357




358




359




360




361




362




363




364




365




367




368




369




370




371




372




373




374




375




376




377




378



379




380




381


52




382




383




384




385




386




387




388




389




390




391




392




393




394




395




396



397




398




399


53




400




401




402




403




404




405




406




407




408




409




410




411




412




413




414




415




416




417



418




419




420


54




421




422




423




424




425




426




427




428




429




430




431




432




433




434




435




436




437




438



439




440




441


55




442




443




444




445




446




447




448




449




450




451




452




453




454




455




456




457




458




459



460




461




462


56




463




464




465




466




467




468




469




470




471




472




473




474




475




476




477




478




479




480




481




482




483




484




485




486




487




488




489




490




491




492




493




494




495




496




497




498



499




500




501


S8




502




503




504




505




506




507




508




509




510




511




512




513




514




515




516




517




518




519



520




521




522


59




523




524




525




526




527




528




529




530




531




532




533




534




535




536




537




538




539




540



541




542




543


60




544




545




546




547




548




549




550




551




552




553




554




555




556




557




558




559




560




561




562




563




564




565




566




567




568




569




570




571




572




573




574




575




576




577




578




579




580




581




582



583




584




585


62




586




587




588




589




590




591




592




593




594




595




596




597




598




599




600



601




602




603


63




604




605




606




607




608




609




610




611




612




613




614




615




616




617




618



619




620




621


64




622




623




624




625




626




627




628




629




630




631




632




633




634




635




636




637




638




639



640




641




642


65




643




644




645




646




647




648




649




650




651




652




653




654




655




656




657




658




659




660



661




662




663


66




664




665




666




667




668




669




670




671




672




673




674




675




676




677




678




679




680




681




682




683




684




685




686




687




688




689




690




691




692




693




694




695




696




697




698




699




700




701




702




703




704




705




706




707




708




709




710




711




712




713




714




715




716




717




718




719




720




721




722




723




724




725




726




727




728




729




730




731




732




733




734




735




736




737




738




739




740




741




742




743




744




745




746




747




748




749




750




751




752




753




754




755




756




757




758




760




761




762




763




764




765




766




767




768




769




770




771




772




773




774




775




776




777




778




780




781




782




783




784




785




786




787




788




789




790




791




793




794




795




796




797




798




799




800




801




802




803




804




805




806




807




808




809




810




811




812




813




814




815




816




817




818




819




820




821




822




823




824




825




826




827




828




829




830




831




832




833




834




835




836




837




838




839




840




841




842




843




844




845




846




847




848




849




850




851




852




853




854




855




856




857




858




859




860




861




862




863




864




865




866




867




868




869




870




871




872




873




874




875




876




877




878




879




880




881




882




883




884




885




886




887




888




889




890




891




892




893




894




895




896




897




898




899




900




901




902




903




904




905




906




907




908




909




910




911




912




913




914




915




916




917




918




919




920




921




922




923




924




925




926




927




928




929




930




931




932




933




934




935




936




937




938




939




940




941




942




943




944




945




946




947




948




949




950




951




952




953




954




955




956




957




958




959




960




961




962




963




964




965




966




967




968




969




970




971




972




973




974




975




976




977




978




979




980




981




982




983




984




985




986




987




988




989




990




991




992




993




994




995




996




997




998




999




1000




1001




1002




1003




1004




1005




1006




1007




1008




1009




1010




1011




1012




1013




1014




1015




1016




1017




1018




1019




1020




1021




1022




1023




1024




1025




1026




1027




1028




1029




1030




1031




1032




1033




1034




1035




1036




1037




1038




1039




1040




1041




1042




1043




1044




1045




1046




1047




1048




1055




1056




1057




1058




1059




1060




1061




1062




1063




1064




1065




1072




1073




1074




1075




1078




1079




1080




1081




1082




1083




1084




1085




1086




1087




1088




1092




1093




1094




1095




1096




1097




1098




1099




1100




1101




1102




1103




1104




1105




1106




1107




1108




1109




1110




1111




1112




1113




1114




1115




1116



1117



1118



1119

En otra forma de realización de la presente invención, un compuesto de la fórmula (I) o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o formas polimórficas está seleccionado de:

Comp	Nombre
1	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
2	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–ciclobutilpiridin–3–sulfonamida,

89

Comp	Nombre
3	6–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
4	5–[3–ciano–1–ciclobutil–6–(ciclobutiloxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida,
5	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
6	6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
7	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
8	6–(3–ciano–1–ciclobutil–5–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
9	N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida,
10	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
11	6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
12	6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
13	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
14	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
15	N–ter–butil–6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)piridin–3–sulfonamida,

90

Comp	Nombre
16	6–[3–ciano–1–ciclobutil–6–(propan–2–ilsulfanil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
17	6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
18	N–ter–butil–6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida,
19	6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
20	N–ter–butil–6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida,
21	6–[3–ciano–1–ciclopentil–5–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
22	1–ciclobutil–2–[5–(piperidin–1–ilsulfonil)piridin–2–il]–6–(propan–2–ilsulfanil)–1H–indol–3–carbonitrilo,
23	6–[3–ciano–1–ciclobutil–5–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
24	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
25	6–[3–ciano–1–ciclobutil–5–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
26	5–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida,
27	5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–2–sulfonamida,
28	5–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–2–sulfonamida,

91

Comp	Nombre
29	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
30	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
31	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
32	6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
33	6–[3–ciano–1–ciclopentil–5–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
34	6–[3–ciano–1–ciclopentil–5–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
35	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
36	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
37	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
38	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
39	5–[3–ciano–1–ciclopropil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida,
40	5–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida,
41	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

92

Comp	Nombre
42	6–[3–ciano–1–ciclopropil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
43	6–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
44	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
45	6–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
46	6–[3–ciano–5–fluoro–1–(tetrahidrofuran–3–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
47	6–[3–ciano–5–fluoro–1–(tetrahidrofuran–3–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
48	6–(3–ciano–1–ciclobutil–6–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
49	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
50	6–(6–cloro–3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
51	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
52	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
53	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida,
54	6–{3–ciano–6–metil–1–[(3R)–tetrahidrofuran–3–il]–1H–indol–2–il}–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

93

Comp	Nombre
55	6–{3–ciano–6–metil–1–[(3R)–tetrahidrofuran–3–il]–1H–indol–2–il}–N–(propan–2–il)piridin–3–sulfonamida,
56	6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
57	6–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
58	6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
59	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
60	6–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
61	6–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
62	6–[6–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
63	6–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
64	6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
65	6–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
66	6–(3–ciano–1–ciclopentil–7–fluoro–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
67	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–fluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

94

Comp	Nombre
68	6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
69	6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
70	6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
71	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
72	6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
73	6–[5–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
74	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
75	6–[3–ciano–6–etil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
77	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–fluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
78	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida,
79	6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
80	6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
81	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

95

Comp	Nombre
82	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
83	6–[3–ciano–6–ciclopropil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
84	6–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
85	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
86	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida,
87	6–(3–ciano–1–ciclopentil–7–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
88	6–(7–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
89	6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
90	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–3–sulfonamida,
92	6–(3–ciano–1–ciclohexil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
93	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
94	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
95	6–(3–ciano–6–ciclopropil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

96

Comp	Nombre
96	6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
97	2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
98	2–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
99	6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
100	6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
101	6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
102	6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
103	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
104	6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
105	6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
106	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida,
107	6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
108	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

97

Comp	Nombre
109	6–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
110	6–[6–cloro–3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
111	6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
112	6–(5–cloro–3–ciano–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
113	6–(3–ciano–5–fluoro–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
114	2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
115	2–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
116	2–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
117	2–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
118	6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
119	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
120	2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
121	2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

98

Comp	Nombre
122	2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
123	2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
124	2–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
125	2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
126	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
127	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
128	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)pirimidin–5–sulfonamida,
129	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
130	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
131	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
132	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
133	2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
134	2–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

99

Comp	Nombre
135	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
136	2–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
137	2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
138	2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
139	2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
140	2–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
141	2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
142	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
143	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
144	6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
145	2–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
146	2–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
147	6–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

100

Comp	Nombre
148	2–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
149	2–(6–cloro–3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
150	2–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
151	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
152	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
153	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
154	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
155	6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
156	2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
157	2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
158	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
159	2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
160	2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

101

Comp	Nombre
161	6–[3–ciano–1–ciclobutil–6–(metilsulfanil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
162	2–[3–ciano–1–ciclobutil–6–(metilsulfanil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
163	2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
164	2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
165	2–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
166	2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
167	2–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
168	2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
169	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
170	2–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
171	2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
172	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
173	2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

102

Comp	Nombre
174	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
175	2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
176	2–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
177	2–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
178	2–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
179	2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
180	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
181	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
182	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
183	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
184	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
185	2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
186	2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

103

Comp	Nombre
187	2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
188	2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
189	2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
190	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
191	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
192	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
193	2–(3–ciano–1–ciclohexil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
194	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
195	6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
196	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
197	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
198	2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
199	6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

104

Comp	Nombre
200	2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
201	6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
202	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
203	2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
204	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
205	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
206	2–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
207	2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
208	2–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
209	2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
210	6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
211	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
212	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

105

Comp	Nombre
213	6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
214	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
215	6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
216	6–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
217	6–(3–ciano–6–fluoro–1–propil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
218	6–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
219	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
220	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
221	2–[5–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
222	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
223	6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
224	6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
225	6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–6–metoxi–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

106

Comp	Nombre
226	6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
227	6–[3–ciano–6–(difluorometoxi)–1–(2–fluorofenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
228	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
229	6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
230	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
231	2–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
232	2–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
233	2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
234	6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
235	2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
236	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
237	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
238	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

107

Comp	Nombre
239	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–dihidroxipropan–2–il)piridin–3–sulfonamida,
240	2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
241	2–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
242	2–[3–ciano–5–(difluorometoxi)–1–etil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
243	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,
244	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,
245	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,
246	6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,
247	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,
248	6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
249	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
250	6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
251	2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

108

Comp	Nombre
252	6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
253	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida,
254	2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
255	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
256	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
257	2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
258	6–(3–ciano–1–ciclobutil–5–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
259	6–[3–ciano–5–fluoro–1–(piridin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
260	2–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
261	6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
262	6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
263	6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
264	2–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

109

Comp	Nombre
265	2–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
266	6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
267	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
268	N–{5–[3–ciano–1–ciclobutil–6–(pirimidin–2–iloxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,
269	N–{5–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,
270	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida,
271	N–{6–[3–ciano–1–ciclobutil–6–(pirimidin–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–1–sulfonamida,
272	N–(6–{3–ciano–6–[(3–cianopiridin–2–il)oxi]–1–ciclobutil–1H–indol–2–il}piridin–3–il)propan–1–sulfonamida,
273	N–(6–{3–ciano–6–[(3–cianopirazin–2–il)oxi]–1–ciclobutil–1H–indol–2–il}piridin–3–il)propan–1–sulfonamida,
274	N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}ciclopropansulfonamida,
275	N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}metansulfonamida,
276	N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}etansulfonamida,
277	N–[6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)piridazin–3–il]etansulfonamida,

110

Comp	Nombre
278	N–[6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)piridazin–3–il]–2–metilpropan–2–sulfonamida,
279	*N*–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1*H*–indol–2–il]piridin–3–il}etansulfonamida,
280	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida,
281	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida,
282	N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}–N–(propan–2–il)etansulfonamida,
283	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida,
284	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–3–il}etansulfonamida,
285	N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida,
286	N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida,
287	N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]metansulfonamida,
288	N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]etansulfonamida,
289	N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]propan–2–sulfonamida,
290	N–{5–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–2–il}etansulfonamida,

Comp	Nombre
291	N–{5–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–2–il}propan–2–sulfonamida,
292	N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(2,2–difluoroetil)ciclopropansulfonamida,
293	N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(2–hidroxietil)ciclopropansulfonamida,
294	N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(cianometil)ciclopropansulfonamida,
295	N–{5–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,
296	N–[6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida,
297	N–[6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida,
298	N–[6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida,
299	N–{5–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,
300	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
301	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–cianoetil)piridin–3–sulfonamida,
302	2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
303	2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

112

Comp	Nombre
304	6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
305	6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
306	2–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
307	6–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
308	6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
309	6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
310	6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
311	6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
312	6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
313	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
314	2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
315	2–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
316	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

113

Comp	Nombre
317	6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
318	6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
319	6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
320	6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
321	2–[3–ciano–1–ciclobutil–6–(morfolin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
322	6–[3–ciano–1–ciclobutil–6–(morfolin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
323	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
324	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
325	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
326	2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
327	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
328	6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
329	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

114

Comp	Nombre
330	2–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
331	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
332	2–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
333	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
334	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
335	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
336	6–[3–ciano–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
337	2–[3–ciano–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
338	6–(3–ciano–1–ciclobutil–6–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
339	6–(3–ciano–1–ciclobutil–5–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
340	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
341	6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
342	6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

115

Comp	Nombre
343	6–(3–ciano–6–ciclobutil–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
344	2–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
345	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
346	6–(3,5–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
347	6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
348	6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
349	6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
350	N–[(1S)–1–ciclopropiletil]–6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]piridin–3–sulfonamida,
351	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
352	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
353	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
354	6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
355	6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

116

Comp	Nombre
356	6–[3–ciano–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
357	2–[3–ciano–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
358	6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
359	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
360	6–(6–cloro–3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
361	2–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
362	6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
363	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
364	6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
365	6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
367	N–[(1S)–1–ciclopropiletil]–2–(3,5–diciano–1–ciclopentil–1H–indol–2–il)pirimidin–5–sulfonamida,
368	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
369	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

117

Comp	Nombre
370	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
371	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
372	6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
373	6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
374	6–(3–ciano–1–ciclopentil–5–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
375	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
376	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
377	2–[3–ciano–1–ciclobutil–5–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
378	6–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
379	2–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
380	2–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
381	6–(3–ciano–1–ciclopentil–5–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
382	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

118

Comp	Nombre
383	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
384	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
385	2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
386	6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
387	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
388	2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
389	2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
390	2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
391	2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
392	2–(3,5–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
393	2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
394	6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
395	6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

119

Comp	Nombre
396	6–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
397	6–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
398	2–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
399	2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
400	2–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
401	2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
402	2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
403	2–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
404	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
405	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
406	2–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
407	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
408	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

120

Comp	Nombre
409	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
410	6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
411	2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
412	6–[3–ciano–1–(ciclohex–2–en–1–il)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
413	6–[3–ciano–1–(ciclohex–2–en–1–il)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
414	2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
415	2–[6–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
416	2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
417	2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
418	2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
419	2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
420	2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
421	6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

121

Comp	Nombre
422	6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
423	6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
424	6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
425	6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
426	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
427	6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
428	6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
429	6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
430	6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
431	6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
432	6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
433	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
434	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

122

Comp	Nombre
435	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
436	6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
437	6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
438	6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
439	6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
440	6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
441	6–(5–cloro–3–ciano–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
442	6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
443	6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
444	6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
445	6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
446	6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
447	2–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

123

Comp	Nombre
448	2–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
449	2–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
450	2–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
451	2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
452	2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
453	6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
454	2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
455	2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
456	6–[3–ciano–1,6–di(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
457	6–[3–ciano–1–ciclopentil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
458	6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
459	6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
460	6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

124

Comp	Nombre
461	6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
462	6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
463	2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
464	2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
465	6–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
466	2–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
467	6–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
468	6–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
469	2–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
470	6–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
471	2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
472	2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
473	2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

125

Comp	Nombre
474	2–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
475	2–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
476	6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
477	2–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
478	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
479	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
480	6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
481	6–(3–ciano–1–ciclobutil–6–etil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
482	6–(3–ciano–1–ciclopentil–6–fluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
483	6–(3–ciano–1–ciclopentil–6–fluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
484	6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
485	6–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
486	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

126

Comp	Nombre
487	6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
488	6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
489	6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
490	6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
491	6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
492	6–(3–ciano–1–ciclobutil–6–fluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
493	6–(3–ciano–1–ciclobutil–6–fluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
494	2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
495	2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
496	2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
497	2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
498	2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
499	2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

Comp	Nombre
500	6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
501	6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
502	6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
503	6–[3–ciano–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
504	6–[3–ciano–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
505	6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
506	6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
507	2–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
508	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
509	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
510	6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
511	6–(1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
512	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

128

Comp	Nombre
513	6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
514	6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
515	6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
516	2–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
517	2–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
518	6–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
519	6–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
520	2–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
521	6–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
522	6–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
523	2–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
524	2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
525	6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

129

Comp	Nombre
526	2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,
527	2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
528	2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
529	2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
530	2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
531	2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
532	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
533	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
534	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
535	6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
536	2–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
537	6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
538	6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

130

Comp	Nombre
539	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
540	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
541	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
542	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
543	N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida,
544	2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
545	2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
546	2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
547	2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
548	2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
549	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
550	6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
551	2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

131

Comp	Nombre
552	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida,
553	6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
554	6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
555	6–(3–ciano–1–ciclobutil–4,6–difluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
556	6–(3–ciano–1–ciclobutil–4,6–difluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
557	2–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
558	6–(3–ciano–1–ciclopentil–4,6–difluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
559	6–(3–ciano–1–ciclopentil–4,6–difluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
560	6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
561	2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
562	2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
563	2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
564	6–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

132

Comp	Nombre
565	2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
566	2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
567	2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
568	1–ciclobutil–6–(difluorometoxi)–2–(5–sulfamoilpiridin–2–il)–1H–indol–3–carboxamida,
569	2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
570	2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
571	6–(3–ciano–1–ciclopentil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
572	2–(3–ciano–1–ciclopentil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
573	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
574	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
575	6–(3–ciano–1–ciclopentil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
576	6–(3–ciano–1–ciclopentil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
577	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

133

Comp	Nombre
578	6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
579	6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
580	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
581	1–ciclobutil–6–(difluorometoxi)–2–{5–[(1,3–difluoropropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
582	1–ciclobutil–6–ciclopropil–2–{5–[(1,3–difluoropropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
583	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
584	6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
585	6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
586	2–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
587	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida,
588	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida,
589	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
590	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

134

Comp	Nombre
591	2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
592	2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
593	6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
594	6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
595	6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
596	6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
597	2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
598	2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
599	2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
600	2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
601	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
602	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
603	2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

135

Comp	Nombre
604	6–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
605	2–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
606	6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
607	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
608	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
609	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
610	2–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
611	2–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
612	6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
613	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
614	6–(3–ciano–1–ciclopentil–4–fluoro–5–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
615	6–(3–ciano–1–ciclopentil–4–fluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
616	6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

136

Comp	Nombre
617	6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,
618	6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
619	2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,
620	2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,
621	2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
622	2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
623	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
624	N–ter–butil–6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]piridin–3–sulfonamida,
625	6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
626	6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
627	6–(3–ciano–1–ciclobutil–4–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
628	6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
629	6–(3–ciano–1–ciclobutil–4–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

137

Comp	Nombre
630	6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
631	6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
632	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
633	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
634	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
635	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
636	6–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
637	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
638	2–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
639	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
640	6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
641	6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
642	6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

138

Comp	Nombre
643	N–ter–butil–6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida,
644	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
645	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1–metilciclopropil)piridin–3–sulfonamida,
646	6–[1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
647	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–etil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
648	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
649	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
650	6–[3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
651	N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida,
652	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–ciclopropilpiridin–3–sulfonamida,
653	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
654	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
655	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

139

Comp	Nombre
656	2–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
657	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
658	6–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida,
659	2–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,
660	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
661	6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
662	6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
663	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
664	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
665	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
666	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
667	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
668	2–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

140

Comp	Nombre
669	6–(3–ciano–1–ciclopentil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
670	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
671	6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
672	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
673	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
674	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–hidroxi–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
675	6–(5–bromo–3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
676	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
677	6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
678	6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
679	2–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
680	6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
681	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

141

Comp	Nombre
682	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
683	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxamida,
684	6–(5–bromo–3–ciano–1–ciclobutil–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
685	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–(metilsulfanil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
686	6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
687	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
688	6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
689	6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
690	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
691	6–(3–ciano–1–ciclopentil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
692	6–(5–bromo–3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
693	6–(3–ciano–1–ciclopentil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
694	6–(3–ciano–1–ciclopentil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

142

Comp	Nombre
695	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
696	6–[3–ciano–1–ciclobutil–5–(2,2–difluoroetil)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida,
697	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
698	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
699	1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
700	1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
701	1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
702	6–[3–ciano–1–ciclobutil–5–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
703	1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
704	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
705	6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
706	1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
707	1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida,

143

Comp	Nombre
708	6–[5–cloro–3–ciano–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
709	N–{[6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–il]sulfonil}–N–[(2R)–1,1,1–trifluoropropan–2–il]acetamida,
710	N–ter–butil–6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida,
711	6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
712	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(difluorometil)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
713	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
714	1–ciclohexil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
715	1–ciclohexil–5–fluoro–6–metil–2–(5–sulfamoilpiridin–2–il)–1H–indol–3–carboxamida,
716	1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
717	1–ciclohexil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxilato de metilo,
718	1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
719	N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)piridin–3–sulfonamida,

144

Comp	Nombre
720	N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida,
721	N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(difluorometil)piridin–3–sulfonamida,
722	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida,
723	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,
724	6–{3–ciano–5–fluoro–1–[5–(trifluorometil)piridin–2–il]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
725	6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
726	6–(3–ciano–1–ciclobutil–6–etoxi–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
727	6–[1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
728	6–(1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
729	1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
730	1–ciclopentil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
731	1–ciclobutil–6–ciclopropil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

145

Comp	Nombre
732	1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
733	5–cloro–1–ciclobutil–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida,
734	5–cloro–1–ciclobutil–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
735	5–cloro–1–ciclobutil–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
736	6–cloro–1–ciclobutil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
737	1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
738	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida,
739	6–[3–ciano–5–fluoro–6–metil–1–(3–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
740	6–{3–ciano–5–fluoro–6–metil–1–[5–(trifluorometil)piridin–2–il]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
741	ácido 1–ciclohexil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico,
742	6–[3–ciano–5–fluoro–1–(5–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
743	6–[3–ciano–1–(5–cianopiridin–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
744	6–[3–ciano–5–fluoro–6–metil–1–(5–nitropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

146

Comp	Nombre
745	5–cloro–1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida,
746	1–ciclohexil–6–(difluorometoxi)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida,
747	1–ciclohexil–6–(difluorometoxi)–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida,
748	5–fluoro–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
749	6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
750	6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
751	6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
752	N–ter–butil–6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]piridin–3–sulfonamida,
753	2–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,
754	1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxilato de metilo,
755	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxilato de metilo,
756	1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxilato de metilo,

147

Comp	Nombre
757	6–(3–ciano–1–ciclobutil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
758	ácido 1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico,
760	6–(1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
761	1–ciclopentil–5–fluoro–N,6–dimetil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
762	1–ciclopentil–N–etil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
763	1–ciclopentil–5–fluoro–6–metil–N–(propan–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
764	N–ter–butil–6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida,
765	ácido 1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxílico,
766	ácido 2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxílico,
767	5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
768	5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
769	5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

148

Comp	Nombre
770	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxilato de metilo,
771	1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropa–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxilato de metilo,
772	6–[3–ciano–1–ciclobutil–5–fluoro–6–(metilsulfanil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
773	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–4–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
774	1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxilato de metilo,
775	ácido 1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxílico,
776	ácido 2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxílico,
777	6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
778	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
780	6–cloro–1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida,
781	1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–6–(trifluorometoxi)–1H–indol–3–carboxamida,
782	1–ciclopentil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–6–(trifluorometoxi)–1H–indol–3–carboxamida,
783	1–ciclopentil–5–fluoro–N,N,6–trimetil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

149

Comp	Nombre
784	6–[3–ciano–6–(difluorometoxi)–4–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
785	6–[5–cloro–3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
786	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–propil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
787	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
788	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–propil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
789	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
790	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluorobutan–2–il)piridin–3–sulfonamida,
791	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–fenilpiridin–3–sulfonamida,
793	ácido 1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico,
794	ácido 2–[5–(ter–butilsulfamoil)pirimidin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxílico,
795	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida,
796	6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
797	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–4–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

150

Comp	Nombre
798	1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–[5–(fenilsulfamoil)piridin–2–il]–1H–indol–3–carboxamida,
799	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida,
800	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxamida,
801	1–ciclobutil–5–fluoro–N,6–dimetil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
802	2–[5–(ter–butilsulfamoil)pirimidin–2–il]–1–ciclobutil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida,
803	6–[5–cloro–3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
804	6–[5–cloro–3–ciano–1–(5–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
805	N–ter–butil–6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)piridin–3–sulfonamida,
806	1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
807	6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
808	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
809	1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

151

Comp	Nombre
810	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–4–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
811	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–7–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
812	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida,
813	6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
814	6–[3–ciano–5–fluoro–1–(3–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
815	6–[3–ciano–5–fluoro–1–(6–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
816	6–[3–ciano–5–fluoro–1–(4–metoxipiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
817	6–[3–ciano–5–fluoro–6–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
818	6–[3–ciano–6–ciclopropil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
819	6–[3–ciano–6–ciclopropil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
820	6–[3–ciano–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
821	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida,
822	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

152

Comp	Nombre
823	N–ter–butil–6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,
824	N–ter–butil–6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,
825	1–ciclobutil–6–(difluorometoxi)–4–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
826	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida,
827	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
828	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–hidroxi–6–metil–1H–indol–3–carboxamida,
829	1–ciclopentil–6–ciclopropil–5–fluoro–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
830	1–ciclopentil–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
831	6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
832	N–ter–butil–6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida,
833	1–ciclobutil–5–hidroxi–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
834	1–ciclopentil–5–metoxi–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

153

Comp	Nombre
835	ácido 1–ciclohexil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico,
836	diamida N–[6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–il]–N'–[(2S)–1,1,1–trifluoropropan–2–il]sulfúrica,
837	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
838	1–ciclopentil–6–ciclopropil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
839	6–(difluorometoxi)–4–fluoro–1–(propan–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
840	1–(ciclopropilmetil)–6–(difluorometoxi)–4–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
841	1–ciclopentil–5–hidroxi–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
842	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
843	6–[3–ciano–5–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
844	6–[3–ciano–1–(3–fluoropiridin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
845	6–[3–ciano–5–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
846	5–metil–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

154

Comp	Nombre
847	6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
848	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
849	6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
850	1–ciclopentil–6–ciclopropil–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
851	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
852	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
853	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
854	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
855	N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,
856	6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
857	1–ciclohexil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
858	6–(3–ciano–1–ciclobutil–6–etil–4–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

155

Comp	Nombre
859	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
860	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida,
861	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1–metilciclopropil)–N–(pirimidin–2–il)piridin–3–sulfonamida,
862	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
863	1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
864	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
865	6–[3–ciano–5–fluoro–6–metil–1–(5–metilpirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
866	6–[3–ciano–5–fluoro–1–(4–metoxipirimidin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
867	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
868	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
869	N–ter–butil–6–[6–etil–5–fluoro–3–(metilsulfonil)–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,
870	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
871	1–ciclopentil–6–etil–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

156

Comp	Nombre
872	1–ciclopentil–6–etil–5–fluoro–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
873	6–[3–ciano–5–fluoro–6–metil–1–(4–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
874	5–fluoro–6–metil–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
875	5–fluoro–6–metil–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
876	5–fluoro–1–(5–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
877	5–fluoro–1–(6–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
878	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
879	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
880	6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
881	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
882	N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,
883	2–[5–(ter–butilsulfamoil)piridin–2–il]–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–3–carboxamida,

157

Comp	Nombre
884	N–ter–butil–6–(3–ciano–6–etil–5–fluoro–1–fenil–1H–indol–2–il)piridin–3–sulfonamida,
885	6–[3–ciano–5–fluoro–6–metil–1–(5–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
886	6–[3–ciano–5–fluoro–6–metil–1–(4–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
887	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
888	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
889	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
890	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
891	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
892	6–[3–ciano–5–fluoro–6–metil–1–(piridazin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
893	6–[3–ciano–5–fluoro–6–metil–1–(piridin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
894	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
895	6–[6–bromo–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
896	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

158

Comp	Nombre
897	6–[3–ciano–1–(pirazin–2–il)–5–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
898	6–[3–ciano–1–(pirazin–2–il)–5–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
899	N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(pirazin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,
900	N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(3–fluoropiridin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,
901	6–[3–ciano–6–fluoro–5–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
902	5–fluoro–1–(3–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
903	6–[5–fluoro–6–metil–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
904	5–fluoro–6–metil–1–(5–metilpirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
905	5–fluoro–6–metil–1–(4–metilpirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
906	5–fluoro–1–(4–metoxipirimidin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
907	6–[6–acetil–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
908	6–[3–ciano–6–etenil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
909	6–etil–5–fluoro–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

159

Comp	Nombre
910	6–(3–ciano–1–ciclopropil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
911	6–[3–ciano–5–fluoro–6–(1–hidroxietil)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
912	5–fluoro–6–metil–1–(piridazin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
913	5–fluoro–6–metil–1–(piridin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
914	6–[1–(5–cloropirimidin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
915	6–[3–ciano–5–fluoro–6–metil–1–(6–metilpirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
916	5–metil–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
917	6–[3–ciano–6–fluoro–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
918	6–fluoro–5–metil–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
919	6–[3–ciano–6–fluoro–5–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
920	6–[3–ciano–1–(4–fluorofenil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
921	6–(3–ciano–5–metil–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
922	6–[3–ciano–1–(pirimidin–2–il)–5–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

160

Comp	Nombre
923	6–[3–ciano–5–fluoro–6–metil–1–(6–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
924	6–[3–ciano–5–fluoro–1–(5–fluoropirimidin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
925	6–[3–ciano–5–fluoro–6–metil–1–(5–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
926	6–[3–ciano–5–fluoro–1–(4–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
927	6–[3–ciano–5–fluoro–6–(2–metil–1,3–dioxolan–2–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
928	ácido 1–ciclohexil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxílico,
929	6–[3–ciano–6–etil–5–fluoro–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
930	6–[3–ciano–6–etil–5–fluoro–1–(6–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
931	6–[3–ciano–6–etil–5–fluoro–1–(5–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
932	6–[3–ciano–6–etil–5–fluoro–1–(4–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
933	6–[3–ciano–5–fluoro–6–metil–1–(piridin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
934	6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

161

Comp	Nombre
935	6–[3–ciano–6–etil–5–fluoro–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
936	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
937	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(2–metilpropil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
938	6–[6–bromo–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–ter–butilpiridin–3–sulfonamida,
939	N–ter–butil–6–[3,6–diacetil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,
940	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(2–hidroxietil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
941	6–[3–ciano–1–(1,6–dihidropirimidin–2–il)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
942	6–[1–(5–cloropirimidin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
943	6–[3–ciano–6–etil–5–fluoro–1–(2–metilpirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
944	6–[5–fluoro–1–(2–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
945	6–[3–ciano–5–fluoro–1–(5–fluoropiridin–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
946	6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
947	6–[3–cloro–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

162

Comp	Nombre
948	6–[3–ciano–1–(5–fluoropirimidin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
949	6–[3–ciano–6–fluoro–1–(5–fluoropirimidin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
950	6–[3–ciano–1–(pirimidin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
951	6–[3–ciano–1–(pirazin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
952	6–[3–ciano–1–(piridin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
953	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(ciclobutilmetil)piridin–3–sulfonamida,
954	6–[3–ciano–6–etil–5–fluoro–1–(piridin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
955	6–[3–ciano–6–etil–5–fluoro–1–(4–metoxipiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
956	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,
957	6–[5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
958	6–[5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
959	6–[5–fluoro–6–metil–1–(1,3–tiazol–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
960	6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

163

Comp	Nombre
961	6–[3–ciano–5–fluoro–1–(5–fluoro–6–metilpiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
962	6–[1–(6–cloropiridin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
963	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
964	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
965	6–[1–(3–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
966	6–[1–(5–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
967	6–[3–ciano–5–fluoro–6–(prop–2–en–1–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
968	6–[3–cloro–5–fluoro–6–(prop–2–en–1–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
969	6–[5–fluoro–6–(prop–2–en–1–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
970	6–[3–ciano–5–fluoro–6–(2–hidroxietil)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
971	6–[1–(3–cloropiridin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
972	6–[3–cloro–5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
973	6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

164

Comp	Nombre
974	6–[3–ciano–6–etil–5–fluoro–1–(piridin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
975	6–[3–ciano–6–etil–5–fluoro–1–(piridazin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
976	6–[3–ciano–6–etil–5–fluoro–1–(5–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
977	6–[3–ciano–5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
978	6–etil–5–fluoro–1–(pirimidin–2–il)–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,
979	6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
980	6–etil–5–fluoro–1–(4–metilpiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
981	6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
982	6–etil–5–fluoro–1–(2–metilpirimidin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
983	6–[1–(5–cloropiridin–3–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
984	6–{3–ciano–5–fluoro–1–[5–(hidroximetil)–1,3–tiazol–2–il]–6–metil–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

165

Comp	Nombre
985	2–[3–ciano–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–1–il]–1,3–tiazol–5–carboxilato de metilo,
986	2–[3–ciano–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–1–il]–1,3–tiazol–4–carboxilato de metilo,
987	6–[5–fluoro–6–metil–1–(tiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
988	6–[5–fluoro–1–(furan–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
989	6–[5–fluoro–6–metil–1–(tiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
990	6–[3–ciano–5–fluoro–6–metil–1–(tiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
991	6–[3–ciano–5–fluoro–1–(furan–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
992	6–[3–ciano–5–fluoro–6–metil–1–(tiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
993	6–[1–(4–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
994	6–etil–5–fluoro–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida
995	6–etil–5–fluoro–1–(6–fluoropiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
996	5–cloro–1–ciclobutil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

Comp	Nombre
997	1–ciclobutil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
998	ácido 2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxílico,
999	2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,
1000	6–[3–ciano–5–fluoro–6–metil–1–(3–metiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1001	6–[3–ciano–1–(4,6–difluoropiridin–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1002	6–[3–ciano–6–etil–5–fluoro–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1003	6–[1–(4–clorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1004	6–[3–ciano–6–etil–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1005	6–[3–ciano–6–etil–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1006	6–{3–ciano–6–etil–5–fluoro–1–[4–(trifluorometil)fenil]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1007	6–[3–ciano–1–(4–cianofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1008	6–[3–ciano–6–etil–5–fluoro–1–(3–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1009	6–[3–ciano–6–etil–5–fluoro–1–(3–metilfenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

Comp	Nombre
1010	6–[3–ciano–6–etil–5–fluoro–1–(3–metoxifenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1011	6–{3–ciano–6–etil–5–fluoro–1–[3–(trifluorometil)fenil]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1012	6–[3–ciano–1–(3–cianofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1013	6–[3–ciano–5–fluoro–1–(2–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1014	6–[3–ciano–5–fluoro–1–(3–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1015	6–[3–ciano–5–fluoro–1–(6–fluoropiridin–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1016	6–[3–ciano–5–fluoro–6–metil–1–(1–metil–1H–pirazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1017	6–[3–ciano–5–fluoro–6–metil–1–(5–metil–1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1018	6–[1–(3–clorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1019	6–etil–5–fluoro–1–(4–fluorofenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1020	1–(4–clorofenil)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1021	6–etil–5–fluoro–1–(4–metilfenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1022	6–etil–5–fluoro–1–[4–(trifluorometil)fenil]–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

Comp	Nombre
1023	6–etil–5–fluoro–1–(3–fluorofenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1024	6–etil–5–fluoro–1–(3–metilfenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1025	6–etil–5–fluoro–1–(3–metoxifenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1026	6–etil–5–fluoro–1–[3–(trifluorometil)fenil]–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1027	1–(3–clorofenil)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1028	ácido 2–{5–[(ter–butilsulfonil)amino]pirimidin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxílico,
1029	ácido 2–{2–[(ter–butilsulfonil)amino]pirimidin–5–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxílico,
1030	6–[3–ciano–5–fluoro–6–metil–1–(3–metil–1H–pirazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1031	6–[3–ciano–5–fluoro–6–metil–1–(5–metiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1032	6–[1–(5–clorotiofen–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1033	6–[3–ciano–1–(5–cianotiofen–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1034	6–[3–ciano–5–fluoro–6–metil–1–(5–sulfamoiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1035	6–[1–(5–acetiltiofen–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

Comp	Nombre
1036	2–{2–[(ter–butilsulfonil)amino]pirimidin–5–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,
1037	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,
1038	6–[3–ciano–5–fluoro–6–metil–1–(4–metil–1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1039	6–etil–5–fluoro–1–(5–metilpiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1040	6–etil–5–fluoro–1–(piridin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1041	6–etil–5–fluoro–1–(pirimidin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1042	1–(3–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1043	1–(5–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1044	1–(5–cloropiridin–3–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1045	6–etil–5–fluoro–1–(piridin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1046	6–etil–5–fluoro–1–(piridazin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1047	6–etil–5–fluoro–1–(5–metilpirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
1048	1–(4–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

Comp	Nombre
1055	6–[1–(2–acetiltiofen–3–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1056	6–[3–ciano–5–fluoro–6–metil–1–(4–metiltiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1057	6–[1–(2–clorotiofen–3–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1058	6–[3–ciano–5–fluoro–6–metil–1–(5–metiltiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1059	6–[5–fluoro–6–metil–1–(1,3–oxazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1060	6–[1–(5–cianofuran–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1061	6–[3–ciano–1–(3,4–difluorofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1062	6–[1–(3–cloro–4–fluorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1063	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,
1064	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,
1065	N–{5–[3–ciano–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,
1072	6–[3–ciano–1–(3–cianofuran–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1073	6–[3–ciano–5–fluoro–6–metil–1–(1,3–oxazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

Comp	Nombre
1074	6–[3–ciano–1–(4–ciano–1,3–oxazol–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1075	6–[3–ciano–6–etil–5–fluoro–1–(2–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1078	6–{3–ciano–6–[(1,1–dideuterio)etil]–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1079	6–{3–ciano–6–[(1,1–dideuterio)etil]–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,
1080	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,
1081	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,
1082	N–(5–{3–ciano–1–[(1S)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–2–il}piridin–2–il)–2–metilpropan–2–sulfonamida,
1083	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxamida,
1084	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,
1085	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,
1086	ácido 2–{6–[(ter–butilsulfonil)amino]–4–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,
1087	2–{6–[(ter–butilsulfonil)amino]–4–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,

Comp	Nombre
1088	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida,
1092	N–[6–(3–ciano–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–2–il)piridin–3–il]–2–metilpropan–2–sulfonamida,
1093	ácido 2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–3–carboxílico,
1094	ácido 2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,
1095	2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–3–carboxamida,
1096	2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,
1097	2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida,
1098	6–[3–ciano–6–ciclopropil–4–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
1099	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–5–fluoro–6–(fluorometoxi)–1H–indol–3–carboxilato de metilo,
1100	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–5–fluoro–1–fenil–1H–indol–3–carboxamida,
1101	N–[5–(3–ciano–6–ciclopropil–5–fluoro–1–fenil–1H–indol–2–il)piridin–2–il]–2–metilpropan–2–sulfonamida,
1102	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–5–fluoro–6–(fluorometoxi)–1H–indol–3–carboxamida,
1103	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxílico,

Comp	Nombre
1104	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxamida,
1105	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–4–fluoro–1–(4–fluorofenil)–1H–indol–3–carboxamida,
1106	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–etil–4–fluoro–1–(4–fluorofenil)–1H–indol–3–carboxamida,
1107	6–[3–ciano–5–fluoro–6–(1,1,1–trideuterio)metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,
1108	N–ter–butil–6–(3–ciano–5–fluoro–6–metil–1–fenil–1H–indol–2–il)piridin–3–sulfonamida,
1109	2–[5–(ter–butilsulfamoil)piridin–2–il]–6–etil–5–fluoro–1–fenil–1H–indol–3–carboxamida,
1110	2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclobutil–6–etil–4–fluoro–1H–indol–3–carboxamida,
1111	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–etil–4–fluoro–1–fenil–1H–indol–3–carboxamida,
1112	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2–deuterio)propan–2–il]piridin–3–sulfonamida,
1113	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,
1114	6–[3–ciano–1–ciclobutil–5–fluoro–6–(1,1,1–trideuterio)metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,
1115	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclohexil–5–fluoro–6–metil–1H–indol–3–carboxamida,

Comp	Nombre
1116	2–[5–(ter–butilsulfamoil)piridin–2–il]–5–fluoro–6–metil–1–fenil–1H–indol–3–carboxamida,
1117	N–ter–butil–6–(3–ciano–6–ciclopropil–5–fluoro–1–fenil–1H–indol–2–il)piridin–3–sulfonamida,
1118	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclobutil–6–etil–4–fluoro–1H–indol–3–carboxamida o
1119	6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–6–(1,1,1–trideuterio)metil–1H–indol–2–il]–N–[(2–deuterio)propan–2–il]piridin–3–sulfonamida.

En otra forma de realización de la presente invención, un compuesto de la fórmula (I) o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o formas polimórficas está seleccionado de:

Comp	Nombre
7	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,
31	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
35	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
44	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
51	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,
107	6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

Comp	Nombre
108	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
190	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,
277	N–[6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)piridazin–3–il]etansulfonamida,
300	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
371	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,
387	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
407	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,
408	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
409	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
421	6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
512	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
532	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
541	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

Comp	Nombre
549	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
601	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
634	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
640	6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
650	6–[3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
657	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
682	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
683	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxamida,
704	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
716	1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
749	6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
810	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–4–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
820	6–[3–ciano–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

Comp	Nombre
821	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida,
849	6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
937	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(2–metilpropil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
960	6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
977	6–[3–ciano–5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1037	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,
1064	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,
1065	N–{5–[3–ciano–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,
1085	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,
1088	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida,
1092	N–[6–(3–ciano–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–2–il)piridin–3–il]–2–metilpropan–2–sulfonamida,
1100	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–5–fluoro–1–fenil–1H–indol–3–carboxamida,
1110	2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclobutil–6–etil–4–fluoro–1H–indol–3–carboxamida o

Comp	Nombre
1111	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–etil–4–fluoro–1–fenil–1H–indol–3–carboxamida.

En otra forma de realización de la presente invención, un compuesto de la fórmula (I) o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o formas polimórficas está seleccionado de:

Comp	Nombre
300	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
387	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
409	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
512	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
541	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
549	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
601	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
634	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
650	6–[3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

Comp	Nombre
682	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
704	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
820	6–[3–ciano–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
849	6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,
960	6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,
1037	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,
1064	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,
1065	N–{5–[3–ciano–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,
1088	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida o
1100	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–5–fluoro–1–fenil–1H–indol–3–carboxamida.

Definiciones químicas

Los términos químicos utilizados con anterioridad y a lo largo de la descripción de la invención, a menos que específicamente se defina de otra manera, deben ser entendidos por un experto en la técnica por tener los siguientes significados indicados.

Tal como se usa en la presente, el término "alquilo C_{1-8}" se refiere, en general, a radicales hidrocarbonados saturados que tienen de uno a ocho átomos de carbono en una configuración de cadena lineal o ramificada, incluyendo metilo, etilo, n–propilo, isopropilo, n–butilo, isobutilo, sec–butilo, ter–butilo, n–pentilo, n–hexilo, n–heptilo, n–octilo y similares. En algunas formas de realización, alquilo C_{1-8} incluye alquilo C_{1-6}, alquilo C_{1-4} y similares. Un radical alquilo C_{1-8} puede estar opcionalmente sustituido cuando está permitido por valencias disponibles.

Tal como se usa en la presente, el término "alquenilo C_{2-8}" se refiere, en general, a radicales hidrocarbonados parcialmente insaturados que tienen de dos a ocho átomos de carbono en una configuración de cadena lineal o ramificada y uno o varios enlaces dobles de carbono–carbono, incluyendo etenilo, alilo, propenilo y similares. En algunas formas de realización, alquenilo C_{2-8} incluye alquenilo C_{2-6}, alquenilo C_{2-4} y similares. Un radical alquenilo C_{2-8} puede estar opcionalmente sustituido cuando está permitido por valencias disponibles.

Tal como se usa en la presente, el término "alcoxi C_{1-8}" se refiere, en general, a radicales hidrocarbonados saturados que tienen de uno a ocho átomos de carbono en una configuración de cadena lineal o ramificada de la fórmula: –O–alquilo C_{1-8}, incluyendo metoxi, etoxi, n–propoxi, isopropoxi, n–butoxi, isobutoxi, sec–butoxi, ter–butoxi, n–pentoxi, n–hexoxi y similares. En algunas formas de realización, alcoxi C_{1-8} incluye alcoxi C_{1-6}, alcoxi C_{1-4} y similares. Un radical alcoxi C_{1-8} puede estar opcionalmente sustituido cuando está permitido por valencias disponibles.

Tal como se usa en la presente, el término "cicloalquilo C_{3-14}" se refiere, en general, a un radical hidrocarbonado monocíclico, bicíclico o policíclico saturado, incluyendo ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, cicloheptilo, ciclooctilo, 1H–indanilo, indenilo, tetrahidro–naftalenilo y similares. En algunas formas de realización, cicloalquilo C_{3-14} incluye cicloalquilo C_{3-8}, cicloalquilo C_{5-8}, cicloalquilo

C_{3-10} y similares. Un radical cicloalquilo C_{3-14} puede estar opcionalmente sustituido cuando está permitido por valencias disponibles.

Tal como se usa en la presente, el término "cicloalquenilo C_{3-14}" se refiere, en general, a un radical hidrocarbonado monocíclico, bicíclico o policíclico parcialmente insaturado que tiene uno o varios enlaces dobles de carbono–carbono químicamente estables, incluyendo ciclopropenilo, ciclobutenilo, ciclopentenilo, ciclohexenilo, cicloheptenilo, ciclooctenilo y similares. En algunas formas de realización, cicloalquenilo C_{3-14} incluye cicloalquenilo C_{3-8}, cicloalquenilo C_{5-8}, cicloalquenilo C_{3-10} y similares. Un radical cicloalquenilo C_{3-14} puede estar opcionalmente sustituido cuando está permitido por valencias disponibles.

Tal como se usa en la presente, el término "arilo" se refiere, en general, a un radical de estructura anular de átomo de carbono monocíclico, bicíclico o policíclico, incluyendo fenilo, naftilo, antracenilo, fluorenilo, azulenilo, fenantrenilo y similares. Un radical arilo puede estar opcionalmente sustituido cuando está permitido por valencias disponibles.

Tal como se usa en la presente, el término "heteroarilo" se refiere, en general, a un radical de estructura anular de átomo de carbono monocíclico, bicíclico o policíclico en donde uno o varios miembros del anillo de átomo de carbono fueron reemplazados, donde esté permitido por la estabilidad estructural, con uno o varios heteroátomos, tales como un átomo de O, S o N, incluyendo furanilo, tienilo (o tiofenilo), 2H–pirrolilo, 3H–pirrolilo, pirazolilo, imidazolilo, isoxazolilo, isotiazolilo, oxazolilo, tiazolilo, triazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, piranilo, tiopiranilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo, triazinilo, indol, indazolilo, isoindolilo, benzofuranilo, benzotienilo, benzimidazolilo, benzoxazolilo, purinilo, quinolinilo, isoquinolinilo, quinazolinilo, quinoxalinilo, 1,3–diazinilo, 1,2–diazinilo, 1,2–diazolilo, 1,4–diazanaftalenilo, acridinilo y similares.

Un radical heteroarilo puede estar opcionalmente sustituido en un miembro anular del átomo de carbono o nitrógeno donde esté permitido por las valencias disponibles.

Tal como se usa en la presente, el término "heterociclilo" se refiere, en general, a un radical de estructura anular del átomo de carbono monocíclico, bicíclico o policíclico saturado o parcialmente insaturado en donde uno o varios miembros del anillo de átomo de carbono fueron reemplazados, donde esté permitido por la estabilidad estructural, con un heteroátomo tales como un átomo de O, S o N, incluyendo oxiranilo, oxetanilo, azetidinilo, dihidrofuranilo, tetrahidrofuranilo, dihidrotienilo, tetrahidrotienilo, pirrolinilo, pirrolidinilo, dihidropirazolilo, pirazolinilo, pirazolidinilo, dihidroimidazolilo, imidazolinilo, imidazolidinilo, isoxazolinilo, isoxazolidinilo, isotiazolinilo, isotiazolidinilo, oxazolinilo, oxazolidinilo, tiazolinilo, tiazolidinilo, triazolinilo, triazolidinilo, oxadiazolinilo, oxadiazolidinilo, tiadiazolinilo, tiadiazolidinilo, tetrazolinilo, tetrazolidinilo, dihidro–2H–piranilo, tetrahidro–2H–piranilo, tetrahidro–tiopiranilo, dihidro–piridinilo, tetrahidro–piridinilo, hexahidro–piridinilo, dihidro–pirimidinilo, tetrahidro–pirimidinilo, dihidro–pirazinilo, tetrahidro–pirazinilo, dihidro–piridazinilo, tetrahidro–piridazinilo, piperazinilo, piperidinilo, morfolinilo, tiomorfolinilo, dihidro–triazinilo, tetrahidro–triazinilo, hexahidro–triazinilo, dihidro–indol, tetrahidro–indol, dihidro–indazolilo, tetrahidro–indazolilo, dihidro–isoindolilo, tetrahidro–isoindolilo, dihidro–benzofuranilo, tetrahidro–benzofuranilo, dihidro–benzotienilo, tetrahidro–benzotienilo, dihidro–benzimidazolilo, tetrahidro–benzimidazolilo, dihidro–benzoxazolilo, tetrahidro–benzoxazolilo, benzo[1,3]dioxolilo, benzo[1,4]dioxanilo, dihidro–purinilo, tetrahidro–purinilo, dihidro–quinolinilo, tetrahidro–quinolinilo, dihidro–isoquinolinilo, tetrahidro–isoquinolinilo, dihidro–quinazolinilo, tetrahidro–quinazolinilo, dihidro–quinoxalinilo, tetrahidro–quinoxalinilo y similares. Un radical

heterociclilo puede estar opcionalmente sustituido en un miembro anular del átomo de carbono o nitrógeno donde esté permitido por las valencias disponibles.

Tal como se usa en la presente, el término "alquenil C_{2-8}–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–alquenilo C_{2-8}.

Tal como se usa en la presente, el término "alcoxi C_{1-8}–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–O–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alcoxi C_{1-8}–alquil C_{1-8}–amino–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–NH–alquil C_{1-8}–O–alquilo C_{1-8} u –O–alquil C_{1-8}–N(alquil C_{1-8}–O–alquilo C_{1-8})$_2$.

Tal como se usa en la presente, el término "alcoxi C_{1-8}–carbonilo" se refiere a un radical de la fórmula: –C(O)–O–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alcoxi C_{1-8}–carbonil–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–C(O)–O–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alcoxi C_{1-8}–carbonil–amino" se refiere a un radical de la fórmula: –NH–C(O)–O–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alquil C_{1-8}–amino" se refiere a un radical de la fórmula: –NH–alquilo C_{1-8} o –N(alquilo C_{1-8})$_2$.

Tal como se usa en la presente, el término "alquil C_{1-8}–amino–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–NH–alquilo C_{1-8} o –alquil C_{1-8}–N(alquilo C_{1-8})$_2$.

Tal como se usa en la presente, el término "alquil C_{1-8}–amino–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–NH–alquilo C_{1-8} o –alquil C_{1-8}–N(alquilo C_{1-8})$_2$.

Tal como se usa en la presente, el término "alquil C_{1-8}–amino–alquil C_{1-8}–amino–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–NH–alquil C_{1-8}–NH–alquilo C_{1-8} u –O–alquil C_{1-8}–N(alquil C_{1-8}–NH–alquilo C_{1-8})$_2$.

Tal como se usa en la presente, el término "alquil C_{1-8}–amino–carbonilo" se refiere a un radical de la fórmula: –C(O)–NH–alquilo C_{1-8} o –C(O)–N(alquilo C_{1-8})$_2$.

Tal como se usa en la presente, el término "alquil C_{1-8}–amino–carbonil–amino" se refiere a un radical de la fórmula: –NH–C(O)–NH–alquilo C_{1-8} o –NH–C(O)–N(alquilo C_{1-8})$_2$.

Tal como se usa en la presente, el término "alquil C_{1-8}–carbonilo" se refiere a un radical de la fórmula: –C(O)–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alquil C_{1-8}–carboniloxi" se refiere a un radical de la fórmula: –O–C(O)–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alquil C_{1-8}–carboniloxi–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–O–C(O)–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alquil C_{1-8}–carboniloxi–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–O–C(O)–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alquil C_{1-8}–sulfinilo" se refiere a un radical de la fórmula: –SO–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alquil C_{1-8}–sulfonilo" se refiere a un radical de la fórmula: –SO_2–alquilo C_{1-8}.

Tal como se usa en la presente, el término "amino–sulfonilo" se refiere a un radical de la fórmula: –SO_2–NH_2.

Tal como se usa en la presente, el término "alquil C_{1-8}–sulfonil–amino" se refiere a un radical de la fórmula: –NH–SO_2–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alquil C_{1-8}–tio" se refiere a un radical de la fórmula: –S–alquilo C_{1-8}.

Tal como se usa en la presente, el término "alquinil C_{2-8}–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–alquinilo C_{2-8}.

Tal como se usa en la presente, el término "amino" se refiere a un radical de la fórmula: –NH_2.

Tal como se usa en la presente, el término "amino–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–NH_2.

Tal como se usa en la presente, el término "amino–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–NH_2.

Tal como se usa en la presente, el término "amino–alquil C_{1-8}–amino–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–NH–alquil C_{1-8}–NH_2 u –O–alquil C_{1-8}–N(alquil C_{1-8}–NH_2)$_2$.

Tal como se usa en la presente, el término "amino–carbonilo" se refiere a un radical de la fórmula: –C(O)–NH_2.

Tal como se usa en la presente, el término "amino–carbonil–amino" se refiere a un radical de la fórmula: –NH–C(O)–NH_2.

Tal como se usa en la presente, el término "aril–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–arilo.

Tal como se usa en la presente, el término "aril–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–arilo.

Tal como se usa en la presente, el término "aril–carbonil–amino" se refiere a un radical de la fórmula: –NH–C(O)–arilo.

Tal como se usa en la presente, el término "ariloxi" se refiere a un radical de la fórmula: –O–arilo.

Tal como se usa en la presente, el término "carboxilo" se refiere a un radical de la fórmula: –COOH, –C(O)OH o –CO_2H.

Tal como se usa en la presente, el término "carboxil–amino" se refiere a un radical de la fórmula: –NH–COOH, –NH–C(O)OH o –NH–CO_2H.

Tal como se usa en la presente, el término "ciano–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–CN.

Tal como se usa en la presente, el término "1–ciano–etilo" se refiere a un radical de la fórmula: –CH(CN)–CH_3.

Tal como se usa en la presente, el término "cicloalquil C_{3-14}–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–cicloalquilo C_{3-14}.

Tal como se usa en la presente, el término "cicloalquil C_{3-14}–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–cicloalquilo C_{3-14}.

Tal como se usa en la presente, el término "cicloalquil C_{3-14}–oxi" se refiere a un radical de la fórmula: –O–cicloalquilo C_{3-14}.

Tal como se usa en la presente, el término "1–ciclopropil–etilo" se refiere a un radical de la fórmula: –CH(ciclopropil)–CH_3.

Tal como se usa en la presente, el término "ciclopropil–metilo" se refiere a un radical de la fórmula: –CH_2–ciclopropilo.

Tal como se usa en la presente, el término "formilo" se refiere a un radical de la fórmula: –C(O)–H

Tal como se usa en la presente, el término "halo" o "halógeno" se refiere, en general, a un radical de átomo de halógeno, incluyendo flúor, cloro, bromo y yodo.

Tal como se usa en la presente, el término "halo–alquenilo C_{2-8}" se refiere a un radical de la fórmula: –alquenil C_{2-8}–halo, en donde el alquenilo C_{2-8} puede estar parcial o completamente sustituido donde esté permitido por las valencias disponibles con uno o varios átomos de halógeno, incluyendo fluoroetenilo, difluoroetenilo o difluoroalilo y similares. En algunas formas de realización, el difluoroetenilo incluye 2,2–difluorovinilo o 1,2–difluorovinilo y similares; el difluoroalilo incluye 1,1–difluoroalilo y similares. En algunas formas de realización, el halo–alquenilo C_{2-8} incluye halo–alquenilo C_{2-6}, halo–alquenilo C_{2-4} y similares.

Tal como se usa en la presente, el término "halo–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–halo, en donde el alquilo C_{1-8} puede estar parcial o completamente sustituido donde esté permitido por las valencias disponibles con uno o varios átomos de halógeno, incluyendo fluorometoxi,

difluorometoxi, trifluorometoxi, fluoroetoxi, difluoroetoxi o trifluoroetoxi y similares. En algunas formas de realización, el difluoroetoxi incluye 2,2–difluoroetoxi, 1,2–difluoroetoxi o 1,1–difluoroetoxi y similares. En algunas formas de realización, halo–alcoxi C_{1-8} incluye halo–alcoxi C_{1-6}, halo–alcoxi C_{1-4} y similares.

Tal como se usa en la presente, el término "halo–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–halo, en donde el alquilo C_{1-8} puede estar parcial o completamente sustituido donde esté permitido por las valencias disponibles con uno o varios átomos de halógeno, incluyendo fluorometilo, difluorometilo, trifluorometilo, fluoroetilo, difluoroetilo, trifluoroetilo, fluoroisopropilo, difluoroisopropilo, trifluoroisopropilo, fluoro–ter–butilo, difluoro–ter–butilo, trifluoro–ter–butilo y similares. En algunas formas de realización, el difluoroetilo incluye 2,2–difluoroetilo, 1,2–difluoroetilo o 1,1–difluoroetilo y similares; difluoroisopropil incluye 1,3–difluoropropan–2–ilo y similares; el trifluoroisopropilo incluye 1,1,1–trifluoropropan–2–ilo y similares; el trifluoro–ter–butil incluye 1,1,1–trifluoro–2–metilpropan–2–ilo y similares. En algunas formas de realización, el halo–alquilo C_{1-8} incluye halo–alquilo C_{1-6}, halo–alquilo C_{1-4} y similares.

Tal como se usa en la presente, el término "heteroaril–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–heteroarilo.

Tal como se usa en la presente, el término "heteroaril–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–heteroarilo.

Tal como se usa en la presente, el término "heteroariloxi" se refiere a un radical de la fórmula: –O–heteroarilo.

Tal como se usa en la presente, el término "heterociclil–alcoxi C_{1-8}" se refiere a un radical de la fórmula: –O–alquil C_{1-8}–heterociclilo.

Tal como se usa en la presente, el término "heterociclil–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–heterociclilo.

Tal como se usa en la presente, el término "heterociclil–carboniloxi" se refiere a un radical de la fórmula: –O–C(O)–heterociclilo.

Tal como se usa en la presente, el término "heterocicliloxi" se refiere a un radical de la fórmula: –O–heterociclilo.

Tal como se usa en la presente, el término "hidroxi–alquilo C_{1-8}" se refiere a un radical de la fórmula: –alquil C_{1-8}–OH, en donde el alquilo C_{1-8} puede estar parcial o completamente sustituido donde esté permitido por las valencias disponibles con uno o varios radicales hidroxi.

Tal como se usa en la presente, el término "sustituyente" significa variables posicionales en los átomos de una molécula de núcleo que están sustituidos en una posición atómica designada, reemplazando uno o varios hidrógenos en el átomo designado, siempre que la valencia normal del átomo designado no se exceda y que la sustitución dé como resultado un compuesto estable. Las combinaciones de sustituyentes y/o variables están permitidas sólo si estas combinaciones dan como resultado compuestos estables. También se ha de notar que se asume que cualquier carbono así como heteroátomo con valencias que parecen no estar satisfechas tal como se describen o muestran en la presente tienen una cantidad suficiente de átomos de hidrógeno para satisfacer las valencias descritas o mostradas.

A los fines de esta invención, cuando uno o varias variables de sustituyentes para un compuesto de la fórmula (I) comprenden funcionalidades incorporadas en un compuesto de la fórmula (I), cada funcionalidad que aparecen en cualquier ubicación dentro del compuesto revelado se puede seleccionar de modo independiente y como apropiada, independiente y/o opcionalmente sustituido.

Tal como se usa en la presente, las expresiones "seleccionado de modo independiente" o "cada uno seleccionado" se refiere a variables funcionales en

una lista de sustituyentes que se puede producir más de una vez en la estructura de la fórmula (I) o de la fórmula (Ia), el patrón de sustitución en cada aparición es independientemente del patrón en cualquier otra aparición. Además, se entiende que el uso de una variable de sustituyente genérica en cualquier fórmula o estructura para un compuesto de la presente invención incluye el reemplazo del sustituyente genérico con especies de sustituyentes que están incluidas dentro del género particular, por ejemplo, el arilo puede estar reemplazado por fenilo o naftalenilo y similares y el compuesto resultante ha de ser incluido dentro del alcance de los compuestos representativos de la presente invención.

Tal como se usa en la presente, la expresión "cada instancia de" cuando se usa en una frase como "...arilo, aril–alquilo C_{1-8}, heterociclilo y heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo y heterociclilo está opcionalmente sustituido con uno o dos sustituyentes..." incluye una sustitución independiente opcional en cada uno de los anillos arilo y heterociclilo y en las porciones de arilo y heterociclilo de aril–alquilo C_{1-8} y heterociclil–alquilo C_{1-8}.

Tal como se usa en la presente, la expresión "opcionalmente sustituido" significa una sustitución opcional con las variables de sustituyentes, grupos, radicales o restos especificadas.

Tal como se usa en la presente, las expresiones "compuesto estable o "estructura estable" significa un compuesto que es suficientemente robusto para sobrevivir un aislamiento a un grado útil de pureza a partir de la mezcla de reacción y sus formulaciones en un agente terapéutico eficaz.

Los nombres de los compuestos usados en la presente se obtuvieron usando ACD Labs Index Name software Versión 10.0, suministrado por ACD Labs; y/o se suministraron usando Autonom function de ChemDraw Ultra 10.0.4, provisto por CambridgeSoft. Cuando el nombre del compuesto revelado en la

presente entra en conflicto con la estructura representada, la estructura mostrada prevalecerá al uso del nombre para definir el compuesto pretendido.

Formas del compuesto

Tal como se usa en la presente, el término "forma" implica un compuesto de la fórmula (I) o de la fórmula (Ia) aislado para usar, seleccionado de un ácido libre, base libre, sal, hidrato, solvato, clatrato, isotopólogo, racemato, enantiómero, diastereómero, estereoisómero, polimorfo o forma tautomérica de él.

Tal como se usa en la presente, el término "aislado" implica el estado físico de un compuesto de la fórmula (I) o de la fórmula (Ia) después de ser aislado y/o purificado a partir de un proceso de síntesis (por ejemplo, de una mezcla de reacción) o fuente natural o combinaciones de ellos de acuerdo con un proceso o procesos de aislamiento o purificación descritos en la presente o que son bien conocidos por el experto en la técnica (por ejemplo, cromatografía, recristalización y similares) en una pureza suficiente para ser caracterizable por técnicas analíticas estándar descritas en la presente o bien conocidas por el experto en el arte.

Tal como se usa en la presente, el término "protegido" implica que un grupo funcional en un compuesto de la fórmula (I) está en una forma modificada para excluir reacciones colaterales en un sitio protegido cuando el compuesto se somete a una reacción. Los grupos protectores apropiados serán reconocidos por los expertos en la técnica, así como por referencia a manuales estándar tales como, por ejemplo, T. W. Greene *et al*, *Protective Groups in organic Synthesis* (1991), Wiley, New York.

Las prodrogas y solvatos de los compuestos de la invención también están contemplados en la presente.

Tal como se usa en la presente, el término "prodroga" implica una forma de un presente compuesto (por ejemplo, un precursor farmacológico) que se

transforma in *vivo* para obtener un compuesto activo de la fórmula (I) o una de sus formas. La transformación se puede producir por medio de diversos mecanismos (por ejemplo, por procesos químicos metabólicos y/o no metabólicos), tales como, por ejemplo, a través de hidrólisis y/o metabolismo en sangre, hígado y/u otros órganos y tejidos. Se provee una discusión sobre el uso de prodrogas en T. Higuchi y W. Stella, "Pro–drugs as Novel Delivery Systems," Vol. 14 de A.C.S. Symposium Series y en Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association y Pergamon Press, 1987.

En un ejemplo, cuando un compuesto de la fórmula (I) o una de sus formas contiene un grupo funcional ácido carboxílico, una prodroga puede comprender un éster formado por el reemplazo del átomo de hidrógeno del grupo ácido con un grupo funcional tales como alquilo y similares. En otro ejemplo, cuando un compuesto de la fórmula (I) o una de sus formas contiene un grupo funcional alcohol, una prodroga se puede formar por el reemplazo del átomo de hidrógeno del grupo alcohol con un grupo funcional tales como alquilo o carboniloxi y similares. En otro ejemplo, cuando un compuesto de la fórmula (I) o una de sus formas contiene un grupo funcional amina, una prodroga se puede formar por el reemplazo de uno o varios átomos de hidrógeno de amina con un grupo funcional tales como alquilo o carbonilo sustituido.

Uno o varios compuestos de la invención pueden existir en formas no solvatadas así como formas solvatadas con solventes farmacéuticamente aceptables tales como agua, etanol y similares y se pretende que la invención comprenda las formas tanto solvatadas como no solvatadas.

Tal como se usa en la presente, el término "solvato" significa una asociación física de un compuesto de esta invención con una o varias moléculas de solventes. Esta asociación física incluye la modificación de los grados del enlace iónico y covalente, incluyendo enlace de hidrógeno. En ciertas instancias,

el solvato será capaz de aislamiento, por ejemplo, cuando una o varias moléculas de solvente se incorporan en la red cristalina del sólido cristalino. Tal como se usa en la presente, "solvato" comprende los solvatos tanto de fase en solución como aislables. Los ejemplos no limitativos de los solvatos apropiados incluyen etanolatos, metanolatos y similares.

Uno o varios compuestos de la invención se pueden convertir opcionalmente en un solvato. La preparación de solvatos se conoce en general. Se describió la preparación de los solvatos del fluconazol antifúngico en acetato de etilo así como a partir de agua (ver M. Caira *et al*, *J. Pharmaceutical Sci.*, 93(3), 601–611 (2004)). También se describieron similares preparaciones de solvatos, hemisolvatos, hidratos y similares (ver E. C. van Tonder *et al*, *AAPS PharmSciTech.*, 5(1), artículo 12 (2004); y A. L. Bingham *et al*, *Chem. Commun.*, 603–604 (2001)). Un proceso no limitativo típico incluye la disolución de un compuesto en una cantidad deseada del solvente deseado (orgánico o agua o mezclas de ellos) a una temperatura superior a la ambiente y enfriamiento de la solución a una velocidad suficiente como para formar cristales que luego se aíslan por medio de métodos estándar. Las técnicas analíticas tales como, por ejemplo, espectroscopia infrarroja, muestran la presencia del solvente (o agua) en los cristales como un solvato (o hidrato).

Tal como se usa en la presente, el término "hidrato" implica un solvato en donde la molécula de solvente es agua.

Los compuestos de la fórmula (I) pueden formar sales que también están dentro del alcance de esta invención. Se entiende que la referencia a un compuesto de la fórmula (I) en la presente incluye la referencia a sus sales, a menos que se indique otra cosa. El término "sal(es)", tal como se emplea en la presente, denota sales ácidas formadas con ácidos inorgánicos y/u orgánicos, así como sales básicas formadas con bases inorgánicas y/u orgánicas. Además,

cuando un compuesto de la fórmula (I) contiene tanto un resto básico como, pero sin limitación, una piridina o imidazol, como un resto ácido como, pero sin limitación, un ácido carboxílico, se pueden formar zwitteriones ("sales internas") y están incluidas dentro del término "sal(es)" tal como se usa en la presente.

Se prefieren las sales farmacéuticamente aceptables (es decir, no tóxicas, fisiológicamente aceptables), a pesar de que también son de utilidad otras sales. Las sales de los compuestos de la fórmula (I) se pueden formar, por ejemplo, haciendo reaccionar un compuesto de la fórmula (I) con una cantidad de ácido o de base, como una cantidad equivalente, en un medio como uno en el que la sal precipita o en un medio acuoso seguido de liofilización.

Las sales por adición de ácidos de ejemplo incluyen acetatos, ascorbatos, benzoatos, bencensulfonatos, bisulfatos, boratos, butiratos, citratos, canforatos, canforsulfonatos, fumaratos, clorhidratos, bromhidratos, yodhidratos, lactatos, maleatos, metansulfonatos, naftalensulfonatos, nitratos, oxalatos, fosfatos, propionatos, salicilatos, succinatos, sulfatos, tartaratos, tiocianatos, toluensulfonatos (también conocidos como tosilatos), y similares.

Además, los ácidos que se consideran en general apropiados para la formación de sales farmacéuticamente aceptables a partir de compuestos farmacéuticos básicos se tratan, por ejemplo, en P. Stahl *et al*, Camille G. (eds.) *Handbook of Pharmaceutical Salts. Properties, Selection and Use.* (2002) Zurich: Wiley–VCH; S. Berge *et al, Journal of Pharmaceutical Sciences* (1977) 66(1) 1–19; P. Gould, *International J. of Pharmaceutics* (1986) 33, 201–217; Anderson *et al*, *The Practice of Medicinal Chemistry* (1996), Academic Press, New York; y en *The Orange Book* (Food & Drug Administration, Washington, D.C. en su página web). Estas descripciones se incorporan en la presente por referencia.

Las sales básicas de ejemplo incluyen sales de amonio, sales de metales alcalinos tales como sales de sodio, de litio y de potasio, sales de metales

alcalinotérreos tales como sales de calcio y de magnesiuo, sales con bases orgánicas (por ejemplo, aminas orgánicas) tales como diciclohexilaminas, t–butilaminas y sales con aminoácidos tales como arginina, lisina y similares. Los grupos que contienen nitrógeno básico se pueden cuaternizar con agentes tales como haluros de alquilo inferior (por ejemplo, cloruros, bromuros y yoduros de metilo, etilo y butilo), sulfatos de dialquilo (por ejemplo, sulfatos de dimetilo, dietilo y dibutilo), haluros de cadena larga (por ejemplo, cloruros, bromuros y yoduros de decilo, laurilo y estearilo), haluros de aralquilo (por ejemplo, bromuros de bencilo y fenetilo) y otros.

Todas estas sales ácidas y sales básicas son sales farmacéuticamente aceptables dentro del alcance de la invención y todas las sales ácidas y básicas son consideradas equivalentes a las formas libres de los correspondientes compuestos a los fines de la invención.

Los ésteres farmacéuticamente aceptables de los presentes compuestos incluyen los siguientes grupos: ésteres de ácido carboxílico, ésteres de sulfonato, ésteres de fosfonato de ésteres de aminoácidos y ésteres de mono–, di– o trifosfato.

Los compuestos de la fórmula I y sus sales, solvatos, ésteres y prodrogas también pueden existir en su forma tautomérica (por ejemplo, como una amida o iminoéter). Todas estas formas tautoméricas están contempladas en la presente como parte de la presente invención.

Los compuestos de la fórmula (I) pueden contener centros asimétricos o quirales y, en consecuencia, existen en diferentes formas estereoisoméricas. Se pretende que todas las formas estereoisoméricas de los compuestos de la fórmula (I) así como sus mezclas, incluyendo mezclas racémicas, formen parte de la presente invención.

Los compuestos de la invención pueden incluir uno o varios centros quirales y como tales pueden existir como mezclas racémicas (*R/S*) o como enantiómeros y diastereómeros sustancialmente puros. Los compuestos también pueden existir como enantiómeros (*R*) o (*S*) sustancialmente puros (cuando está presente un centro quiral). En una forma de realización, los compuestos de la invención son isómeros (*S*) y pueden existir como composiciones enantioméricamente puras que comprenden sustancialmente sólo el isómero (*S*). En otra forma de realización, los compuestos de la invención son isómeros (*R*) y pueden existir como composiciones enantioméricamente puras que comprenden sustancialmente sólo el isómero (*R*). Tal como reconocerá el experto en la técnica, cuando más de un centro quiral está presente, los compuestos de la invención también pueden existir como un isómero (*R,R*), (*R,S*), (*S,R*) o (*S,S*), tal como se define por las recomendaciones de nomenclatura *IUPAC*.

Tal como se usa en la presente, la expresión "sustancialmente puro" se refiere a compuestos que consisten sustancialmente en un isómero individual en una cantidad superior o igual al 90%, en una cantidad superior o igual al 92%, en una cantidad superior o igual al 95%, en una cantidad superior o igual al 98%, en una cantidad superior o igual al 99% o una cantidad igual al 100% del isómero individual.

En un aspecto de la invención, un compuesto de la fórmula (I) es un enantiómero (*S*) sustancialmente puro presente en una cantidad superior o igual al 90%, en una cantidad superior o igual al 92%, en una cantidad superior o igual al 95%, en una cantidad superior o igual al 98%, en una cantidad superior o igual al 99% o una cantidad igual al 100%.

En un aspecto de la invención, un compuesto de la fórmula (I) es un enantiómero (*R*) sustancialmente puro presente en una cantidad superior o igual al 90%, en una cantidad superior o igual al 92%, en una cantidad superior o igual

al 95%, en una cantidad superior o igual al 98%, en una cantidad superior o igual al 99% o una cantidad igual al 100%.

Tal como se usa en la presente, un "racemato" es cualquier mezcla de formas isoméricas que no son "enantioméricamente puras", incluyendo mezclas tales como, sin limitación, en una relación de aproximadamente 50/50, de aproximadamente 60/40, de aproximadamente 70/30 o de aproximadamente 80/20.

Además, la presente invención comprende todos los isómeros geométricos y posicionales. Por ejemplo, si un compuesto de la fórmula (I) incorpora un enlace doble o un anillo fusionado, las formas tanto cis como trans, así como las mezclas, están comprendidas dentro del alcance de la invención. Las mezclas diastereoméricas se pueden separar en sus diastereómeros individuales sobre la base de sus diferencias fisicoquímicas por medio de métodos conocidos por los expertos en la técnica tales como, por ejemplo, por cromatografía y/o cristalización por fraccionamiento. Los enantiómeros se pueden separar usando columna de HPLC quiral u otros métodos de cromatografía conocidos por los expertos en la técnica. Los enantiómeros también se pueden separar convirtiendo la mezcla enantiomérica en una mezcla diastereomérica por reacción con un compuesto ópticamente activo apropiado (por ejemplo, auxiliar quiral tales como un alcohol quiral o cloruro de ácido de Mosher), separando los diastereómeros y convirtiendo (por ejemplo, hidrolizando) los diastereómeros individuales en los correspondientes enantiómeros puros. Además, algunos de los compuestos de la fórmula (I) pueden ser atropisómeros (por ejemplo, biarilos sustituidos) y son considerados como parte de esta invención.

También es posible que los compuestos de la fórmula (I) puedan existir en diferentes formas tautoméricas y todas esas formas están comprendidas dentro

del alcance de la invención. Además, por ejemplo, todas las formas de ceto–enol e imina–enamina de los compuestos están incluidas en la invención.

Todos los estereoisómeros (por ejemplo, isómeros geométricos, isómeros ópticos y similares) de los presentes compuestos (incluyendo aquellos de las sales, solvatos, ésteres y prodrogas de los compuestos así como las sales, solvatos y ésteres de las prodrogas), tales como los que pueden existir debido a carbonos asimétricos en diversos sustituyentes, incluyendo formas enantioméricas (que pueden existir incluso en ausencia de carbonos asimétricos), formas rotaméricas, atropisómeros y formas diastereoméricas, están contemplados dentro del alcance de esta invención, porque son isómeros posicionales (tales como, por ejemplo, 4–piridilo y 3–piridilo). Por ejemplo, si un compuesto de la fórmula (I) incorpora un enlace doble o un anillo fusionado, tanto las formas cis como trans, así como sus mezclas, están comprendidas dentro del alcance de la invención. Además, por ejemplo, todas las formas de ceto–enol e imina–enamina de los compuestos están incluidas en la invención. Los estereoisómeros individuales de los compuestos de la invención pueden estar, por ejemplo, sustancialmente libres de otros isómeros o pueden estar presentes en una mezcla racémica, tal como se describió más arriba.

El uso de los términos "sal", "solvato", "éster", "prodroga" y similares, se pretende usar de manera equivalente a la sal, solvato, éster y prodroga de enantiómeros, estereoisómeros, rotámeros, tautómeros, isómeros posicionales, racematos, isotopólogos o prodrogas de los presentes compuestos.

El término "isotopólogo" se refiere a compuestos isotópicamente enriquecidos de la presente invención que son idénticos a los mencionados en la presente, pero de hecho uno o varios átomos están reemplazados por un átomo que tiene una masa atómica o número de masa diferente de la masa atómica o número de masa usualmente hallado en la naturaleza. Los ejemplos de isótopos

que se pueden incorporar en compuestos de la invención incluyen isotótopos de hidrógeno, carbono, nitrógeno, oxígeno, fósforo, flúor y cloro, tales como H^2, H^3, C^{13}, C^{14}, N^{15}, O^{18}, O^{17}, P^{31}, P^{32}, S^{35}, F^{18}, Cl^{35} y Cl^{36}, respectivamente, cada uno de los cuales también está dentro del alcance de esta invención.

Ciertos compuestos isotópicamente enriquecidos de la presente invención (por ejemplo, los rotulados con H^3 y C^{14}) son de utilidad en los ensayos de distribución de compuestos y/o tejidos de sustrato. Los isótopos tritiados (es decir, H^3) y carbono–14 (es decir, C^{14}) se prefieren en particular por la facilidad de preparación y detectabilidad. Además, la sustitución con isótopos más pesados tales como deuterio (es decir, H^2) puede lograr ciertas ventajas terapéuticas resultantes de una mayor estabilidad metabólica (por ejemplo, mayor vida media in vivo o menor cantidad de requerimientos posológicos) y, así, se pueden preferir en ciertas circunstancias. Los compuestos de la fórmula (I) isotópicamente enriquecidos se pueden preparar, en general, de acuerdo con los procedimientos análogos a los descritos en los esquemas y/o en los ejemplos de la presente, sustituyendo un reactivo apropiado isotópicamente enriquecido por un reactivo no isotópicamente enriquecido.

Cuando los compuestos están enriquecidos con deuterio, la relación deuterio a hidrógeno en las áreas deuteradas de las moléculas excede sustancialmente la relación deuterio a hidrógeno natural. Wikipedia (http://en.wikipedia.org/wiki/Deuterium) sugiere que el deuterio tiene una abundancia natural en los océanos de la Tierra de aproximadamente un átomo en 6500 de hidrógeno (~154 PPM). Así, el deuterio representa aproximadamente el 0,015% (sobre una base en peso, 0,030%) de todo el hidrógeno natural en los océanos de la Tierra. Sin embargo, otras fuentes sugieren una abundancia mucho mayor de, por ejemplo, $6 \cdot 10^{-4}$ (6 átomos en 10.000 ó 0,06% de base atómica).

Las formas cristalinas y amorfas polimórficas de los compuestos de la fórmula (I) y de las sales, solvatos, ésteres y prodrogas de los compuestos de la fórmula (I) también están incluidas en la presente invención.

Uso de la invención

La presente invención se refiere a compuestos de utilidad para el tratamiento o la mejora de una infección viral por modulación de la replicación viral. De acuerdo con la presente invención, se identificaron los compuestos que modulan la replicación del virus HCV y se proveen los métodos de uso de estos compuestos para tratar o mejorar la infección de HCV o trastornos o síntomas asociados con ella.

Una forma de realización de la presente invención se refiere a un método para tratar una infección viral en un sujeto que lo necesita que comprende la administración de una cantidad efectiva de un compuesto de la fórmula (I) o una de sus formas al sujeto.

Una forma de realización de la presente invención incluye el uso de un compuesto de la fórmula (I) o una de sus formas en la preparación de un medicamento para tratar una infección viral en un sujeto que lo necesita que comprende la administración de una cantidad efectiva del medicamento al sujeto.

Una forma de realización de la presente invención incluye el uso de un compuesto de la fórmula (I) o una de sus formas en la preparación de un kit farmacéutico que comprende el compuesto de la fórmula (I) o una de sus formas e instrucciones para administrar el compuesto para tratar una infección viral en un sujeto que lo necesita.

Para cada una de tales formas de realización para tratar una infección viral en un sujeto que lo necesita, el uso de un compuesto de la fórmula (I) o una de

sus formas también incluye un uso del compuesto de la fórmula (Ia) o una de sus formas.

Otra forma de realización de la presente invención se refiere al uso de un compuesto de la fórmula (I) o de la fórmula (Ia) o una de sus formas para tratar una infección viral inhibiendo la replicación viral.

Una forma de realización de la presente invención incluye el uso de un compuesto de la fórmula (I) o de la fórmula (Ia) o una de sus formas para tratar o mejorar la infección por HCV o trastornos o síntomas asociados con ello por inhibición de la replicación del virus de hepatitis C.

Una forma de realización de la presente invención incluye un método para tratar o mejorar la infección por HCV o trastornos o síntomas asociados con ello en un sujeto que lo necesita que comprende la administración de una cantidad efectiva de un compuesto de la fórmula (I) o una de sus formas al sujeto.

Una forma de realización de la presente invención incluye el uso de un compuesto de la fórmula (I) o una de sus formas en la preparación de un medicamento para tratar o mejorar la infección por HCV o trastornos o síntomas asociados con ello en un sujeto que lo necesita que comprende la administración de una cantidad efectiva del medicamento al sujeto.

Una forma de realización de la presente invención incluye el uso de un compuesto de la fórmula (I) o una de sus formas en la preparación de un kit farmacéutico que comprende el compuesto de la fórmula (I) o una de sus formas e instrucciones para administrar el compuesto para tratar o mejorar la infección por HCV o trastornos o síntomas asociados con ello en un sujeto que lo necesita.

Para cada una de tales formas de realización para tratar o mejorar la infección por HCV o trastornos o síntomas asociados con ello en un sujeto que lo necesita, el uso de un compuesto de la fórmula (I) o una de sus formas también incluye un uso del compuesto de la fórmula (Ia) o una de sus formas.

En un aspecto, para cada una de tales formas de realización, el sujeto es tratamiento naif. En otro aspecto, para cada una de tales formas de realización, el sujeto no es tratamiento naif.

Tal como se usa en la presente, el término "tratamiento" se refiere a: (i) prevenir una enfermedad, trastorno o condición de que ocurra en un sujeto que puede tener predisposición a la enfermedad, trastorno y/o condición, pero que aún no fue diagnosticada; (ii) inhibición de una enfermedad, trastorno o condición, es decir, detención de su desarrollo; y/o (iii) alivio de una enfermedad, trastorno o condición, es decir, causa regresión de la enfermedad, trastorno y/o condición.

Tal como se usa en la presente, el término "sujeto" se refiere a un animal o cualquier organismo vivo que tiene sensación y el poder del movimiento voluntario y que requiere para su existencia de oxígeno y comida orgánica. Los ejemplos no limitativos incluyen miembros de las especies humana, equina, porcina, bovina, murina, canina y felina. En algunas formas de realización, el sujeto es un mamífero o un animal vertebrado de sangre caliente. En otras formas de realización, el sujeto es un humano. Tal como se usa en la presente, el término "paciente" se puede usar indistintamente con "sujeto" y "humano".

Otro aspecto de la invención se refiere a un método para tratar una infección viral por medio de un virus de tipo salvaje o un virus que es resistente a un agente antiviral actualmente disponible, en un sujeto que lo necesita, que comprende la administración al sujeto de una cantidad efectiva de un compuesto de la fórmula (I) o una de sus formas.

Los ejemplos no limitativos de infecciones virales incluidas dentro del alcance de la invención incluyen infecciones virales que resultan de virus del género picornavirus (tales como poliovirus, virus de hepatitis A, coxsackievirus y rhinovirus), virus del género coronaviridae (tales como síndrome respiratorio agudo severo (SARS)), virus del género arbovirus, virus del género flavivirus

(tales como virus de hepatitis C, fiebre amarilla, dengue y virus del Nilo Occidental), herpesvirus (tales como virus herpes simplex y herpesvirus asociado con el sarcoma de Kaposi y otros virus con un modo similar de replicación), un virus de inmunodeficiencia humana (HIV) o un virus de leucemia humana (HTLV).

Tal como se usa en la presente, las expresiones "cantidad efectiva" o "cantidad terapéuticamente efectiva" implican una cantidad de compuesto de la fórmula (I) o una forma, composición o medicamento efectivo para inhibir las enfermedades antes indicadas y, así, para producir el efecto terapéutico, mejorador, inhibidor o preventivo deseado en un sujeto que lo necesita.

En general, la cantidad efectiva estará en un rango de aproximadamente 0,001 mg/kg/día a aproximadamente 500 mg/kg/día o de aproximadamente 0,01 mg/kg/día a aproximadamente 500 mg/kg/día o de aproximadamente 0,1 mg a aproximadamente 500 mg/kg/día o de aproximadamente 1,0 mg/día a aproximadamente 500 mg/kg/día, en una dosis individual, dividida o continua para un paciente o sujeto que tiene un peso en un rango de entre aproximadamente 40 a aproximadamente 200 kg (dosis que se puede ajustar para pacientes o sujetos por sobre o por debajo de este rango, en particular niños de menos de 40 kg). Se espera que el sujeto adulto típico tenga un peso medio en un rango de entre aproximadamente 70 y aproximadamente 100 kg.

La dosis administrada para lograr una concentración plasmática objeto efectiva también se puede administrar en base al peso del sujeto o paciente. Las dosis administradas sobre una base en peso puede estar en el rango de aproximadamente 0,01 mg/kg/día a aproximadamente 50 mg/kg/dia o de aproximadamente 0,015 mg/kg/día a aproximadamente 20 mg/kg/día o de aproximadamente 0,02 mg/kg/día a aproximadamente 10 mg/kg/día o de aproximadamente 0,025 mg/kg/día a aproximadamente 10 mg/kg/día o de aproximadamente 0,03 mg/kg/día a aproximadamente 10 mg/kg/día, en donde

dicha cantidad se administra por vía oral una vez (una vez en aproximadamente un período de 24 horas), dos veces (una vez en aproximadamente un período de 12 horas) o tres veces (una vez en aproximadamente un período de 8 horas) diariamente de acuerdo con el peso del sujeto.

En otra forma de realización, cuando las dosis diarias se ajustan en base al peso del sujeto o del paciente, los compuestos de la invención se pueden formular para suministro a aproximadamente 0,02, 0,025, 0,03, 0,05, 0,06, 0,075, 0,08, 0,09. 0,10, 0,20, 0,25, 0,30, 0,50, 0,60, 0,75, 0,80, 0,90, 1,0, 1,10, 1,20, 1,25, 1,50, 1,75, 2,0, 5,0, 10, 20 ó 50 mg/kg/día. Las dosis diarias ajustadas en base al peso del sujeto o del paciente se pueden administrar como una dosis individual, dividida o continua. En formas de realización donde una dosis del compuesto se administra más de una vez por día, se puede administrar dos, tres o más veces por día.

Dentro del alcance de la presente invención, la "cantidad efectiva" de un compuesto de la fórmula (I) o una de sus formas para usar en la preparación de un medicamento, la preparación de un kit farmacéutico o en un método para tratar o mejorar la infección por HCV o trastornos o síntomas asociados con ello en un sujeto que lo necesita, incluye una cantidad en un rango de aproximadamente 1,0 mg a aproximadamente 3500 mg administrada una vez por día; 10,0 mg a aproximadamente 600 mg administrada una vez por día; 0,5 mg a aproximadamente 2000 mg administrada dos veces por día; o una cantidad en un rango de aproximadamente 5,0 mg a aproximadamente 300 mg administrada dos veces por día.

Por ejemplo, la cantidad efectiva puede ser la cantidad requerida para tratar una infección de HCV o la cantidad requerida para inhibir la replicación o infectividad viral, en un sujeto o, más específicamente, en un ser humano. En algunas instancias, el efecto deseado se puede determinar analizando (1) la

presencia de ARN de HCV; (2) la presencia de anticuerpos anti–HCV; (3) el nivel de alanina aminotransferasa sérica (ALT) y aspartato aminotransferasa (AST) (ALT y AST son elevados en pacientes con infección crónica por HCV); (4) daño hepatocelular resultante de una infección por HCV, incluyendo esteatosis, fibrosis y cirrosis; (5) carcinoma hepatocelular como resultado de infección crónica por HCV; y (6) secuelas extrahepáticas (los ejemplos no limitativos incluyen pruritis, encefalopatías, trastornos mentales tales como ansiedad o depresión) de infección por HCV u otros virus. La cantidad efectiva para un sujeto dependerá de diversos factores, incluyendo el peso corporal, la estatura y la salud del sujeto. las cantidades efectivas para un paciente dado se pueden determinar por medio de experimentación de rutina que está dentro de los conocimientos y el juicio del médico.

Para cualquier compuesto, la cantidad efectiva se puede estimar inicialmente ya sea en ensayos de cultivos celulares o en modelos animales relevantes, tales como un modelo de ratón, chimpancé, marmoseta o mono tití. Los modelos animales relevantes también se pueden usar para determinar el rango de concentración y la ruta de administración apropiados. Esta información luego se puede usar para determinar dosis y rutas de administración útiles en seres humanos. La eficacia terapéutica y la toxicidad se pueden determinar por medio de procedimientos farmacéuticos estándar en cultivos celulares o animales experimentales, por ejemplo, ED_{50} (la dosis terapéuticamente efectiva en el 50% de la población) y LD_{50} (la dosis letal en el 50% de la población). La relación de la dosis entre los efectos terapéuticos y tóxicos es el índice terapéutico y se puede expresar como la relación LD_{50}/ED_{50}. En algunas formas de realización, la cantidad efectiva es una para lograr un gran índice terapéutico. En otras formas de realización, la dosis está dentro de un rango de concentraciones de circulación que incluyen ED_{50} con poca o ninguna toxicidad. La dosis puede variar dentro de

este rango según la forma de dosificación empleada, la sensibilidad del paciente y la ruta de administración.

Más específicamente, las relaciones de concentración–efecto biológico observadas con respecto a un compuesto de la fórmula (I) o una de sus formas indican una concentración plasmática blanco que va de aproximadamente 0,001 µg/mL a aproximadamente 50 µg/mL, de aproximadamente 0,01 µg/mL a aproximadamente 20 µg/mL, de aproximadamente 0,05 µg/mL a aproximadamente 10 µg/mL o de aproximadamente 0,1 µg/mL a aproximadamente 5 µg/mL. Para lograr estas concentraciones en plasma, los compuestos de la invención se pueden administrar en dosis que varían de 0,1 µg a 100,000 mg, según la ruta de administración en dosis individuales, divididas o continuas para un paciente que pesa entre aproximadamente 40 y aproximadamente 100 kg (dosis que se puede ajustar para pacientes por sobre o por debajo de este rango de peso, en particular niños de menos de 40 kg).

La dosis exacta será determinada por el facultativo, a la luz de factores relacionados con el sujeto. La dosis y la administración se pueden ajustar para proveer niveles suficientes de agente(s) activo(s) o para mantener el efecto deseado. Los factores que se pueden tomar en cuenta incluyen la gravedad del estado patológico, el estado general de salud del sujeto, la etinicidad, la edad, el peso y el sexo, la dieta, el tiempo y la frecuencia de administración, la combinación o las combinaciones de las drogas, las sensibilidades de reacción, la experiencia con otras terapias de HCV y tolerancia/respuesta a la terapia. Las composiciones farmacéuticas de acción prolongada se pueden administrar cada 2, 3 ó 4 días, una vez por semana o una vez cada dos semanas según la vida media y la tasa de clearance de la formulación particular.

Los compuestos y composiciones de la presente invención se pueden administrar al sujeto por medio de cualquier ruta de suministro de drogas

conocida en la técnica. Los ejemplos no limitativos incluyen las rutas de administración oral, ocular, rectal, bucal, tópica, nasal, oftálmica, subcutánea, intramuscular, intravenosa (bolo e infusión), intracerebral, transdérmica y pulmonar.

Metabolitos de los compuestos de la invención

También entran dentro del alcance de la presente invención los productos metabólicos in *vivo* de los compuestos descritos en la presente. Estos productos pueden resultar, por ejemplo, de la oxidación, reducción, hidrólisis, amidación, esterificación y similares del compuesto administrado, primariamente debido a procesos enzimáticos. Conforme a ello, la invención incluye compuestos producidos por medio de un proceso que comprende poner en contacto un compuesto de esta invención con un tejido de mamífero o un mamífero durante un período suficiente para obtener uno de sus productos metabólicos.

Estos productos típicamente se identifican al preparar un isotopólogo radiorrotulado (por ejemplo C^{14} o H^3) de un compuesto de la invención, administrando el compuesto radiorrotulado en una dosis detectable (por ejemplo, mayor que aproximadamente 0,5 mg/kg) a un mamífero tales como una rata, un ratón, un conejillo de Indias, un perro, un mono o un ser humano, permitiendo un tiempo suficiente para que se produzca el metabolismo (típicamente de aproximadamente 30 segundos a aproximadamente 30 horas) e identificando los productos de conversión metabólica de muestras de orina, bilis, sangre u otras muestras biológicas. Estos productos se aíslan con facilidad porque están "radiorrotulados" en virtud de estar isotópicamente enriquecidos (otros se aíslan por medio del uso de anticuerpos capaces de unir epitopos sobrevivientes en el metabolito). Las estructuras metabolíticas se determinan de manera convencional, por ejemplo, por análisis de MS o RMN. En general, el análisis de los metabolitos

se puede realizar de la misma manera que los estudios de metabolismo con drogas convencionales bien conocidos por los expertos en la técnica. Los productos de conversión, siempre que no se hallen de otro modo in *vivo*, son de utilidad en ensayos de diagnóstico para la posología terapéutica de los compuestos de la invención incluso si no poseen actividad biológica propia.

Composiciones farmacéuticas

Las formas de realización de la presente invención incluyen el uso de un compuesto de la fórmula (I) o una de sus formas en una composición farmacéutica para la prevención o el tratamiento de una infección viral que comprende una cantidad efectiva de un compuesto de la fórmula (I) o una de sus formas en mezcla con un excipiente farmacéuticamente aceptable.

Tal como se usa en la presente, el término "composición" significa un producto que comprende los ingredientes especificados en las cantidades especificadas, así como cualquier producto que resulta, directa o indirectamente, de la combinación de los ingredientes especificados en las cantidades especificadas.

La composición farmacéutica se puede formular de modo de lograr un pH fisiológicamente compatible, que va de aproximadamente pH 3 a aproximadamente pH 11. En algunas formas de realización, la composición farmacéutica se formula para obtener un pH de aproximadamente pH 3 a aproximadamente pH 7. En otras formas de realización, la composición farmacéutica se formula para obtener un pH de aproximadamente pH 5 a aproximadamente pH 8.

La expresión "excipiente farmacéuticamente aceptable" se refiere a un excipiente para administrar un agente farmacéutico, como los compuestos de la presente invención. La expresión se refiere a cualquier excipiente farmacéutico

que se puede administrar sin una toxicidad indebida. Los excipientes farmacéuticamente aceptables se pueden determinar en parte por la composición particular que se administra, así como por el modo particular de administración y/o forma posológica. Los ejemplos no limitativos de excipientes farmacéuticamente aceptables incluyen portadores, solventes, estabilizantes, adyuvantes, diluyentes, *etc.* Conforme a ello, existe una amplia variedad de formulaciones apropiadas de composiciones farmacéuticas de la presente invención (ver, por ejemplo, Remington's Pharmaceutical Sciences).

Los excipientes apropiados pueden ser moléculas portadoras que incluyen grandes macromoléculas de lento metabolismo tales como proteínas, polisacáridos, ácidos polilácticos, ácidos poliglicólicos, aminoácidos poliméricos, copolímeros de aminoácidos y partículas virales inactivas. Otros excipientes de ejemplo incluyen antioxidantes tales como ácido ascórbico; agentes quelantes tales como EDTA; carbohidratos tales como dextrina, hidroxialquilcelulosa, hidroxialquilmetilcelulosa, ácido esteárico; líquidos tales como aceites, agua, solución fisiológica, glicerol y etanol; agentes humectantes o emulsionantes; sustancias amortiguadoras del pH; y similares. Los liposomas también están incluidos dentro de la definición de excipientes farmacéuticamente aceptables.

Las composiciones farmacéuticas de la invención se pueden formular en cualquier forma posible para el método de administración pretendido. Las formulaciones apropiadas para la administración oral incluyen sólidos, soluciones, emulsiones y suspensiones líquidas, mientras que las formulaciones inhalables apropiadas para la administración pulmonar incluyen líquidos y polvos. Las formulaciones alternativas incluyen jarabes, cremas, ungüentos, comprimidos y sólidos liofilizados que se pueden reconstituir con un solvente fisiológicamente compatible antes de la administración.

Cuando se pretenden para uso oral, se pueden preparar, por ejemplo, comprimidos, cápsulas, pastillas, suspensiones acuosas u oleosas, soluciones no acuosas, polvos dispersables o gránulos (incluyendo partículas micronizadas o nanopartículas), emulsiones, cápsulas duras o blandas, jarabes o elíxires. Las composiciones pretendidas para uso oral se pueden preparar de acuerdo con cualquier método conocido en la técnica para la preparación de composiciones farmacéuticas y estas composiciones pueden contener uno o varios agentes incluyendo agentes endulzantes, agentes saborizantes, agentes colorantes y agentes conservantes, a fin de proveer una preparación sabrosa.

Los excipientes farmacéuticamente aceptables apropiados para usar junto con comprimidos incluyen, por ejemplo, diluyentes inertes, tales como celulosas, carbonato de calcio o de sodio, lactosa, fosfato de calcio o de sodio; agentes desintegrantes, tales como croscarmelaosa sódica, povidona entrecruzada, almidón de maíz o ácido algínico; agentes aglutinantes, tales como povidona, almidón, gelatina o acacia; y agentes lubricantes, tales como estearato de magnesio, ácido esteárico o talco. Los comprimidos pueden no estar recubiertos o pueden estar recubiertos por medio de técnicas conocidas incluyendo microencapsulación para retardar la desintegración y la adsorción en el tracto gastrointestinal y proveer así una acción sostenida durante un período prolongado. Por ejemplo, se puede emplear un material demorado en el tiempo como monoestearato de glicerilo o diestearato de glicerilo solo o con una cera.

Las formulaciones para uso oral también se pueden presentar como cápsulas de gelatina dura cuando el ingrediente activo se mezcla con un diluyente sólido inerte, por ejemplo, celulosas, lactosa, fosfato de calcio o caolín o como cápsulas de gelatina blanda, en donde el ingrediente activo se mezcla con un medio no acuoso u oleoso, tales como glicerina, propilenglicol, polietilenglicol, aceite de maní, parafina líquida o aceite de oliva.

En otras formas de realización, las composiciones farmacéuticas de la invención se pueden formular como suspensiones que comprenden un compuesto de la fórmula (I) o una de sus formas en mezcla con al menos un excipiente farmacéuticamente aceptable apropiado para la preparación de una suspensión. En otras formas de realización más, las composiciones farmacéuticas de la invención se pueden formular como polvos dispersables y gránulos para la preparación de una suspensión por adición de uno o varios excipientes.

Los excipientes apropiados para usar en conexión con suspensiones incluyen agentes de suspensión, tales como carboximetilcelulosa sódica, metilcelulosa, hidroxipropilmetilcelulosa, alginato de sodio, polivinilpirrolidona, goma tragacanto, goma acacia, agentes de dispersión o humectantes tales como un fosfátido natural (por ejemplo, lecitina), un producto de condensación de un óxido de alquileno con un ácido graso (por ejemplo, estearato de polioxietileno), un producto de condensación de óxido de etileno con un alcohol alifático de cadena larga (por ejemplo, heptadecaetilenoxicetanol), un producto de condensación de óxido de etileno con un éster parcial derivado de un ácido graso y un anhídrido de hexitol (por ejemplo, monooleato de polioxietilensorbitano); y agentes espesantes, tales como carbómero, cera de abejas, parafina dura o alcohol cetílico. Las suspensiones también pueden contener uno o varios conservantes tales como ácido acético, p–hidroxi–benzoato de metilo y/o n–propilo; uno o varios agentes colorantes; uno o varios agentes saborizantes; y uno o varios agentes endulzantes tales como sacarosa o sacarina.

Las composiciones farmacéuticas de la invención también pueden estar en forma de emulsiones de aceite en agua. La fase oleosa puede ser un aceite vegetal, tales como aceite de oliva o aceite de arachís, un aceite mineral, tales como parafina líquida o una mezcla de ellos. Los agentes emulsionantes apropiados incluyen gomas naturales, tales como goma acacia y goma

tragacanto; fosfátidos naturales, tales como lecitina de soja, ésteres o ésteres parciales derivados de ácidos grasos; anhídridos de hexitol, tales como monooleato de sorbitano; y productos de condensación de estos ésteres parciales con óxido de etileno, tales como monooleato de polioxietilensorbitano. La emulsión también puede contener agentes endulzantes y saborizantes. Los jarabes y elíxires se pueden formular con agentes endulzantes, tales como glicerol, sorbitol o sacarosa. Estas formulaciones también pueden contener un agente demulcente, conservante, conservante, saborizante o colorante.

Además, las composiciones farmacéuticas de la invención pueden estar en forma de una preparación inyectable estéril, tales como una emulsión acuosa inyectable estéril o una suspensión oleaginosa. Esta emulsión o suspensión se puede formular de acuerdo con la técnica conocida usando esos agentes dispersantes o humectantes y agentes de suspensión apropiados que se mencionaron con anterioridad. La preparación inyectable estéril también puede ser una solución o suspensión inyectable estéril en un diluyente o solvente no tóxico parenteralmente aceptable, como una solución en 1,2–propano–diol. La preparación inyectable estéril también se puede preparar como un polvo liofilizado. Entre los vehículos y solventes aceptables que se pueden emplear son agua, solución de Ringer y solución isotónica de cloruro de sodio. Además, se pueden emplear aceites fijos estériles como un solvente o medio de suspensión. A este fin, se puede emplear cualquier aceite blando fijo incluyendo mono– o di–glicéridos sintéticos. Además, los ácidos grasos tales como ácido oleico se pueden usar igualmente en la preparación de inyectables.

Los compuestos de la invención pueden ser sustancialmente insolubles en agua y poco solubles en la mayoría de los solventes próticos farmacéuticamente aceptables y aceites vegetales, pero en general solubles en ácidos grasos de cadena media (por ejemplo, ácidos caprílico y cáprico) o triglicéridos y en ésteres

de propilenglicol de ácidos grasos de cadena media. Así, están contemplados en la invención los compuestos que fueron modificados por sustituciones o adiciones de restos químicos o bioquímicos que los hacen más apropiados para su administración (por ejemplo, mayor solubilidad, bioactividad, palatabilidad, reducción de reacciones adversas, *etc.*), por ejemplo, por esterificación, glicosilación, PEGilación, etc.

En algunas formas de realización, el compuesto de la invención se formula para administración oral en una composición a base de lípidos apropiada para compuestos de baja solubilidad. Las formulaciones a base de lípidos pueden mejorar en general la biodisponibilidad oral de tales compuestos. Como tales, las composiciones farmacéuticas de la invención pueden comprender una cantidad efectiva de un compuesto de la fórmula (I) o una de sus formas, junto con al menos un excipiente farmacéuticamente aceptable seleccionado de ácidos grasos de cadena media o sus ésteres de propilenglicol (por ejemplo, ésteres de propilenglicol de ácidos grasos comestibles tales como ácidos grasos caprílico y cáprico) y tensioactivos farmacéuticamente aceptables, tales como aceite de ricino hidrogenado de polioxilo 40.

En otras formas de realización, la biodisponibilidad de los compuestos de baja solubilidad se puede mejorar usando técnicas de optimización del tamaño de las partículas incluyendo la preparación de nanopartículas o nanosuspensiones usando técnicas conocidas por los expertos en la técnica. Las formas de compuesto presentes en tales preparaciones incluyen formas amorfas, parcialmente amorfas, parcialmente cristalinas o cristalinas.

En formas de realización alternativas, la composición farmacéutica también puede comprender uno o varios mejoradores acuosos de la solubilidad, tales como una ciclodextrina. Los ejemplos no limitativos de ciclodextrina incluyen derivados de hidroxipropilo, hidroxietilo, glucosilo, maltosilo y maltotriosilo de a–,

ß– y γ–ciclodextrina e hidroxipropil–ß–ciclodextrina (HPBC). En algunas formas de realización, la composición farmacéutica también comprende HPBC en un rango de aproximadamente 0,1% a aproximadamente 20%, de aproximadamente 1% a aproximadamente 15% o de aproximadamente 2,5% a aproximadamente 10%. La cantidad de mejorador de la solubilidad empleada puede depender de la cantidad del compuesto de la presente invención en la composición.

Preparación de los compuestos de la invención


Ejemplos de síntesis generales

Los métodos para preparar ciertos compuestos de utilidad para el tratamiento o la mejora de la infección por HCV o trastornos o síntomas asociados con ello están disponibles a través de metodología de síntesis estándar bien conocida y, además, fueron descritos en la solicitud de patente de los Estados Unidos N.° 11/653.450 (referencia indicada con anterioridad), solicitud de patente de los Estados Unidos N.° 11/653.448 (referencia indicada con anterioridad), solicitud de patente de los Estados Unidos N.° 11/331.180 (referencia indicada con anterioridad) y solicitud de patente de los Estados Unidos N.° 11/180.961 (referencia indicada con anterioridad), cada una de las cuales se incorpora por referencia en su totalidad y para todos los fines.

De manera similar, tal como se describió en la presente, los métodos para preparar los compuestos de la invención están disponibles por medio de metodología de síntesis estándar bien conocida. Muchos de los materiales de partida de indol son asequibles en comercios o se pueden preparar usando las rutas descritas más abajo con técnicas conocidas por los expertos en el arte.

Esquema A

Los compuestos de la fórmula (I) se pueden preparar tal como se describe en el Esquema A siguiente.



El compuesto de indol **A1** sustituido se puede sustituir en la posición 3 con ciano usando un compuesto agente de cianación **A2** apropiado (tal como isocianato de clorosulfonilo o un isocianato de dialquilfosforilo y similares) en un solvente apropiado o una mezcla de solventes (tales como DMF, CH_3CN o dioxano y similares) para obtener un compuesto **A3**. El compuesto **A3** se puede hacer reaccionar luego con un compuesto **A4** (en donde L representa un grupo saliente y en donde Z es como se definió previamente) para obtener un compuesto **A5**, representativo de un compuesto de la fórmula (I).

Con respecto al compuesto **A4**, cuando el grupo funcional reactivo Z incluye, pero sin limitación, alquilo C_{1-8} y aril–alquilo C_{1-8} y el grupo saliente L incluye, pero sin limitación, un haluro (tales como cloro, bromo o yodo) o un grupo saliente de alquilsulfonato, la reacción se puede llevar a cabo en un solvente apropiado en presencia de una base inorgánica (tales como carbonato de potasio o hidruro de sodio y similares) o una base orgánica (tales como una trialquilamina y similares).

Con respecto al compuesto **A4**, cuando el grupo funcional reactivo Z incluye, pero sin limitación, arilo o heteroarilo y el grupo saliente L incluye, pero sin limitación, un grupo saliente haluro (tales como cloro, bromo o yodo), la reacción se puede llevar a cabo en un solvente polar o no polar a una temperatura de aproximadamente ambiente a aproximadamente 200 °C en presencia de un catalizador de cobre (tales como CuI y similares) y una base (tales como Cs_2CO_3 o K_3PO_4 y similares) y opcionalmente con un ligando de amina (tales como 1,2–bis(metilamino)etano o 1,2–ciclohexandiamina y similares).


De modo alternativo, el compuesto **A1** se puede hacer reaccionar con el compuesto **A4** para dar un compuesto **A6** que se puede hacer reaccionar luego con el compuesto **A2** tal como se describió con anterioridad para obtener el compuesto **A5**.

Además, la yodación del compuesto **A6** provee el compuesto **A7**. La posterior reacción del compuesto **A7** con cianuro de cobre (CuCN) en condiciones apropiadas provee el compuesto **A5**.

La reacción del grupo ciano del compuesto **A5** en condiciones básicas (tal como hidróxido de potasio) da como resultado el compuesto **A8**, la amida primaria y la posterior reacción da como resultado el compuesto **A9**, el ácido carboxílico.

Esquema B

Los compuestos de la fórmula (I), en donde X es un aldehído, se pueden preparar tal como se describe en el Esquema B siguiente.




El compuesto de indol sustituido con aldehído **B1** se puede preparar haciendo reaccionar el compuesto **A1** con un reactivo de formilación (tales como oxicloruro de fósforo en presencia de DMF). La conversión del compuesto **B1** en el compuesto **B2**, representativo de un compuesto de la fórmula (I), se puede realizar por tratamiento con el compuesto **A4** tal como se describió previamente en el Esquema A.

De modo alternativo, el compuesto **A6** se puede hacer reaccionar con un reactivo de formilación para proporcionar directamente el compuesto **B2**.

Esquema C

Los compuestos intermediarios de la fórmula (I), en donde X es una oxima de formaldehído, se pueden preparar tal como se describe en el Esquema C siguiente.




El compuesto de indol sustituido con aldehído **B2** se puede convertir en el compuesto de indol sustituido con oxima **C1** por medio de un reactivo de aminación (tal como hidroxilamina). La conversión del compuesto **C1** por medio de deshidratación, por tratamiento con anhídrido acético y una base o reacción

con cloruro de tionilo da como resultado el compuesto **A5**, representativo de un compuesto de la fórmula (I).

Esquema D

Los compuestos de la fórmula (I), en donde X es nitro, se pueden preparar tal como se describe en el Esquema D siguiente.




Un compuesto de nitroindol **D1** se puede obtener haciendo reaccionar el compuesto **A1** con un agente nitrante (tales como ácido nítrico o nitrito de sodio y similares) en un solvente (tales como ácido acético, anhídrido acético o ácido sulfúrico y similares o en un sistema de solventes mixto que también contiene un solvente orgánico tales como diclorometano y similares). La reacción se puede llevar a cabo a una temperatura de aproximadamente –30 °C a aproximadamente 50 °C.

El compuesto **D1** se puede hacer reaccionar con el compuesto **A4** para proveer el compuesto **D2**, representativo de un compuesto de la fórmula (I).

De modo alternativo, el compuesto **A6** se puede hacer reaccionar en lugar del compuesto **A1** para proporcionar directamente el compuesto **D2**.

Esquema E

Los compuestos de la fórmula (I), en donde X es carboxilo, se pueden preparar tal como se describe en el Esquema E siguiente.




El compuesto **B2** se puede hacer reaccionar con un reactivo (tales como permanganato de potasio y similares) en condiciones acuosas para proveer el compuesto **E1**, representativo de un compuesto de la fórmula (I).

Además, el compuesto **E1** se puede hacer reaccionar con cloruro de tionilo, seguido de la reacción con una amina sustituida (en donde el átomo de nitrógeno puede estar mono– o disustituida con Ra, en donde Ra es alquilo C_{1-8}) para proveer un compuesto análogo sustituido con amido **E2**, representativo de un compuesto de la fórmula (I).

Esquema F

Los compuestos de la fórmula (I), en donde X es ciano, se pueden preparar tal como se describe en el Esquema F siguiente.




El compuesto de anilina sustituido **F1** se puede diazotizar y la sal de diazonio resultante se redujo para dar un compuesto de fenilhidrazina **F2**. El compuesto **F2** se hace reaccionar luego con compuesto de cetona **F3** en condiciones ácidas para proveer el compuesto **A1**, que se puede llevar a cabo tal como se describe en el Esquema A para proveer el compuesto **A5**, representativo de un compuesto de la fórmula (I).

Las condiciones para la reacción de ciclación entre el compuesto **F2** y el compuesto **F3** se puede llevar a cabo en condiciones típicas utilizadas por un experto en la técnica. Por ejemplo, se pueden proveer condiciones ácidas usando un ácido de Bronstead (tales como ácido acético, ácido clorhídrico o ácido polifosfórico y similares) o un ácido de Lewis (tales como cloruro de zinc y similares). La reacción se puede llevar a cabo en presencia de un cosolvente

(tales como CH_2Cl_2 o THF y similares), típicamente dentro de un rango de temperaturas de aproximadamente 0 °C a aproximadamente 120 °C.

Esquema G

Los compuestos de la fórmula (I) se pueden preparar tal como se describe en el Esquema G siguiente.



Un compuesto **G1** se puede convertir en el compuesto halogenado **G2** (en donde Rb representa un átomo de halógeno tales como yodo o bromo) por reacción con una base fuerte (tales como n–butil–litio, s–butil–litio, diisopropilamida de litio, hexametildisilazida de litio o potasio y similares) en presencia de un solvente no reactivo apropiado (tales como éter o THF) o en mezclas de solventes que contienen un solvente no reactivo para proveer un intermediario aniónico de 2–indolilo. La reacción se lleva a cabo típicamente en el rango de aproximadamente –78 °C a aproximadamente temperatura ambiente. La generación del intermediario se puede neutralizar con una fuente electrolítica de halógeno (tales como yodo, bromo o N–bromosuccinimida y similares) para obtener el compuesto **G2**.

El compuesto **G2** se puede hacer reaccionar luego con un ácido borónico en una reacción de Suzuki o con trialquilestannano en una reacción de Stille en presencia de un catalizador de paladio (tales como tetrakis(trifenilfosfina)paladio (0), dicloruro de bis(trifenilfosfina)paladio (II) o acetato de paladio) y un ligando de fosfina añadido, para obtener un compuesto de la fórmula (I).


La reacción se lleva a cabo en un solvente apropiado (tales como DMF, tolueno, dimetoxi etano o dioxano y similares) a una temperatura de aproximadamente ambiente a aproximadamente 150 °C. Para las condiciones de Suzuki, la reacción se puede realizar con una base en condiciones acuosas (tales como carbonato de sodio acuoso o bicarbonato de sodio y similares) o en condiciones anhidras (tales como con fluoruro de cesio o potasio y similares). Para las condiciones de Stille, la reacción se puede realizar con un cocatalizador de cobre (tales como yoduro de cobre y similares).

De modo alternativo, el compuesto **G1** se puede convertir en un derivado del compuesto **G3** (en donde Rc representa ácido borónico o trialquilestannano) haciendo reaccionar el intermediario aniónico de 2–indolilo anterior con un derivado de trialquilborato o halo–trialquilestannano (en donde halo puede ser cloro, bromo o yodo), respectivamente. El compuesto **G3** se puede hacer reaccionar luego con un compuesto **G4** (en donde L representa un grupo saliente haluro tales como bromo o yodo), ya sea en condiciones de Suzuki o Stille para proveer un compuesto de la fórmula (I).

Otro método consiste en hacer reaccionar el compuesto **G1** en condiciones de Heck (tales como acetato de paladio, óxido de plata (I), ácido o–nitrobenzoico) en un solvente apropiado (tales como DMF) con **G4** para obtener un compuesto de la fórmula (I).

Esquema H

Los compuestos de la fórmula (I), en donde X es ciano, se pueden preparar tal como se describe en el Esquema H siguiente.




Un compuesto **H1** se puede proteger por reacción con un grupo protector (en donde PG_1 representa un grupo protector reactivo tales como anhídrido de Boc y similares) para proveer un compuesto **H2** (en donde PG representa un grupo protector tales como Boc, bencilo, alquilo, aril–sulfonilo o trialquil–sililo y similares). El tratamiento del compuesto **H2** con una base fuerte (tales como diisopropilamida de litio y similares) en un solvente aprótico (tales como THF y similares), seguido de neutralización con un derivado de trialquilborato obtiene un compuesto **H3**.

La reacción del compuesto **H3** con el compuesto **G4** en condiciones de reacción descritas en el Esquema G provee el compuesto **H4** y la eliminación del grupo protector da como resultado el compuesto **A1**, que se puede llevar a cabo tal como se describió en el Esquema A para proveer el compuesto **A5**, representativo de un compuesto de la fórmula (I).

Esquema I

Los compuestos de la fórmula (I) se pueden preparar tal como se describe en el Esquema I siguiente.



Tal como se describe en el Esquema H, el compuesto **I1** se puede usar en lugar del compuesto **H1** para proveer un compuesto protegido **I2**.

Tal como se describe en el Esquema G, el compuesto **I2** se puede usar en lugar del compuesto **G1** para proveer un compuesto halogenado **I3** (en donde Rd representa un átomo de halógeno tales como yodo o bromo).


Tal como se describe en el Esquema H, el compuesto **I3** se puede usar en lugar del compuesto **H4** para proveer un compuesto desprotegido **I4**.

Tal como se describe en el Esquema G, el compuesto **I4** se puede usar en lugar del compuesto **G2** en una reacción de Suzuki con un ácido o éster borónico en presencia de un catalizador de paladio apropiado y un ligando de fosfina agregado, para obtener un compuesto **I5**.

Tal como se describe en el Esquema A, el compuesto **I5** se puede usar en lugar del compuesto **A1** para proveer un compuesto de la fórmula (I).

Esquema J

Los compuestos de la fórmula (I) se pueden preparar tal como se describe en el Esquema J siguiente.



Tal como se describe en el Esquema G, el compuesto **G1** se hace reaccionar para proveer el intermediario aniónico de 2–indolilo que se puede neutralizar con una fuente haluro de zinc (tales como metal de haluro de zinc o soluciones de ellas) para dar un compuesto de organozinc **J1**. El compuesto **J1** se puede hacer reaccionar luego con un compuesto **J2** (en donde L representa un grupo saliente tales como halógeno o triflato y similares) en una reacción de Negishi en presencia de un catalizador de paladio apropiado para obtener un compuesto de la fórmula (I).


De modo alternativo, el compuesto **G2** (en donde Rb es como se describió con anterioridad) se puede hacer reaccionar con un compuesto **J3** en presencia de un catalizador de paladio apropiado para proveer un compuesto de la fórmula (I).


Las condiciones para las reacciones anteriores incluyen la presencia de un catalizador de paladio (tales como tetrakis(trifenilfosfina)paladio (0) o dicloruro de bis(trifenilfosfina)paladio (II)) en un solvente apropiado y una temperatura en un rango de aproximadamente ambiente a aproximadamente 150 °C.

El compuesto **J3** se puede preparar por tratamiento de un haluro de arilo con zinc activado o por tratamiento de un compuesto sustituido con litio o magnesio R_1–Ar con haluro de zinc.

Esquema K

Los compuestos de la fórmula (I) se pueden preparar tal como se describe en el Esquema I siguiente.






El compuesto **K1** se yoda en condiciones apropiadas (tales como yoduro de potasio y yodato de potasio o monocloruro de yodo) para proveer el compuesto **K2**. El compuesto **K2** se puede hacer reaccionar luego con un compuesto **K3** en una reacción de Sonogashira en presencia de un catalizador de paladio apropiado (tales como dicloruro de bis(trifenilfosfina)paladio y similares) y un cocatalizador de cobre (tales como yoduro de cobre y similares) para obtener el compuesto **K4**. El compuesto **K4** se hace reaccionar con *ter*–butóxido de potasio o un catalizador de cobre apropiado (tales como yoduro de cobre y similares) para proveer el compuesto **A6**, representativo de un compuesto de la fórmula (I).

De modo alternativo, el compuesto **K2** se puede hacer reaccionar con trimetilsililacetileno en condiciones de Sonogashira para dar un compuesto **K5**. La

eliminación del grupo trimetilsilili se lleva a cabo empleando hidróxido de potasio para obtener el compuesto **K6**. La reacción del compuesto **K6** con un compuesto **L–Y** (donde L e Y se definieron con anterioridad) en condiciones de Sonogashira provee el compuesto **K4** que se puede hacer reaccionar luego tal como se describió con anterioridad para obtener el compuesto **A6**, representativo de un compuesto de la fórmula (I).

Esquema L


Los compuestos de la fórmula (I) se pueden preparar tal como se describe en el Esquema L siguiente.



La reacción del compuesto **A7** con un sintón de yoduro de vinilo con un catalizador apropiado (tales como acetato de paladio (II), dppp) y posterior tratamiento de ácido acuoso da como resultado el compuesto **L1**, representativo de un compuesto de la fórmula (I).

Esquema M


Los compuestos de la fórmula (I) se pueden preparar tal como se describe en el Esquema M siguiente.




El compuesto **A6** se puede hacer reaccionar con un agente de tiometilación (tales como N–tiometil–ftalimida) en un solvente apropiado (tales como dimetlilacetamida) para proveer el compuesto **M1**. La posterior oxidación del compuesto **M1** con un oxidante apropiado (tales como mCPBA) y solvente (tales como cloroformo) da como resultado el compuesto **M2**, representativo de un compuesto de la fórmula (I).

Esquema O

Los compuestos de la fórmula (I) se pueden preparar tal como se describe en el Esquema O siguiente.





El compuesto **H1** se puede hacer reaccionar con un reactivo de acilación (tales como cloruro de tricloroacetilo y luego KOH) para proveer el compuesto **O1**. El compuesto **O1** se puede hacer reaccionar con el compuesto **A4** para proveer el compuesto **O2.** El compuesto **O2** se puede convertir en el compuesto halogenado **O3** (en donde Rb representa un átomo de halógeno tales como yodo o bromo) por reacción con una base fuerte (tales como n–butil–litio, s–butil–litio, diisopropilamida de litio, hexametildisilazida de litio o potasio y similares) en presencia de un solvente no reactivo apropiado (tales como éter o THF) o en mezclas de solventes que contiene un solvente no reactivo para proveer un intermediario aniónico de 2–indolilo. La reacción se lleva a cabo típicamente en el rango de aproximadamente –78 °C a aproximadamente temperatura ambiente. La generación del intermediario se puede neutralizar con una fuente electrolítica de halógeno (tales como yodo, bromo o N–bromosuccinimida y similares) para obtener el compuesto **O3.**

El compuesto **O3** se puede hacer reaccionar luego con un ácido borónico en una reacción de Suzuki o con trialquilestannano en una reacción de Stille en presencia de un catalizador de paladio (tales como tetrakis(trifenilfosfina)paladio (0), dicloruro de bis(trifenilfosfina)paladio (II) o acetato de paladio) y un ligando de fosfina añadido, para obtener un compuesto del compuesto **O4**, representativo de un compuesto de la fórmula (I).

La reacción se lleva a cabo en un solvente apropiado (tales como DMF, tolueno, dimetoxi etano o dioxano y similares) a una temperatura de aproximadamente ambiente a aproximadamente 150 °C. Para las condiciones de

Suzuki, la reacción se puede realizar con una base en condiciones acuosas (tales como carbonato de sodio acuoso o bicarbonato de sodio y similares) o en condiciones anhidras (tales como con fluoruro de cesio o potasio y similares). Para las condiciones de Stille, la reacción se puede realizar con un cocatalizador de cobre (tales como yoduro de cobre y similares).

De modo alternativo, el compuesto **O2** se puede convertir en un derivado del compuesto **O5** (en donde Rc representa ácido borónico o trialquilestannano) haciendo reaccionar el intermediario aniónico de 2–indolilo descrito con anterioridad con un derivado de trialquilborato o halo–trialquilestannano (en donde halo puede ser cloro, bromo o yodo), respectivamente. El compuesto **O5** se puede hacer reaccionar luego con un compuesto **G4** (en donde L representa un grupo saliente haluro tales como bromo o yodo), en condiciones de Suzuki o de Stille para proveer el compuesto **O4**, representativo de un compuesto de la fórmula (I).

Otro método consiste en hacer reaccionar el compuesto **O2** en condiciones de Heck (tales como acetato de paladio, óxido de plata (I), ácido o–nitrobenzoico) para obtener un compuesto del compuesto **O4**, representativo de un compuesto de la fórmula (I).

El compuesto **O4** se puede hacer reaccionar con KOH en un solvente apropiado para proveer el compuesto **E1** que se puede hacer reaccionar como en el Esquema E para proveer **E2**, representativo de un compuesto de la fórmula (I).

Ejemplos de síntesis específicos

Para ayudar a comprender la presente invención, se incluyen los siguientes ejemplos. Los experimentos relacionados con esta invención no se deben construir, de hecho, como limitantes específicamente de la invención y estas variaciones de la invención, ahora conocidas o desarrolladas más adelante, que estarán dentro de la competencia de un experto en la técnica, se considerarán

dentro del alcance de la invención tal como se describe en la presente y se reivindica más adelante en la presente.

A diferencia de los ejemplos de trabajo, salvo que se indique lo contrario, todos los números que expresan cantidades de ingredientes, condiciones de reacción, datos experimentales, etc. usados en la memoria descriptiva y las reivindicaciones se han de entender como modificados por el término "aproximadamente". Conforme a ello, todos estos números representan aproximaciones que se pueden variar dentro de las propiedades deseadas que se busca obtener por medio de una reacción o como resultado de condiciones experimentales variables. En consecuencia, dentro de un rango esperado de reproducibilidad experimental, el término "aproximadamente" en el contexto de los datos resultantes, se refiere a un rango para los datos siempre que puedan variar de acuerdo con una desviación estándar de la media. Asimismo, para los resultados experimentales provistos, los datos resultantes se pueden redondear hacia arriba o hacia abajo para presentar los datos de manera consistente, sin perder las figuras significativas. Por último y no como un intento de limitar la aplicación de la doctrina de equivalentes al alcance de las reivindicaciones, cada parámetro numérico se debe construir a la luz de la cantidad de dígitos significativos y técnicas de redondeo ordinarias.

Como los rangos numéricos y parámetros establecidos para el alcance amplio de la invención son aproximaciones, los valores numéricos establecidos en los ejemplos de trabajo se informan de la manera más precisa posible. Sin embargo, cualquier valor numérico contiene inherentemente ciertos errores que resultan necesariamente de la desviación estándar hallada en sus respectivas mediciones de ensayo.

Ejemplos de síntesis

La presente invención se describe con mayor detalle con referencia a los siguientes ejemplos no limitativos que se ofrecen para ilustrar más completamente la invención, pero no se construyen como limitativos de su alcance. Los ejemplos ilustran la preparación de ciertos compuestos de la invención y el ensayo de estos compuestos in *vitro* y/o in *vivo*. Los expertos en el arte entenderán que las técnicas descritas en estos ejemplos representan técnicas descritas por los inventores para que funcionen bien en la práctica de la invención y como tales constituyen modos preferidos para su práctica. Sin embargo, los expertos en la técnica deberán apreciar a la luz de la presente descripción que se pueden hacer muchos cambios en los métodos específicos que se describen y aún obtener un resultado igual o similar sin apartarse del espíritu y el alcance de la invención.

Tal como se usó con anterioridad y a lo largo de la descripción de la invención, se entiende que las siguientes abreviaturas, a menos que se indique otra cosa, han de tener los siguientes significados:

Abreviatura	**Significado**
AcOH o HOAc	ácido acético
^{t}Bu o *t*Bu	ter–butilo
CSI	isocianato de clorosulfonilo
DCM	diclorometano (CH_2Cl_2)
DIPA	diisopropilamina
DMF	dimetilformamida
DME	éter dimetílico
DMSO	dimetilsulfóxido
HPLC	cromatografía líquida de alto rendimiento
iPR	isopropilo
KF	fluoruro de potasio


Abreviatura	**Significado**
LDA	diamina
MeOH	metanol
MS	espectroscopia de masa
MTBE	éter metil–*ter*–butílico
RMN	resonancia magnética nuclear
Pd^{o}	paladio
$Pd_2(dba)_3$	tris(dibencilidenacetona)dipaladio (0)
$PdCl_2dppf$	[1,1'–bis(difenilfosfino)ferroceno]dicloropaladio (II)
$Pd(Pf_3)_4$	tetrakis(trifenilfosfina)paladio
$PHBF_4$	tetrafluoroborato de fosfonio
TA	temperatura ambiente
Bu_3SnI o $ISnBu_3$	yoduro de tributilestaño
TFA	ácido trifluoroacético
THF	tetrahidrofurano
TLC	cromatografía en capa fina
TMS	trimetilsililo
Tos	tosilo

Ejemplo 1

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida

(compuesto **35**)

Etapa A. Preparación de clorhidrato de 1, 3–difluoro–2–propilamina





1,3–difluoro–2–propanol (60,75 g, 633 mmol) se disolvió en piridina (375 mL) a 0 °C. Se añadió cloruro de tosilo (134 g, 700 mmol) en porciones y se agitó durante la noche a temperatura ambiente. Se eliminó la piridina a presión reducida y el residuo se diluyó con acetato de etilo. La mezcla se lavó secuencialmente con HCl acuoso diluido, agua, $NaHCO_3$ sat. ac. y salmuera. La capa orgánica se secó sobre $MgSO_4$, se filtró y se concentró. El residuo se enfrió hasta –78 °C hasta que se empezaron a formar cristales. El material se trituró con hexano helado (2X200 mL) y se filtró para proveer O–Tosil–1,3–difluoro–2–propanol en forma de un sólido blanco de bajo punto de fusión (143,9 g, 91%).

O–Tosil–1, 3–difluoro–2–propanol (30 g, 120 mmol), azida sódica (16 g, 246 mmol) y DMSO (60 mL) se combinaron y se calentaron a 70 °C durante 5 h. La mezcla de reacción luego se diluyó en 500 mL de agua y se extrajo con acetato de etilo (4X40 mL). La capa orgánica se lavó con 40 mL de agua y salmuera. La mezcla se secó sobre $MgSO_4$ y se filtró en una botella Parr de 500 mL. Se añadió Pd/C (10%, 1,5 g) y la mezcla se agitó en un hidrogenador Parr a 50 psi de H_2 durante 30 minutos. La botella luego se evacuó rápidamente, se

cargó nuevamente hasta 50 psi y se agitó durante otros 30 minutos. Este proceso se repitió tres veces más. La mezcla luego se filtró a través de celite y se burbujeó HCl (gas) hasta que se saturó por completo con HCl (30 minutos). Se evaporaron el acetato de etilo y HCl para proveer el compuesto del título en forma de un sólido blanco (12,3 g, 78%). ^{1}H RMN (DMSO–d_6, 500 MHz): d 8,83 (3H, br s), 4,81 (1H, m), 4,72 (2H, m), 4,63 (1H, m), 3,78 (1H, m).

Parte B. Preparación de 6–cloro–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida






Una solución de SO_2 se preparó añadiendo cloruro de tionilo (24,2 mL) en agua agitada (144 mL) con cloruro de cobre (I) (87,0 mg). La solución se agitó luego a temperatura ambiente durante la noche. Se añadió 5–amino–2–cloropiridina (10,0 g, 77,8 mmol) en HCl concentrado acuoso en agitación (80 mL) en porciones. La mezcla se agitó hasta que todo el sólido se disolvió y luego se enfrió hasta –5 °C. En la mezcla se añadió gota a gota una solución de nitrito de sodio (5,9 g, 85,6 mmol) disuelta en 24 mL de agua mientras se mantenía la temperatura entre –5 °C y 0 °C. La mezcla resultante se agitó durante 30 minutos después de terminar la adición y luego se añadió gota a gota en la solución acuosa de SO_2. La temperatura se mantuvo a menos de 0 °C durante la adición. Después de la adición, la mezcla se agitó durante 1 h a menos de 0 °C y luego se filtró. La torta se lavó con agua helada, se disolvió en CH_2Cl_2, se secó sobre

Na_2SO_4 y se concentró para dar cloruro de 2–cloropiridin–5–sulfonilo en forma de un sólido gris (13,6 g, 82%). ^{1}H RMN (500 MHz, $CDCl_3$): d 9,04 (1H, d, J = 2,4 Hz), 8,27 (1H, dd, J = 8,5 Hz, J = 2,6 Hz), 7,62 (1H, dd, J = 8,5 Hz, J = 0,4 Hz).

Se añadió cloruro de 2–cloropiridin–5–sulfonilo (18 g, 85 mmol) a una solución de clorhidrato de 1,3–difluoro–2–propilamina (11,2 g, 58,1 mmol) en piridina (25 mL) a 0 °C. La mezcla de reacción se agitó a temperatura ambiente durante 30 minutos, se diluyó con acetato de etilo (200 mL) y se lavó con HCl acuoso 3 N (3X100 mL). La capa orgánica se secó sobre Na_2SO_4, se filtró y se concentró. El residuo se trituró con hexano (2X50 mL) y se filtró para proveer el compuesto del título en forma de un sólido blanquecino (15,7 g, 70%). ^{1}H RMN (500 MHz, $CDCl_3$): d 8,79 (1H, d, *J* = 2,4Hz), 8,17 (1H, dd, *J* = 2,6 Hz, 2,5 Hz), 7,49 (1H, d, *J* = 8,2 Hz), 5,25 (1Hbr s), 4,58 (2H, m), 4,47 (2H, m), 3,77 (1H, m).

Parte C. Preparación de ácido 3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–ilborónico



A 6–bromo–1H–indol (41,36 g, 211,0 mmol) en DMF (150 mL) a –78 °C se añadió isocianato de clorosulfonilo (20 mL, 225 mmol). Después de completar la adición, la mezcla se dejó calentar hasta temperatura ambiente y se agitó durante 2 h. La mezcla de reacción se vertió en hielo (500 mL) y se agitó durante 30 minutos. El precipitado se recogió en un filtro y se secó en un horno de vacío para dar 6–bromo–1H–indol–3–carbonitrilo en forma de un sólido de color beige claro (46,73 g, 100%).


Al 6–bromo–1H–indol–3–carbonitrilo (20,28 g, 91,79 mmol) se añadió carbonato de cesio (76 g, 233 mmol), DMF (20 mL) y luego bromuro de ciclobutilo (96%, 11 mL, 112 mmol). Esta mezcla se agitó durante la noche a 100 °C, se enfrió hasta temperatura ambiente y luego se vertió en agua helada (500 mL). El precipitado se recogió en un filtro y se lavó con éter etílico (3X10 mL) y se secó en un horno de vacío a 50 °C para dar una primera fracción de 6–bromo–1–ciclobutil–1H–indol–3–carbonitrilo en forma de un sólido de color tostado claro (19,70 g). El lavado de éter etílico se recogió, se concentró y se trituró con éter para dar una segunda fracción de 6–bromo–1–ciclobutil–1H–indol–3–carbonitrilo en forma de un sólido anaranjado claro (2,90 g) (89% de rendimiento combinado).

A 6–bromo–1–ciclobutil–1H–indol–3–carbonitrilo (1,13 g, 4,11 mmol) en un recipiente inundado con nitrógeno se añadió ácido ciclopropilborónico (0,62 g, 6,1 mmol), $Pd_2(dba)_3$ (0,19 g, 0,21 mmol), tetrafluoroborato de tri–ter–butilfosfonio (0,14 g, 0,48 mmol), fluoruro de potasio (1,43 g, 24,6 mmol). Los reactivos secos se trataron en tres ciclos de alto vacío/relleno de nitrógeno. Se añadió THF desgasificado (16 mL) y la mezcla se agitó durante la noche a 30 °C. THF se eliminó bajo una corriente de nitrógeno y luego se añadió CH_2Cl_2 (30 mL). La mezcla se agitó durante 2 horas, se filtró a través de celite, se concentró y se cromatografió en sílice (0–10% de acetato de etilo 1:1 en CH_2Cl_2 / hexanos) para dar 0,68 g de sólido blanco con aproximadamente 1% de 3–ciano–1–N–ciclobutilindol. La impureza se eliminó por medio de un lavado con hexano caliente; el sólido se calentó hasta 70 °C en hexano y luego se filtró (material combinado, 11,2 g, dio 9,1 g de material puro) para proveer 1–ciclobutil–6–ciclopropil–1H–indol–3–carbonitrilo. ^{1}H RMN (500 MHz, acetona–d_6): d 8,15 (1H, s), 7,54 (1H, d, J = 7,9 Hz), 7,35 (1H, s), 7,06 (1H, dd, J = 8,2 Hz, J = 1,4 Hz), 5,09 (1H, p, J = 8,0 Hz), 2,72–2,61 (2H, m), 2,59–2,48 (2H, m), 2,12–2,05 (2H, m),

2,03–1,93 (3H, m), 1,00 (2H, ddd, J = 8,4 Hz, J = 6,4 Hz, J = 4,4 Hz), 0,80–0,74 (2H, m).

A una solución de 1–ciclobutil–6–ciclopropil–1H–indol–3–carbonitrilo (2,0 g, 8,47 mmol) y borato de triisopropilo (3,52 mL, 15,25 mmol) en THF (35 mL) a –78 °C se añadió LDA (1,5 M en ciclohexano, 7,3 mL, 11,01 mmol). La mezcla se agitó a –78 °C durante 30 min, se neutralizó con agua helada (60 mL) y se agitó durante 15 min sin enfriamiento. La mezcla se extrajo con acetato de etilo 1:1 en hexano (20 mL). La capa acuosa se acidificó con HCl ac. 2 N hasta pH 5 y luego se extrajo con CH_2Cl_2 (60 mL). La capa orgánica se secó sobre Na_2SO_4 y se concentró para dar el compuesto del título en forma de un sólido (2,5 g, 70% puro por LCMS) que se usó en la siguiente etapa sin ulterior purificación.

Parte D. Preparación de 6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida



Una mezcla de ácido 3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–ilborónico (0,46 g, 1,15 mmol), 6–cloro–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida (0,17 g, 0,63 mmol), tetrafluoroborato de tri–ter–butilfosfonio (20 mg, 0,069 mmol), $Pd_2(dba)_3$ (32 mg, 0,035 mmol) y fluoruro de potasio (0,4 g, 6,9 mmol) en THF (4,0 mL) se agitó a 40 °C durante la noche. El solvente luego se evaporó y el residuo se purificó por cromatografía flash con 0–10% de acetato de etilo en CH_2Cl_2 para proveer el compuesto del título **35** (220 mg, 74%). Punto de fusión: 175–178; MS *m/z* 471,1 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 9,23 (1H, s), 8,33 (1H, dd, J = 8,2 Hz, J = 2,2 Hz), 8,01 (1H, d, J = 8,2 Hz), 7,68 (1H, d, J = 8,3 Hz), 7,45 (1H, s), 7,05 (1H, t, J = 7,0 Hz), 5,36 – 5,31 (1H, m), 5,23 (1H, d, J = 8,4

Hz), 4,63 – 4,44 (4H, m), 3,98 – 3,83 (1H, m), 2,69 – 2,60 (2H, m), 2,50 – 2,40 (2H, m), 2,14 – 2,08 (1H, m), 2,00 – 1,82 (2H, m), 1,12 – 1,05 (2H, m), 0,82 – 0,77 (2H, m).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento del Ejemplo 1 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados de (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos):

Comp	Nombre	p.f.	MS
5	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	203–205	413,2
6	6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	160–162	413,2
7	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	174–176	435,3
8	6–(3–ciano–1–ciclobutil–5–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	172–174	435,2
9	N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida	181–185	427,1
14	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	N/A	429,3
15	N–ter–butil–6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)piridin–3–sulfonamida	195–197	443,2
27	5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–2–sulfonamida	N/A	435,3

Comp	Nombre	p.f.	MS
28	5–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–2–sulfonamida	N/A	429,2
29	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	206–208	449,0
30	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	182–186	465,0
37	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	200–202	465,0
38	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	171–172	463,3
46	6–[3–ciano–5–fluoro–1–(tetrahidrofuran–3–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	194–197	465,1
47	6–[3–ciano–5–fluoro–1–(tetrahidrofuran–3–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	185–188	429,0
56	6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	206–208	448,5
57	6–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	188–190	449,0
58	6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	162–164	448,5
60	6–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	168–170	437,0
61	6–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	155–156	437,3
62	6–[6–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	223–227	464,9

Comp	Nombre	p.f.	MS
63	6–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	200–202	453,0
64	6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	236–240	479,0
65	6–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	212–215	452,8
66	6–(3–ciano–1–ciclopentil–7–fluoro–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	152–153	427,0
71	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	192–193	436,5
72	6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	479,0
73	6–[5–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	464,9
79	6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	493,9
83	6–[3–ciano–6–ciclopropil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	184–190	459,1
84	6–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	471,0
85	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	194–200	485,0
86	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida	166–170	503,5
87	6–(3–ciano–1–ciclopentil–7–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	128–129	462,9

Comp	Nombre	p.f.	MS
88	6–(7–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	149–150	410,8
89	6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	203–207	492,9
90	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–3–sulfonamida	N/A	393,0
92	6–(3–ciano–1–ciclohexil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	193–198	499,0
97	2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	210–215	458,0
104	6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	138–141	477,0
109	6–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	209–208	421,4
114	2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	>198,0 desco mp.	430,0
115	2–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	228–229	430,0
120	2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	202–220	418,6
123	2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	192–197	402,0
124	2–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	169–174	436,0

Comp	Nombre	p.f.	MS
125	2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	211–212	450,0
126	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	165–168	472,0
138	2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	193–195	414,0
139	2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	218–219	414,6
140	2–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	158–160	402,6
141	2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	216–217	428,1
147	6–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	226–228	457,7
148	2–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	259–260	422,7
153	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	166–171	501,0
156	2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	N/A	418,0
157	2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	233–238	479,9
163	2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	193–195	449,9
164	2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	176–178	449,9

Comp	Nombre	p.f.	MS
165	2–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	149–150	438,1
166	2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	167–169	464,0
173	2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	215–219	486,1
175	2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	210–212	465,9
176	2–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	243–246	465,8
187	2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	N/A	453,9
188	2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	N/A	479,9
189	2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	N/A	443,9
193	2–(3–ciano–1–ciclohexil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	>200 desco mp.	500,0
221	2–[5–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	245–250	465,9
234	6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	193–199	477,1
235	2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	213–218	478,1

Comp	Nombre	p.f.	MS
240	2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	201–206	464,0
243	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida	N/A	477,0
244	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida	135–138	477,1
247	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida	176–178	483,2
251	2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	200–202	442,1
257	2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	N/A	454,1
264	2–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	184–188	486,0
265	2–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	192–194	450,0
266	6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	178–180	449,0
287	N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]metansulfonamida	239–241	407,1
288	N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]etansulfonamida	241–243	421,3
289	N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]propan–2–sulfonamida	226–228	435,3
298	N–[6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida	230–235	455,3

Comp	Nombre	p.f.	MS
302	2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	216–221	450,2
303	2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	215–220	414,3
306	2–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	168–170	544,1
307	6–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	166–168	463,0
308	6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	144–145	493,2
309	6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	115–117	505,2
310	6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	204,5–205,0	473,1
311	6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	185–186	491,2
312	6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	147,5–148,5	463,2
314	2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	239–245	444,0
315	2–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	N/A	428,0

Comp	Nombre	p.f.	MS
316	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	482,9
317	6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	453,0
318	6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	463,0
319	6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	200–213	480,9
320	6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	133–134	519,0
321	2–[3–ciano–1–ciclobutil–6–(morfolin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	223–225	517,3
322	6–[3–ciano–1–ciclobutil–6–(morfolin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	241–242	516,3
324	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	214–215	490,2
325	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	242–243	464,2
330	2–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	N/A	482,0
331	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	217–222	481,0

Comp	Nombre	p.f.	MS
332	2–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	221–227	446,0
333	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	212–220	445,1
334	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	200–206	499,0
335	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	182–189	471,1
338	6–(3–ciano–1–ciclobutil–6–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	198–199	477,2
339	6–(3–ciano–1–ciclobutil–5–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	168–169	477,2
342	6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	Foam	485,3
343	6–(3–ciano–6–ciclobutil–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	176–178	517,3
344	2–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	205–210	472,2
345	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–200	477,2
346	6–(3,5–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	225–228	488,3

Comp	Nombre	p.f.	MS
347	6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	199–201	456,1
348	6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	190–192	420,2
349	6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	187–188	474,2
350	N–[(1S)–1–ciclopropiletil]–6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]piridin–3–sulfonamida	203–208	463,2
358	6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	168–170	546,9
360	6–(6–cloro–3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	203–206	501,0
361	2–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	226–232	464,4
362	6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	205–209	481,3
363	6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	198–207	499,2
364	6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	497,2
365	6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	207–214	497,3

Comp	Nombre	p.f.	MS
367	N–[(1S)–1–ciclopropiletil]–2–(3,5–diciano–1–ciclopentil–1H–indol–2–il)pirimidin–5–sulfonamida	218–223	461,2
372	6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	175–180	463,3
373	6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	186–188	445,3
374	6–(3–ciano–1–ciclopentil–5–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	159,5–160,5	491,1
375	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	198–204	482,9
376	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	193–198	483,2
377	2–[3–ciano–1–ciclobutil–5–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	131–134	464,0
378	6–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	481,1
379	2–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	N/A	482,1
380	2–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	186–188	500,1
381	6–(3–ciano–1–ciclopentil–5–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	167–168	473,1

Comp	Nombre	p.f.	MS
384	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	172–174	513,0
385	2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	216–218	514,1
388	2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	219–222	410,2
389	2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	220–223	464,1
390	2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	218–223	492,2
391	2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	180–185	478,2
392	2–(3,5–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	250–254	489,4
393	2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	236–238	496,1
394	6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	213–215	495,1
395	6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	171–172	467,2

Comp	Nombre	p.f.	MS
396	6–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	132–133	481,1
397	6–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	174–175	467,1
401	2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	238–239	504,3
402	2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	259–260	464,2
403	2–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	235–236	452,3
404	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	223–224	478,3
405	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	254–255	480,3
406	2–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	211–212	494,3
410	6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	209–211	495,2

Comp	Nombre	p.f.	MS
411	2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	224–226	496,3
412	6–[3–ciano–1–(ciclohex–2–en–1–il)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	187–188	493,1
413	6–[3–ciano–1–(ciclohex–2–en–1–il)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	186–187	493,0
414	2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	190–195	464,3
415	2–[6–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	N/A	483,9
416	2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	195–200	414,2
417	2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	220–224	497,8
418	2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	241–248	471,9
419	2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	243–249	497,8

Comp	Nombre	p.f.	MS
420	2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	N/A	471,8
425	6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	422,9
426	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	449,0
427	6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	206–212	478,9
428	6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	206–212	478,9
429	6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	193–199	450,9
430	6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	209–216	492,9
431	6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	209–216	492,9
432	6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	199–209	465,0
433	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	475,0
434	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	466,8
435	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	481,3

Comp	Nombre	p.f.	MS
436	6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	165–167	467,2
444	6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	189–193	478,9
445	6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	213–215	497,4
446	6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	209–210	496,8
447	2–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	275–279	480,3
448	2–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	>300	498,2
451	2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	198–203	468,3
452	2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	175–180	450,4
453	6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	181–183	479,4
454	2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	232–234	483,9

Comp	Nombre	p.f.	MS
455	2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	217–222	492,0
456	6–[3–ciano–1,6–di(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	165–173	461,0
457	6–[3–ciano–1–ciclopentil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	163–172	487,0
458	6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	166–172	463,0
459	6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	561,2
460	6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	132–134	473,4
461	6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	226–227	511,2
462	6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	220–222	511,3
463	2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	251–253	494,2
464	2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	253–255	512,2

Comp	Nombre	p.f.	MS
465	6–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	203–204	455,9
466	2–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	240–241	456,9
467	6–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	223–225	474,0
468	6–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	219–221	470,0
469	2–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	246–247	471,0
470	6–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	203–205	488,0
478	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	222–227	477,4
479	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	165–171	529,2
480	6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	182–187	477,0
484	6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	134–142	463,0
485	6–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	167–173	451,0

Comp	Nombre	p.f.	MS
486	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	477,0
487	6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	180–189	491,0
494	2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	223–225	468,3
495	2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	217–219	482,4
496	2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	207–208	440,2
497	2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	N/A	454,3
498	2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	198–199	440,2
499	2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	169–170	468,3
500	6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	181–186	479,3
505	6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	195–196	479,2
506	6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	198–198,5	479,2

Comp	Nombre	p.f.	MS
507	2–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	217–218	444,1
510	6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	200–200,5	497,2
511	6–(1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	137–139	420,2
513	6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	195–203	473,3
514	6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	218–223	511,2
515	6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	217–224	511,2
516	2–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	215–220	512,2
517	2–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	228–234	494,2
518	6–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	198–204	507,2
519	6–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	197–204	507,2
520	2–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	209–215	490,2
521	6–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	217,5–218	493,3

Comp	Nombre	p.f.	MS
522	6–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	186–187	511,0
523	2–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	216,0–216,5	458,2
524	2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	151–155	446,4
525	6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	181–185	435,3
526	2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	223–225	442,4
527	2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	250–253	478,2
528	2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	219–221	468,3
529	2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	176–179	428,3
530	2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	184–186	454,2
531	2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	184–188	440,2
535	6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	495,3
536	2–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	176–177	496,3

Comp	Nombre	p.f.	MS
537	6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	187–188	513,2
538	6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	186–188	513,3
544	2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	178–181	440,3
545	2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	168–171	436,3
546	2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	172–176	456,3
547	2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	214–218	482,2
548	2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	175–180	468,3
550	6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	149–150	461,2
551	2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	217–219	462,3
560	6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	175–180	491,2

Comp	Nombre	p.f.	MS
561	2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	174–178	436,3
562	2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	168–171	450,3
563	2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	171–174	424,2
564	6–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	170–173	423,2
565	2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	175–177	398,4
566	2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	195–198	452,4
567	2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	160–163	434,3
569	2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	203–205	480,3
570	2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	182–183	452,3
571	6–(3–ciano–1–ciclopentil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	167–169	475,5
572	2–(3–ciano–1–ciclopentil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	200–202	476,2
590	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	146–155	485,1


Comp	Nombre	p.f.	MS
591	2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	N/A	496,1
592	2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	168–175	486,1
593	6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	178–184	509,1
594	6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	499,1
595	6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	181–189	527,1
596	6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	194–199	541,1
597	2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	181–189	500,2
598	2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	204–218	474,1
599	2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	174–210	510,1
600	2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	240–246	528,1

Comp	Nombre	p.f.	MS
603	2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	217–222	428,3
604	6–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	138–143	427,3
605	2–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	257–260	492,3
606	6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	169–174	463,2
607	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	176–181	491,3
616	6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	495,2
617	6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	485,2
618	6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	513,1
619	2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	144–150	486,2
620	2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	152–161	485,1


Comp	Nombre	p.f.	MS
621	2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	180–188	496,2
622	2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	195–205	514,2
696	6–[3–ciano–1–ciclobutil–5–(2,2–difluoroetil)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida	N/A	471,2
702	6–[3–ciano–1–ciclobutil–5–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	143–147	513,3

Ejemplo 2


6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida (compuesto **31**)




Etapa A: Una solución de 6–metoxi–1H–indol (100,0 g, 679,0 mmol) en DMF (560 mL) se enfrió hasta –78 °C y se trató con isocianato de clorosulfonilo (71 mL, 815 mmol). Después de la adición, la mezcla de reacción se agitó durante 1 hora. La solución oscura se vertió en hielo agua (2 L) y el sólido marrón claro se recogió por filtración, se lavó con agua adicional y se secó para obtener 6–metoxi–1H–indol–3–carbonitrilo en forma de un sólido marrón claro (104,8 g, 90%).



Etapa B: A 6–metoxi–1H–indol–3–carbonitrilo (98,2 g, 0,57 mol) se añadió carbonato de cesio (430 g, 1,32 mol), DMF (165 mL) y bromuro de ciclobutilo (96%, 67,5 mL, 0,69 mol). La mezcla se calentó hasta 90 °C y se agitó durante la noche. La mezcla se enfrió hasta 37 °C y se vertió en agua helada (500 mL), lavando con agua. Después de agitar durante 1 hora, el precipitado se recogió en un filtro y se secó bajo una corriente de nitrógeno para dar 1–ciclobutil–6–metoxi–1H–indol–3–carbonitrilo en forma de un sólido tostado (124,1 g, 96%).




Etapa C: 1–ciclobutil–6–metoxi–1H–indol–3–carbonitrilo (100 g, 442 mmol) se disolvió en CH_2Cl_2 (700 mL) y se enfrió hasta –20 °C. Se agregó tribromuro de boro (300 g, 1,2 mol) gota a gota durante 2,5 horas a la solución enfriada. La reacción se vertió en hielo agua (2 L), se neutralizó hasta pH 7 con hidróxido de sodio acuoso 5 N y se agitó durante la noche a temperatura ambiente. El solvente orgánico restante se evaporó y la suspensión resultante se filtró. El sólido se lavó con agua (2X200 mL), 1/1 hexano/éter etílico (2X125 mL) y se secó en una corriente de nitrógeno para dar 1–ciclobutil–6–hidroxi–1H–indol–3–carbonitrilo en forma de un polvo beige (90,0 g, 96%).




Etapa D: 1–ciclobutil–6–hidroxi–1H–indol–3–carbonitrilo (31,7 g, 149,5 mmol) se disolvió en 160 mL de isopropanol a 75 °C y se burbujeó $CClF_2H$ (gas)

en la mezcla de reacción a través de una aguja. A ésta mezcla se añadió NaOH acuoso al 20% (40 mL) a través de un embudo de adición. Se añadieron porciones adicionales de NaOH acuoso al 20% (40 mL) cada 30 minutos. Después de 2 horas de tiempo de reacción total, la mezcla se enfrió hasta temperatura ambiente y la capa orgánica se separó y se concentró. La capa acuosa se extrajo en acetato de etilo y las fases orgánicas combinadas se lavaron con salmuera y luego se secaron sobre $MgSO_4$, se filtraron y se concentraron. El residuo se disolvió en 4/1 hexano/CH_2Cl_2 (800 mL) y se agitó con alúmina básica (80 g, pH 9,5) y luego se filtró y se concentró para obtener una primera fracción cruda (28 g). La alúmina se lavó con CH_2Cl_2 para proveer una segunda fracción cruda (8,7 g) que se purificó de la misma manera para proveer una tercera fracción cruda (4,0 g). Las fracciones crudas combinadas se purificaron nuevamente de la misma manera para obtener 1–ciclobutil–6–(difluorometoxi)–1H–indol–3–carbonitrilo en forma de un sólido blanco (28,3 g, 72%). ^{1}H RMN ($CDCl_3$, 500 MHz): d 7,76 (1H, s), 7,72 (1H, d, J = 8,5 Hz), 7,18 (1H, d, J = 2 Hz), 7,12 (1H, dd, J = 8,5 Hz, 2,0 Hz), 6,55 (1H, t, J = 75 Hz), 4,82 (1H, p, J = 8 Hz), 2,66 (2H, m), 2,47 (2H, m), 2,01 (2H, m).



Etapa E: A una solución de 1–ciclobutil–6–(difluorometoxi)–1H–indol–3–carbonitrilo (1,5 g, 5,7 mmol) y borato de triisopropilo (2,4 mL, 10,3 mmol) en THF (25 mL) a –78 °C se añadió LDA (1,5 M en ciclohexano, 5,0 mL, 7,5 mmol). La mezcla se agitó a –78 °C durante 30 min y luego se neutralizó con agua helada (60 mL) y se agitó durante 15 min sin enfriamiento. La mezcla se extrajo con acetato de etilo 1:1 en hexano (20 mL). La capa acuosa se acidificó con HCl ac. 2 N hasta pH 5 y se extrajo con CH_2Cl_2 (60 mL). La capa orgánica se secó sobre

Na_2SO_4 y se concentró para dar ácido 3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–ilborónico en forma de un sólido (1,8 g, 60% puro por LCMS) que se usó en la siguiente etapa sin ulterior purificación.



Etapa F: Una mezcla de ácido 3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–ilborónico (0,68 g, 1,33 mmol), 6–cloro–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida (0,25 g, 0,93 mmol), tetrafluoroborato de tri–ter–butilfosfonio (22 mg, 0,076 mmol) y $Pd_2(dba)_3$ (34 mg, 0,037 mmol) y fluoruro de potasio (0,17 g, 2,93 mmol) en THF (8,0 mL) se agitó a 35 °C durante la noche. El solvente luego se evaporó y el residuo se purificó por cromatografía flash con 0–10% de acetato de etilo en CH_2Cl_2 para proveer el compuesto del título **31** en forma de un sólido (210 mg, 46%). Punto de fusión: 159–161; MS *m/z* 497,0 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 9,25 (1H, dd, J = 2,2 Hz, J = 0,6 Hz), 8,37 (1H, dd, J = 8,2 Hz, J = 2,3 Hz), 8,03 (1H, dd, J = 8,3 Hz, J = 0,8 Hz), 7,80 (1H, d, J = 8,7 Hz), 7,50 (1H, d, J = 1,9 Hz), 7,18 (1H, dd, J = 8,6 Hz, J = 1,9 Hz), 6,60 (1H, t, J 3,7 Hz), 5,37–5,33 (1H, m), 5,20 (1H, d, J = 9,2 Hz), 4,64 – 4,46 (4H, m), 3,96–3,90 (1H, m), 2,62 – 2,55 (2H, m), 2,46 – 2,40 (2H, m), 1,95 – 1,88 (2H, m).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 2 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
1	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	157–159	449,1
2	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–ciclobutilpiridin–3–sulfonamida	130–132	461,4
3	6–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	166–170	449,3
4	5–[3–ciano–1–ciclobutil–6–(ciclobutiloxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida	178–180	465,3
10	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	191–193	479,1
11	6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	203–205	479,3
12	6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	160–162	467,3
13	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	154–156	461,3
16	6–[3–ciano–1–ciclobutil–6–(propan–2–ilsulfanil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	129–131	469,2
17	6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	N/A	493,1

Comp	Nombre	p.f.	MS
18	N–ter–butil–6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida	182–184	507,1
19	6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	148–153	461,3
20	N–ter–butil–6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida	167–170	475,3
21	6–[3–ciano–1–ciclopentil–5–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	177–179	475,2
22	1–ciclobutil–2–[5–(piperidin–1–ilsulfonil)piridin–2–il]–6–(propan–2–ilsulfanil)–1H–indol–3–carbonitrilo	169–171	495,2
23	6–[3–ciano–1–ciclobutil–5–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	174–176	479,3
24	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	158–160	515,2
25	6–[3–ciano–1–ciclobutil–5–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	179–182	515,3
26	5–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida	N/A	479,2
32	6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	166–172	497,1
33	6–[3–ciano–1–ciclopentil–5–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	172–175	511,1
34	6–[3–ciano–1–ciclopentil–5–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	159–160	529,3

Comp	Nombre	p.f.	MS
36	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	142–145	485,1
39	5–[3–ciano–1–ciclopropil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida	209–210	447,7
40	5–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida	186–188	461,2
41	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	150–151	497,2
42	6–[3–ciano–1–ciclopropil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	219–220	483,0
43	6–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	135–140	473,3
44	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	144–145	457,2 (M–H)
45	6–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	156–158	485,2
48	6–(3–ciano–1–ciclobutil–6–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	201–202	459,0
49	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	177–178	511,3
51	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	158–159	461,1
52	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	157–158	475,2

Comp	Nombre	p.f.	MS
53	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida	189–195	529,1
54	6–{3–ciano–6–metil–1–[(3R)–tetrahidrofuran–3–il]–1H–indol–2–il}–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	152–153	461,2
55	6–{3–ciano–6–metil–1–[(3R)–tetrahidrofuran–3–il]–1H–indol–2–il}–N–(propan–2–il)piridin–3–sulfonamida	164–167	425,2
59	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	171–173	475,1
67	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–fluoro–2–metilpropan–2–il)piridin–3–sulfonamida	224–229	507,4
68	6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	132–133	515,0
69	6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	116–117	503,3
70	6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	141–143	529,3
74	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	213–214	424,4
75	6–[3–ciano–6–etil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	185–186	411,0

Comp	Nombre	p.f.	MS
77	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–fluoro–2–metilpropan–2–il)piridin–3–sulfonamida	171–178	493,4
78	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida	159–165	515,0
80	6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	188–195	433,0
81	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	175–182	445,0
82	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	445,0
93	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	182–187	527,0
94	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	186–193	541,0
98	2–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	196–201	438,0
99	6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	187–190	489,0
100	6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	175–178	525,0

Comp	Nombre	p.f.	MS
103	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	492,9
105	6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	146–148	542,8
106	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida	162–168	541,0
116	2–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	200–203	480,7
117	2–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	216–218	494,0
121	2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	134–138	410,2
122	2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	140–145	446,0
127	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	192–194	462,0
128	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)pirimidin–5–sulfonamida	227–229	515,9
129	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	205–207	497,9
132	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	236–238	446,0

Comp	Nombre	p.f.	MS
133	2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	261–262	446,0
134	2–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	213–215	433,9
135	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	229–231	460,0
136	2–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	207–209	497,9
137	2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	219–221	485,9
158	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	168–173	459,2
159	2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	193–198	424,2
160	2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	202–207	460,0
161	6–[3–ciano–1–ciclobutil–6–(metilsulfanil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	182–186	488,9
162	2–[3–ciano–1–ciclobutil–6–(metilsulfanil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	199–201	478,1
167	2–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	205–206	398,1
168	2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	245–247	410,1

Comp	Nombre	p.f.	MS
169	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	217–219	410,0
170	2–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	182–184	462,0
171	2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	193–196	450,1
172	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	200–202	426,0
177	2–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	202–204	515,9
178	2–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	181–187	529,9
179	2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	174–176	526,0
185	2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	220–222	438,2
186	2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	214–222	474,2
190	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	199–210	489,1
198	2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	211–215	474,1

Comp	Nombre	p.f.	MS
199	6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	210–215	473,5
200	2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida	183–188	438,1
229	6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	174–177	461,2
230	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	217–219	462,1
231	2–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	232–234	476,1
232	2–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	177–179	486,0
233	2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	199–201	512,0
239	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–dihidroxipropan–2–il)piridin–3–sulfonamida	132–135	493,1
241	2–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	225–230	474,0
242	2–[3–ciano–5–(difluorometoxi)–1–etil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	180–185	436,2
245	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida	165–166	457,1
246	6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida	N/A	487,0

Comp	Nombre	p.f.	MS
253	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida	214–218	503,1
255	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	191–195	475,0
256	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	189–194	475,1
258	6–(3–ciano–1–ciclobutil–5–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	163–164	459,2
267	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	166–168	495,0
268	N–{5–[3–ciano–1–ciclobutil–6–(pirimidin–2–iloxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida	275–277	503,3
269	N–{5–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida	214–215	475,3
270	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida	156–158	459,3
271	N–{6–[3–ciano–1–ciclobutil–6–(pirimidin–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–1–sulfonamida	206–208	489,2
272	N–(6–{3–ciano–6–[(3–cianopiridin–2–il)oxi]–1–ciclobutil–1H–indol–2–il}piridin–3–il)propan–1–sulfonamida	199–201	513,3
273	N–(6–{3–ciano–6–[(3–cianopirazin–2–il)oxi]–1–ciclobutil–1H–indol–2–il}piridin–3–il)propan–1–sulfonamida	252–254	514,2

Comp	Nombre	p.f.	MS
274	N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}ciclopropansulfonamida	175–177	452,3
275	N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}metansulfonamida	225–227	426,3
276	N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}etansulfonamida	181–183	440,4
277	N–[6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)piridazin–3–il]etansulfonamida	212–214	412,3
278	N–[6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)piridazin–3–il]–2–metilpropan–2–sulfonamida	218–220	440,3
279	*N*–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1*H*–indol–2–il]piridin–3–il}etansulfonamida	149–154	439,9
280	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida	150–155	451,1
281	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida	168–172	453,5
282	N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}–N–(propan–2–il)etansulfonamida	170–175	455,2
283	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida	188–193	493,3
284	N–{6–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–3–il}etansulfonamida	190–195	479,3
285	N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida	180–185	425,3

Comp	Nombre	p.f.	MS
286	N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida	180–185	427,2
290	N–{5–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–2–il}etansulfonamida	N/A	479,3
291	N–{5–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–2–il}propan–2–sulfonamida	N/A	493,3
292	N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(2,2–difluoroetil)ciclopropansulfonamida	232–235	489,1
293	N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(2–hidroxietil)ciclopropansulfonamida	212–214	469,3
294	N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(cianometil)ciclopropansulfonamida	236–238	464,1
295	N–{5–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida	239–240	475,3
296	N–[6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida	241–245	421,2
297	N–[6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida	200–205	407,1
299	N–{5–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida	263–264	462,5
301	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–cianoetil)piridin–3–sulfonamida	188–190	472,1


Comp	Nombre	p.f.	MS
304	6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	181–183	561,0
305	6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	195–197	533,2
323	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	221–223	516,2
326	2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	231–232	530,2
341	6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	149–151	543,0
359	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	163–166	503,1
398	2–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	211–212	516,2
399	2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	219–221	504,3
400	2–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	207–208	504,2

Comp	Nombre	p.f.	MS
471	2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	150–152	516,0
472	2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	187–189	544,0
473	2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	176–179	490,0
543	N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida	178–180	475,3


Ejemplo 3

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida


(compuesto **108**)



Etapa A: A una solución de 4–fluoro–3–metilanilina (8,75 g, 70 mmol) en metanol (65 mL) y agua (65 mL) se añadió bicarbonato de sodio (5,88 g, 70 mmol) seguido de la adición en porciones de I_2 en polvo (17,78 g, 70 mmol). La mezcla se agitó a temperatura ambiente durante la noche, luego se trató con agua (300 mL). La mezcla acuosa se extrajo con CH_2Cl_2 (3X200 mL). Las capas orgánicas se combinaron y se lavaron con tiosulfato de sodio sat. ac., agua y salmuera. La mezcla se secó sobre Na_2SO_4 y se concentró. El residuo se purificó por cromatografía flash con 30–100% de CH_2Cl_2/hexano para dar 4–fluoro–2–yodo–5–metilanilina (12,1 g, 69%), que contenía ~10% del isómero no deseado (4–fluoro–2–yodo–3–metilanilina).




Etapa B: A una mezcla de 4–fluoro–2–yodo–5–metilanilina (12,0 g, 47,8 mmol, más aproximadamente 10% del isómero no deseado), $PdCl_2(Pf_3)_2$ (1,68 g, 2,39 mmol) y yoduro de cobre (I) (0,455 g, 2,39 mmol) en trietilamina (125 mL) a 0 °C se añadió trimetilsililacetileno (5,15 g, 52,6 mmol) gota a gota. La mezcla se calentó hasta temperatura ambiente y se agitó durante la noche. El solvente se evaporó y el residuo se disolvió en éter etílico y se filtró. El filtrado se evaporó y se purificó por cromatografía flash con 5–35% de acetato de etilo en hexano para dar 4–fluoro–5–metil–2–((trimetilsilil)etinil)anilina (10,3 g, 97%), que contenía ~10% del isómero no deseado (4–fluoro–3–metil–2–((trimetilsilil)etinil)anilina).




Etapa C: Una mezcla de 4–fluoro–5–metil–2–((trimetilsilil)etinil)anilina (más aproximadamente 10% del isómero no deseado) (10,3 g, 46,6 mmol) y yoduro de cobre (I) (17,75 g, 93,2 mmol) en DMF (200 mL) se agitó a 100 °C durante 4 horas. La mezcla se trató luego con éter etílico (300 mL) y se filtró. El filtrado se lavó con agua (200 mL) y se extrajo con éter. Las capas orgánicas se combinaron y se lavaron con agua, salmuera y se secaron sobre Na_2SO_4 y se concentraron. El residuo se purificó por cromatografía flash con 5–35% de acetato de etilo en hexano para dar 1,9 g de 5–fluoro–6–metil–2–(trimetilsilil)–1H–indol con ~10% del isómero no deseado, 5–fluoro–4–metil–2–(trimetilsilil)–1H–indol más producto desililado, 5–fluoro–6–metil–1H–indol (2,8 g) con ~10% del isómero no deseado,

5–fluoro–4–metil–1H–indol. El material sililado, 5–fluoro–6–metil–2–(trimetilsilil)–1H–indol con ~10% del isómero no deseado, se redisolvió en metanol (20 mL) y se agitó con carbonato de potasio durante la noche, se filtró y se concentró. Todo el material desililado se combinó (3,7 g) y se recristalizó en CH_2Cl_2 y hexano para proveer 5–fluoro–6–metil–1H–indol (1,9 g).




Etapa D: A una solución de 5–fluoro–6–metil–1H–indol (1,9 g, 12,8 mmol) en DMF (13 mL) a –78 °C se añadió isocianato de clorosulfonilo (1,33 mL, 15,3 mmol). Después de la adición, se retiró el baño de enfriamiento y la mezcla se dejó calentar hasta temperatura ambiente. La mezcla se vertió luego en agua helada, se filtró y se lavó con agua y salmuera. La torta se disolvió luego en acetonitrilo y se concentró para dar 5–fluoro–6–metil–1H–indol–3–carbonitrilo (2,2 g, 100%).




Etapa E: Una mezcla de 5–fluoro–6–metil–1H–indol–3–carbonitrilo (1,0 g, 5,8 mmol), bromuro de ciclobutilo (0,81 mL, 8,6 mmol) y carbonato de cesio (3,9 g, 12,1 mmol) en DMF (10 mL) se agitó a 90 °C durante la noche. La mezcla se vertió luego en agua helada y se extrajo con acetato de etilo. Las capas orgánicas se combinaron y se lavaron con agua, salmuera y se secaron sobre Na_2SO_4 y se evaporaron. El residuo se purificó por cromatografía flash con 5–35% de acetato de etilo en hexano para dar 1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carbonitrilo (1,2 g, 92%). ^{1}H RMN (500 MHz, $CDCl_3$): 7,68 (1H, s), 7,35 (1H, d, J = 9,6 Hz),

7,17 (1H, d, J = 6,1 Hz), 4,83 – 4,79 (1H, m), 2,68 – 2,60 (2H, m), 2,48 – 2,37 (5H, m), 2,05 – 1,96 (2H, m).



Etapa F: A una solución de 1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carbonitrilo (1,2 g, 5,3 mmol) y borato de triisopropilo (2,18 mL, 9,47 mmol) en THF (20 mL) a –78 °C se añadió LDA (1,5 M en ciclohexano, 4,6 mL, 6,84 mmol). La mezcla se agitó a –78 °C durante 30 min y se neutralizó con agua helada (60 mL) y se agitó durante 15 min sin enfriamiento. La mezcla se extrajo con acetato de etilo 1:1 en hexano (20 mL). La capa acuosa se acidificó con HCl ac. 2 N hasta pH 5 y luego se extrajo con CH_2Cl_2 (60 mL). La capa orgánica se secó sobre Na_2SO_4 y se concentró para dar ácido 3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–ilborónico en forma de un sólido (1,44 g, 98% puro por LCMS) que se usó en la siguiente etapa sin ulterior purificación.



Etapa G: Una mezcla de 3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–ilborónico (0,45 g, 1,5 mmol), 6–cloro–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida (0,27 g, 1,0 mmol), tetrafluoroborato de tri–ter–butilfosfonio (29 mg, 0,1 mmol) y $Pd_2(dba)_3$ (46 mg, 0,05 mmol) y fluoruro de potasio (0,23 g, 4,0 mmol) en THF (5,0 mL) se agitó a 40 °C durante la noche. El solvente luego se evaporó y el residuo se purificó por cromatografía flash con 0–10% de acetato de etilo en

CH_2Cl_2 para proveer el compuesto del título **108** (220 mg, 48%). Punto de fusión: 186–188; MS *m/z* 463,0 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 9,24 (1H, d, J = 1,7 Hz), 8,35 (1H, dd, J = 8,3 Hz, J = 2,3 Hz), 8,02 (1H, d, J = 8,2 Hz), 7,51 (1H, d, J = 6,0 Hz), 7,42 (1H, dd, J = 9,2 Hz), 5,35–5,20 (1H, m), 5,19 (1H, d, J = 9,0 Hz), 4,63–4,45 (4H, m), 3,94–3,90 (1H, m), 2,65–2,59 (2H, m), 2,59 (3H, s), 2,48–2,40 (2H, m), 1,95–1,87 (2H, m).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 3 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa y p.f. representa punto de fusión en °C) de:


Comp	Nombre	p.f.	MS
50	6–(6–cloro–3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	211–213	482,8
101	6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	234–237	443,0
102	6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	217–219	478,9
107	6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	182–186	488,9
110	6–[6–cloro–3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	202–204	483,0

285

Comp	Nombre	p.f.	MS
145	2-(3-ciano-1-ciclobutil-6-ciclopropil-5-fluoro-1H-indol-2-il)-N-(1,3-difluoropropan-2-il)pirimidin-5-sulfonamida	237-238	477,0
146	2-(3-ciano-1-ciclobutil-5-fluoro-6-metil-1H-indol-2-il)-N-(1,3-difluoropropan-2-il)pirimidin-5-sulfonamida	243-249	464,1
149	2-(6-cloro-3-ciano-1-ciclobutil-5-fluoro-1H-indol-2-il)-N-(1,3-difluoropropan-2-il)pirimidin-5-sulfonamida	>245 desco mp.	483,9
150	2-(3-ciano-1-ciclobutil-5-fluoro-6-metoxi-1H-indol-2-il)-N-(1,3-difluoropropan-2-il)pirimidin-5-sulfonamida	245-247	480,0
225	6-[3-ciano-1-(ciclopropilmetil)-5-fluoro-6-metoxi-1H-indol-2-il]-N-(1,3-difluoropropan-2-il)piridin-3-sulfonamida	196-199	479,0


Ejemplo 4

6-[3-ciano-1-ciclobutil-6-(difluorometoxi)-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida (compuesto **300**)




Etapa A: cloruro de 2-cloropiridin-5-sulfonilo (12 g, 56,6 mmol) se añadió a una solución de clorhidrato de (S)-1,1,1-trifluoropropan-2-amina (7,8 g, 51,2 mmol) en piridina (15 mL) a 0 °C. La mezcla se agitó a temperatura ambiente durante 10 minutos y se diluyó con acetato de etilo (200 ml) y se lavó con HCl ac. 3 N (2X100 mL). La capa orgánica se secó sobre Na_2SO_4, se filtró y se concentró.

El sólido se trituró con hexano (2X40 mL) y se filtró para proveer (2,2,2–trifluoro–1–metil–etil)–amida del ácido (*S*)–6–cloro–piridin–3–sulfónico en forma de un sólido blanquecino (11,84 g, 75%). ^{1}H RMN (500 MHz, $CDCl_3$): d 8,81 (1H, d, *J* = 2,4 Hz), 8,18 (1H, dd, *J* = 2,5 Hz, 2,6 Hz), 7,51 (1H, d, *J* = 8,8 Hz), 4,92 (1H, br s), 4,08 (1H, m), 1,45 (3H, d, *J* = 7,0 Hz).



Etapa B: A 1–ciclobutil–6–difluorometoxi–1*H*–indol–3–carbonitrilo (830 mg, 3,17 mmol) en THF (10 mL) se añadió yoduro de tributilestaño (1,13 mL, 4,04 mmol) y la solución se enfrió hasta –78 °C. Una solución de LDA (1,5 M en ciclohexano, 3,4 mL, 5,1 mmol) se añadió gota a gota. Después de completar la adición, se retiró el baño y la mezcla se agitó a temperatura ambiente durante 1 hora. Luego se eliminó el THF al vacío y el residuo se filtró a través de gel de sílice usando CH_2Cl_2 como eluyente y la mezcla se concentró. El residuo se purificó por cromatografía flash usando 30–50% de CH_2Cl_2/hexanos para proveer 1–ciclobutil–6–difluorometoxi–2–tributilstannanil–1*H*–indol–3–carbonitrilo en forma de un aceite incoloro claro (1,23 g, 70%).



Etapa C: El 1–ciclobutil–6–difluorometoxi–2–tributilstannanil–1*H*–indol–3–carbonitrilo (650 mg, 1,17 mmol) se combinó con (2,2,2–trifluoro–1–metil–etil)–amida del ácido (*S*)–6–cloro–piridin–3–sulfónico (338 mg, 1,17 mmol, >98% ee),

yoduro cuproso (68 mg, 0,36 mmol) y tetrakis(trifenilfosfina)paladio (105 mg, 0,091 mmol) bajo nitrógeno. Dioxano (2,6 mL) se añadió y la mezcla se agitó a 100 °C durante 1 hora. La mezcla se diluyó en acetato de etilo (50 mL) y se filtró. El filtrado se concentró al vacío y se purificó por medio de dos separaciones cromatográficas en gel de sílice sucesivas (5% de acetato de etilo en CH_2Cl_2; luego 20% de acetato de etilo en hexanos). La trituración con 1/1 hexanos/éter etílico dio como resultado el compuesto del título **300** en forma de un sólido blanco (260 mg, 43%). Punto de fusión: 159–162; MS *m/z* 515,4 $M+H^+$; ^1H RMN ($CDCl_3$, 500 MHz): d 9,23 (1H, d, J = 2 Hz), 8,34 (1H, dd, J = 8,0 Hz, 2,5 Hz), 8,03 (1H, d, J = 8,0 Hz), 7,80 (1H, d, J = 8,5 Hz), 7,49 (1H, d, J = 1,5 Hz), 7,17 (1H, dd, J = 8,5 Hz, 2 Hz), 6,59 (1H, t, J = 75 Hz), 5,35 (1H, p, J = 8,5 Hz), 4,98 (1H, br s), 4,17 (1H, m), 2,56 (2H, m), 2,43 (2H, m), 1,92 (2H, m), 1,48 (3H, d, J = 8,5 Hz).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 4 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
118	6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	469,5
119	6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	154–155	455,0
130	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	172–174	488,0
131	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	165–167	462,0

Comp	Nombre	p.f.	MS
142	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	128–130	439,0
143	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	159–160	453,0
144	6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	136–138	439,0
151	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	163–168	487,1
152	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	505,0
154	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	454,9
155	6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	469,0
174	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	176–182	501,3
180	2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	211–212	490,1
181	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	143–145	464,0
182	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	116–118	478,0

Comp	Nombre	p.f.	MS
183	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	147–149	480,0
184	2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	112–114	516,1
191	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	171–177	533,1
192	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	204–208	463,0
194	6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	166–168	503,0
195	6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	170–172	543,0
196	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	159–164	515,0
197	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	165–169	463,0
201	6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	173–178	435,1

Comp	Nombre	p.f.	MS
202	2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	129–131	136,1
203	2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	205–207	436,0
204	2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	180–182	450,1
205	2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	204–206	452,0
206	2–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	192–194	466,0
207	2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	169–170	476,0
208	2–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	152–154	476,1
209	2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	183–185	502,0
210	6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	211–216	450,8
211	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	178–181	503,0
212	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	192–196	489,0

Comp	Nombre	p.f.	MS
213	6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	208–212	491,1
214	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	176–182	477,0
215	6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	178–180	467,0
216	6–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	173–175	466,9
217	6–(3–ciano–6–fluoro–1–propil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–197	455,0
218	6–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	141–144	481,2
219	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	109–110	467,2
220	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	158–160	481,0
222	6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	202–206	483,0
223	6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	497,0
224	6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	497,0
236	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	170–176	461,1

Comp	Nombre	p.f.	MS
237	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	N/A	435,1
238	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	181–187	435,1
250	6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	161–163	467,0
252	6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	188–189	465,0
254	2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida	185–189	476,1
261	6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	208–210	494,9
262	6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	161–162	467,0
263	6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	124–126	475,0
313	6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	209–214	489,2
327	6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	202–206	493,2
328	6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	193–199	475,0
329	6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	176–183	479,3
351	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	203–208	463,2

Comp	Nombre	p.f.	MS
352	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	176–180	477,0
353	6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	165–168	463,2
354	6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	207–212	491,2
355	6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	211–216	450,9
369	6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	191–197	489,1
370	6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	165–175	533,0
371	6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	202–211	491,1
382	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	170–174	543,1
383	6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	178–181	503,2

Comp	Nombre	p.f.	MS
421	6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–220	481,2
422	6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	186–201	463,2
423	6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	211–216	477,3
424	6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	191–195	495,3
481	6–(3–ciano–1–ciclobutil–6–etil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	160–165	491,0
482	6–(3–ciano–1–ciclopentil–6–fluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	207–211	477,0
483	6–(3–ciano–1–ciclopentil–6–fluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	219–223	495,3
492	6–(3–ciano–1–ciclobutil–6–fluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	185–190	481,2
493	6–(3–ciano–1–ciclobutil–6–fluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	209–213	463,2
508	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	215–219	513,2

Comp	Nombre	p.f.	MS
509	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	199–203	495,2
532	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	186–191	499,2
533	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	158–170	481,2
555	6–(3–ciano–1–ciclobutil–4,6–difluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	181–186	499,2
556	6–(3–ciano–1–ciclobutil–4,6–difluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	207–212	481,2
557	2–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	191–198	464,0
558	6–(3–ciano–1–ciclopentil–4,6–difluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	214–219	495,2
559	6–(3–ciano–1–ciclopentil–4,6–difluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	218–224	513,1
577	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	180–187	513,4

Comp	Nombre	p.f.	MS
578	6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	168–175	495,1
579	6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	203–205	509,1
580	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	226–232	527,3
586	2–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	226–232	478,2
587	6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida	228–232	489,1
588	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida	172–176	555,3
589	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	188–194	529,3
613	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	223–232	493,2
614	6–(3–ciano–1–ciclopentil–4–fluoro–5–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	200–205	509,2


Comp	Nombre	p.f.	MS
615	6–(3–ciano–1–ciclopentil–4–fluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	186–197	495,1
625	6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	207–211	495,4
626	6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	218–223	509,3
627	6–(3–ciano–1–ciclobutil–4–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	205–210	481,4
628	6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	242–246	507,1
629	6–(3–ciano–1–ciclobutil–4–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	241–246	493,1
653	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	212–217	513,2
654	6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	241–246	525,2
655	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida	222–226	427,2

Comp	Nombre	p.f.	MS
656	2–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	230–234	496,0
666	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	185–190	499,0
667	6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	235–241	510,8
668	2–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	N/A	481,9


Ejemplo 5

6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida


(compuesto **96**)




Etapa A: Una solución de 5–fluoroindol (4,03 g, 29,82 mmol) en DMF (30 ml) se enfrió hasta –30 ^{0}C y se trató con isocianato de clorosulfonilo (6,33 g, 44,73 mmol). Después de la adición, la mezcla de reacción se agitó a 0 ^{0}C durante 3 h. La mezcla de reacción se vertió en hielo agua (350 mL) y el sólido se recogió por filtración, se lavó con agua y se secó para obtener un sólido amarillo claro (4,58 g, 96% de rendimiento).



Etapa B: A una solución de 5–fluoro–1H–indol–3–carbonitrilo (500 mg, 3,1 mmol) en DMF (10 mL) se añadió 2–fluoropiridina (390 mg, 4,1 mmol) y carbonato de cesio (2,1 g, 6,2 mmol). La mezcla se calentó a 90 °C durante 16 horas, se enfrió hasta temperatura ambiente y se vertió en agua (200 mL). Después de agitar durante 1 hora, se recogió un precipitado y se lavó con agua (200 mL) y hexano (200 mL). El sólido se secó al vacío para proveer un polvo amarillo claro (650 mg, 88%). ^{1}H RMN ($CDCl_3$, 500 MHz): d 8,65 (1H, m), 8,24 (1H, s), 8,15 (1H, m), 7,95 (1H, m), 7,50 (2H, m), 7,36 (1H, m), 7,17 (1H, m).



Etapa C: A una solución de 5–fluoro–1–(piridin–2–il)–1H–indol–3–carbonitrilo (490 mg, 2,1 mmol) en THF (10 mL) a 0 °C se añadió yoduro de tributilestaño (1,56 g, 3,7 mmol) seguido de LDA (2,1 mL, 3,1 mmol). La mezcla se agitó a 0 °C durante 30 minutos, se neutralizó con cloruro de amonio ac. sat. (10 mL) y se extrajo con acetato de etilo (100 mL). La capa orgánica se filtró a través de una capa corta de gel de sílice y celite y se concentró para proveer un aceite amarillo claro (0,8 g, 75%).



Etapa D: A una solución de 5–fluoro–1–(piridin–2–il)–2–(tributilestannil)–1H–indol–3–carbonitrilo (200 mg, 0,37 mmol) en dioxano (0,6 mL) se añadió 6–cloro–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida (65 mg, 0,24 mmol), paladio tetrakis–trifenilfosfina (29 mg, 0,024 mmol) y yoduro de cobre (I) (4 mg, 0,048 mmol). La mezcla se purgó con argón, se calentó hasta 95 °C y se agitó durante 16 horas. La mezcla se enfrió hasta temperatura ambiente, se filtró a través de una capa de celite, luego se condensó y se purificó por cromatografía flash para proveer el compuesto del título **96** en forma de un polvo amarillo claro (49 mg, 42%). Punto de fusión: 170–172; MS *m/z* 472,0 $M+H^+$; ^1H RMN ($CDCl_3$, 500 MHz): d 8,75 (1H, d, *J* = 1,9 Hz), 8,43 (1H, dd, *J* = 1,3 Hz, 4,9 Hz), 8,17 (1H, dd, *J* = 2,4 Hz, 8,4 Hz), 7,97 (1H, d, *J* = 8,4 Hz), 7,83 (1H, m), 7,40 (1H, m), 7,34 (3H, m), 7,08 (1H, m), 5,06 (1H, d, *J* = 9,0 Hz), 4,38 (4H, m), 3,78 (1H, m).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 5 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
95	6–(3–ciano–6–ciclopropil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	171–175	493,0

Comp	Nombre	p.f.	MS
111	6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	181–185	466,9
112	6–(5–cloro–3–ciano–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	192–196	486,9
113	6–(3–ciano–5–fluoro–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	165–168	471,1
226	6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	200–202	519,0
227	6–[3–ciano–6–(difluorometoxi)–1–(2–fluorofenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	188–191	537,0
228	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	192–198	537,1
248	6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	159–162	468,0
249	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	186–190	519,8
259	6–[3–ciano–5–fluoro–1–(piridin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	199–203	472,0
260	2–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	169–171	468,1
336	6–[3–ciano–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	198–200	501,0
337	2–[3–ciano–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	209–211	502,2

Comp	Nombre	p.f.	MS
356	6–[3–ciano–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	208–210	485,8
357	2–[3–ciano–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida	200–202	450,1
368	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–198	550,0
386	6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–212	490,0
387	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	199–203	538,0
437	6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	177–178	506,1
438	6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	219–221	488,1
439	6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida	208–210	437,0
440	6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	196–198	465,2
441	6–(5–cloro–3–ciano–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–212	505,3
442	6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	186–188	506,2
443	6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	187–188	487,8

Comp	Nombre	p.f.	MS
449	2–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	163–166	507,1
450	2–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	234–235	490,9
474	2–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	209–210	491,3
475	2–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	210–212	487,2
476	6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	199–203	486,2
477	2–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	213–216	538,2
488	6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	199–201	477,9
489	6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	198–199	506,2
490	6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida	136–139	477,9
491	6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	150–154	506,3
501	6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	210–213	494,3
502	6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	185–189	512,3

Comp	Nombre	p.f.	MS
503	6–[3–ciano–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	165–167	486,3
504	6–[3–ciano–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	177–179	468,2
512	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	186–189	539,3
534	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	159–161	538,2
540	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	233–236	486,2
553	6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	209–211	537,1
554	6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	212–213	537,2
583	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	170–173	553,2
584	6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	N/A	526,3
585	6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	210–212	499,2
602	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	231–234	505,1


Comp	Nombre	p.f.	MS
608	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	473,0
610	2–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	206–208	520,2
611	2–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	216–218	538,2
612	6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	218–220	551,3
623	6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	N/A	550,8
624	N–ter–butil–6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]piridin–3–sulfonamida	216–218	497,2
635	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	173–176	521,8
649	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	199–203	555,0
657	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	161–163	556,0
663	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	179–180	552,9

Comp	Nombre	p.f.	MS
664	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	195–198	567,2
670	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	179–180	552,9
671	6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–198	567,2
672	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	142–143	523,2
673	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	202–205	490,8
677	6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–198	487,2
686	6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	208–209	499,9
687	6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	215–216	569,2
688	6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	196–198	487,0
689	6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	202–205	501,2

Comp	Nombre	p.f.	MS
690	6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	170–174	550,8
695	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	505,2
698	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	170–174	504,1


Ejemplo 6

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida (compuesto **409**)




Etapa A: Un recipiente redondo seco de 2 L se cargó con 1–bromo–2–fluoro–4–metil–5–nitrobenceno (24,5 g, 0,1 mol, 97%), DMF–DIPA (39 g, 0,22 mol), Et_3N (16 mL, 0,11 mol) y DMF seca (100 mL). La mezcla se agitó a 130 °C durante 2 h. Después de eliminar las sustancias volátiles, el residuo se disolvió en una mezcla de tolueno (650 mL) y ácido acético (390 mL) seguido de la adición de hierro en polvo (55 g) y gel de sílice (50 g). La mezcla roja oscura se calentó hasta 100 °C con vigorosa agitación. El color oscuro desapareció después de calentar a reflujo durante 20 min, lo cual indicó que la reacción había acabado. La mezcla luego se enfrió hasta 25 °C, se diluyó con EtOAc y se filtró. La torta se


lavó cuidadosamente con EtOAc. Los filtrados combinados se lavaron con $Na_2S_2O_5$ sat. ac., $NaHCO_3$ sat. ac. y salmuera, se secaron sobre Na_2SO_4 y se concentraron. El residuo se purificó en una columna de gel de sílice eluyendo con 5/1 hexanos/CH_2Cl_2 para proveer 6–bromo–5–fluoro–1*H*–indol en forma de un sólido cristalino blanco (16,2 g, 76 %).




Etapa B: A 6–bromo–5–fluoro–1*H*–indol (9,4 g, 43,9 mmol) en DMF (50 mL) a –78 °C se añadió isocianato de clorosulfonilo (4,6 mL, 53 mmol). Después de completar la adición la mezcla se dejó calentar hasta temperatura ambiente y se agitó durante 2 h. La mezcla de reacción se vertió en hielo agua y se agitó durante 30 minutos. El precipitado se recogió en un filtro, se lavó con agua helada y se secó en un horno de vacío para dar 6–bromo–5–fluoro–1*H*–indol–3–carbonitrilo en forma de un sólido de color beige claro (10,5 g, 100%).



Etapa C: Al 6–bromo–5–fluoro–1*H*–indol–3–carbonitrilo (10,5 g, 43,9 mmol) se añadió carbonato de cesio (30 g, 92,2 mmol), DMF (80 mL) y luego bromuro de ciclopentilo (6,2 mL, 65,8 mmol). Esta mezcla se agitó a 88 °C durante 40 h, se enfrió hasta temperatura ambiente y luego se vertió en agua helada. El precipitado se recogió, se lavó con agua y se secó para dar 6–bromo–1–ciclopentil–5–fluoro–1*H*–indol–3–carbonitrilo en forma de un sólido gris claro (12,6 g, 93%).




Etapa D: A una solución de 6–bromo–1–ciclopentil–5–fluoro–1*H*–indol–3–carbonitrilo (6,6 g, 21,5 mmol) y $PdCl_2$dppf (0,31 g, 0,43 mmol) en dioxano (45 mL) se añadió una solución de dimetilzinc en tolueno (1,2 M, 35,8 mL, 43 mmol). La atmósfera se reemplazó con nitrógeno. La mezcla se agitó a 90 °C durante 90 min y luego se enfrió hasta temperatura ambiente. La reacción se neutralizó por cuidadosa adición de metanol. Acetato de etilo (200 mL) se añadió y la mezcla se lavó con HCl acuoso 2 N, agua y salmuera, se secó sobre Na_2SO_4 y se concentró. El residuo se purificó en gel de sílice eluyendo con un gradiente del 5 al 35% de acetato de etilo en hexano para proveer 1–ciclopentil–5–fluoro–6–metil–1*H*–indol–3–carbonitrilo (4,4 g, 85%)



Etapa E: A una solución de 1–ciclopentil–5–fluoro–6–metil–1*H*–indol–3–carbonitrilo (4,4 g, 18,2 mmol) y borato de triisopropilo (7,6 mL, 33 mmol) en THF (75 mL) a –78 °C se añadió LDA (1,5 M en ciclohexano, 15,8 mL, 23,7 mmol). La mezcla se agitó a –78 °C durante 30 min, se neutralizó con agua helada (200 mL) y se agitó durante 15 min sin enfriamiento. La mezcla se extrajo con acetato de etilo 1:1 en hexano (20 mL). La capa acuosa se acidificó con HCl ac. 2 N a pH 5 y luego se extrajo con CH_2Cl_2 (100 mL). La capa orgánica se secó sobre Na_2SO_4 y se concentró para dar ácido 3–ciano–1–ciclobutil–6–ciclopropil–1*H*–indol–2–

ilborónico en forma de un sólido (6,2 g, 90% puro por LCMS) que se usó en la siguiente etapa sin ulterior purificación.



Etapa F: Una mezcla de ácido 3–ciano–1–ciclobutil–6–ciclopropil–1*H*–indol–2–ilborónico preparada como con anterioridad (6,0 g, 18,8 mmol, 90%), (*R*)–6–cloro–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (3,63 g, 12,5 mmol) (preparada de modo similar a lo descrito en el Ejemplo 4, Etapa A), tetrafluoroborato de tri–ter–butilfosfonio (0,36 g, 1,2 mmol), $Pd_2(dba)_3$ (0,57 g, 0,62 mmol) y fluoruro de potasio (7,25 g, 125 mmol) en THF (80 mL) se agitó a 40 °C durante la noche. El solvente luego se evaporó y el residuo se purificó en gel de sílice eluyendo con un gradiente de 0 a 10% de acetato de etilo en CH_2Cl_2 para proveer (*R*)–6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (5,83 g, 94%). Punto de fusión: 191–193 °C; MS *m/z* 495,0 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 9,24 (1H, t, J = 1,1 Hz), 8,34 (1H, dd, J = 8,3 Hz, J = 2,4 Hz), 8,05 (1H, dd, J = 8,3, 0,7 Hz), 7,43 (1H, d, J = 9,2 Hz), 7,37 (1H, d, J = 6,0 Hz), 5,26 – 5,19 (2H, m), 4,20 – 4,12 (1H, m), 2,46 (3H, d, J = 1,9 Hz), 2,31 – 2,26 (2H, m), 2,20 – 2,16 (2H, m), 2,07 – 2,04 (2H, m), 1,80 – 1,76 (2H, m), 1,45 (3H, d, J = 7,0 Hz).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 6 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
340	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	218–219	481,0
407	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	211–213	477,1
408	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	168–171	495,0
539	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	238–243	495,3
609	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	211–214	481,3
630	6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	201–203	507,1
631	6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	190–194	507,1

Comp	Nombre	p.f.	MS
632	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	205,5–206	509,2
633	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	201–202	509,2
637	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	198–199	521,2
638	2–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	184–185	492,2
639	6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	179,5–180,0	491,2
640	6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	205–206	495,2
641	6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	199–199,5	495,2
642	6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	203–203,5	507,2
643	N–ter–butil–6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida	208–209	455,2
644	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	N/A	507,7

Comp	Nombre	p.f.	MS
645	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1–metilciclopropil)piridin–3–sulfonamida	208–209	453,2
651	N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida	223–228	441,2
652	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–ciclopropilpiridin–3–sulfonamida	N/A	425,2
661	6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	189–190	521,3
662	6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	180–181	521,2
665	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	529,2
678	6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	224–229	509,2
679	2–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	N/A	510,2
680	6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	224–229	509,3


Comp	Nombre	p.f.	MS
681	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	223–225	509,2
697	6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	531,2
705	6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	248–254	523,3
709	N–{[6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–il]sulfonil}–N–[(2R)–1,1,1–trifluoropropan–2–il]acetamida	162–163	536,9
710	N–ter–butil–6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida	244–245	470,0
749	6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	511,2
750	6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	N/A	525,2
751	6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	511,1
752	N–ter–butil–6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]piridin–3–sulfonamida	N/A	471,2

Comp	Nombre	p.f.	MS
753	2–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida	N/A	512,2
764	N–ter–butil–6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida	186–188	453,1
772	6–[3–ciano–1–ciclobutil–5–fluoro–6–(metilsulfanil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	201–203	513,2
821	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida	201–207	509,1
826	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida	212–217	495,5
831	6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	183–185	533,2
832	N–ter–butil–6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida	186–188	479,2
836	diamida N–[6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–il]–N'–[(2S)–1,1,1–trifluoropropan–2–il]sulfúrica	206–208	510,6
837	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	237–242	509,3

Comp	Nombre	p.f.	MS
842	1–ciclopentil–6–ciclopropil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	255–257	537,5
856	6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	N/A	521,2
858	6–(3–ciano–1–ciclobutil–6–etil–4–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	187–188	505,1
868	6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	206–211	509,3
910	6–(3–ciano–1–ciclopropil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	481,1


Ejemplo 7

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida (compuesto **549**)




Etapa A: A 6–bromo–5–fluoro–1*H*–indol–3–carbonitrilo (49,2 g, 206 mmol) [preparado como en el Ejemplo 6, Etapa B] se añadió carbonato de cesio (133 g, 408 mmol), DMF (200 mL) y bromuro de ciclobutilo (30 mL, 311 mmol). Esta


mezcla se agitó a 90 °C durante tres días, se enfrió hasta temperatura ambiente y se vertió en agua helada. El precipitado se recogió, se lavó con agua y se secó para dar 6–bromo–1–ciclobutil–5–fluoro–1*H*–indol–3–carbonitrilo en forma de un sólido gris claro (55 g, 90%).




Etapa B: Una mezcla de 6–bromo–1–ciclobutil–5–fluoro–1*H*–indol–3–carbonitrilo (29,9 g, 102 mmol), bis(pinacolato)diboro (33,7 g, 133 mmol), complejo de $PdCl_2$dppf–CH_2Cl_2 (4,16 g, 5,1 mmol) y acetato de potasio (30 g, 306 mmol) en dioxano (300 mL) se agitó a 80 °C durante la noche. La mezcla luego se enfrió hasta temperatura ambiente, se trató con acetato de etilo (200 mL) y se filtró a través de un taco de celite–sílice. El filtrado se concentró, se disolvió en acetona (300 mL) y se enfrió hasta 0 °C. A esta solución se añadió una suspensión de Oxone (125,5 g, 204 mmol) en agua (300 mL). La mezcla se agitó a temperatura ambiente durante 15 min, se diluyó con acetato de etilo y se separó. La capa acuosa se extrajo con acetato de etilo. Las extracciones orgánicas se combinaron y se lavaron con $NaHSO_3$ sat. ac. y salmuera, se secaron sobre Na_2SO_4 y se concentraron. El residuo se purificó en gel de sílice para proveer 1–ciclobutil–5–fluoro–6–hidroxi–1*H*–indol–3–carbonitrilo en forma de un sólido gris claro (19,2 g, 82%).



Etapa C: A una solución de 1–ciclobutil–5–fluoro–6–hidroxi–1*H*–indol–3–carbonitrilo (1,11 g, 4,83 mmol) en dioxano (10 mL) se añadió NaOH acuoso al 25% (2,5 mL, 16 mmol). Se burbujeó gas clorodifluorometano a través de la mezcla a 80 °C durante 3 h. La mezcla se diluyó con agua (20 mL) y se extrajo con acetato de etilo, se secó sobre Na_2SO_4 y se concentró. El residuo se purificó en gel de sílice eluyendo con un gradiente de 5 a 35% de acetato de etilo en hexano para dar 1–ciclobutil–6–(difluorometoxi)–5–fluoro–1*H*–indol–3–carbonitrilo (1,1 g, 82%).



Etapa D: A una solución de 1–ciclobutil–6–(difluorometoxi)–5–fluoro–1*H*–indol–3–carbonitrilo (0,83 g, 2,96 mmol) y trimetilborato (0,5 mL, 4,44 mmol) en THF (12 mL) a –78 °C se añadió LDA (1,5 M en ciclohexano, 2,6 mL, 3,85 mmol). La mezcla se agitó a –78 °C durante 45 min, luego se neutralizó con HCl 1 N (3,85 mL, 3,85 mmol). Se evaporaron las sustancias volátiles orgánicas y la mezcla se trató con diclorometano (30 mL) y agua (15 mL) que se acidificó hasta pH ~5. La capa orgánica se secó sobre Na_2SO_4 y se evaporó para dar un residuo (0,94 g, ~50% de ácido borónico deseado por LC/MS), que se usó en la siguiente etapa sin ulterior purificación.



Etapa E: A una mezcla del ácido borónico crudo de la etapa D (0,30 g, ~40% de pureza, 0,37 mmol), (*S*)–6–cloro–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (0,076 g, 0,26 mmol) y $PdCl_2$dppf (0,02 g, 0,027 mmol) en acetonitrilo (2,0 mL) se añadió una solución acuosa de K_2CO_3 (2,0 M, 0,55 mL, 1,1 mmol). La mezcla se agitó a temperatura ambiente durante un período de tres días. La elaboración acuosa seguida de cromatografía flash con diclorometano y acetato de etilo (0 a 10%) dio el compuesto del título (0,063 g, 45%). Punto de fusión: 172–175 °C; MS *m/z* 533,2 $M+H^+$; ^{1}H RMN (500 MHz, $CDCl_3$): d 9,23 (1H, d, J = 2,0 Hz), 8,35 (1H, dd, J = 8,5 Hz, J = 2,5 Hz), 8,02 (1H, d, J = 8,5 Hz), 7,60 (1H, d, J = 2,0 Hz), 7,58 (1H, d, J = 6,0 Hz), 6,64 (1H, t, J = 73,5 Hz), 5,37 – 5,30 (1H, m), 4,99 (1H, d, J = 9,5 Hz), 4,19 – 4,13 (1H, m), 2,54 – 2,40 (4H, m), 1,94 – 1,86 (2H, m), 1,47 (3H, d, J = 7,0 Hz).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 7 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
542	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	160–164	515,2

Comp	Nombre	p.f.	MS
573	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	190–194	529,2
574	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	181–184	547,4
575	6–(3–ciano–1–ciclopentil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida	N/A	479,1
576	6–(3–ciano–1–ciclopentil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	214–216	497,2
648	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	173–175	533,2
676	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	162–165	546,9
691	6–(3–ciano–1–ciclopentil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	232–233	493,1
711	6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	194–196	483,9
712	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(difluorometil)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	583,4

Comp	Nombre	p.f.	MS
713	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	197–200	547,3
719	N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)piridin–3–sulfonamida	242–245	443,2
720	N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida	N/A	493,3
721	N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(difluorometil)piridin–3–sulfonamida	N/A	543,2
722	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida	172–175	437,2
725	6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	497,3
726	6–(3–ciano–1–ciclobutil–6–etoxi–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	193–196	511,2
738	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida	166–173	N/A
733	5–cloro–1–ciclobutil–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida	171–173	516,2
780	6–cloro–1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida	251–253	448,1


Comp	Nombre	p.f.	MS
781	1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–6–(trifluorometoxi)–1H–indol–3–carboxamida	222–223	498,1
782	1–ciclopentil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–6–(trifluorometoxi)–1H–indol–3–carboxamida	238–241	512,2
784	6–[3–ciano–6–(difluorometoxi)–4–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	193–194	519,2
786	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–propil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	162–168	521,2
787	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	149–153	533,2
788	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–propil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	160–166	521,2
789	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	148–153	533,2
790	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluorobutan–2–il)piridin–3–sulfonamida	N/A	546,5
791	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–fenilpiridin–3–sulfonamida	178–179	513,2

Comp	Nombre	p.f.	MS
797	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–4–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–212	531,1
808	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	169–171	545,2
812	6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida	173–178	437,2
813	6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	N/A	495,1
822	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	204–210	547,1
827	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	150–155	547,1
862	6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	185–186	461,3
936	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	184–188	521,0
937	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(2–metilpropil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	130–134	535,3

Comp	Nombre	p.f.	MS
940	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(2–hidroxietil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	203–208	523,1
1065	N–{5–[3–ciano–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida	278–280	521,6
1082	N–(5–{3–ciano–1–[(1S)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–2–il}piridin–2–il)–2–metilpropan–2–sulfonamida	215,5–217,0	496,6
1092	N–[6–(3–ciano–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–2–il)piridin–3–il]–2–metilpropan–2–sulfonamida	252–255	495,5
1118	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclobutil–6–etil–4–fluoro–1H–indol–3–carboxamida	263–268	473,3


Ejemplo 8

6–[3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida (compuesto **650**)




Etapa A: A una solución de 6–ciclopropil–1H–indol–1–carboxilato de ter–butilo (1,93 g, 7,51 mmol) y triisopropilborato (2,58 mL, 11,26 mmol) en THF se añadió LDA (1,5 M en ciclohexano, 7,0 mL, 10,5 mmol) a –78 °C. La mezcla se agitó a –78 °C durante 30 min, se neutralizó con agua helada (60 mL) y se agitó durante 15 min sin enfriamiento. La mezcla se extrajo con acetato de etilo 1:1 en hexano (20 mL). La capa acuosa se acidificó con HCl ac. 2 N a pH 5 y luego se extrajo con CH_2Cl_2 (60 mL). La capa orgánica se secó sobre Na_2SO_4 y se concentró para dar ácido 1–(ter–butoxicarbonil)–6–ciclopropil–1H–indol–2–

ilborónico en forma de un sólido (2,0 g, 88% de rendimiento) que se usó en la siguiente etapa sin ulterior purificación.




Etapa B: Una mezcla de ácido 1–(ter–butoxicarbonil)–6–ciclopropil–1H–indol–2–ilborónico (1,10 g, 3,64 mmol), (S)–6–cloro–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (1,05 g, 3,64 mmol), $PdCl_2$(dppf) (178 mg, 0,22 mmol), K_2CO_3 ac. (2 M, 5,46 mL, 10,9 mmol) en acetonitrilo (8 mL) se agitó a 50 °C durante la noche. El solvente luego se evaporó y el residuo se purificó en gel de sílice eluyendo con 0 a 10% de acetato de etilo en CH_2Cl_2 para proveer 6–ciclopropil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–1–carboxilato de (S)–ter–butilo (1,51 g, 81% de rendimiento). MS *m/z* 510,3 $M+H^+$; ^{1}H RMN (500 MHz, $CDCl_3$): d 9,65 (1H, s), 8,50 (1H, m), 8,01 (1H, d, J = 8,2 Hz), 7,85 (1H, s), 7,52 – 7,49 (2H, m), 6,98 (1H, d, J = 8,2 Hz), 4,98 (1H, d, J = 8,4 Hz), 4,02 (1H, m), 2,02 – 1,98 (1H, m), 1,34 (3H, d, J = 7,5 Hz), 0,98 – 0,96 (2H, m), 0,76 – 0,72 (2H, m).




Etapa C: A una solución de 6–ciclopropil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–1–carboxilato de (S)–ter–butilo (503 mg, 0,99 mmol) y K_2CO_3 (276 mg, 2 mmol) en DMF (5 mL) se añadió bromuro de alilo (0,11 mL, 1,30 mmol). La mezcla se agitó a temperatura ambiente durante 2 h y se

neutralizó con agua (60 mL). La mezcla se extrajo con CH_2Cl_2 (3X20 mL). El solvente luego se evaporó y se obtuvo 2–(5–(N–alil–N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–6–ciclopropil–1H–indol–1–carboxilato de (S)–ter–butilo en forma de un aceite amarillo claro (500 mg, 92% de rendimiento). MS *m/z* 550,3 $M+H^+$. Este material se usó en la siguiente etapa sin ulterior purificación.




Etapa D: A una solución de 2–(5–(N–alil–N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–6–ciclopropil–1H–indol–1–carboxilato de (S)–ter–butilo (500 mg, 0,91 mmol) en acetonitrilo se añadió pirrolidina (0,35 mL, 4,55 mmol). La mezcla se agitó a temperatura ambiente durante 5 h y el solvente se evaporó. El residuo se purificó en gel de sílice eluyendo con 0 a 10% de acetato de etilo en CH_2Cl_2 para proveer (S)–N–alil–6–(6–ciclopropil–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (370 mg, 91% de rendimiento). MS *m/z* 450,2 $M+H^+$;^{1}H RMN (500 MHz, $CDCl_3$): d 9,28 (1H, s), 8,85 (1H, s), 7,96 (1H, d, J = 5,5 Hz), 7,74 (1H, d, J = 9,5 Hz), 7,49 (1H, d, J = 5,5 Hz), 7,09 (1H, s), 7,01 (1H, s), 6,82 – 6,80 (1H, m), 5,75 (1H, m), 5,16 – 5,10 (2H, m), 4,64 – 4,62 (1H, m), 3,89 (2H, d, J = 5,0 Hz), 2,00 – 1,96 (1H, m), 1,35 (3H, d, J = 6,0 Hz), 0,98 – 0,96 (2H, m), 0,75 – 0,72 (2H, m).




Etapa E: A una solución de (S)–N–alil–6–(6–ciclopropil–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (370 mg, 0,82 mmol) en DMF (5 mL) se añadió isocianato de clorosulfonilo (0,14 mL, 1,6 mmol) a –30 °C. La mezcla luego se calentó hasta 0 °C y se agitó durante 2 h. La mezcla luego se

neutralizó con agua (60 mL), se extrajo con CH_2Cl_2 (3X20 mL) y se lavó con salmuera (3X30 mL). La capa orgánica se recogió, se secó sobre Na_2SO_4, se concentró y se purificó en gel de sílice eluyendo con 0 a 10% de acetato de etilo en CH_2Cl_2 para proveer (S)–N–alil–6–(3–ciano–6–ciclopropil–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (186 mg, 50% de rendimiento). MS *m/z* 475,2 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 9,80 (1H, s), 9,02 (1H, s), 8,44 (1H, dd, J = 1,0, 9,0 Hz), 8,11 (1H, dd, J = 2,5, 8,5 Hz), 7,59 (1H, d, J = 8,5 Hz), 7,20 (1H, s), 7,00 (1H, d, J = 2,5, 8,5 Hz), 5,52 (1H, m), 5,28 – 5,20 (2H, m), 4,50 (1H, m), 3,98 (1H, bs), 2,02 – 1,96 (1H, m), 1,43 (3H, d, J = 7,0 Hz), 0,98 – 0,96 (2H, m), 0,75 – 0,72 (2H, m).



Etapa F: Una mezcla de (S)–N–alil–6–(3–ciano–6–ciclopropil–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (140 mg, 0,30 mmol), 2–bromo–pirimidina (98 mg, 0,59 mmol), yoduro de cobre (I) (11 mg, 0,06 mmol), (1R,2R)–N1,N2–dimetilciclohexano–1,2–diamina (0,02 mL, 0,12 mmol) y K_3PO_4 (134 mg, 0,60 mmol) en tolueno se agitó a 100 °C durante 16 h. La mezcla luego se filtró a través de celite y el solvente se evaporó. El residuo se purificó en gel de sílice eluyendo con 0 a 10% de acetato de etilo en CH_2Cl_2 para proveer (S)–N–alil–6–(3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (140 mg, 86%). MS *m/z* 553,3 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 8,65 (1H, d, J = 3,0 Hz), 8,62 (2H, d, J = 4,0 Hz), 8,14 (1H, dd, J = 4,0, 8,0 Hz), 8,01 (1H, d, J = 9,0 Hz), 7,75 (1H, s), 7,64 (1H, d, J = 7,5 Hz), 7,21 – 7,19 (1H, m), 7,04 (1H, d, J = 9,0 Hz), 5,60 (1H, m), 5,28 – 5,25

(2H, m), 4,50 (1H, m), 3,86 (1H, d, J = 6,5 Hz), 2,02 – 1,96 (1H, m), 1,32 (3H, d, J = 8,5 Hz), 0,98 – 0,96 (2H, m), 0,75 – 0,72 (2H, m).




Etapa G: A una solución de (S)–N–alil–6–(3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (70 mg, 0,13 mmol) y $PdCl_2$(dppf) (10 mg, 0,013 mmol) en THF (1 mL) se añadió $NaBH(AcO)_3$ (40 mg, 0,19 mmol). La mezcla se agitó a temperatura ambiente durante 16 h y se añadió CH_2Cl_2 (20 mL). La mezcla se lavó con NH_4Cl sat. ac. (20 mL), se concentró y se purificó en gel de sílice eluyendo con 0 a 10% de acetato de etilo en CH_2Cl_2 para proveer (S)–6–(3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (54 mg, 83%). Punto de fusión: 181–184 °C; MS *m/z* 513,2 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 9,28 (1H, s), 8,72 (1H, d, J = 2,0 Hz), 8,60 (2H, d, J = 9,0 Hz), 8,19 (1H, d, J = 2,5 Hz), 8,18 (1H, d, J = 2,0 Hz), 8,02 (1H, d, J = 9,0 Hz), 7,76 (1H, s), 7,65 (1H, d, J = 8,0 Hz), 7,21 – 7,20 (1H, m), 7,05 (1H, d, J = 9,0 Hz), 5,50 (1H, s), 4,02 – 3,98 (1H, m), 2,02 – 1,96 (1H, m), 1,31 (3H, d, J = 6,0 Hz), 0,98 – 0,96 (2H, m), 0,75 – 0,72 (2H, m).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 8 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:


Comp	Nombre	p.f.	MS
541	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	160–164	504,8
601	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	201–203	491,2
634	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	505,1
682	6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	556,9
704	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–198	519,1

Ejemplo 9

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxamida (compuesto **683**)



Etapa A: Una mezcla de ácido 3–ciano–1–ciclopentil–5–fluoro–6–metil–1*H*–indol–2–ilborónico (125 mg, 0,42 mmol, 90%) [preparado como en el Ejemplo 6, Etapa E], *N–ter*–butil–6–cloropiridin–3–sulfonamida (69 mg, 0,28 mmol), tetrafluoroborato de tri–ter–butilfosfonio (10 mg, 0,034 mmol), $Pd_2(dba)_3$ (16 mg, 0,017 mmol) y fluoruro de potasio (150 mg, 2,58 mmol) en THF (2,0 mL) se agitó a 40 °C durante la noche. El solvente luego se evaporó y el residuo se purificó en gel de sílice eluyendo con 0 a 10% de acetato de etilo en CH_2Cl_2 para proveer *N–ter*–butil–6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1*H*–indol–2–il)piridin–3–sulfonamida (99 mg, 78%).



Etapa B: A una solución de *N–ter*–butil–6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1*H*–indol–2–il)piridin–3–sulfonamida (90 mg, 0,2 mmol) en TFA (2,0 mL) se añadieron 2 gotas de agua. La mezcla se agitó a 40 °C durante 30 min y luego se evaporó. El residuo se purificó en gel de sílice eluyendo con 5 a 30% de acetato de etilo en CH_2Cl_2 para proveer el compuesto del título (19 mg, 20%). MS *m/z* 473,3 $M+H^+$; ^1H RMN (500 MHz, DMSO–d_6): d 9,10 (1H, dd, J = 2,0, 1,0 Hz), 8,29 (1H, dd, J = 10,5, 2,5 Hz), 7,89 (1H, s), 7,81 (1H, dd, J = 8,5, 1,0 Hz), 7,59

(1H, d, J = 10,5 Hz), 7,49 (1H, d, J = 6,5 Hz), 7,02 (2H, br s), 4,63 – 4,56 (1H, m), 2,46 (3H, s), 2,16 – 2,08 (2H, m), 1,96 – 1,85 (4H, m), 1,60 – 1,56 (2H, m), 1,17 (9H, s).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 9 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
552	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida	204–205	419,2
568	1–ciclobutil–6–(difluorometoxi)–2–(5–sulfamoilpiridin–2–il)–1H–indol–3–carboxamida	230–231	437,2
581	1–ciclobutil–6–(difluorometoxi)–2–{5–[(1,3–difluoropropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	211–213	515,3
582	1–ciclobutil–6–ciclopropil–2–{5–[(1,3–difluoropropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	N/A	489,3
699	1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	243–245	513,3
700	1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	244–246	512,8

Comp	Nombre	p.f.	MS
701	1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	211–214	527,3
703	1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	184–186	550,8
706	1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	273–279	527,3
707	1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida	N/A	528,3
714	1–ciclohexil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	245–250	542,1
715	1–ciclohexil–5–fluoro–6–metil–2–(5–sulfamoilpiridin–2–il)–1H–indol–3–carboxamida	254–257	432,0
716	1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	272–276	528,0
718	1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	218–220	565,4
723	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida	158–160	511,3

Comp	Nombre	p.f.	MS
729	1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	207–209	565,1
730	1–ciclopentil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	220–221	525,3
731	1–ciclobutil–6–ciclopropil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	225–227	525,2
732	1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	195–197	499,2
733	5–cloro–1–ciclobutil–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida	171–173	516,2
734	5–cloro–1–ciclobutil–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	207–209	516,2
735	5–cloro–1–ciclobutil–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	208–210	515,2
736	6–cloro–1–ciclobutil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	241–243	519,2

Comp	Nombre	p.f.	MS
737	1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	190–194	499,2
745	5–cloro–1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida	245–247	448,2
746	1–ciclohexil–6–(difluorometoxi)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida	217–219	562,3
747	1–ciclohexil–6–(difluorometoxi)–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida	216–218	508,3
748	5–fluoro–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	507,8
767	5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	258–262	529,2
768	5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	200–206	543,2
769	5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	261–264	529,3
798	1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–[5–(fenilsulfamoil)piridin–2–il]–1H–indol–3–carboxamida	204–206	531,2

Comp	Nombre	p.f.	MS
806	1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	220–222	565,1
809	1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	197–200	563,1
825	1–ciclobutil–6–(difluorometoxi)–4–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	254–256	549,1
828	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–hidroxi–6–metil–1H–indol–3–carboxamida	292–293	455,1
829	1–ciclopentil–6–ciclopropil–5–fluoro–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	233–234	537,1
830	1–ciclopentil–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	237–238	525,1
833	1–ciclobutil–5–hidroxi–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	256–258	495,1
834	1–ciclopentil–5–metoxi–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	273–275	523,1
838	1–ciclopentil–6–ciclopropil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	255–257	537,5

Comp	Nombre	p.f.	MS
839	6–(difluorometoxi)–4–fluoro–1–(propan–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	197–198	537,1
840	1–(ciclopropilmetil)–6–(difluorometoxi)–4–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	211–212	549,1
841	1–ciclopentil–5–hidroxi–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	272–274	509,1
849	6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	235–236	537,3
850	1–ciclopentil–6–ciclopropil–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	236–237	551,2
857	1–ciclohexil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	273–274	539,1
863	1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	215–217	579,2
871	1–ciclopentil–6–etil–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	185–188	539,2

Comp	Nombre	p.f.	MS
872	1–ciclopentil–6–etil–5–fluoro–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	196–197	537,2
874	5–fluoro–6–metil–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	142–148	521,5
875	5–fluoro–6–metil–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	162–169	522,5
876	5–fluoro–1–(5–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	224–228	539,5
877	5–fluoro–1–(6–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	210–214	539,5
902	5–fluoro–1–(3–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	130–138	539,5
904	5–fluoro–6–metil–1–(5–metilpirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	202–208	536,5
905	5–fluoro–6–metil–1–(4–metilpirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	205–210	536,5

Comp	Nombre	p.f.	MS
906	5–fluoro–1–(4–metoxipirimidin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	167–174	552,5
909	6–etil–5–fluoro–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	536,2
912	5–fluoro–6–metil–1–(piridazin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	176–181	522,5
913	5–fluoro–6–metil–1–(piridin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	223–227	521,5
980	6–etil–5–fluoro–1–(4–metilpiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	137–145	550,3
981	6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	200–204	554,3
982	6–etil–5–fluoro–1–(2–metilpirimidin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	115–120	551,3
994	6–etil–5–fluoro–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	120–127	537,3


Comp	Nombre	p.f.	MS
995	6–etil–5–fluoro–1–(6–fluoropiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	230–233	554,3
996	5–cloro–1–ciclobutil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	244–245	501,1
997	1–ciclobutil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	224–227	485,1
1019	6–etil–5–fluoro–1–(4–fluorofenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	210–217	553,3
1020	1–(4–clorofenil)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	240–247	569,2 – 571,2
1021	6–etil–5–fluoro–1–(4–metilfenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	228–233	549,3
1022	6–etil–5–fluoro–1–[4–(trifluorometil)fenil]–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	253–259	603,3
1023	6–etil–5–fluoro–1–(3–fluorofenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	233–238	554,0

Comp	Nombre	p.f.	MS
1024	6–etil–5–fluoro–1–(3–metilfenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	179–189	550,1
1025	6–etil–5–fluoro–1–(3–metoxifenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	566,1
1026	6–etil–5–fluoro–1–[3–(trifluorometil)fenil]–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	604,0
1027	1–(3–clorofenil)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	200–205	569,2 – 571,2
1039	6–etil–5–fluoro–1–(5–metilpiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	550,5
1040	6–etil–5–fluoro–1–(piridin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	537,3
1041	6–etil–5–fluoro–1–(pirimidin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	537,2
1042	1–(3–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	570,5 572,5


Comp	Nombre	p.f.	MS
1043	1–(5–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	256–254	570,5 572,5
1044	1–(5–cloropiridin–3–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	570,2 572,2
1045	6–etil–5–fluoro–1–(piridin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	219–224	536,3
1046	6–etil–5–fluoro–1–(piridazin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	206–212	537,3
1047	6–etil–5–fluoro–1–(5–metilpirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	257–261	551,5
1048	1–(4–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	200–204	570,5 572,5

Ejemplo 10

6–(3–ciano–1–ciclopentil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida (compuesto **693**)



Etapa A: A una solución de (2,2,2–trifluoro–1–metil–etil)–amida del ácido (R)–6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–piridin–3–sulfónico (0,48 g, 1,05 mmol) en ácido acídico (3 mL) se añadió bromo (0,35 g, 2,1 mmol) gota a gota. La solución se agitó a 90 °C durante 30 min, se enfrió hasta temperatura ambiente y luego se diluyó con agua (20 mL). El precipitado se recogió y se lavó cuidadosamente con agua, luego se secó para dar (2,2,2–trifluoro–1–metil–etil)–amida del ácido (R)–6–(5–bromo–3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–piridin–3–sulfónico en forma de un sólido amarillo claro (0,54 g, 93%).



Etapa B: Una mezcla de (2,2,2–trifluoro–1–metil–etil)–amida del ácido (R)–6–(5–bromo–3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–piridin–3–sulfónico (0,54 g, 0,97 mmol), bis(pinacolato)diboro (0,5 g, 2,0 mmol), complejo de $PdCl_2$dppf–CH_2Cl_2 (16 mg, 0,02 mmol) y acetato de potasio (0,40 g, 4,0 mmol) en dioxano (5 mL) se agitó a 80 °C durante la noche. La mezcla luego se enfrió hasta temperatura ambiente, se diluyó con acetato de etilo y se filtró a través de un taco de celite–sílice. El filtrado se concentró, se disolvió en acetona (10 mL) y se enfrió hasta 0 °C. A esta solución se añadió una solución acuosa de Oxone (10 mL, 1,0 M). La mezcla se agitó a temperatura ambiente durante 15 min y se diluyó con acetato de etilo y agua. La capa acuosa se extrajo con acetato de etilo. Las extracciones orgánicas se combinaron y se lavaron con $NaHSO_3$ ac. y salmuera, se secaron sobre Na_2SO_4 y se concentraron. La purificación en gel de sílice eluyendo con 40% de acetato de etilo en hexano dio (2,2,2–trifluoro–1–metil–etil)–amida del ácido (R)–6–(3–ciano–1–ciclopentil–5–hidroxi–6–metil–1H–indol–2–il)–piridin–3–sulfónico en forma de un sólido amarillo (0,40 g, 84%); Punto de fusión:

239–240 °C; MS *m/z* 493,2 $M+H^+$; ^{1}HRMN (500MHz, CD_3COCD_3) δ 9,24 (dd, J = 2,30, 0,65 Hz, 1H), 8,50 (dd, J = 8,25, 2,35 Hz, 1H), 8,42 (s, 1H), 8,10 (dd, J = 8,25, 0,85 Hz, 1H), 7,47 (bs, 1H), 7,54 (s, 1H), 7,15 (s, 1H), 5,30 – 5,26 (m, 1H), 4,40 – 4,35 (m, 1H), 2,40 (s, 3H), 2,34 – 2,31 (m, 2H), 2,16 – 2,14 (m, 2H), 2,10 – 2,07 (m, 2H), 1,74 – 1,72 (m, 2H), 1,21 (d, J = 2,25 Hz, 3H).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 10 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:


Comp	Nombre	p.f.	MS
636	6–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	549,0
646	6–[1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	151–153	503,9
647	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–etil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	160–162	543,0
658	6–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida	218–226	507,1
659	2–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida	228–232	532,1

Comp	Nombre	p.f.	MS
660	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	168–170	529,2
669	6–(3–ciano–1–ciclopentil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	211–211,5	506,9
674	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–hidroxi–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	174–177	530,9
675	6–(5–bromo–3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	204–204,5	555,2
684	6–(5–bromo–3–ciano–1–ciclobutil–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	223–224	545,1
685	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–(metilsulfanil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	561,2
692	6–(5–bromo–3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,	226,5–227	555,2
694	6–(3–ciano–1–ciclopentil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210,5–211	507,3
728	6–(1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	193–195	458,2

Comp	Nombre	p.f.	MS
757	6–(3–ciano–1–ciclobutil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	222–223	491,2
796	6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	193–195	477,0
805	N–ter–butil–6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)piridin–3–sulfonamida	211–213	437,1
807	6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	209–210	477,0


Ejemplo 11

N–*ter*–butil–6–(6–etil–5–fluoro–3–(metilsulfonil)–1–(pirimidin–2–il)–1*H*–indol–2–il)piridin–3–sulfonamida (compuesto **869**) (PS107236)




Etapa A: Una mezcla de N–*ter*–butil–6–(6–etil–5–fluoro–3–1*H*–indol–2–il)piridin–3–sulfonamida (300 mg, 0,80 mmol), 2–(metiltio)isoindolin–1,3–diona (198 mg, 1,04 mmol), $MgBr_2$ (60 mg, 0,32 mmol) y DMA (1,5 mL) se calentó a 90 °C durante 15 horas. La mezcla de reacción se diluyó en agua y se extrajo en acetato de etilo. La capa orgánica se lavó con agua y salmuera. La capa orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida. La purificación

por cromatografía en gel de sílice (4:1 hexanos : acetato de etilo) dio como resultado N–*ter*–butil–6–(6–etil–5–fluoro–3–(metiltio)–1*H*–indol–2–il)piridin–3–sulfonamida (328 mg, 97%) en forma de un sólido amarillo.



Etapa B: Una suspensión de N–*ter*–butil–6–(6–etil–5–fluoro–3–(metiltio)–1*H*–indol–2–il)piridin–3–sulfonamida (250 mg, 0,60 mmol) en $CHCl_3$ (4 mL) se enfrió hasta 0 °C. m–CPBA (425 mg, 2,46 mmol) se añadió en una porción y se agitó a temperatura ambiente durante 1 hora. La mezcla de reacción se diluyó en CH_2Cl_2 y se lavó con $NaHCO_3$ ac. La capa orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida. La purificación por cromatografía en gel de sílice (30 – 40% de acetato de etilo en hexanos), seguido de trituración con éter, dio como resultado N–*ter*–butil–6–(6–etil–5–fluoro–3–(metilsulfonil)–1*H*–indol–2–il)piridin–3–sulfonamida (124 mg, 45%) en forma de un sólido blanco.




Etapa C: Una mezcla de N–*ter*–butil–6–(6–etil–5–fluoro–3–(metilsulfonil)–1*H*–indol–2–il)piridin–3–sulfonamida (115 mg, 0,25 mmol), 2–bromopirimidina (88 mg, 0,55 mmol), CuI (28 mg, 0,15 mmol), K_2CO_3 (160 mg, 1,15 mmol) y DMF (0,5 mL) se calentó a 110 °C durante 15 horas. La mezcla de reacción se diluyó en agua y se extrajo en acetato de etilo. La capa orgánica se

lavó con agua y luego con salmuera. La capa orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida. La purificación por cromatografía en gel de sílice (40% de acetato de etilo en hexanos) dio como resultado N–*ter*–butil–6–(6–etil–5–fluoro–3–(metilsulfonil)–1–(pirimidin–2–il)–1*H*–indol–2–il)piridin–3–sulfonamida (121 mg, 91%) en forma de un sólido blanco. Punto de fusión: 244–248 °C; MS *m/z* 532,2 $M+H^+$; ^1H RMN (DMSO–d^6, 500 MHz): d 8,82 (d, 1H, J = 2 Hz), 8,73 (d, 2H, 5,0 Hz), 8,23 (dd, 1H, J = 8,0 Hz, 2 Hz), 8,05 (d, 1H, J = 6,5 Hz), 7,96 (d, 1H, J = 8 Hz), 7,87 (s, 1H), 7,76 (d, 1H, 10,5 Hz), 7,51 (t, 1H, J = 5 Hz), 3,38 (s, 3H), 2,78 (q, 2H, J = 7,5 Hz), 1,23 (t, 3H, 7,5 Hz), 1,13 (s, 9H).


Ejemplo 12

1–ciclopentil–5–fluoro–6–metil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carboxilato de (S)–metilo (compuesto **756**) (PS106824)




Etapa A: A una solución de 6–bromo–5–fluoro–1H–indol (14,9 g, 70 mmol) en THF (160 mL) a 0 °C se añadió cloruro de tricloroacetilo (7,4 mL, 90 mmol) gota a gota. La mezcla se agitó a temperatura ambiente durante el fin de semana y luego se dividió en acetato de etilo y agua. El acetato de etilo se lavó con HCl (1 N), se secó y se evaporó. El residuo se disolvió en metanol (500 mL), al que se añadió 50% de KOH (5 mL) y la mezcla se calentó a reflujo durante 6 h. La mezcla luego se evaporó hasta que comenzaron a aparecer cristales y luego se filtró. El sólido se lavó con metanol y se recogió para dar el compuesto del título (10,6 g). El filtrado se concentró y se trituró con CH_2Cl_2 y hexano para dar el

segundo lote (3,8 g). El licor madre se purificó por cromatografía flash con CH_2Cl_2 y acetato de etilo (0 a 20%) para dar 6–bromo–5–fluoro–1H–indol–3–carboxilato de metilo (0,75 g). El rendimiento total era de aproximadamente el 80%.




Etapa B: Una mezcla de 6–bromo–5–fluoro–1H–indol–3–carboxilato de metilo (9,0 g, 33 mmol), bromociclopentano (5,3 mL, 49,6 mmol) y Cs_2CO_3 (21,5 g, 66 mmol) en DMF (40 mL) se agitó a 80 °C durante la noche. La mezcla se vertió luego en agua helada, se filtró y se lavó con agua. El sólido se recogió y se secó para dar 6–bromo–1–ciclopentil–5–fluoro–1H–indol–3–carboxilato de metilo (10,3 g, rendimiento del 91%), que se usó en la siguiente etapa sin ulterior purificación.




Etapa C: Una mezcla de 6–bromo–1–ciclopentil–5–fluoro–1H–indol–3–carboxilato de metilo (3,4 g, 10 mmol), dimetilzinc (1,2 M, 16,7 mL, 20 mmol) y $PdCl_2dppf$ (163 mg, 0,2 mmol) en dioxano (20 mL) se agitó a 88 °C durante 2 h bajo una atmósfera de nitrógeno. La mezcla luego se enfrió y el metanol se añadió lentamente seguido de HCl 2 N. La mezcla se trató con acetato de etilo, se lavó con agua y salmuera, se secó y se evaporó. El residuo se purificó por

cromatografía flash con diclorometano y hexano (1:1) para dar 1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxilato de metilo (2,66 g, rendimiento del 97%).



Etapa D: A una solución de 1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxilato de metilo (2,64 g, 9,6 mmol) y triisopropilborato (4,0 mL, 17,28 mmol) en THF (40 mL) a –78 °C se añadió LDA (1,5 M, 8,3 mL, 12,48 mmol) gota a gota. La mezcla se agitó durante 45 min y luego se trató con agua helada y se extrajo con diclorometano. La capa orgánica se secó sobre sulfato de sodio y se evaporó para dar ácido 1–ciclopentil–5–fluoro–3–(metoxicarbonil)–6–metil–1H–indol–2–ilborónico en forma de un semisólido (3,1 g, ~50% puro), que se usó en la siguiente etapa sin ulterior purificación.



Etapa E: Una mezcla de ácido 1–ciclopentil–5–fluoro–3–(metoxicarbonil)–6–metil–1H–indol–2–ilborónico (2,2 mmol), (*S*)–6–cloro–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (0,53 g, 1,83 mmol), $PdCl_2dppf$ (0,15 g, 0,183 mmol), K_2CO_3 ac. (2,0 M, 3,6 mL, 7,2 mmol) en acetonitrilo (10 mL) se agitó a temperatura ambiente durante el fin de semana. La mezcla se trató con acetato de etilo y se lavó con agua y salmuera y luego se concentró. El residuo se purificó por cromatografía flash con 0 – 15% de acetato de etilo en CH_2Cl_2 para proveer

1–ciclopentil–5–fluoro–6–metil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carboxilato de (S)–metilo (0,52 g, 54%). MS *m/z* 528,2 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 9,21 (1H, d, J = 1,8 Hz), 8,25 (1H, dd, J = 8,2 Hz, J = 2,2 Hz), 7,87 (1H, d, J = 10,6 Hz), 7,73 (1H, d, J = 8,2 Hz), 7,27 (1H, d, J = 5,2 Hz), 5,09 (1H, d, J = 9,6 Hz), 4,39 – 4,31 (1H, m), 4,17 – 4,10 (1H, m), 3,70 (3H, s), 2,44 (3H, d, J = 1,8 Hz), 2,41 – 2,36 (2H, m), 2,20 – 1,96 (4H, m), 1,67 – 1,63 (2H, m), 1,45 (3H, d, J = 7,0 Hz).


Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 12 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+ (a menos que se indique otra cosa), p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
717	1–ciclohexil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxilato de metilo	232–240	528,2
754	1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxilato de metilo	N/A	542,2
755	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxilato de metilo	N/A	488,3
770	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxilato de metilo	N/A	474,3

Comp	Nombre	p.f.	MS
771	metil 1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxilato	N/A	514,2
774	1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxilato de metilo	N/A	515,2
1099	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–5–fluoro–6–(fluorometoxi)–1H–indol–3–carboxilato de metilo	166–167	536,0

Ejemplo 13

Ácido (S)–1–ciclopentil–5–fluoro–6–metil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carboxílico (compuesto **758**) (PS106830)



Una mezcla de 1–ciclopentil–5–fluoro–6–metil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carboxilato de (S)–metilo (0,45 g, 0,85 mmol), NaOH al 25% ac. (2,0 mL) en etanol (4,0 mL) se agitó a 80 °C durante la noche. La mezcla se trató luego con agua y se extrajo con éter. La capa acuosa se acidificó con HCl 1 N a pH 4 y se extrajo con acetato de etilo. Las capas orgánicas se lavaron con salmuera, se secaron sobre Na_2SO_4 y se evaporaron para dar ácido (S)–1–ciclopentil–5–fluoro–6–metil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carboxílico (0,36 g, 82%). MS *m/z* 514,2 $M+H^+$; ^1H RMN (500 MHz, acetona–d6): d 10,55 (1H, br s), 9,17

(1H, d, J = 2,2 Hz), 8,38 (1H, dd, J = 8,2 Hz, J = 2,2 Hz), 7,96 (1H, dd, J = 8,2, 0,8 Hz), 7,89 (1H, d, J = 10,7 Hz), 7,70 (br s, 1H), 7,57 (1H, d, J = 6,4 Hz), 4,63 – 4,56 (1H, m), 4,34 – 4,29 (1H, m), 2,44 (3H, d, J = 1,8 Hz), 2,29 – 2,25 (2H, m), 2,10 – 1,90 (4H, m), 1,67 – 1,56 (2H, m), 1,25 (3H, d, J = 7,0 Hz).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 13 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+ (a menos que se indique otra cosa), p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:


Comp	Nombre	p.f.	MS
741	ácido 1–ciclohexil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico	216–220	514,2
765	ácido 1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxílico	233–234	528,2
766	ácido 2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxílico	238–240	474,2
775	ácido 1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxílico	N/A	500,7
776	ácido 2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxílico	N/A	459,7

Comp	Nombre	p.f.	MS
793	ácido 1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico	234–240	500,6
794	ácido 2–[5–(ter–butilsulfamoil)pirimidin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxílico	194–201	461,2
835	ácido 1–ciclohexil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico	205–213	540,7
928	ácido 1–ciclohexil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxílico	N/A	594,3
998	ácido 2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxílico	224–226	502,3
1028	ácido 2–{5–[(ter–butilsulfonil)amino]pirimidin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxílico	236–237	503,6
1029	ácido 2–{2–[(ter–butilsulfonil)amino]pirimidin–5–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxílico	N/A	503,6
1036	2–{2–[(ter–butilsulfonil)amino]pirimidin–5–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida	>300	502,6
1037	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida	297–299	501,7
1064	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico	N/A	540,6

Comp	Nombre	p.f.	MS
1080	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico	N/A	526,3
1084	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico	N/A	526,1
1086	ácido 2–{6–[(ter–butilsulfonil)amino]–4–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico	N/A	540,7
1093	ácido 2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–3–carboxílico	N/A	514,8
1094	ácido 2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico	N/A	540,2
1103	ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxílico	165–descomp.	488,5

Ejemplo 14

(S)–1–ciclopentil–5–fluoro–N,6–dimetil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carboxamida (compuesto **761**) (PS106833)



Una mezcla de ácido (S)–1–ciclopentil–5–fluoro–6–metil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carboxílico (300 mg, 0,58 mmol) en $SOCl_2$ (4 mL) se agitó a 66 °C durante 2 h. Las sustancias volátiles se eliminaron por medio de una corriente de nitrógeno seguido de vacío para dar cloruro de (S)–1–ciclopentil–5–fluoro–6–metil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carbonilo en forma de un sólido. El anterior cloruro de (S)–1–ciclopentil–5–fluoro–6–metil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carbonilo preparado (100 mg, 0,188 mmol) se trató con una solución de metilamina en THF (2,0 M, 5 mL, 10 mmol) y se agitó a temperatura ambiente durante 5 min. La mezcla se trató luego con acetato de etilo, se lavó con agua y salmuera, se secó sobre Na_2SO_4 y se evaporó para dar (S)–1–ciclopentil–5–fluoro–N,6–dimetil–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–3–carboxamida (66 mg, 67%). MS *m/z* 527,3 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 9,18 (1H, br s), 8,30 (1H, dd, J = 8,0 Hz, J = 2,0 Hz), 7,73 (1H, d, J = 8,5 Hz), 7,66 (1H, d, J = 10,5 Hz), 7,28 (1H, br s), 6,26 (1H, br s), 5,91 (1H, d, J = 9,5 Hz), 4,51 – 4,40 (1H, m), 4,15 – 4,10 (1H, m), 2,84 (3H, s), 2,43 (3H, d, J = 1,5 Hz), 2,30 – 2,23 (2H, m), 2,10 – 1,90 (4H, m), 1,68 – 1,62 (2H, m), 1,42 (3H, d, J = 8,5 Hz).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 14 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+ (a menos que se indique otra cosa), p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:


Comp	Nombre	p.f.	MS
762	1–ciclopentil–N–etil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	160–162	541,3
763	1–ciclopentil–5–fluoro–6–metil–N–(propan–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	234–236	555,3
783	1–ciclopentil–5–fluoro–N,N,6–trimetil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	278–280	541,2
795	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida	215–218	473,2
799	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida	248–250	487,3
800	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxamida	189–193	459,3
801	1–ciclobutil–5–fluoro–N,6–dimetil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	513,2

Comp	Nombre	p.f.	MS
802	2–[5–(ter–butilsulfamoil)pirimidin–2–il]–1–ciclobutil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida	211–213	474,2
999	2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida	264–265	501,4
1063	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida	296–297	539,6
1081	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida	239–241	525,4
1085	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida	228–230	525,1
1087	2–{6–[(ter–butilsulfonil)amino]–4–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida	250–254	539,4
1095	2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–3–carboxamida	234–235	513,4
1096	2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida	147–151	539,2
1100	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–5–fluoro–1–fenil–1H–indol–3–carboxamida	272–274	507,3
1102	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–5–fluoro–6–(fluorometoxi)–1H–indol–3–carboxamida	274–276	521,0


Comp	Nombre	p.f.	MS
1104	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxamida	255,5–259,0	487,5

Ejemplo 15


N–ter–butil–6–(3,6–diacetil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il)piridin–3–sulfonamida (compuesto **939**) (PS107454)



Etapa A: A una suspensión de 6–(6–bromo–5–fluoro–1H–indol–2–il)–N–ter–butilpiridin–3–sulfonamida (2,4 g, 5,6 mmol) en acetonitrilo (5,6 mL) y DMF (11,2 mL) a 0 °C se añadió isocianato de clorosulfonilo (0,97 mL, 11,2 mmol) gota a gota. La mezcla se agitó a 0 °C durante 15 min y luego 30 min a temperatura ambiente. La reacción se neutralizó por adición de agua helada. La mezcla se extrajo con acetato de etilo, se secó y se concentró. El residuo se trató con diclorometano y se filtró. El sólido se recogió como una mezcla de 6–(6–bromo–3–ciano–5–fluoro–1H–indol–2–il)–N–ter–butilpiridin–3–sulfonamida y 6–(6–bromo–3–cloro–5–fluoro–1H–indol–2–il)–N–ter–butilpiridin–3–sulfonamida, que se usó en la siguiente etapa sin ulterior purificación.




Etapa B: La mezcla preparada anteriormente (0,71 g) se combinó con 2–bromopirimidina (0,5 g, 3,14 mmol), carbonato de potasio (0,65 g, 4,71 mmol) y CuI (60 mg, 0,314 mmol) en DMF (2,0 mL) se agitó a 110 °C durante 24 h bajo una atmósfera de nitrógeno. La mezcla se trató luego con acetato de etilo, se lavó con cloruro de amonio acuoso y salmuera, se secó sobre sulfato de sodio y se evaporó. El residuo se purificó con diclorometano y acetato de etilo (0 a 8%) para dar una mezcla (0,6 g) de 6–(6–bromo–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il)–N–ter–butilpiridin–3–sulfonamida (~86%) y 6–(6–bromo–3–cloro–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il)–N–ter–butilpiridin–3–sulfonamida (~14%), que se usó en la siguiente etapa de reacción sin ulterior purificación.



Etapa C: Una mezcla de 6–(6–bromo–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il)–N–ter–butilpiridin–3–sulfonamida y 6–(6–bromo–3–cloro–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il)–N–ter–butilpiridin–3–sulfonamida (84 mg, 0,156 mmol), $Pd(OAc)_2$ (7,6 mg, 0,034 mmol), 1,3–bis(difenilfosfino)propano (31 mg, 0,075 mmol), K_2CO_3 (0,19 g, 1,36 mmol), éter butilvinílico (0,73 mL, 5,66 mmol) en DMF (3,0 mL) y agua (0,35 mL) se agitó a 120 °C durante la noche bajo una atmósfera de N_2. La mezcla luego se acidificó hasta pH ~1 con HCl 1 N, se agitó a temperatura ambiente durante 1 h, se extrajo con acetato de etilo seguido de secado con Na_2SO_4, evaporación y purificación por cromatografía flash con 5 a 20% de acetato de etilo en CH_2Cl_2 para dar N–ter–butil–6–(3,6–diacetil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il)piridin–3–sulfonamida (58 mg, 73%). MS *m/z* 510,1 $M+H^+$; ^1H RMN (500 MHz, acetona–d_6): d 9,07 (1H, d, J = 2,2 Hz), 8,77 (1H, d, J = 6,2 Hz), 8,58 (2H, d, 4,9 Hz), 8,28 (1H, dd, J = 8,2, 2,2 Hz), 8,12 (1H, d, J = 10,2 Hz), 7,78 (1H, dd, J = 8,2, 0,7 Hz), 7,21 (1H, t, J =4,9 Hz), 4,80 (1H, br s), 2,75 (3H, d, J = 5,4 Hz), 2,21 (3H, s), 1,25 (9H, s).

Ejemplo 16

(compuesto **883**) (PS107300)



Un recipiente a presión se cargó con (S)–6–(3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (600 mg, 1,25 mmol),. NaOH ac. (50%, 2 mL) y etanol (2 mL). La mezcla se selló y se calentó hasta 120 °C durante la noche. Después de enfriar la mezcla de

reacción se vertió en agua helada (20 mL) y se extrajo con acetato de etilo, se secó sobre $MgSO_4$ y se purificó por cromatografía en gel de sílice para obtener 2–(5–(N–ter–butilsulfamoil)piridin–2–il)–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–3–carboxamida (315 mg, 51%). MS *m/z* 496,2 $M+H^+$; ^1H RMN (500 MHz, $CDCl_3$): d 8,84 (1H, m), 8,31 (1H, m), 8,02 (1H, q, J = 4,0 Hz), 7,79 (1H, m), 7,76 (1H, s), 7,50 (1H, dd, J = 3,75 Hz, 3,74 Hz), 7,31 (1H, d, J = 3,6 Hz), 7,26 (2H, m), 7,21 (1H, m), 6,58 (1H, s), 2,63 (2H, q, J = 1,3 Hz), 1,09 (9H, s), 1,02 (3H, t, J = 2,4 Hz).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 16 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+ (a menos que se indique otra cosa), p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:


Comp	Nombre	p.f.	MS
846	5–metil–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	N/A	505,2
916	5–metil–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	240–245	505,2
918	6–fluoro–5–metil–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	245–249	523,2

Comp	Nombre	p.f.	MS
978	6–etil–5–fluoro–1–(pirimidin–2–il)–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida	261–269	551,3
979	6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida	240–247	549,2
1083	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxamida	256,0–259,0	487,5
1088	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida	290–294	513,7
1097	2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida	275–285 rango de descomp.	513,4
1105	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–4–fluoro–1–(4–fluorofenil)–1H–indol–3–carboxamida	290–295	525,3
1106	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–etil–4–fluoro–1–(4–fluorofenil)–1H–indol–3–carboxamida	280–288	513,3
1109	2–[5–(ter–butilsulfamoil)piridin–2–il]–6–etil–5–fluoro–1–fenil–1H–indol–3–carboxamida	237,9–238,9	493,3
1110	2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclobutil–6–etil–4–fluoro–1H–indol–3–carboxamida	259–263	473,3

Comp	Nombre	p.f.	MS
1111	2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–etil–4–fluoro–1–fenil–1H–indol–3–carboxamida	288–294	495,2
1115	2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclohexil–5–fluoro–6–metil–1H–indol–3–carboxamida	274,5–275,6	487,4
1116	2–[5–(ter–butilsulfamoil)piridin–2–il]–5–fluoro–6–metil–1–fenil–1H–indol–3–carboxamida	241,2–242,5	479,3


Ejemplo 17

(compuesto **810**) (PS106988)




Etapa A: Una mezcla de (*S*)–6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1*H*–indol–2–il)–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (31,9 g, 66,2 mmol), NaOH 5 N ac. (25 mL) e isopropanol (140 mL) se agitó a 60 °C. Se burbujeó gas clorodifluorometano en esta mezcla a velocidad constante. El calentamiento se continuó durante 10 horas, con NaOH 5 N ac. adicional (3 mL) añadido en incrementos de 30 minutos. La mezcla de reacción se diluyó en H_2O (800 mL) y se acidificó con HCl6 N ac. Se extrajo con EtOAc (2 x 200 mL). Los extractos orgánicos combinados se lavaron con agua (2 x 300 mL), luego se añadió salmuera (50 mL). La capa orgánica se secó posteriormente sobre $MgSO_4$ y se filtró y el filtrado se concentró al vacío. La mezcla de producto se redisolvió en CH_2Cl_2 (500 mL) y se absorbió en sílice (100 g). CH_2Cl_2 se eliminó al vacío. Los sólidos se cargaron en una columna de 100 g de sílice adicional. La elución con CH_2Cl_2/ hexanos (1:1 a 3:1) y luego con acetato de etilo en CH_2Cl_2 (0% a 5%)

dio como resultado 28,6 g de producto crudo. Esto se lavó con Et_2O (100 mL) para obtener (*S*)–6–(3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1*H*–indol–2–il)–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (25,6 g, 72%) en forma de un sólido blanco.



Etapa B: Una mezcla de (*S*)–6–(3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1*H*–indol–2–il)–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (500 mg, 0,94 mmol), Fe en polvo (700 mg, 13 mmol), Br_2 (300 µL, 5,9 mmol) y 1,2–dicloroetano (3 mL) se calentó a 50 °C durante 3 horas. La mezcla de reacción se vertió luego en solución acuosa de $NaHSO_3$. Esto se extrajo en CH_2Cl_2. La capa orgánica se secó sobre $MgSO_4$ y se filtró y el filtrado se concentró al vacío. La purificación por cromatografía en gel de sílice (acetato de etilo en hexanos, 20% a 30%) dio como resultado (*S*)–6–(4–bromo–3–ciano–1–ciclobutil–6 (difluorometoxi)–5–fluoro–1*H*–indol–2–il)–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (266 mg, 46%) en forma de un sólido blanco.



Etapa C: Una solución de MeZnCl (2 M en THF, 370 µL, 0,74 mmol) se añadió a una mezcla de (*S*)–6–(4–bromo–3–ciano–1–ciclobutil–6 (difluorometoxi)–5–fluoro–1*H*–indol–2–il)–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (200 mg, 0,33 mmol), $Pd(dppf)Cl_2$ (25 mg, 0,034 mmol) y THF (1,2 mL). Esto se calentó


a 40 °C durante 25 horas. La mezcla de reacción se vertió luego en HCl acuoso. Se extrajo con acetato de etilo y la capa orgánica se lavó con salmuera. La capa orgánica se secó sobre $MgSO_4$ y se filtró y el filtrado se concentró al vacío. La purificación por cromatografía en gel de sílice (20% de acetato de etilo en hexanos), seguido de lavado con hexanos / éter (1:1) dio como resultado (*S*)–6–(3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–4–metil–1*H*–indol–2–il)–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (117 mg, 65%) en forma de un sólido blanco. Punto de fusión: 182–186 °C; MS *m/z* 547,0 $M+H^+$; ^1H RMN ($CDCl_3$, 500 MHz): d 9,22 (d, 1H, J = 2 Hz), 8,35 (dd, 2H, J = 8,5 Hz, 2 Hz), 8,02 (d, 1H, 8,5 Hz), 7,40 (d, 1H, J = 6,5 Hz), 6,62 (t, 1H, J = 75 Hz), 5,26 (penteto, 1H, J = 8,5 Hz), 4,95 (d, 1H, J = 9,5 Hz), 4,16 (m, 1H), 2,75 (d, 3H, J = 2,0 Hz), 2,47 (m, 2H), 2,38 (m, 2H), 1,87 (m, 2H), 1,47 (d, 3H, J = 7 Hz).

El compuesto **811** se preparó como en el Ejemplo 17 excepto en que las etapas de bromación y freonación de esa secuencias eran inversas.


Comp	Nombre	p.f.	MS
811	6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–7–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	168–174	547,1

Ejemplo 18

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida (compuesto **1113**) (PS108336)




Etapa A: A una solución de ácido *p*–toluensulfónico monohidratado (3 g, 16 mmol) y 2–metiltetrahidrofurano (600 mL) se añadieron (*S*, L–)–alfa metilbencilamina (40 g, 310 mmol), tetraetilortosilicato (28 mL, 125 mmol) y 1,1,1–trifluoroacetona (65 mL, 690 mmol). La mezcla se agitó a reflujo durante 17 horas y a 0 °C durante 1 hora. La mezcla se filtró a través de un taco delgado de gel de sílice y la torta filtrante se enjuagó con EtOAc. El filtrado se concentró usando un evaporador rotativo y se usó sin ulterior purificación.




Etapa B: El residuo anterior se añadió como una solución en THF (130 mL), gota a gota durante 1 hora, a una suspensión de deuteruro de litio y aluminio (34,9 g, 831 mmol) en THF (700 mL) a 0 °C. La mezcla se agitó a 0 °C durante 1 hora y a temperatura ambiente durante 2 horas. La mezcla luego se volvió a enfriar hasta 0 °C, se añadió MTBE (400 mL), seguido de la adición lenta y secuencial de H_2O (35 mL), NaOH ac. (5 N, 35 mL) y H_2O (105 mL). La mezcla se agitó a temperatura ambiente durante 15 minutos, se añadió $MgSO_4$ y la mezcla se agitó a temperatura ambiente durante 15 minutos más. La mezcla se filtró a través de Celite y la torta filtrante se enjuagó con EtOAc. El filtrado se concentró y el residuo se transfirió a un embudo de separación. Se añadieron MTBE (500 mL) y HCl acuoso (3 N, 500 mL) y la capa orgánica se extrajo con HCl acuoso (3 N, 2X250 mL). Las capas acuosas combinadas se enfriaron hasta 0 °C, se añadió NaOH acuoso (50%, 200 mL), la mezcla se transfirió a un embudo de separación y la capa acuosa se extrajo con CH_2Cl_2 (3X500 mL). La capas orgánicas

combinadas se secaron con Na_2SO_4 y se concentraron usando un evaporador rotativo. El residuo se pasó a través de un tapón de gel de sílice, eluyendo con hexanos, para proveer (S)–1,1,1–trifluoro–2–deutero–N–((S)–1–feniletil)propan–2–amina (34,2 g, 50% de (*S*, L–)–alfa–metilbencilamina).




Etapa C: A una mezcla de (S)–1,1,1–trifluoro–2–deutero–N–((S)–1–feniletil)propan–2–amina (34,2 g, 157 mmol) disuelta en MeOH (475 mL) se añadió Pd/C al 10% (5 g, 4,7 mmol). La mezcla se hidrogenó a temperatura ambiente bajo una atmósfera de gas hidrógeno durante 20 h. La mezcla se filtró por gravedad a través de Celite, enjuagando la torta filtrante con EtOAc. El filtrado se enfrió hasta 0 °C y se añadió HCl (4 M en dioxano, 235 mL). La solución se concentró usando a evaporador rotativo para proveer clorhidrato de (S)–1,1,1–trifluoro–2–deutero–propan–2–amina (22,9 g, 97%). El clorhidrato de (S)–1,1,1–trifluoro–2–deutero–propan–2–amina (25,0 g, 165,7 mmol) se añadió a H_2O (100 mL) y la mezcla se enfrió hasta 0 °C. A la mezcla se añadió NaOH acuoso (50%, 45 mL), gota a gota durante 10 minutos y el material se destiló de esta solución a aproximadamente 50 °C, para dar (S)–1,1,1–trifluoro–2–deutero–propan–2–amina (15,7 g, 67%, 53,3% ee, con aproximadamente 19% en peso de H_2O). Este material se añadió a ácido D–tartárico (25 g, 170 mmol, 99,8% ee) y MeOH (300 mL) y la mezcla se agitó a reflujo durante 30 minutos. La mezcla se enfrió lentamente hasta 0 °C, lo que permitió la formación de cristales. Los cristales se aislaron por filtración, dando sal de tartrato de (S)–1,1,1–trifluoro–2–deutero–propan–2–amina (28,4 g, 84%, 84,0% ee, con aproximadamente 4% de MeOH y 9% en peso de H_2O). Este material se recristalizó en MeOH (230 mL), dando sal


de tartrato de (S)–1,1,1–trifluoro–2–deutero–propan–2–amina (24,3 g, 85%, 95,7% ee, aproximadamente 9% de MeOH y 5% en peso de H_2O). Este material se recristalizó nuevamente en MeOH (200 mL), dando sal de tartrato de (S)–1,1,1–trifluoro–2–deutero–propan–2–amina (20,7 g, 85%, 98,7% ee, aproximadamente 5% de MeOH y 10% en peso de H_2O). Este material se añadió a H_2O (150 mL) y la mezcla se enfrió hasta 0 °C. NaOH (50%, 18 mL) se añadió, gota a gota durante 5 minutos y se destilaron 6,7 g de material de la solución a aproximadamente 49 °C. Este material se enfrió hasta 0 °C y se añadió HCl acuoso concentrado (15 mL). La mezcla se agitó a temperatura ambiente durante 25 minutos y luego se concentró usando un evaporador rotativo (eliminación azeotrópica de H_2O usando MeOH y EtOH), dando clorhidrato de (S)–1,1,1–trifluoro–2–deutero–propan–2–amina (8,7 g, 87% a partir de sal de tartrato de (S)–1,1,1–trifluoro–2–deutero–propan–2–amina, 98,6% ee).



Etapa D: El clorhidrato de (S)–1,1,1–trifluoro–2–deutero–propan–2–amina (3 g, 19,9 mmol, 98,6% ee) se convirtió en (S)–6–cloro–N–(1,1,1–trifluoro–2–deutero–propan–2–il)piridin–3–sulfonamida (5,3 g, 91%) de manera análoga al Ejemplo 1B.



Etapa E: 1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carbonitrilo (133 mg, 0,58 mmol) se convirtió en ácido 3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–ilborónico de manera análoga al Ejemplo 7D y se usó sin ulterior purificación.




Etapa F: (S)–6–cloro–N–(1,1,1–trifluoro–2–deutero–propan–2–il)piridin–3–sulfonamida (100 mg, 0,35 mmol) y ácido 3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–ilborónico se convirtieron en el compuesto 1113 (34 mg, 20%) de manera análoga al Ejemplo 7E. Punto de fusión: 215–217 °C; MS *m/z* 482,0 $M+H^+$; ^1H RMN (500 MHz, acetona–d_6) d 9,21 (1H, dd, *J* = 2,3, 0,7 Hz), 8,49 (1H, dd, *J* = 8,3, 2,4 Hz), 8,08 (1H, dd, *J* = 8,2, 0,8 Hz), 7,77 (1H, d, *J* = 6,2 Hz), 7,72 (1H, br), 7,37 (1H, d, *J* = 9,5 Hz), 5,33 (1H, m), 2,58 (2H, m), 2,41 (3H, d, *J* = 2,0 Hz), 2,40 (2H, m), 1,82 (2H, m), 1,26 (3H, s).

Se prepararon compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 18 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
1114	6–[3–ciano–1–ciclobutil–5–fluoro–6–(1,1,1–trideuterio)metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida	213–215	485,0


Ejemplo 19

6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–6–(1,1,1–trideuterio)metil–1H–indol–2–il]–N–[(2–deuterio)propan–2–il]piridin–3–sulfonamida (compuesto **1119**) (PS108444)




Etapa A: *t*–Butil 6–bromo–5–fluoro–1H–indol–1–carboxilato (30 g, 96 mmol, sintetizado de manera análoga al Ejemplo 8A) se añadió a THF (110 mL) y la mezcla se enfrió hasta 0 °C. A esta mezcla se añadió complejo de cloruro de *i*–propilmagnesio–cloruro de litio (90 mL, 117 mmol) en porciones durante 10 minutos y la mezcla se agitó a 0 °C durante 3 horas. Se añadió yodometano–d_3 (8 mL, 128,6 mmol), seguido de una solución de cianuro de cobre (I) (1,7 g, 19,0 mmol), cloruro de litio (1,6 g, 37,7 mmol) y THF (80 mL). La mezcla se agitó a


temperatura ambiente durante 18 horas. Se añadieron éter dietílico (100 mL) y H_2O (100 mL) y la mezcla se filtró a través de Celite, enjuagando la torta filtrante con éter dietílico (200 mL). El filtrado se extrajo con éter dietílico (2X80 mL). Los extractos orgánicos combinados se lavaron con salmuera (100 mL), se secaron con Na_2SO_4 y se concentraron usando a evaporador rotativo y se usaron sin ulterior purificación.




Etapa B: El residuo anterior se añadió a NaOH acuoso (50%, 15 mL) y MeOH (190 mL). La mezcla se agitó a reflujo durante 1 hora y luego se concentró usando un evaporador rotativo. El residuo se añadió a CH_2Cl_2 (200 mL), H_2O (200 mL) y la capa acuosa se extrajo con CH_2Cl_2 (2X200 mL). La capas orgánicas combinadas se secaron con Na_2SO_4 y se concentraron. El residuo se purificó usando cromatografía en gel de sílice (2X80 g de SiO_2, 0% a 10% de EtOAc en hexanos), dando 5–fluoro–6–(metil–d_3)–1H–indol (13,6 g, 93% a partir de 6–bromo–5–fluoro–1H–indol–1–carboxilato de *t*–butilo).




Etapa C: El compuesto anterior, 5–fluoro–6–(metil–d_3)–1H–indol (5 g, 32,9 mmol), se convirtió en 5–fluoro–6–(metil–d_3)–1H–indol–3–carbonitrilo (5,6 g, 95%) de manera análoga al Ejemplo 6B.



Etapa D: El compuesto anterior, 5–fluoro–6–(metil–d_3)–1H–indol–3–carbonitrilo (850 mg, 4,8 mmol), se convirtió en 1–(ciclopropilmetil)–5–fluoro–6–(metil–d_3)–1H–indol–3–carbonitrilo (901 mg, 81%) de manera análoga al Ejemplo 6C.



Etapa E: El compuesto anterior, 1–(ciclopropilmetil)–5–fluoro–6–(metil–d_3)–1H–indol–3–carbonitrilo (169 mg, 0,73 mmol), se convirtió en ácido 3–ciano–1–(ciclopropilmetil)–5–fluoro–6–(metil–d_3)–1H–indol–2–ilborónico de manera análoga al Ejemplo 7D



Etapa F: El compuesto anterior, ácido 3–ciano–1–(ciclopropilmetil)–5–fluoro–6–(metil–d_3)–1H–indol–2–ilborónico y 6–cloro–N–(2–deutero–propan–2–il)piridin–3–sulfonamida (103 mg, 0,44 mmol, sintetizada de manera análoga al procedimiento del Ejemplo 21) se convirtieron en el compuesto 1119 (101 mg, 53%) de manera análoga al Ejemplo 7E. Punto de fusión: 216–218 °C; MS *m/z*


431,3 M+H$^+$; ^{1}H RMN (500 MHz, acetona–d_6) d 9,21 (1H, dd, *J* = 2,4, 0,6 Hz), 8,51 (1H, dd, *J* = 8,3, 2,4 Hz), 8,21 (1H, dd, *J* = 8,4, 0,6 Hz), 7,76 (1H, d, *J* = 6,2 Hz), 7,42 (1H, d, *J* = 9,6 Hz), 6,86 (1H, br), 4,59 (2H, d, *J* = 7,1 Hz), 1,20 (1H, m), 1,13 (6H, s), 0,38 (2H, m), 0,19 (2H, m).

Se prepararon compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 19 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH$^+$, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp	Nombre	p.f.	MS
1112	6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2–deuterio)propan–2–il]piridin–3–sulfonamida	220–222	427,9


Ejemplo 20

(S)–6–(3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (compuesto **704**)




Etapa A: A una solución de 6–bromo–5–fluoro–1H–indol (1,25 g, 5,3 mmol) en CH_2Cl_2 (10 mL) se añadieron dicarbonato de di–ter–butilo (1,5 g, 7,0 mmol) y DMAP (13 mg, 0,1 mmol). La mezcla de reacción se mantuvo bajo agitación durante 2 h a temperatura ambiente, luego se dividió en CH_2Cl_2 y agua. La capa orgánica se lavó con agua, salmuera y se secó sobre Na_2SO_4 y se evaporó. El sólido blanco resultante, 6–bromo–5–fluoro–1H–indol–1–carboxilato de *ter*–butilo, se secó al aire y se usó en la siguiente etapa sin ulterior purificación. ^{1}H RMN

(500 MHz, $CDCl_3$): d 8,33 (1H, br s), 7,53 (1H, d, J = 3,0 Hz) 7,20 (1H, d, J = 8,5 Hz), 6,43 (1H, dd, J = 3,5, 0,5 Hz), 1,59 (9H, s).




Etapa B: A una solución de 6–bromo–5–fluoro–1H–indol–1–carboxilato de *ter*–butilo (1,57 g, 5,0 mmol) en dioxano (10 mL) se añadió una solución de Et_2Zn en heptano (3,5 mL, 1,0M, 3,5 mmol) a temperatura ambiente. La mezcla se mantuvo bajo agitación durante 30 min a 90 °C y luego se enfrió hasta 0 °C, en donde se añadió bicarbonato de sodio saturado gota a gota. La mezcla se trató luego con agua y se extrajo con CH_2Cl_2. La capa orgánica se secó sobre Na_2SO_4 y se evaporó. El aceite resultante se pasó a través de un tapón de sílice y se eluyó con 10% de de acetato de etilo en hexano. El eluyente se evaporó para dar 6–etil–5–fluoro–1*H*–indol–1–carboxilato de *ter*–butilo en forma de un aceite que se solidificó en reposo (1,25 g, 95%).




Etapa C: A una solución de 6–etil–5–fluoro–1H–indol–1–carboxilato de *ter*–butilo (0,93 g, 3,5 mmol) y borato de tri–isopropilo (1,2 mL, 5,25 mmol) en THF (7 mL) a –78 °C se añadió LDA (1,5 M en ciclohexano, 2,8 mL, 4,2 mmol) bajo nitrógeno. La mezcla se agitó a –78 °C durante 15 min, luego 2 h a 0 °C. La reacción se neutralizó por adición de ácido acético (0,24 mL, 4,2 mmol) durante un período de 15 min, seguido de la eliminación de solventes por evaporación

rotativa. El ácido borónico resultante (> 90% puro por LCMS) se usó en la siguiente etapa sin ulterior purificación.




Etapa D: A una solución de ácido 1–(*ter*–butoxicarbonil)–6–etil–5–fluoro–1H–indol–2–ilborónico, preparado como con anterioridad, (S)–6–cloro–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (0,91 g, 3,15 mmol) y $PdCl_2$dppf (0,23 g, 0,31 mmol) en acetonitrilo (21 mL) se añadió una solución de carbonato de potasio (2,0 M, 7 mL, 14 mmol). La mezcla se agitó a 50 °C durante la noche, se enfrió hasta temperatura ambiente y luego se neutralizó por adición de HCl (1 N) en agua helada hasta pH ~ 8. La mezcla se extrajo con acetato de etilo. Las capas orgánicas combinadas se secaron sobre Na_2SO_4 y se concentraron. La mezcla cruda resultante se usó en la siguiente etapa sin ulterior purificación.




Etapa E: Una mezcla de 6–etil–5–fluoro–2–(5–(N–(1,1,1–trifluoropropan–2–il)sulfamoil)piridin–2–il)–1H–indol–1–carboxilato de (*S*)–ter–butilo, preparado como con anterioridad y pirrolidina (1,5 mL, 18 mmol) en acetonitrilo (15 mL) se agitó a 50 °C durante 2 h. Los solventes luego se evaporaron y el residuo se dividió en acetato de etilo y HCl (1 N). La fase acuosa luego se extrajo con acetato de etilo. Las capas orgánicas combinadas se lavaron con HCl 1 N y salmuera. Después de concentrar, la mezcla cruda se trituró con CH_2Cl_2/hexano para proveer (*S*)–6–(6–etil–5–fluoro–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida en forma de sólidos de color amarillo claro (1,16 g, 80 %

de rendimiento a partir de (S)–6–cloro–*N*–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida).



Etapa F: A una solución de (*S*)–6–(6–etil–5–fluoro–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (0,22 g, 0,53 mmol) en una mezcla de DMF (0,5 mL) y acetonitrilo (0,5 mL) se añadió isocianato de clorosulfonilo gota a gota a –50 °C. La mezcla de reacción se mantuvo bajo agitación a 0 °C durante 0,5 h y luego se neutralizó con hielo, seguido de vertido en agua. Después de 0,5 h de agitación a temperatura ambiente, el sólido resultante se recogió por filtración y se lavó con agua, hexano y CH_2Cl_2. Después de secar al aire, se obtuvo (*S*)–6–(3–ciano–6–etil–5–fluoro–1 H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida y se usó en la siguiente etapa sin ulterior purificación.



Etapa G: Una mezcla de (*S*)–6–(3–ciano–6–etil–5–fluoro–1 H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida (0,22 g, 0,5 mmol), preparada como con anterioridad, 2–bromopirimidina (0,167 g, 1,0 mmol), carbonato de potasio (0,212 g, 1,5 mmol) y yoduro de cobre (I) (20 mg, 0,1 mmol) se mezclaron con DMF (2,5 mL). El sistema se evacuó y se reemplazó con una atmósfera de argón. La mezcla de reacción se agitó a 110 °C durante 70 h, luego se enfrió

hasta 0 °C, se diluyó con acetato de etilo y se neutralizó con HCl 1 N. La capa de acetato de etilo se lavó con agua, salmuera, se secó sobre Na_2SO_4, se filtró a través de un taco de gel de sílice y se evaporó. El producto crudo se trituró con CH_2Cl_2 y hexano y luego se recristalizó en acetato de etilo y hexano. Después de secar al aire, se obtuvo la (S)–6–(3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1 H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida sólida blanquecina. Punto de fusión: 195–198 °C; MS *m/z* 519,1 $M+H^+$; ^1H RMN (500 MHz, acetona–d_6): d 8,90 (1H, dd, J = 2,5, 1,0 Hz), 8,83 (2H, d, J = 4,5 Hz), 8,49 (1H, dd, J = 8,0, 2,5 Hz), 8,16 (1 H, t, J = 6,5 Hz), 8,15 (1 H, d, J = 9,0 Hz), 7,68 (1 H, br s), 7,57–7,54 (2H, m), 4,32 (1 H, br s), 2,85 (2 H, q, J = 7,5 Hz), 1,29 (3 H, t, J = 7,5 Hz), 1,28 (3 H, d, J = 7,2 Hz).

Se pueden preparar compuestos representativos adicionales de la presente invención de acuerdo con el procedimiento de Ejemplo 20 sustituyendo los materiales de partida, reactivos y condiciones de reacción apropiados e incluyen los compuestos seleccionados (en donde MS representa espectr. de masa como MH^+, a menos que se indique otra cosa, p.f. representa punto de fusión en °C y N/A indica que no se obtuvieron los datos) de:

Comp.	Nombre	p.f.	MS
708	6–[5–cloro–3–ciano–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	193–196	507,3
724	6–{3–ciano–5–fluoro–1–[5–(trifluorometil)piridin–2–il]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	216–218	558,2
739	6–[3–ciano–5–fluoro–6–metil–1–(3–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	219–221	518,2
740	6–{3–ciano–5–fluoro–6–metil–1–[5–(trifluorometil)piridin–2–il]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	253–255	572,2

Comp.	Nombre	p.f.	MS
742	6–[3–ciano–5–fluoro–1–(5–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	239–241	512,8
743	6–[3–ciano–1–(5–cianopiridin–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	276–277	528,9
744	6–[3–ciano–5–fluoro–6–metil–1–(5–nitropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	260–263	548,9
777	6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–212	535,8
778	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	205–208	517,8
785	6–[5–cloro–3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–212	521,2
803	6–[5–cloro–3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–212	519,4
804	6–[5–cloro–3–ciano–1–(5–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–212	537,9
814	6–[3–ciano–5–fluoro–1–(3–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	193–198	521,5
815	6–[3–ciano–5–fluoro–1–(6–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–212	522,3
816	6–[3–ciano–5–fluoro–1–(4–metoxipiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–213	518,2

Comp.	Nombre	p.f.	MS
817	6–[3–ciano–5–fluoro–6–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	220–223	505,4
818	6–[3–ciano–6–ciclopropil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	240–242	548,2
819	6–[3–ciano–6–ciclopropil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	220–223	530,1
820	6–[3–ciano–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	236–240	531,2
823	N–ter–butil–6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida	N/A	451,3
824	N–ter–butil–6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida	N/A	465,3
843	6–[3–ciano–5–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	174–179	487,2
844	6–[3–ciano–1–(3–fluoropiridin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	216–220	504,2
845	6–[3–ciano–5–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	236–241	487,4
847	6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	180–186	504,4
848	6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	199–204	505,1
851	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	231–236	533,5

Comp.	Nombre	p.f.	MS
852	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	178–183	532,2
853	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	219–226	505,1
854	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	192–197	504,0
855	N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida	208–210	479,6
859	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	N/A	533,1
860	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida	169–179	477,1
861	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1–metilciclopropil)–N–(pirimidin–2–il)piridin–3–sulfonamida	193–200	555,1
864	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida	N/A	531,5
865	6–[3–ciano–5–fluoro–6–metil–1–(5–metilpirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	518,5
866	6–[3–ciano–5–fluoro–1–(4–metoxipirimidin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	534,5
867	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	192–198	533,1

Comp.	Nombre	p.f.	MS
870	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–198	532,1
873	6–[3–ciano–5–fluoro–6–metil–1–(4–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	518,5
878	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	197–200	519,1
879	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	178–182	518,1
880	6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	209–216	536,1
881	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	258–262	533,1
882	N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]piridin–3–sulfonamida	200–205	478,2
884	N–ter–butil–6–(3–ciano–6–etil–5–fluoro–1–fenil–1H–indol–2–il)piridin–3–sulfonamida	175–180	477,2
885	6–[3–ciano–5–fluoro–6–metil–1–(5–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	250–254	517,5
886	6–[3–ciano–5–fluoro–6–metil–1–(4–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	200–204	517,5
887	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	219–224	531,0

Comp.	Nombre	p.f.	MS
888	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	201–204	519,2
889	6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	197–202	518,2
890	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	231–236	533,2
891	6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	178–183	532,2
892	6–[3–ciano–5–fluoro–6–metil–1–(piridazin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	245–250	504,5
893	6–[3–ciano–5–fluoro–6–metil–1–(piridin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	217–221	503,5
894	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	198–202	504,5
895	6–[6–bromo–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	224–226	569,1
896	6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	214–219	504,5
897	6–[3–ciano–1–(pirazin–2–il)–5–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	255–258	541,2
898	6–[3–ciano–1–(pirazin–2–il)–5–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	191–195	557,2
899	N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(pirazin–2–il)–1H–indol–2–il]piridin–3–sulfonamida	196–201	479,4

Comp.	Nombre	p.f.	MS
900	N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(3–fluoropiridin–2–il)–1H–indol–2–il]piridin–3–sulfonamida	200–203	496,2
901	6–[3–ciano–6–fluoro–5–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	125–130	505,2
903	6–[5–fluoro–6–metil–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	224–230	484,5
907	6–[6–acetil–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	220–221	533,0
908	6–[3–ciano–6–etenil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	517,2
914	6–[1–(5–cloropirimidin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	213–218	538,9
915	6–[3–ciano–5–fluoro–6–metil–1–(6–metilpirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	211–215	518,5
917	6–[3–ciano–6–fluoro–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	175–180	504,3
919	6–[3–ciano–6–fluoro–5–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	233–238	505,2
920	6–[3–ciano–1–(4–fluorofenil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–200	503,2
921	6–(3–ciano–5–metil–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	160–165	485,2
922	6–[3–ciano–1–(pirimidin–2–il)–5–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	180–183	541,2

Comp.	Nombre	p.f.	MS
923	6–[3–ciano–5–fluoro–6–metil–1–(6–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	219–225	517,5
924	6–[3–ciano–5–fluoro–1–(5–fluoropirimidin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	244–248	522,5
925	6–[3–ciano–5–fluoro–6–metil–1–(5–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	179–184	518,5
926	6–[3–ciano–5–fluoro–1–(4–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	229–233	521,5
927	6–[3–ciano–5–fluoro–6–(2–metil–1,3–dioxolan–2–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	577,2
929	6–[3–ciano–6–etil–5–fluoro–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	225–229	519,0
930	6–[3–ciano–6–etil–5–fluoro–1–(6–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	205–211	536,0
931	6–[3–ciano–6–etil–5–fluoro–1–(5–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	532,3
932	6–[3–ciano–6–etil–5–fluoro–1–(4–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	188–190	532,1
933	6–[3–ciano–5–fluoro–6–metil–1–(piridin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	250–255	503,5
934	6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	203–208	509,5

Comp.	Nombre	p.f.	MS
935	6–[3–ciano–6–etil–5–fluoro–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	187–191	523,5
938	6–[6–bromo–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–ter–butilpiridin–3–sulfonamida	266–268	531,2
941	6–[3–ciano–1–(1,6–dihidropirimidin–2–il)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	521,3
942	6–[1–(5–cloropirimidin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	222–229	553,3
943	6–[3–ciano–6–etil–5–fluoro–1–(2–metilpirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	138–146	533,1
944	6–[5–fluoro–1–(2–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	176–180	496,5
945	6–[3–ciano–5–fluoro–1–(5–fluoropiridin–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	199–204	521,5
946	6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–225	537,0
947	6–[3–cloro–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	248–250	540,0
948	6–[3–ciano–1–(5–fluoropirimidin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	202–207	505,2
949	6–[3–ciano–6–fluoro–1–(5–fluoropirimidin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	226–231	523,2

Comp.	Nombre	p.f.	MS
950	6–[3–ciano–1–(pirimidin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	206–210	541,2
951	6–[3–ciano–1–(pirazin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	208–213	541,2
952	6–[3–ciano–1–(piridin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	173–176	540,2
953	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(ciclobutilmetil)piridin–3–sulfonamida	207–214	491,2
954	6–[3–ciano–6–etil–5–fluoro–1–(piridin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	205–212	518,2
955	6–[3–ciano–6–etil–5–fluoro–1–(4–metoxipiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	227–233	548,1
956	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida	177–179	520,2
957	6–[5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	484,5
958	6–[5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	485,5
959	6–[5–fluoro–6–metil–1–(1,3–tiazol–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	484,5
960	6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	184–189	509,5
961	6–[3–ciano–5–fluoro–1–(5–fluoro–6–metilpiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	240–246	535,5

Comp.	Nombre	p.f.	MS
962	6–[1–(6–cloropiridin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	253–257	537,9
963	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	250–257	519,2
964	6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	202–206	519,2
965	6–[1–(3–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	200–208	552,2
966	6–[1–(5–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	252–259	552,2
971	6–[1–(3–cloropiridin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	221–225	537,9
973	6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	234–238	509,5
974	6–[3–ciano–6–etil–5–fluoro–1–(piridin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	209–215	518,3
975	6–[3–ciano–6–etil–5–fluoro–1–(piridazin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	240–247	519,1
976	6–[3–ciano–6–etil–5–fluoro–1–(5–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	201–206	533,2
977	6–[3–ciano–5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	232–240	510,5
983	6–[1–(5–cloropiridin–3–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	107–109	552,3

Comp.	Nombre	p.f.	MS
984	6–{3–ciano–5–fluoro–1–[5–(hidroximetil)–1,3–tiazol–2–il]–6–metil–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	180–185	539,5
985	2–[3–ciano–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–1–il]–1,3–tiazol–5–carboxilato de metilo	N/A	567,5
986	2–[3–ciano–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–1–il]–1,3–tiazol–4–carboxilato de metilo	N/A	567,5
987	6–[5–fluoro–6–metil–1–(tiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	483,5
988	6–[5–fluoro–1–(furan–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	467,4
989	6–[5–fluoro–6–metil–1–(tiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	483,5
990	6–[3–ciano–5–fluoro–6–metil–1–(tiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	233–240	508,5
991	6–[3–ciano–5–fluoro–1–(furan–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	215–219	492,4
992	6–[3–ciano–5–fluoro–6–metil–1–(tiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	196–203	508,5
993	6–[1–(4–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	185–190	552,2
1000	6–[3–ciano–5–fluoro–6–metil–1–(3–metiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	197,0–203,8	523,5

Comp.	Nombre	p.f.	MS
1001	6–[3–ciano–1–(4,6–difluoropiridin–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	190,2–196,8	540,5
1002	6–[3–ciano–6–etil–5–fluoro–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	236–243	535,6
1003	6–[1–(4–clorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	279–289	551,3 553,3
1004	6–[3–ciano–6–etil–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	531,7
1005	6–[3–ciano–6–etil–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	261–266	547,2
1006	6–{3–ciano–6–etil–5–fluoro–1–[4–(trifluorometil)fenil]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	276–282	585,7
1007	6–[3–ciano–1–(4–cianofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	288–293	542,2
1008	6–[3–ciano–6–etil–5–fluoro–1–(3–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210–214	535,3
1009	6–[3–ciano–6–etil–5–fluoro–1–(3–metilfenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	193–198	531,4
1010	6–[3–ciano–6–etil–5–fluoro–1–(3–metoxifenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	229–233	547,2
1011	6–{3–ciano–6–etil–5–fluoro–1–[3–(trifluorometil)fenil]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	240–245	585,3
1012	6–[3–ciano–1–(3–cianofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	244–248	542,3

Comp.	Nombre	p.f.	MS
1013	6–[3–ciano–5–fluoro–1–(2–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	243,4–246,9	522,5
1014	6–[3–ciano–5–fluoro–1–(3–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	204,2–210,5	522,5
1015	6–[3–ciano–5–fluoro–1–(6–fluoropiridin–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	246,8–252,7	522,5
1016	6–[3–ciano–5–fluoro–6–metil–1–(1–metil–1H–pirazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	233,7–239,3	507,5
1017	6–[3–ciano–5–fluoro–6–metil–1–(5–metil–1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	223,1–228,1	524,5
1018	6–[1–(3–clorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	195–198	551,3 553,3
1030	6–[3–ciano–5–fluoro–6–metil–1–(3–metil–1H–pirazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	238,8–244,0	507,5
1031	6–[3–ciano–5–fluoro–6–metil–1–(5–metiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	246,8–249,4	523,5
1032	6–[1–(5–clorotiofen–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	244,8–247,4	544,0
1033	6–[3–ciano–1–(5–cianotiofen–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	182,0–184,6	534,5

Comp.	Nombre	p.f.	MS
1034	6–[3–ciano–5–fluoro–6–metil–1–(5–sulfamoiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	131,6–137,7	588,6
1035	6–[1–(5–acetiltiofen–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	235,6–238,7	551,6
1038	6–[3–ciano–5–fluoro–6–metil–1–(4–metil–1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	206,3–211,7	524,5
1055	6–[1–(2–acetiltiofen–3–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	208,7–212,4	551,6
1056	6–[3–ciano–5–fluoro–6–metil–1–(4–metiltiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	223,2–227,1	523,5
1057	6–[1–(2–clorotiofen–3–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	226,7–231,8	544,0
1058	6–[3–ciano–5–fluoro–6–metil–1–(5–metiltiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	210,5–215,2	523,5
1059	6–[5–fluoro–6–metil–1–(1,3–oxazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	469,4
1060	6–[1–(5–cianofuran–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	493,4
1061	6–[3–ciano–1–(3,4–difluorofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	229–235	N/A
1062	6–[1–(3–cloro–4–fluorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	228–232	N/A

Comp.	Nombre	p.f.	MS
1072	6–[3–ciano–1–(3–cianofuran–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	238,0–243,6	518,5
1073	6–[3–ciano–5–fluoro–6–metil–1–(1,3–oxazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	494,4
1074	6–[3–ciano–1–(4–ciano–1,3–oxazol–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	212,2–216,9	519,4
1075	6–[3–ciano–6–etil–5–fluoro–1–(2–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	N/A	535,5
1078	6–{3–ciano–6–[(1,1–dideuterio)etil]–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida	180–182	521,5
1079	6–{3–ciano–6–[(1,1–dideuterio)etil]–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida	180–182	522,5
1098	6–[3–ciano–6–ciclopropil–4–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida	198–200	545,3
1101	N–[5–(3–ciano–6–ciclopropil–5–fluoro–1–fenil–1H–indol–2–il)piridin–2–il]–2–metilpropan–2–sulfonamida	249–250	489,3
1107	6–[3–ciano–5–fluoro–6–(1,1,1–trideuterio)metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida	200–202	508,9
1108	N–ter–butil–6–(3–ciano–5–fluoro–6–metil–1–fenil–1H–indol–2–il)piridin–3–sulfonamida	200,6–202,4	463,3

Comp.	Nombre	p.f.	MS
1117	N–ter–butil–6–(3–ciano–6–ciclopropil–5–fluoro–1–fenil–1H–indol–2–il)piridin–3–sulfonamida	219,2–220,8	489,4

Ejemplos biológicos

Los siguientes ejemplos biológicos demuestran la utilidad de los compuestos de la presente invención para tratar infecciones virales.

Ejemplo 1

Ensayo de replicón de HCV

La falta de un cultivo celular confiable y fácilmente accesible y los modelos de animal pequeños que permiten la replicación de HCV limitó el desarrollo de nuevos agentes anti–HCV. Los sistemas de HCV subgenómicos de autorreplicación, denominados replicones de HCV, fueron descritos y ampliamente usados para evaluar la eficacia de inhibidores anti–HCV (ver Blight KJ, et al., 2000, Efficient initiation de HCV RNA replication in cell culture. Science **290**:1972–1974; Blight KJ, et al., 2002, Highli permissive cell lines for subgenomic and genomic virus de hepatitis C RNA replication. J Virol **76**:13001–13014; Ikeda M, et al., 2002. Selectable subgenomic and genome–length dicistronic RNAs derived from an infectious molecular clone of the HCV–N strain of virus de hepatitis C replicate efficiently in cultured Huh7 cells. J Virol **76**:2997–3006; Lohmann V, et al., 1999, Replication of subgenomic virus de hepatitis C RNAs in a hepatoma cell line. Science **285**:110–113; Pietschmann T, et al., 2002, Persistent and transient replication of full–length virus de hepatitis C genomes in cell culture. J Virol **76**:4008–4021; y, Pietschmann T, et al., 2001, Characterization of cell lines carrying self–replicating virus de hepatitis C RNAs. J Virol **75**:1252–1264).

Tal como se describió en la patente de los Estados Unidos 6.630.343, se analizan los inhibidores de HCV en el replicón bicistrónico cuantificando la

reducción del ARN de replicón (número de acceso a GenBank AJ242654) y/o la señal informante de Fluc. Las células que contienen replicones se pueden cultivar con un compuesto de ensayo de la presente invención hasta por 3 días. Se usa interferón (IFN) a como un control positivo. En general, los valores de IC_{50} de replicón mostrados en la Tabla 1 representan valores de IC_{50} determinados por reducción del ARN de replicones.

Tal como se indica en la Tabla 1, los compuestos de ensayo de la presente invención pueden demostrar un valor de IC_{50} de reducción del ARN de replicones superior a aproximadamente 2 μM a aproximadamente 5 μM (*), un valor de IC_{50} de entre aproximadamente 0,5 μM y aproximadamente 2 μM (**) o un valor de IC_{50} inferior a aproximadamente 0,5 μM (***).

Tabla 1
IC_{50} de replicón (μM)

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
1	***	26	**	51	***
2	***	27	***	52	***
3	***	28	*	53	***
4	*	29	***	54	***
5	***	30	***	55	***
6	***	31	***	56	***
7	**	32	***	57	***
8	**	33	***	58	***
9	***	34	***	59	**
10	***	35	***	60	***
11	**	36	***	61	***
12	**	37	***	62	***
13	***	38	***	63	***
14	***	39	*	64	***
15	**	40	**	65	***
16	**	41	***	66	***
17	**	42	***	67	***
18	**	43	***	68	***
19	*	44	***	69	***
20	**	45	***	70	***
21	***	46	***	71	***
22	**	47	***	72	***
23	**	48	***	73	***
24	***	49	***	74	***
25	**	50	***	75	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
77	**	103	***	128	***
78	***	104	***	129	***
79	***	105	***	130	***
80	***	106	***	131	***
81	***	107	***	132	***
82	***	108	***	133	***
83	***	109	***	134	***
84	***	110	***	135	***
85	***	111	***	136	***
86	***	112	***	137	***
87	***	113	***	138	**
88	***	114	***	139	**
89	***	115	***	140	**
90	*	116	***	141	**
92	***	117	**	142	***
93	***	118	***	143	***
94	***	119	***	144	***
95	***	120	***	145	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
96	***	121	***	146	***
97	**	122	***	147	***
98	***	123	***	148	***
99	***	124	***	149	***
100	***	125	***	150	***
101	***	126	***	151	***
102	***	127	***	152	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
153	***	178	***	203	***
154	***	179	***	204	***
155	***	180	**	205	***
156	**	181	***	206	**
157	***	182	***	207	**
158	***	183	**	208	***
159	***	184	***	209	***
160	***	185	***	210	***
161	***	186	***	211	***
162	***	187	***	212	***
163	**	188	***	213	***
164	**	189	***	214	***
165	**	190	***	215	**
166	***	191	**	216	**
167	***	192	***	217	*
168	***	193	***	218	***
169	***	194	***	219	***
170	***	195	***	220	***
171	***	196	***	221	***
172	***	197	***	222	***
173	***	198	**	223	***
174	***	199	***	224	***
175	***	200	**	225	***
176	***	201	***	226	***
177	***	202	***	227	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
228	***	253	***	278	**
229	***	254	**	279	**
230	***	255	***	280	**
231	***	256	***	281	**
232	***	257	**	282	**
233	***	258	***	283	*
234	***	259	***	284	**
235	***	260	***	285	**
236	***	261	***	286	**
237	***	262	***	287	**
238	***	263	***	288	**
239	**	264	**	289	**
240	***	265	**	290	*
241	***	266	**	291	**
242	**	267	***	292	**
243	**	268	***	293	**
244	*	269	**	294	**
245	***	270	*	295	*
246	**	271	**	296	*
247	**	272	**	297	**
248	***	273	***	298	**
249	***	274	*	299	*
250	***	275	*	300	***
251	**	276	*	301	***
252	***	277	***	302	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
303	***	328	***	353	***
304	***	329	***	354	***
305	***	330	***	355	***
306	**	331	***	356	***
307	***	332	***	357	***
308	**	333	***	358	***
309	***	334	***	359	***
310	***	335	***	360	***
311	***	336	***	361	***
312	**	337	**	362	***
313	***	338	***	363	***
314	***	339	***	364	***
315	***	340	***	365	***
316	***	341	***	367	**
317	***	342	**	368	***
318	***	343	*	369	***
319	**	344	***	370	***
320	**	345	***	371	***
321	**	346	***	372	***

322	*	347	**	373	***
323	***	348	**	374	***
324	***	349	**	375	***
325	***	350	**	376	***
326	***	351	***	377	***
327	***	352	***	378	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
379	***	404	***	429	***
380	***	405	***	430	***
381	***	406	***	431	***
382	***	407	***	432	***
383	***	408	***	433	***
384	***	409	***	434	***
385	***	410	***	435	***
386	***	411	**	436	***
387	***	412	***	437	***
388	**	413	***	438	***
389	**	414	***	439	***
390	**	415	***	440	***
391	***	416	***	441	***
392	***	417	**	442	***
393	***	418	**	443	***
394	***	419	**	444	***
395	***	420	**	445	***
396	***	421	***	446	***
397	***	422	***	447	***
398	***	423	***	448	**
399	***	424	***	449	***
400	***	425	**	450	***
401	***	426	***	451	***
402	***	427	***	452	***
403	**	428	***	453	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
454	***	479	***	504	***
455	***	480	***	505	***
456	***	481	***	506	***
457	***	482	***	507	**
458	***	483	***	508	***
459	***	484	***	509	***
460	***	485	***	510	**
461	***	486	***	511	***
462	***	487	***	512	***
463	***	488	***	513	***
464	**	489	**	514	***
465	***	490	*	515	***
466	***	491	**	516	***

467	***	492	***	517	***
468	***	493	***	518	***
469	**	494	*	519	***
470	***	495	*	520	**
471	***	496	**	521	***
472	***	497	***	522	***
473	***	498	**	523	**
474	***	499	***	524	***
475	***	500	***	525	**
476	***	501	***	526	***
477	***	502	***	527	***
478	***	503	**	528	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
529	***	554	***	579	***
530	***	555	***	580	***
531	***	556	***	581	***
532	***	557	***	582	***
533	***	558	***	583	***
534	***	559	***	584	**
535	***	560	***	585	***
536	***	561	**	586	***
537	***	562	***	587	***
538	***	563	**	588	***
539	***	564	***	589	***
540	***	565	***	590	***
541	***	566	**	591	***
542	***	567	***	592	***
543	***	568	*	593	***
544	***	569	**	594	***
545	***	570	**	595	***
546	**	571	***	596	***
547	***	572	***	597	***
548	**	573	***	598	***
549	***	574	***	599	***
550	***	575	***	600	***
551	***	576	***	601	***
552	**	577	***	602	**
553	***	578	***	603	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
604	***	629	*	654	***
605	***	630	***	655	***
606	***	631	***	656	***
607	***	632	***	657	***
608	***	633	***	658	***
609	***	634	***	659	***
610	***	635	***	660	***

611	***	636	***	661	***
612	***	637	***	662	***
613	***	638	***	663	**
614	**	639	***	664	***
615	***	640	***	665	**
616	***	641	***	666	***
617	***	642	***	667	***
618	***	643	***	668	***
619	***	644	***	669	***
620	***	645	***	670	***
621	***	646	*	671	***
622	***	647	**	672	***
623	**	648	***	673	***
624	***	649	***	674	***
625	***	650	***	675	***
626	***	651	***	676	***
627	***	652	***	677	***
628	***	653	***	678	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
679	***	704	***	729	***
680	***	705	***	730	***
681	***	706	***	731	***
682	***	707	***	732	***
683	***	708	***	733	***
684	**	709	***	734	***
685	**	710	***	735	***
686	***	711	***	736	***
687	***	712	*	737	***
688	***	713	***	738	***
689	**	714	***	739	***
690	**	715	***	740	***
691	***	716	***	741	**
692	***	717	**	742	***
693	***	718	***	743	***
694	*	719	**	744	***
695	***	720	***	745	***
696	***	721	**	746	***
697	***	722	***	747	***
698	***	723	***	748	***
699	***	724	**	749	***
700	***	725	***	750	***
701	***	726	***	751	***
702	***	727	***	752	***
703	***	728	*	753	***

Comp	IC_{50}
754	***
755	***
756	***
757	**
758	***
760	***
761	***
762	***
763	**
764	***
765	***
766	***
767	***
768	***
769	***
770	***
771	***
772	***
773	**
774	***
775	**
776	***
774	***
775	**
776	***

Comp	IC_{50}
777	***
778	***
780	***
781	***
782	***
783	*
784	***
785	***
786	***
787	***
788	***
789	***
790	***
791	*
793	***
794	*
795	***
796	***
797	***
798	**
799	***
800	***
801	***
802	***
803	***

Comp	IC_{50}
804	***
805	**
806	***
807	***
808	***
809	***
810	***
811	***
812	*
813	**
814	***
815	***
816	***
817	***
818	***
819	***
820	***
821	***
822	***
823	**
824	***
825	***
826	***
827	***
828	*

Comp	IC_{50}
829	***
830	***
831	***
832	***
833	**
834	*
835	***
836	**
837	***
838	***
839	***
840	***
841	***
842	***
843	***
844	***
845	***
846	***
847	***

Comp	IC_{50}
854	***
855	***
856	***
857	***
858	**
859	**
860	***
861	*
862	***
863	***
864	***
865	***
866	**
867	***
868	***
869	**
870	***
871	***
872	***

Comp	IC_{50}
879	***
880	***
881	***
882	***
883	***
884	***
885	***
886	***
887	***
888	***
889	***
890	***
891	***
892	***
893	***
894	***
895	***
896	***
897	***

848	***	873	***	898	**
849	***	874	***	899	***
850	***	875	***	900	**
851	***	876	***	901	***
852	***	877	***	902	**
853	***	878	***	903	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
904	***	929	***	954	***
905	***	930	***	955	***
906	***	931	***	956	***
907	***	932	***	957	**
908	***	933	***	958	**
909	**	934	***	959	***
910	***	935	***	960	***
911	***	936	***	961	***
912	*	937	***	962	***
913	***	938	***	963	***
914	***	939	*	964	***
915	***	940	**	965	***
916	***	941	**	966	***
917	***	942	***	967	***
918	*	943	**	968	**
919	***	944	**	969	***
920	***	945	***	970	***
921	***	946	***	971	**
922	***	947	***	972	*
923	***	948	***	973	***
924	***	949	***	974	***
925	***	950	***	975	***
926	***	951	***	976	***
927	***	952	***	977	***
928	***	953	***	978	*

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
979	*	1004	***	1029	*
980	**	1005	***	1030	**
981	***	1006	**	1031	***
982	*	1007	***	1032	***
983	***	1008	***	1033	***
984	***	1009	***	1034	**
985	***	1010	***	1035	**
986	***	1011	**	1036	*
987	***	1012	**	1037	***
988	***	1013	***	1038	***
989	***	1014	***	1039	**
990	***	1015	***	1040	***
991	***	1016	***	1041	***

992	***	1017	***	1042	**
993	***	1018	***	1043	***
994	***	1019	***	1044	***
995	***	1020	***	1045	***
996	***	1021	***	1046	*
997	***	1022	***	1047	**
998	**	1023	***	1048	**
999	***	1024	***	1055	**
1000	***	1025	***	1056	***
1001	***	1026	**	1057	***
1002	***	1027	***	1058	***
1003	***	1028	*	1059	***

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
1060	*	1095	**	1119	***
1061	***	1096	***		
1062	***	1097	***		
1063	***	1098	**		
1064	***	1099	**		
1065	***	1100	***		
1072	**	1101	**		
1073	***	1102	***		
1074	***	1103	**		
1075	***	1104	***		
1078	***	1105	***		
1079	***	1106	***		
1080	**	1107	***		
1081	***	1108	***		
1082	***	1109	***		
1083	***	1110	***		
1084	***	1111	***		
1085	***	1112	***		
1086	***	1113	***		
1087	***	1114	***		
1088	***	1115	***		
1092	***	1116	***		
1093	**	1117	***		
1094	***	1118	***		

Ejemplo 2

Evaluación de la actividad del compuesto usando una quimera de HCV– poliovirus

En una quimera de HCV–poliovirus (HCV–PV), el PV 5' UTR está reemplazado por el HCV 5' UTR y las secuencias codificantes del núcleo parciales (los primeros 123 aminoácidos) (nucleótidos 18 a 710 de HCV 1b) (ver Zhao WD y Wimmer E, Genetic analysis of a polyovirus/virus de hepatitis C chimera: new structure for domain II of the internal ribosomal entry site of virus de hepatitis C, *J. Virol.*, **2001**, 75:3719–3730; y, Zhao WD, Wimmer E y Lahser FC, Polyovirus/Hepatitis C virus (internal ribosomal entry site–core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and requirement for core RNA sequences but not for core–related polypeptides, *Journal of Virology*, **1999**, 73:1546–1554). Como consecuencia, la expresión de las proteínas de poliovirus está bajo regulación de HCV IRES. El poliovirus es un picornavirus en el que la iniciación de la traducción de la proteína está mediada por un elemento IRES ubicado en el 5' UTR. En el extremo 5' del genoma de HCV–PV quimérico, está la estructura de ARN de PV de tipo hoja de trébol que provee una señal de replicación de acción *cis* que termina con la proteína ligada al genoma VPg. La cinética de replicación de la quimera HCV–PV coincide con la del poliovirus principal (Mahoney) y puede dar como resultado efectos citopáticos (CPE) en cultivo celular. La heptazima (ver SC Gordon, BR Bacon, IM Jacobson, MI Shiffman, NH Afdhal, JG McHutchison, TJ Kwoh y FA Dorr, A fase II, 12–week study of ISIS 14803, an antisense inhibitor of HCV for the treatment of chronic hepatitis C, AASLD Abst. 795, *Hepatology*, **2002**, 36:362A.), una ribozima que tiene como blanco el HCV IRES, mostró ser activa contra el virus quimérico en cultivo celular (ver Macejak DG, KL Jensen, SF Jamison, K Domenico, EC Roberts, N Chaudhari, I von Carlowitz, L Bellon, MJ Tong, A Conrad, PA Pavco y LM Blatt, Inhibition of virus de hepatitis C (HCV)–RNA–dependent translation and

replication of a chimeric HCV polyovirus using synthetic stabilized ribozymes, *Hepatology*, **2000**, 31:769–776; y, Macejak DG, KL Jensen, PA Pavco, KM fipps, BA Heinz, JM Colacino y LM Blatt, Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA, *J Viral Hepatitis*, **2001**, 8:400–405).

Se ensaya un compuesto en cuanto a la actividad de virus quimérico, sembrándolo en células HeLa e incubando las células a 37 °C bajo 5% de CO_2 durante 24 horas. Las células se infectan luego con HCV–PV en una multiplicidad de infección (MOI) de aproximadamente 0,1 durante 30 min y luego se tratan con un compuesto de ensayo durante un día. La actividad de un compuesto de ensayo se determina por un cambio en la producción de ARN viral.

Tal como se indica en la Tabla 2, los compuestos de ensayo de la presente invención demuestran valores de IC_{50} de HCV–PV superiores a aproximadamente 2 μM a aproximadamente 5 μM (*), un valor de IC_{50} de entre aproximadamente 0,5 μM y aproximadamente 2 μM (**) o un valor de IC_{50} inferior a aproximadamente 0,5 μM (***).

Tabla 2

IC_{50} de HCV PV (μM)

Comp	IC_{50}	Comp	IC_{50}	Comp	IC_{50}
5	***	**51**	***	**92**	***
7	***	**52**	***	**93**	***
10	***	**53**	***	**94**	***
24	***	**54**	***	**95**	***
29	***	**60**	***	**96**	***
30	***	**61**	***	**104**	***
31	***	**64**	***	**110**	***

32	***	**65**	***	**112**	***
34	***	**68**	***	**113**	***
35	***	**71**	***	**122**	***
36	***	**72**	***	**124**	***
37	***	**74**	***	**126**	***
38	***	**78**	***	**129**	***
41	***	**80**	***	**132**	***
42	***	**81**	***	**135**	***
43	***	**82**	***	**145**	***
44	***	**83**	***	**178**	***
45	***	**84**	***	**191**	***
49	***	**85**	***	**198**	***
50	***	**89**	***		


Sin tener en cuenta si un documento citado en la presente estaba indicado específica e individualmente como incorporado por referencia, todos los documentos mencionados en la presente están incorporados por referencia en la presente solicitud para todos los fines en la misma medida en que si cada referencia individual se estableciera por completo en la presente.

A pesar de que ciertas formas de realización fueron descritas detalladamente con anterioridad, los expertos en la técnica entenderán claramente que son posibles muchas modificaciones en las formas de realización sin apartarse de sus enseñanzas. Todas estas modificaciones están comprendidas dentro de las reivindicaciones de la invención.

REIVINDICACIONES

Habiendo así especialmente descrito y determinado la naturaleza de la presente invención y la forma como la misma ha de ser llevada a la práctica, se declara reivindicar como de propiedad y derecho exclusivo:

1. Un compuesto de la fórmula (I):



(I)

o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o sus formas polimórficas, en donde

X es hidrógeno, halógeno, ciano, nitro, carboxilo, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, formilo, amino, alquil C_{1-8}–amino, amino–carbonilo, alquil C_{1-8}–amino–carbonilo o alquil C_{1-8}–sulfonilo;

Ar es heteroarilo o heterociclilo, cada uno opcionalmente sustituido con uno o dos sustituyentes seleccionados, de modo independiente, de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino;

Z es alquilo C_{1-8}, alquenil C_{2-8}–alquilo C_{1-8}, alquinil C_{2-8}–alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, alcoxi C_{1-8}–carbonilo, carboxilo, cicloalquilo C_{3-14}, cicloalquenilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo y heteroarilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de hidroxi, ciano, nitro,

halógeno, alquilo C_{1-8}, alquenilo C_{2-8}, alquinilo C_{2-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino, alquil C_{1-8}–amino, alcoxi C_{1-8}–alquilo C_{1-8}, alquil C_{1-8}–tio, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi o amino–sulfonilo;

R_1 es $-N(R_3)-SO_2-R_4$, $-N(R_3)-SO_2-N(R_5)-R_6$, $-SO_2-N(R_5)-R_6$ o $-SO_2-R_7$;

R_2 es uno, dos, tres o cuatro sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, ciano, nitro, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, alquenilo C_{2-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi, alquil C_{1-8}–carboniloxi–alquilo C_{1-8}, alquil C_{1-8}–carboniloxi–alcoxi C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, amino–alcoxi C_{1-8}, alquil C_{1-8}–amino–alcoxi C_{1-8}, alcoxi C_{1-8}–alquil C_{1-8}–amino–alcoxi C_{1-8}, amino–alquil C_{1-8}–amino–alcoxi C_{1-8}, alquil C_{1-8}–amino–alquil C_{1-8}–amino–alcoxi C_{1-8}, alcoxi C_{1-8}–carbonil–amino, carboxil–amino, amino–carbonilo, amino–carbonil–amino, alquil C_{1-8}–amino–carbonil–amino, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, alquil C_{1-8}–sulfonil–amino, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, cicloalquil C_{3-14}–alcoxi C_{1-8}, cicloalquil C_{3-14}–oxi, arilo, aril–alquilo C_{1-8}, aril–alcoxi C_{1-8}, ariloxi, aril–carbonil–amino, heteroarilo, heteroaril–alquilo C_{1-8}, heteroaril–alcoxi C_{1-8}, heteroariloxi, heterociclilo, heterociclil–alquilo C_{1-8}, heterociclil–alcoxi C_{1-8}, heterocicliloxi o heterociclil–carboniloxi, en donde cada instancia de arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de halógeno, ciano, alquilo C_{1-8}, alcoxi C_{1-8}, alcoxi C_{1-8}–

alquilo C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8} o alquil C_{1-8}–amino–alquilo C_{1-8};

R_3 es hidrógeno o alquilo C_{1-8}, opcionalmente sustituido en el alquilo C_{1-8} con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi, ciano, alcoxi C_{1-8}, amino o alquil C_{1-8}–amino;

R_4 es alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C_{3-14} está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino;

R_5 es hidrógeno, alquilo C_{1-8}, alquil C_{1-8}–carbonil– o cicloalquilo C_{3-14}, opcionalmente sustituido en el alquilo C_{1-8} con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi, ciano o alcoxi C_{1-8};

R_6 es hidrógeno, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, ciano–alquilo C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C_{3-14} está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino; y

R_7 es alquilo C_{1-8}, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo, heteroarilo, cicloalquilo C_{3-14} y heterociclilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, amino o alquil C_{1-8}–amino.

2. El compuesto de acuerdo con la reivindicación 1, en donde

X está seleccionado de hidrógeno, ciano, carboxilo, amino–carbonilo o alquil C_{1-8}–amino–carbonilo;

Ar es heteroarilo;

Z es alquilo C_{1-8}, cicloalquilo C_{3-14}, cicloalquenilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8}, en donde cada instancia de arilo y heteroarilo está opcionalmente sustituido con un sustituyente seleccionado de ciano, halógeno, alquilo C_{1-8}, alcoxi C_{1-8}, amino o alquil C_{1-8}–amino;

R_2 es uno, dos o tres sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, cicloalquil C_{3-14}–alcoxi C_{1-8}, cicloalquil C_{3-14}–oxi, heteroarilo, heteroaril–alquilo C_{1-8}, heteroaril–alcoxi C_{1-8}, heteroariloxi, heterociclilo, heterociclil–alquilo C_{1-8},

heterociclil–alcoxi C_{1-8} o heterocicliloxi, en donde heteroariloxi está opcionalmente sustituido con un sustituyente de ciano;

R_3 es hidrógeno o alquilo C_{1-8}, opcionalmente sustituido en el alquilo C_{1-8} con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi o ciano;

R_4 es alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, arilo, aril–alquilo C_{1-8}, heteroarilo, heteroaril–alquilo C_{1-8}, heterociclilo o heterociclil–alquilo C_{1-8};

R_5 es hidrógeno;

R_6 es hidrógeno, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, ciano–alquilo C_{1-8}, cicloalquilo C_{3-14} o cicloalquil C_{3-14}–alquilo C_{1-8}, en donde cada instancia de cicloalquilo C_{3-14} está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8} o halo–alquilo C_{1-8}; y

R_7 es alquilo C_{1-8} o heterociclilo;

y todas las otras variables previamente definidas.

3. El compuesto de acuerdo con la reivindicación 1, en donde

X es ciano;

Ar es piridinilo, pirimidinilo o piridazinilo;

Z es alquilo C_{1-8}, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclohexenilo, ciclopropil–metilo, fenilo, tiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo, triazinilo o tetrahidrofurano, en donde fenilo está opcionalmente sustituido con un sustituyente seleccionado de ciano, halógeno, alquilo C_{1-8} o alcoxi C_{1-8};

R_2 es uno, dos o tres sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–

alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, ciclopropilo, ciclobutilo, ciclobutoxi, piridiniloxi, pirimidiniloxi, piraziniloxi o morfolinilo, en donde piridinilo y pirazinilo están cada uno opcionalmente sustituidos con un sustituyente de ciano;

R_3 es hidrógeno, metilo, etilo, propilo, isopropilo o ter–butilo, en donde metilo, etilo, propilo e isopropilo están cada uno opcionalmente sustituidos con uno o varios sustituyentes seleccionados cada uno de halógeno, hidroxi o ciano;

R_4 es alquilo C_{1-8} o ciclopropilo;

R_6 es hidrógeno, alquilo C_{1-8}, hidroxi–alquilo C_{1-8}, halo–alquilo C_{1-8}, ciano–alquilo C_{1-8}, ciclopropilo, ciclobutilo o 1–ciclopropil–etilo, en donde cada instancia de ciclopropilo y ciclobutilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halógeno, alquilo C_{1-8} o halo–alquilo C_{1-8}; y

R_7 es alquilo C_{1-8} o piperidinilo;

y todas las otras variables previamente definidas.

4. Un compuesto de acuerdo con la reivindicación 1, en donde el isotopólogo es deuterio.

5. Un compuesto de acuerdo con la reivindicación 4, en donde


R_2 es alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio;

R_4 es alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio o halo–alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio;

R_6 es alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio o halo–alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio; y

R_7 es alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio o halo–alquilo C_{1-8}, en donde de 1 a 3 átomos de hidrógeno están opcionalmente reemplazados con deuterio.

6. Un compuesto de la fórmula (Ia):



(Ia)

o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o formas polimórficas, en donde

R_8 es hidrógeno, halógeno o alcoxi C_{1-8};

R_9 es hidrógeno, halógeno, hidroxi, ciano, nitro, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, alquil C_{1-8}–tio, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alcoxi C_{1-8}, arilo, aril–alcoxi C_{1-8}, heteroarilo, heteroaril–alcoxi C_{1-8}, heterociclilo o heterociclil–alcoxi C_{1-8}, en donde cada instancia de cicloalquilo C_{3-14}, arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados

cada uno de halógeno, ciano, alquilo C_{1-8}, alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8} o alquil C_{1-8}–amino–alquilo C_{1-8};

R_{10} es hidrógeno, halógeno, hidroxi, ciano, nitro, alquilo C_{1-8}, halo–alquilo C_{1-8}, alquenilo C_{2-8}, halo–alquenilo C_{2-8}, hidroxi–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi, alquil C_{1-8}–carboniloxi–alcoxi C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8}, alquil C_{1-8}–amino–alquilo C_{1-8}, amino–alcoxi C_{1-8}, alquil C_{1-8}–amino–alcoxi C_{1-8}, alcoxi C_{1-8}–alquil C_{1-8}–amino–alcoxi C_{1-8}, amino–alquil C_{1-8}–amino–alcoxi C_{1-8}, alquil C_{1-8}–amino–alquil C_{1-8}–amino–alcoxi C_{1-8}, alcoxi C_{1-8}–carbonil–amino, carboxil–amino, amino–carbonilo, amino–carbonil–amino, alquil C_{1-8}–amino–carbonil–amino, alquil C_{1-8}–tio, alquil C_{1-8}–sulfinilo, alquil C_{1-8}–sulfonilo, alquil C_{1-8}–sulfonil–amino, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–alquilo C_{1-8}, cicloalquil C_{3-14}–alcoxi C_{1-8}, cicloalquil C_{3-14}–oxi, arilo, aril–alquilo C_{1-8}, aril–alcoxi C_{1-8}, ariloxi, aril–carbonil–amino, heteroarilo, heteroaril–alquilo C_{1-8}, heteroaril–alcoxi C_{1-8}, heteroariloxi, heterociclilo, heterociclil–alquilo C_{1-8}, heterociclil–alcoxi C_{1-8}, heterocicliloxi o heterociclil–carboniloxi, en donde cada instancia de cicloalquilo C_{3-14}, arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de halógeno, ciano, alquilo C_{1-8}, alcoxi C_{1-8}, alcoxi C_{1-8}–alquilo C_{1-8}, amino, alquil C_{1-8}–amino, amino–alquilo C_{1-8} o alquil C_{1-8}–amino–alquilo C_{1-8}; y

R_{11} es hidrógeno, halógeno, hidroxi, ciano, nitro, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–carbonilo, alcoxi C_{1-8}–carbonilo, alquil C_{1-8}–carboniloxi o alquil C_{1-8}–carboniloxi–alquilo C_{1-8};

y todas las otras variables previamente definidas.

7. El compuesto de acuerdo con la reivindicación 6, en donde

R_8 es hidrógeno o halógeno;

R_9 es hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio o cicloalquilo C_{3-14};

R_{10} es hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio, cicloalquilo C_{3-14}, cicloalquil C_{3-14}–oxi, heteroariloxi o heterociclilo, en donde heteroariloxi está opcionalmente sustituido con un sustituyente de ciano; y

R_{11} es hidrógeno o halógeno;

y todas las otras variables previamente definidas.

8. El compuesto de acuerdo con la reivindicación 6, en donde

R_9 es hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio o ciclopropilo; y

R_{10} es hidrógeno, halógeno, hidroxi, ciano, alquilo C_{1-8}, halo–alquilo C_{1-8}, halo–alquenilo C_{2-8}, alcoxi C_{1-8}, halo–alcoxi C_{1-8}, alquil C_{1-8}–tio, ciclopropilo, ciclobutilo, ciclobutoxi, piridiniloxi, pirimidiniloxi, piraziniloxi o morfolinilo, en donde piridinilo y pirazinilo están opcionalmente sustituidos con un sustituyente de ciano;

y todas las otras variables previamente definidas.

9. El compuesto de acuerdo con la reivindicación 1, en donde el compuesto o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o formas polimórficas está seleccionado de:

6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–ciclobutilpiridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

5–[3–ciano–1–ciclobutil–6–(ciclobutiloxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

N–ter–butil–6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(propan–2–ilsulfanil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–5–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

1–ciclobutil–2–[5–(piperidin–1–ilsulfonil)piridin–2–il]–6–(propan–2–ilsulfanil)–1H–indol–3–carbonitrilo,

6–[3–ciano–1–ciclobutil–5–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–5–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

5–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida,

5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–2–sulfonamida,

5–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–2–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–5–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–5–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–5–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

5–[3–ciano–1–ciclopropil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida,

5–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–2–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopropil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(tetrahidrofuran–3–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(tetrahidrofuran–3–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida,

6–{3–ciano–6–metil–1–[(3R)–tetrahidrofuran–3–il]–1H–indol–2–il}–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–{3–ciano–6–metil–1–[(3R)–tetrahidrofuran–3–il]–1H–indol–2–il}–N–(propan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[6–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–7–fluoro–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–fluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–6–etil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–fluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,1,1–trifluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–7–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(7–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–6–ciclopropil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

6–[6–cloro–3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–5–fluoro–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1,6–diciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(6–cloro–3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(metilsulfanil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(metilsulfanil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–6–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–6–fluoro–1–propil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[5–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–6–metoxi–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(2–fluorofenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–6–(difluorometoxi)–1–propil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–dihidroxipropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–5–(difluorometoxi)–1–etil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(3,3–difluorociclobutil)piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida,

2–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–5–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(piridin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

N–{5–[3–ciano–1–ciclobutil–6–(pirimidin–2–iloxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,

N–{5–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,

N–{6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida,

N–{6–[3–ciano–1–ciclobutil–6–(pirimidin–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–1–sulfonamida,

N–(6–{3–ciano–6–[(3–cianopiridin–2–il)oxi]–1–ciclobutil–1H–indol–2–il}piridin–3–il)propan–1–sulfonamida,

N–(6–{3–ciano–6–[(3–cianopirazin–2–il)oxi]–1–ciclobutil–1H–indol–2–il}piridin–3–il)propan–1–sulfonamida,

N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}ciclopropansulfonamida,

N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}metansulfonamida,

N–{6–[3–ciano–1–ciclobutil–6–(propan–2–iloxi)–1H–indol–2–il]piridazin–3–il}etansulfonamida,

N–[6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)piridazin–3–il]etansulfonamida,

N–[6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)piridazin–3–il]–2–metilpropan–2–sulfonamida,

N–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1*H*–indol–2–il]piridin–3–il}etansulfonamida,

N–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida,

N–{6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida,

N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}–N–(propan–2–il)etansulfonamida,

N–{6–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida,

N–{6–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–3–il}etansulfonamida,

N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}ciclopropansulfonamida,

N–{6–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–3–il}propan–2–sulfonamida,

N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]metansulfonamida,

N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]etansulfonamida,

N–[5–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)piridin–2–il]propan–2–sulfonamida,

N–{5–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–2–il}etansulfonamida,

N–{5–[3–ciano–1–(ciclopropilmetil)–6–(2,2,2–trifluoroetoxi)–1H–indol–2–il]piridin–2–il}propan–2–sulfonamida,

N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(2,2–difluoroetil)ciclopropansulfonamida,

N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(2–hidroxietil)ciclopropansulfonamida,

N–{5–[3–ciano–1–etil–6–(propan–2–iloxi)–1H–indol–2–il]piridin–2–il}–N–(cianometil)ciclopropansulfonamida,

N–{5–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,

N–[6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida,

N–[6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida,

N–[6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)piridin–3–il]ciclopropansulfonamida,

N–{5–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–cianoetil)piridin–3–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(propan–2–il)–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–etil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(morfolin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(morfolin–4–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–[3–ciano–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–6–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1,6–diciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–6–ciclobutil–1–ciclopentil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–6–ciclopropil–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3,5–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–[(1S)–1–ciclopropiletil]–6–[3,6–diciano–1–(ciclopropilmetil)–1H–indol–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–[3–ciano–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(fluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–[(1S)–1–ciclopropiletil]–2–(3,5–diciano–1–ciclopentil–1H–indol–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–etil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–5–(fluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–5–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–5–etil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3,5–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6-(3-ciano-1-ciclobutil-6-fluoro-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

6-(3-ciano-1-ciclopentil-6-fluoro-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

6-[3-ciano-1-(ciclopropilmetil)-6-fluoro-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

2-[3-ciano-1-(ciclopropilmetil)-6-(difluorometoxi)-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-[3-ciano-6-(difluorometoxi)-1-(propan-2-il)-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-[3-ciano-6-(difluorometoxi)-1-propil-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-(3-ciano-1-ciclopentil-6-ciclopropil-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-[3-ciano-1-(ciclopropilmetil)-6-metil-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-[3-ciano-6-metil-1-(propan-2-il)-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-(3-ciano-1-ciclopentil-6-metil-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-(3-ciano-1-ciclobutil-6-metoxi-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-(3-ciano-1-ciclopentil-6-metoxi-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

6-(3-ciano-1-ciclopentil-5-fluoro-6-metil-1H-indol-2-il)-N-(1,3-difluoropropan-2-il)piridin-3-sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–[3–ciano–1–(ciclohex–2–en–1–il)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclohex–2–en–1–il)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[6–cloro–3–ciano–1–(ciclopropilmetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(6–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[6–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(5–cloro–3–ciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[5–cloro–3–ciano–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–ciclopropil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(5–cloro–3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(5–cloro–3–ciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–[3–ciano–1,6–di(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclohexil–6–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(5–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3,6–diciano–1–ciclobutil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3,6–diciano–1–ciclopentil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclohexil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2-[3-ciano-1-ciclohexil-6-(difluorometoxi)-1H-indol-2-il]-N-(propan-2-il)pirimidin-5-sulfonamida,

2-[3-ciano-5-fluoro-1-(piridin-2-il)-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

2-[3-ciano-6-metil-1-(piridin-2-il)-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

6-[3-ciano-6-metil-1-(piridin-2-il)-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

2-[3-ciano-6-(difluorometoxi)-1-(4-fluorofenil)-1H-indol-2-il]-N-(1,3-difluoropropan-2-il)pirimidin-5-sulfonamida,

6-(3-ciano-1-ciclobutil-6-metil-1H-indol-2-il)-N-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-3-sulfonamida,

6-[3-ciano-1-ciclobutil-6-(difluorometoxi)-1H-indol-2-il]-N-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-3-sulfonamida,

6-(3-ciano-1-ciclobutil-5-metil-1H-indol-2-il)-N-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-3-sulfonamida,

6-(3-ciano-1-ciclobutil-6-etil-1H-indol-2-il)-N-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-3-sulfonamida,

6-(3-ciano-1-ciclopentil-6-fluoro-5-metil-1H-indol-2-il)-N-(1,3-difluoropropan-2-il)piridin-3-sulfonamida,

6-(3-ciano-1-ciclopentil-6-fluoro-5-metil-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

6-(3-ciano-1-ciclobutil-5-metil-1H-indol-2-il)-N-[(2R)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

6-[3-ciano-5-metil-1-(propan-2-il)-1H-indol-2-il]-N-[(2R)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

6–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[6–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–fluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–fluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–fluoro–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclohexil–6–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(1–ciclobutil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(6–cloro–3–ciano–1–ciclohexil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–6–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(6–cloro–3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(propan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclohexil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–5–(difluorometil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–5–fluoro–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–4,6–difluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–4,6–difluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–4,6–difluoro–5–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–4,6–difluoro–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–5–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–5–metil–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclopentil–5–metil–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

6–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–[3–ciano–5–metil–1–(propan–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

1–ciclobutil–6–(difluorometoxi)–2–(5–sulfamoilpiridin–2–il)–1H–indol–3–carboxamida,

2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

2–(3–ciano–1–ciclobutil–5–metoxi–1H–indol–2–il)–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclopentil–5–metoxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

1–ciclobutil–6–(difluorometoxi)–2–{5–[(1,3–difluoropropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

1–ciclobutil–6–ciclopropil–2–{5–[(1,3–difluoropropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–6–metil–1–fenil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclopentil–7–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclobutil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[1–(trifluorometil)ciclobutil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–ciclopentil–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

2-(3-ciano-1-ciclopentil-5-fluoro-1H-indol-2-il)-N-(propan-2-il)pirimidin-5-sulfonamida,

6-[3-ciano-5-fluoro-1-(propan-2-il)-1H-indol-2-il]-N-[(1S)-1-ciclopropiletil]piridin-3-sulfonamida,

2-(3-ciano-1-ciclohexil-6-metil-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

6-(3-ciano-1-ciclohexil-5-metil-1H-indol-2-il)-N-[(1S)-1-ciclopropiletil]piridin-3-sulfonamida,

6-(3-ciano-1-ciclopentil-5-metil-1H-indol-2-il)-N-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-3-sulfonamida,

6-[3-ciano-5-fluoro-1-(pirimidin-2-il)-1H-indol-2-il]-N-(1,3-difluoropropan-2-il)piridin-3-sulfonamida,

6-(3-ciano-1-ciclobutil-5-fluoro-6-metil-1H-indol-2-il)-N-[(2R)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

2-[3-ciano-6-(difluorometoxi)-1-fenil-1H-indol-2-il]-N-(1,3-difluoropropan-2-il)pirimidin-5-sulfonamida,

2-[3-ciano-6-(difluorometoxi)-1-fenil-1H-indol-2-il]-N-[(2S)-1,1,1-trifluoropropan-2-il]pirimidin-5-sulfonamida,

6-[3-ciano-6-(difluorometoxi)-1-fenil-1H-indol-2-il]-N-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-3-sulfonamida,

6-(3-ciano-1-ciclobutil-5-fluoro-6-metil-1H-indol-2-il)-N-[1-(trifluorometil)ciclopropil]piridin-3-sulfonamida,

6-(3-ciano-1-ciclopentil-4-fluoro-5-metil-1H-indol-2-il)-N-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-3-sulfonamida,

6-(3-ciano-1-ciclopentil-4-fluoro-5-metil-1H-indol-2-il)-N-[(2S)-1,1,1-trifluoropropan-2-il]piridin-3-sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(1S)–1–ciclopropiletil]pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(propan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

2–[3–ciano–1–(ciclopropilmetil)–6–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–6–(difluorometoxi)–1–fenil–1H–indol–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–4–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–4–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–4–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

2–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

N–ter–butil–6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1–metilciclopropil)piridin–3–sulfonamida,

6–[1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–etil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–ciclopropilpiridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

2–(3–ciano–1–ciclopentil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida,

2–[5–cloro–3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–metil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

2–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclopentil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–etil–5–fluoro–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–hidroxi–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(5–bromo–3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxamida,

6–(5–bromo–3–ciano–1–ciclobutil–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–(metilsulfanil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(4–fluorofenil)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(5–bromo–3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–5–(2,2–difluoroetil)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(2,2–difluoroetil)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

6–[3–ciano–1–ciclobutil–5–(2,2–difluoroetil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida,

6–[5–cloro–3–ciano–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–{[6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–il]sulfonil}–N–[(2R)–1,1,1–trifluoropropan–2–il]acetamida,

N–ter–butil–6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(difluorometil)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclohexil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

1–ciclohexil–5–fluoro–6–metil–2–(5–sulfamoilpiridin–2–il)–1H–indol–3–carboxamida,

1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

1–ciclohexil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxilato de metilo

1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

N–ter–butil–6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)piridin–3–sulfonamida

N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida

N–ter–butil–6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(difluorometil)piridin–3–sulfonamida

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida

6–{3–ciano–5–fluoro–1–[5–(trifluorometil)piridin–2–il]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–(3–ciano–1–ciclobutil–5–fluoro–6–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–(3–ciano–1–ciclobutil–6–etoxi–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–[1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–(1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

1–ciclopentil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclobutil–6–ciclopropil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

5–cloro–1–ciclobutil–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida,

5–cloro–1–ciclobutil–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

5–cloro–1–ciclobutil–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–cloro–1–ciclobutil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(3–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–{3–ciano–5–fluoro–6–metil–1–[5–(trifluorometil)piridin–2–il]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

ácido 1–ciclohexil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico,

6–[3–ciano–5–fluoro–1–(5–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(5–cianopiridin–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(5–nitropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

5–cloro–1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida,

1–ciclohexil–6–(difluorometoxi)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxamida,

1–ciclohexil–6–(difluorometoxi)–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida,

5–fluoro–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]piridin–3–sulfonamida,

2–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]pirimidin–5–sulfonamida,

1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxilato de metilo,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxilato de metilo,

1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxilato de metilo,

6–(3–ciano–1–ciclobutil–5–metoxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

ácido 1–ciclopentil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico,

6–(1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclopentil–5–fluoro–N,6–dimetil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclopentil–N–etil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclopentil–5–fluoro–6–metil–N–(propan–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

N–ter–butil–6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida,

ácido 1–ciclopentil–5–fluoro–6–metil–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxílico,

ácido 2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxílico

5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxilato de metilo,

metil 1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxilato,

6–[3–ciano–1–ciclobutil–5–fluoro–6–(metilsulfanil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–4–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxilato de metilo,

ácido 1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}pirimidin–2–il)–1H–indol–3–carboxílico,

ácido 2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxílico,

6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–cloro–1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–1H–indol–3–carboxamida,

1–ciclobutil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–6–(trifluorometoxi)–1H–indol–3–carboxamida,

1–ciclopentil–2–[5–(propan–2–ilsulfamoil)pirimidin–2–il]–6–(trifluorometoxi)–1H–indol–3–carboxamida,

1–ciclopentil–5–fluoro–N,N,6–trimetil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–6–(difluorometoxi)–4–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–cloro–3–ciano–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–propil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–propil–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluorobutan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–fenilpiridin–3–sulfonamida,

ácido 1–ciclobutil–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico,

ácido 2–[5–(ter–butilsulfamoil)pirimidin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxílico,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida,

6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–4–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–[5–(fenilsulfamoil)piridin–2–il]–1H–indol–3–carboxamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–fluoro–6–metil–1H–indol–3–carboxamida,

1–ciclobutil–5–fluoro–N,6–dimetil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

2–[5–(ter–butilsulfamoil)pirimidin–2–il]–1–ciclobutil–5–fluoro–N,6–dimetil–1H–indol–3–carboxamida,

6–[5–cloro–3–ciano–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–cloro–3–ciano–1–(5–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–ter–butil–6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)piridin–3–sulfonamida,

1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–(3–ciano–1–ciclobutil–5–hidroxi–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

1–ciclobutil–6–(difluorometoxi)–5–fluoro–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–4–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–7–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(ciclopropilmetil)–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–hidroxi–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(3–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(6–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(4–metoxipiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,

1–ciclobutil–6–(difluorometoxi)–4–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclobutil–5–hidroxi–6–metil–1H–indol–3–carboxamida,

1–ciclopentil–6–ciclopropil–5–fluoro–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclopentil–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

N–ter–butil–6–(3–ciano–1–ciclopentil–6–ciclopropil–5–fluoro–1H–indol–2–il)piridin–3–sulfonamida,

1–ciclobutil–5–hidroxi–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclopentil–5–metoxi–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

ácido 1–ciclohexil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxílico,

diamida N–[6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)piridin–3–il]–N'–[(2S)–1,1,1–trifluoropropan–2–il]sulfúrica,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclopentil–6–ciclopropil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–(difluorometoxi)–4–fluoro–1–(propan–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–(ciclopropilmetil)–6–(difluorometoxi)–4–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclopentil–5–hidroxi–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(3–fluoropiridin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

5–metil–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclopentil–6–ciclopropil–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclohexil–5–fluoro–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

1–ciclohexil–5–fluoro–6–metil–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–(3–ciano–1–ciclobutil–6–etil–4–metoxi–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1–metilciclopropil)piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1–metilciclopropil)–N–(pirimidin–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclopentil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

1–ciclopentil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida

6–[3–ciano–5–fluoro–6–metil–1–(5–metilpirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–[3–ciano–5–fluoro–1–(4–metoxipirimidin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

N–ter–butil–6–[6–etil–5–fluoro–3–(metilsulfonil)–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida

6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclopentil–6–etil–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

1–ciclopentil–6–etil–5–fluoro–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–5–fluoro–6–metil–1–(4–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

5–fluoro–6–metil–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

5–fluoro–6–metil–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

5–fluoro–1–(5–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

5–fluoro–1–(6–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–3–carboxamida,

N–ter–butil–6–(3–ciano–6–etil–5–fluoro–1–fenil–1H–indol–2–il)piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(5–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(4–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–2–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–5–metil–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–4–metil–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–4–metil–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridazin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[6–bromo–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(pirazin–2–il)–5–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(pirazin–2–il)–5–(trifluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(pirazin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,

N–ter–butil–6–[3–ciano–6–etil–5–fluoro–1–(3–fluoropiridin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–fluoro–5–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

5–fluoro–1–(3–fluoropiridin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[5–fluoro–6–metil–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

5–fluoro–6–metil–1–(5–metilpirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

5–fluoro–6–metil–1–(4–metilpirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

5–fluoro–1–(4–metoxipirimidin–2–il)–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

6–[6–acetil–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–[3–ciano–6–etenil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–etil–5–fluoro–1–(piridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

6–(3–ciano–1–ciclopropil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–[3–ciano–5–fluoro–6–(1–hidroxietil)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

5–fluoro–6–metil–1–(piridazin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

5–fluoro–6–metil–1–(piridin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

6–[1–(5–cloropirimidin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(6–metilpirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

5–metil–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–6–fluoro–5–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–fluoro–5–metil–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–6–fluoro–5–metil–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(4–fluorofenil)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–5–metil–1–fenil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(pirimidin–2–il)–5–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(6–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(5–fluoropirimidin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(5–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(4–fluoropiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–(2–metil–1,3–dioxolan–2–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

ácido 1–ciclohexil–6–(difluorometoxi)–5–fluoro–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxílico,

6–[3–ciano–6–etil–5–fluoro–1–(pirazin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(6–fluoropiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(5–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(4–metilpiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(2–metilpropil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[6–bromo–3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–ter–butilpiridin–3–sulfonamida,

N–ter–butil–6–[3,6–diacetil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(2–hidroxietil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(1,6–dihidropirimidin–2–il)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(5–cloropirimidin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(2–metilpirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–fluoro–1–(2–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(5–fluoropiridin–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(5–fluoropirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–cloro–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(5–fluoropirimidin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–fluoro–1–(5–fluoropirimidin–2–il)–5–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(pirimidin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(pirazin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(piridin–2–il)–6–(trifluorometil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(ciclobutilmetil)piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(piridin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(4–metoxipiridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,

6–[5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–fluoro–6–metil–1–(1,3–tiazol–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(5–fluoro–6–metilpiridin–2–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(6–cloropiridin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(3–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(5–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–(prop–2–en–1–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–cloro–5–fluoro–6–(prop–2–en–1–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–fluoro–6–(prop–2–en–1–il)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–(2–hidroxietil)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(3–cloropiridin–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–cloro–5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–5–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(piridin–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(piridazin–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(5–metilpirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–etil–5–fluoro–1–(pirimidin–2–il)–2–{5–[(1,1,1–trifluoro–2–metilpropan–2–il)sulfamoil]piridin–2–il}–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[1–(trifluorometil)ciclopropil]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(4–metilpiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(5–fluoropiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(2–metilpirimidin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[1–(5–cloropiridin–3–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–{3–ciano–5–fluoro–1–[5–(hidroximetil)–1,3–tiazol–2–il]–6–metil–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[3–ciano–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–1–il]–1,3–tiazol–5–carboxilato de metilo,

2–[3–ciano–5–fluoro–6–metil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–1–il]–1,3–tiazol–4–carboxilato de metilo,

6–[5–fluoro–6–metil–1–(tiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–fluoro–1–(furan–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–fluoro–6–metil–1–(tiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(tiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(furan–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida

6–[3–ciano–5–fluoro–6–metil–1–(tiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(4–cloropiridin–2–il)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–etil–5–fluoro–1–(pirazin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(6–fluoropiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

5–cloro–1–ciclobutil–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–ciclobutil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxilic acid,

2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,

6–[3–ciano–5–fluoro–6–metil–1–(3–metiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(4,6–difluoropiridin–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(4–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(4–clorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(4–metilfenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(4–metoxifenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–{3–ciano–6–etil–5–fluoro–1–[4–(trifluorometil)fenil]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(4–cianofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(3–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(3–metilfenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(3–metoxifenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–{3–ciano–6–etil–5–fluoro–1–[3–(trifluorometil)fenil]–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(3–cianofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(2–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(3–fluoropiridin–4–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(6–fluoropiridin–3–il)–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(1–metil–1H–pirazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(5–metil–1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(3–clorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–etil–5–fluoro–1–(4–fluorofenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–(4–clorofenil)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(4–metilfenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–[4–(trifluorometil)fenil]–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(3–fluorofenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(3–metilfenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(3–metoxifenil)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–[3–(trifluorometil)fenil]–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–(3–clorofenil)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

ácido 2–{5–[(ter–butilsulfonil)amino]pirimidin–2–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxílico,

ácido 2–{2–[(ter–butilsulfonil)amino]pirimidin–5–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxílico,

6–[3–ciano–5–fluoro–6–metil–1–(3–metil–1H–pirazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(5–metiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(5–clorotiofen–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(5–cianotiofen–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(5–sulfamoiltiofen–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(5–acetiltiofen–2–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–{2–[(ter–butilsulfonil)amino]pirimidin–5–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,

6–[3–ciano–5–fluoro–6–metil–1–(4–metil–1,3–tiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–etil–5–fluoro–1–(5–metilpiridin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(piridin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(pirimidin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–(3–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–(5–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–(5–cloropiridin–3–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida

6–etil–5–fluoro–1–(piridin–4–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(piridazin–3–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–etil–5–fluoro–1–(5–metilpirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

1–(4–cloropiridin–2–il)–6–etil–5–fluoro–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[1–(2–acetiltiofen–3–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(4–metiltiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(2–clorotiofen–3–il)–3–ciano–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(5–metiltiofen–3–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[5–fluoro–6–metil–1–(1,3–oxazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(5–cianofuran–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(3,4–difluorofenil)–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[1–(3–cloro–4–fluorofenil)–3–ciano–6–etil–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,

ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,

N–{5–[3–ciano–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,

6–[3–ciano–1–(3–cianofuran–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(1,3–oxazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–(4–ciano–1,3–oxazol–2–il)–5–fluoro–6–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(2–fluorofenil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–{3–ciano–6–[(1,1–dideuterio)etil]–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–{3–ciano–6–[(1,1–D)etil]–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il}–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,

ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,

N–(5–{3–ciano–1–[(1S)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–2–il}piridin–2–il)–2–metilpropan–2–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxamida,

ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,

ácido 2–{6–[(ter–butilsulfonil)amino]–4–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,

2–{6–[(ter–butilsulfonil)amino]–4–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida,

N–[6–(3–ciano–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–2–il)piridin–3–il]–2–metilpropan–2–sulfonamida,

ácido 2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–3–carboxílico,

ácido 2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,

2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–6–(difluorometoxi)–5–fluoro–1–(propan–2–il)–1H–indol–3–carboxamida,

2–{6–[(ter–butilsulfonil)amino]–2–metilpiridin–3–il}–1–[(1S)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,

2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida,

6–[3–ciano–6–ciclopropil–4–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–5–fluoro–6–(fluorometoxi)–1H–indol–3–carboxilato de metilo,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–5–fluoro–1–fenil–1H–indol–3–carboxamida,

N–[5–(3–ciano–6–ciclopropil–5–fluoro–1–fenil–1H–indol–2–il)piridin–2–il]–2–metilpropan–2–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–5–fluoro–6–(fluorometoxi)–1H–indol–3–carboxamida,

ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxílico,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–etil–5–fluoro–1H–indol–3–carboxamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–4–fluoro–1–(4–fluorofenil)–1H–indol–3–carboxamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–etil–4–fluoro–1–(4–fluorofenil)–1H–indol–3–carboxamida,

6–[3–ciano–5–fluoro–6–(1,1,1–trideuterio)metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,

N–ter–butil–6–(3–ciano–5–fluoro–6–metil–1–fenil–1H–indol–2–il)piridin–3–sulfonamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–6–etil–5–fluoro–1–fenil–1H–indol–3–carboxamida,

2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclobutil–6–etil–4–fluoro–1H–indol–3–carboxamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–etil–4–fluoro–1–fenil–1H–indol–3–carboxamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2–deuterio)propan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–5–fluoro–6–(1,1,1–trideuterio)metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoro(2–deuterio)propan–2–il]piridin–3–sulfonamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclohexil–5–fluoro–6–metil–1H–indol–3–carboxamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–5–fluoro–6–metil–1–fenil–1H–indol–3–carboxamida,

N–ter–butil–6–(3–ciano–6–ciclopropil–5–fluoro–1–fenil–1H–indol–2–il)piridin–3–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclobutil–6–etil–4–fluoro–1H–indol–3–carboxamida o

6–[3–ciano–1–(ciclopropilmetil)–5–fluoro–6–(1,1,1–trideuterio)metil–1H–indol–2–il]–N–[(2–deuterio)propan–2–il]piridin–3–sulfonamida.

10. El compuesto de acuerdo con la reivindicación 9, en donde el compuesto o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o formas polimórficas está seleccionado de:

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(propan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–(propan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–ciclopropil–5–fluoro–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–[1–(trifluorometil)ciclopropil]piridin–3–sulfonamida,

N–[6–(3–ciano–1–ciclobutil–6–metoxi–1H–indol–2–il)piridazin–3–il]etansulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–6–metil–1H–indol–2–il)–N–(1,1,1–trifluoro–2–metilpropan–2–il)piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–(1,3–difluoropropan–2–il)piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–7–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–5,7–difluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclobutil–6–etil–5–fluoro–1H–indol–2–il)–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–[5–(ter–butilsulfamoil)piridin–2–il]–1–ciclopentil–5–fluoro–6–metil–1H–indol–3–carboxamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

1–ciclohexil–5–fluoro–6–metil–2–(5–{[(2R)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–5–fluoro–6–metil–1–(tetrahidro–2H–piran–4–il)–1H–indol–2–il]–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–4–metil–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2S)–1,1,1–trifluorobutan–2–il]piridin–3–sulfonamida,

6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(2–metilpropil)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(1,3,4–tiadiazol–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,

ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,

N–{5–[3–ciano–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–[(1R)–1–ciclopropiletil]–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida,

N–[6–(3–ciano–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–2–il)piridin–3–il]–2–metilpropan–2–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–5–fluoro–1–fenil–1H–indol–3–carboxamida,

2–{5–[(ter–butilsulfonil)amino]piridin–2–il}–1–ciclobutil–6–etil–4–fluoro–1H–indol–3–carboxamida o

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–etil–4–fluoro–1–fenil–1H–indol–3–carboxamida.

11. El compuesto de acuerdo con la reivindicación 10, en donde el compuesto o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopólogos, racematos, enantiómeros, diastereómeros, estereoisómeros o formas polimórficas está seleccionado de:

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–(3–ciano–1–ciclopentil–5–fluoro–6–metil–1H–indol–2–il)–N–[(2R)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(piridin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–1–ciclobutil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–5–fluoro–6–metil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–(difluorometoxi)–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–etil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–[3–ciano–6–ciclopropil–5–fluoro–1–(pirimidin–2–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

6–etil–5–fluoro–1–(pirimidin–2–il)–2–(5–{[(2S)–1,1,1–trifluoropropan–2–il]sulfamoil}piridin–2–il)–1H–indol–3–carboxamida,

6–[3–ciano–5–fluoro–6–metil–1–(1,3–tiazol–4–il)–1H–indol–2–il]–N–[(2S)–1,1,1–trifluoropropan–2–il]piridin–3–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–etil–5–fluoro–1H–indol–3–carboxamida,

ácido 2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–3–carboxílico,

N–{5–[3–ciano–1–ciclohexil–6–(difluorometoxi)–5–fluoro–1H–indol–2–il]piridin–2–il}–2–metilpropan–2–sulfonamida,

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–1–ciclohexil–6–ciclopropil–4–fluoro–1H–indol–3–carboxamida o

2–{6–[(ter–butilsulfonil)amino]piridin–3–il}–6–ciclopropil–5–fluoro–1–fenil–1H–indol–3–carboxamida.

12. Un uso de un compuesto de acuerdo con la reivindicación 1 para tratar una infección viral por modulación de la replicación viral.

13. Un método para tratar una infección viral en un sujeto que lo necesita que comprende la administración de una cantidad efectiva de un compuesto de acuerdo con la reivindicación 1 al sujeto.

14. El método de acuerdo con la reivindicación 13, en donde la infección viral es el resultado de un virus seleccionado de un virus del género picornavirus, un virus del género coronaviridae, un virus del género arbovirus, un virus del género flavivirus, un virus de los herpesvirus, un virus de inmunodeficiencia humana (HIV) o un virus de leucemia humana.

15. El método de acuerdo con la reivindicación 14, en donde un virus del género picornavirus está seleccionado de poliovirus, virus de hepatitis A, coxsackievirus y rhinovirus, en donde un virus del género coronaviridae está seleccionado de síndrome respiratorio agudo severo (SARS), en donde un virus del género flavivirus está seleccionado de virus de hepatitis C, fiebre amarilla, dengue y virus del Nilo Occidental, en donde un virus de los herpesvirus está seleccionado de virus herpes simplex y herpesvirus asociado con el sarcoma de Kaposi.

16. El método de acuerdo con la reivindicación 13, en donde la infección viral es virus de hepatitis C.

17. El método de acuerdo con la reivindicación 13, en donde la cantidad efectiva de un compuesto de acuerdo con la reivindicación 1 o una de sus formas es en un rango de aproximadamente 0,001 mg/kg/día a aproximadamente 500 mg/kg/día.

18. Un uso de un compuesto de acuerdo con la reivindicación 1 o una de sus formas en la preparación de un medicamento para tratar una infección viral en un sujeto que lo necesita.

19. El uso de acuerdo con la reivindicación 18, en donde la infección viral es el resultado de un virus seleccionado de un virus del género picornavirus, un virus del género coronaviridae, un virus del género arbovirus, un virus del género flavivirus, un virus de los herpesvirus, HIV o un virus de leucemia humana.

20. El uso de acuerdo con la reivindicación 19, en donde un virus del género picornavirus está seleccionado de poliovirus, virus de hepatitis A, coxsackievirus y rhinovirus, en donde un virus del género coronaviridae está seleccionado de SARS, en donde un virus del género flavivirus está seleccionado de virus de hepatitis C, fiebre amarilla, dengue y virus del Nilo Occidental, en

donde un virus de los herpesvirus está seleccionado de virus herpes simplex y herpesvirus asociado con el sarcoma de Kaposi.

21. El uso de acuerdo con la reivindicación 18, en donde la infección viral es virus de hepatitis C.

22. Una composición farmacéutica que comprende una cantidad efectiva de un compuesto de acuerdo con la reivindicación 1 o una de sus formas en mezcla con un excipiente farmacéuticamente aceptable.

RESUMEN

La presente invención se refiere a compuestos y sus formas y composiciones farmacéuticas de utilidad para tratar una infección viral o para afectar la actividad viral al modular la replicación viral.

509

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2010/029923

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D401/04 C07D401/14 C07D403/04 C07D405/14 C07D409/14
C07D413/14 C07D417/14 A61P31/12 A61K31/4439 A61K31/444
A61K31/4436 A61K31/443 A61K31/4433 A61K31/506

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/019831 A1 (PTC THERAPEUTICS INC [US]; HWANG PETER SEONGWOO [US]; TAKASUGI JAMES [) 23 February 2006 (2006-02-23)	1,6-8, 12-22
A	claim 1 claims 17, 33 claim 15; compounds 701, 702, 703, 752, 753, 754, 841, 842, 843	2-5,9-11
Y	EP 1 162 196 A1 (JAPAN TOBACCO INC [JP]) 12 December 2001 (2001-12-12) claims 1, 7 claims 32-43	1-22
Y	US 2007/299068 A1 (KARP GARY M [US] ET AL) 27 December 2007 (2007-12-27) claim 1 claim 110	1-22

-/--

[X] Further documents are listed in the continuation of Box C. [X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
28 June 2010	26/08/2010

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Lécaillon, Jennifer

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2010/029923

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2004/065367 A1 (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; BEAUL) 5 August 2004 (2004-08-05) claim 1 claim 59	1-22
X,P	WO 2009/156462 A2 (NOVARTIS AG [CH]; ADAMS CHRISTOPHER [US]; HU QI-YING [US]; MCQUIRE LES) 30 December 2009 (2009-12-30)	1-3, 6-11,22
A	page 215 - page 233	4,5, 12-21

Form PCT/ISA/210 (continuation of second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2010/029923

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

2, 3, 9-11(completely); 1, 4-8, 12-22(partially)

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 2, 3, 9-11(completely); 1, 4-8, 12-22(partially)

   Compounds of Formula (I) and (Ia) in which Ar represents heteroaryl.

   ---

2. claims: 1, 4-8, 12-22(all partially)

   Compounds of Formula (I) and (Ia) in which Ar represents non-aromatic heterocyclyl containing at least one heteroatom different from nitrogen.

   ---

3. claims: 1, 4-8, 12-22(all partially)

   Compounds of Formula (I) and (Ia) in which Ar represents non-aromatic heterocyclyl containing nitrogen as only heteroatom.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2010/029923

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 2006019831 A1	23-02-2006	AU	2005275181 A1	23-02-2006
		BR	PI0511834 A	08-01-2008
		CA	2573185 A1	23-02-2006
		EA	200700243 A1	31-08-2007
		EC	SP077252 A	30-05-2007
		EP	1771169 A1	11-04-2007
		JP	2008506702 T	06-03-2008
		KR	20070083484 A	24-08-2007
EP 1162196 A1	12-12-2001	AR	031230 A1	17-09-2003
		AU	763356 B2	17-07-2003
		AU	2401701 A	09-07-2001
		CA	2363274 A1	05-07-2001
		CN	1342145 A	27-03-2002
		CN	1623984 A	08-06-2005
		CZ	20013424 A3	13-02-2002
		HU	0202263 A2	28-12-2002
		ID	30204 A	15-11-2001
		WO	0147883 A1	05-07-2001
		NO	20014134 A	22-10-2001
		NZ	514403 A	25-10-2002
		RU	2223761 C2	20-02-2004
		SK	13752001 A3	02-07-2002
		TR	200103147 T1	21-06-2002
		US	7112600 B1	26-09-2006
		ZA	200107870 A	25-09-2002
US 2007299068 A1	27-12-2007	NONE		
WO 2004065367 A1	05-08-2004	AR	047754 A1	22-02-2006
		AU	2004205429 A1	05-08-2004
		BR	PI0406926 A	03-01-2006
		CA	2511307 A1	05-08-2004
		CL	762004 A1	14-01-2005
		CN	1764641 A	26-04-2006
		CO	5590912 A1	30-12-2005
		EC	SP055913 A	01-03-2006
		EP	1587787 A1	26-10-2005
		HR	20050662 A2	31-07-2006
		JP	2006517536 T	27-07-2006
		JP	2010077139 A	08-04-2010
		KR	20050095863 A	04-10-2005
		MX	PA05007754 A	30-09-2005
		NZ	541852 A	31-03-2009
		ZA	200504893 A	29-11-2006
WO 2009156462 A2	30-12-2009	PE	00552010 A1	25-02-2010

514

PATENT COOPERATION TREATY PCT/US2010/029923

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92*bis*.1 and Administrative Instructions, Section 422)

To:

ZARADIC, Sandy
HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, NY 11791
ETATS-UNIS D'AMERIQUE

Date of mailing *(day/month/year)*
14 October 2011 (14.10.2011)

Applicant's or agent's file reference
PT2009-6971

IMPORTANT NOTIFICATION

International application No.
PCT/US2010/029923

International filing date *(day/month/year)*
05 April 2010 (05.04.2010)

1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address
SCHERING CORPORATION
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
United States of America
United States of America

State of Nationality:
State of Residence:
Telephone No.: 908-298-4000
Facsimile No.: 908-298-4000
E-mail address:

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

State of Nationality:
State of Residence:
Telephone No.:
Facsimile No.:
E-mail address:
☐ Notifications by e-mail authorized

3. Further observations, if necessary:
The person identified in Box 1 has been deleted from the records.

4. A copy of this notification has been sent to:

☒ the receiving Office
☐ the International Searching Authority
☐ the Authority(ies) specified for supplementary search
☐ the International Preliminary Examining Authority
☒ the designated Offices concerned
☐ the elected Offices concerned
☐ other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 338 70 80

Authorized officer
Safi Horiya
e-mail pt03.pct@wipo.int
Telephone No. +41 22 338 74 03

Form PCT/IB/306 (January 2009) 1/UAGNL3CN0

Industria y Comercio
SUPERINTENDENCIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES
EXTRACTO PARA PUBLICACIÓN
SOLICITUD DE PATENTE DE INVENCIÓN PCT

(21) N° de solicitud: 22) Fecha de solicitud: (30) Prioridad (31) ***Prioridad*** **61/166,893** (32) ***Fecha*** **06/04/2009** (33) ***País*** **US**	(51) Int Cl: **C07D 401/004** (71)Solicitante(s) **PTC THERAPEUTICS, INC.** (72) Inventor(es) **MALCOLM MACCOSS Y OTROS** (74) Apoderado: **LUZ CLEMENCIA DE PAEZ**
(85) Fecha limite inicio fase nacional: 06/11/2011 (86) Datos relativos a la presentación de la solicitud PCT Fecha de presentación de la solicitud: 05/04/2010 No. de solicitud PCT/US2010/029923	(87) Publicación internacional Fecha: 14/10/2010 N° publicación: ***WO 2010/117932 A1***
(54) Titulo: **COMPUESTOS Y MÉTODOS PARA TRATAMIENTO ANTIVIRAL**	

Resumen:

La presente invención se refiere a compuestos y sus formas y composiciones farmacéuticas de utilidad para tratar una infección viral o para afectar la actividad viral al modular la replicación viral.

516

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
NIT : 800.176.089-2
- / -

Industria y Comercio
SUPERINTENDENCIA

RECIBO DE CAJA

No. 11 - 103545

Bogotá D.C., Octubre 21 de 2011 - 17:08:03

RECIBIDO DE : CAVELIER ABOGADOS NI 860.041.367

*** Soporte del Pago ***

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR.PAGO
CONSIGNACION	BANCO DE BOGOTA	062754387	431629962	21/10/2011	39.126.000.00

*** Conceptos Pagados ***

CANT	RENTISTICO	CONCEPTO	Vr.UNDITARIO	Vr.CONCEPTO
1	50005-01-01 SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE INVENCION	571.000.00	571.000.00
				$571.000.00

SON: **QUINIENTOS SETENTA Y UN MIL PESOS MONEDA CORRIENTE***

Responsable: _____
****

Recibo de Caja Aplicado al Expediente No. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 11-147742- -00000-0000
Fecha: 2011-11-01 11:31:46 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 517

COLO: 15565-841-004-0

517

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
NIT : 800.176.089-2
- / -

Industria y Comercio
SUPERINTENDENCIA

RECIBO DE CAJA

No. 11 - 103523

Bogotá D.C., Octubre 21 de 2011 - 17:08:03

RECIBIDO DE : CAVELIER ABOGADOS NI 860.041.367

*** Soporte del Pago ***

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR PAGO
CONSIGNACION	BANCO DE BOGOTA	062754387	431629962	21/10/2011	39.126.000.00

*** Conceptos Pagados ***

CANT	RENTISTICO	CONCEPTO	Vr.UNDITARIO	Vr.CONCEPTO
1	50005-01-01 SOLICITUDES	113 PTC CAP-I EXAMEN DE PATENTIBILIDAD DE MODELO DE UTILIDA	324.000.00	324.000.00
				$324.000.00

SON: **TRESCIENTOS VEINTICUATRO MIL PESOS MONEDA CORRIENTE***

Responsable: _____
****

Recibo de Caja Aplicado al Expediente No. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 11-147742- -00000-0000
Fecha: 2011-11-01 11:31:46 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 517

COLO: 15565-841-004-0

Industria y Comercio
SUPERINTENDENCIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

No. 11-147742- -00000-0000

Fecha: 2011-11-01 11:31:46 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 517

PATENTE DE INVENCIÓN ☐ **MODELO DE UTILIDAD** ☐ **Art 33 Decisión 486/00**

- ☐ Indicación que se solicita una patente.
- ☐ Datos de identificación del solicitante o de la persona que presenta la solicitud
- ☐ Descripción de la invención
- ☐ Dibujos de ser estos pertinentes
- ☐ Comprobante de pago de las tasas establecidas (De ser el caso formato de descuento)

Completa ☐ Incompleta ☐

PATENTE DE INVENCIÓN PCT ☑ **MODELO DE UTILIDAD PCT** ☐ **Art.33 Decisión 486/00, Circular Única**

- ☑ Indicación que se solicita una PCT
- ☑ Copia de la solicitud en español, tal como fue presentada inicialmente (capítulo descriptivo, reivindicatorio, resumen)
- ☑ Dibujos de ser estos pertinentes
- ☑ Comprobante de pago de las tasas establecidas (de ser el caso formato de descuento)

Completa ☑ Incompleta ☐

DISEÑO INDUSTRIAL ☐ **(Art. 119 Decisión 486/00)**

- ☐ Indicación que se solicita Diseño industrial
- ☐ Datos de identificación del solicitante o de la persona que presenta la solicitud
- ☐ Representación gráfica y fotográfica del Diseño industrial o muestra del material que incorpora el diseño
- ☐ Comprobante de pago de las tasas establecidas

Completa ☐ Incompleta ☐

ESQUEMA DE TRAZADO ☐ **(Art. 92 Decisión 486/00)**

- ☐ Indicación que se solicita un esquema de trazado
- ☐ Datos de identificación del solicitante o de la persona que presenta la solicitud
- ☐ Representación gráfica de un esquema de trazado
- ☐ Comprobante de pago de las tasas establecidas

Completa ☐ Incompleta ☐